VIOLIN Logo
VIOLIN Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

VIOLIN Curated References

Actinobacillus pleuropneumoniae

  1. Byrd et al., 1992: Byrd W, Harmon BG, Kadis S. Protective efficacy of conjugate vaccines against experimental challenge with porcine Actinobacillus pleuropneumoniae. Veterinary immunology and immunopathology. 1992; 34(3-4); 307-324. [PubMed: 1455686].
  2. Chiang et al., 2009: Chiang CH, Huang WF, Huang LP, Lin SF, Yang WJ. Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model. Vaccine. 2009; 27(34); 4565-4570. [PubMed: 19520199].
  3. Chiers et al., 1998: Chiers K, van Overbeke I, De Laender P, Ducatelle R, Carel S, Haesebrouck F. Effects of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with inactivated vaccines containing the Apx toxins. The Veterinary quarterly. 1998; 20(2); 65-69. [PubMed: 9563163].
  4. Haesebrouck et al., 2004: Haesebrouck F, Pasmans F, Chiers K, Maes D, Ducatelle R, Decostere A. Efficacy of vaccines against bacterial diseases in swine: what can we expect?. Veterinary microbiology. 2004; 100(3-4); 255-268. [PubMed: 15145504].
  5. Ingham et al., 2002: Ingham A, Zhang Y, Prideaux C. Attenuation of Actinobacillus pleuropneumoniae by inactivation of aroQ. Veterinary microbiology. 2002; 84(3); 263-273. [PubMed: 11731178].
  6. Lee et al., 2006: Lee KY, Kim DH, Kang TJ, Kim J, Chung GH, Yoo HS, Arntzen CJ, Yang MS, Jang YS. Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria. FEMS immunology and medical microbiology. 2006; 48(3); 381-389. [PubMed: 17054716].
  7. Li et al., 2008: Li L, Zhou R, Li T, Kang M, Wan Y, Xu Z, Chen H. Enhanced biofilm formation and reduced virulence of Actinobacillus pleuropneumoniae luxS mutant. Microbial pathogenesis. 2008; 45(3); 192-200. [PubMed: 18585450].
  8. Liu et al., 2007: Liu J, Chen X, Lin L, Tan C, Chen Y, Guo Y, Jin M, Guo A, Bei W, Chen H. Potential use an Actinobacillus pleuropneumoniae double mutant strain DeltaapxIICDeltaapxIVA as live vaccine that allows serological differentiation between vaccinated and infected animals. Vaccine. 2007; 25(44); 7696-7705. [PubMed: 17767980].
  9. Park et al., 2009: Park C, Ha Y, Kim S, Chae C, Ryu DY. Construction and characterization of an Actinobacillus pleuropneumoniae serotype 2 mutant lacking the Apx toxin secretion protein genes apxIIIB and apxIIID. The Journal of veterinary medical science / the Japanese Society of Veterinary Science. 2009; 71(10); 1317-1323. [PubMed: 19887737].
  10. Prideaux et al., 1998: Prideaux CT, Pierce L, Krywult J, Hodgson AL. Protection of mice against challenge with homologous and heterologous serovars of Actinobacillus pleuropneumoniae after live vaccination. Current microbiology. 1998; 37(5); 324-332. [PubMed: 9767712].
  11. Prideaux et al., 1999: Prideaux CT, Lenghaus C, Krywult J, Hodgson AL. Vaccination and protection of pigs against pleuropneumonia with a vaccine strain of Actinobacillus pleuropneumoniae produced by site-specific mutagenesis of the ApxII operon. Infection and immunity. 1999; 67(4); 1962-1966. [PubMed: 10085043].
  12. Shin et al., 2007: Shin SJ, Shin SW, Kang ML, Lee DY, Yang MS, Jang YS, Yoo HS. Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice. Journal of veterinary science. 2007; 8(4); 383-392. [PubMed: 17993753].
  13. ThePigSite Pig Health: Actinobacillus Pleuropneumonia (App) [http://www.thepigsite.com/pighealth/article/309/actinobacillus-pleuropneumonia-app]
  14. Tonpitak et al., 2002: Tonpitak W, Baltes N, Hennig-Pauka I, Gerlach GF. Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine. Infection and immunity. 2002; 70(12); 7120-7125. [PubMed: 12438394].
  15. Van et al., 2001: Van Overbeke I, Chiers K, Ducatelle R, Haesebrouck F. Effect of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with a vaccine containing Apx toxins and transferrin-binding proteins. Journal of veterinary medicine. B, Infectious diseases and veterinary public health. 2001; 48(1); 15-20. [PubMed: 11254095].
  16. Xu et al., 2006: Xu F, Chen X, Shi A, Yang B, Wang J, Li Y, Guo X, Blackall PJ, Yang H. Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae. Veterinary microbiology. 2006; 118(3-4); 230-239. [PubMed: 16930871].
  17. Xu et al., 2007: Xu FZ, Shi AH, Chen XL, Yang B, Wang JL. [Construction and immunogenicity of an attenuated mutant of Actinobacillus pleuropneumoniae by insertional inactivation of apxIC]. Wei sheng wu xue bao = Acta microbiologica Sinica. 2007; 47(5); 923-927. [PubMed: 18062275].

Adenovirus

  1. FDA: Adenovirus Vaccine: FDA: Adenovirus Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm247508.htm]
  2. Harrison, 2010: Harrison SC. Virology. Looking inside adenovirus. Science (New York, N.Y.). 2010; 329(5995); 1026-1027. [PubMed: 20798308].
  3. Tompkins et al., 2007: Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging infectious diseases. 2007; 13(3); 426-435. [PubMed: 17552096].

Aeromonas hydrophila

  1. Hernanz et al., 1998: Hernanz Moral C, Flaño del Castillo E, López Fierro P, Villena Cortés A, Anguita Castillo J, Cascón Soriano A, Sánchez Salazar M, Razquín Peralta B, Naharro Carrasco G. Molecular characterization of the Aeromonas hydrophila aroA gene and potential use of an auxotrophic aroA mutant as a live attenuated vaccine. Infection and immunity. 1998; 66(5); 1813-1821. [PubMed: 9573055].
  2. Mu et al., 2011: Mu W, Guan L, Yan Y, Liu Q, Zhang Y. A novel in vivo inducible expression system in Edwardsiella tarda for potential application in bacterial polyvalence vaccine. Fish & shellfish immunology. 2011; 31(6); 1097-1105. [PubMed: 21964456].
  3. Wiki: Aeromonas Hydrophila: Aeromonas Hydrophila [http://microbewiki.kenyon.edu/index.php/Aeromonas_Hydrophila]

Aeromonas salmonicida

  1. Gudmundsdottir et al., 1997: BJARNHEIDUR K. GUDMUNDSDÓTTIR, BERGLJÓT MAGNADÓTTIR. Protection of Atlantic salmon (Salmo salarL.) against an experimental infection ofAeromonas salmonicidassp.achromogenes. Fish & shellfish immunology. 1997; 7(1); 55-69.
  2. Lund et al., 2003: Lund V, Espelid S, Mikkelsen H. Vaccine efficacy in spotted wolffish Anarhichas minor: relationship to molecular variation in A-layer protein of atypical Aeromonas salmonicida. Diseases of aquatic organisms. 2003; 56(1); 31-42. [PubMed: 14524499].
  3. Sundvold et al., 2010: Sundvold H, Ruyter B, Ostbye TK, Moen T. Identification of a novel allele of peroxisome proliferator-activated receptor gamma (PPARG) and its association with resistance to Aeromonas salmonicida in Atlantic salmon (Salmo salar). Fish & shellfish immunology. 2010; 28(2); 394-400. [PubMed: 20004720].
  4. USGS Fish Disease Leaflets: Furunculosis and Other Diseases Caused by Aeromonas Salmonicida [http://www.lsc.usgs.gov/fhb/leaflets/FHB66.pdf]
  5. Vaughan et al., 1993: Vaughan LM, Smith PR, Foster TJ. An aromatic-dependent mutant of the fish pathogen Aeromonas salmonicida is attenuated in fish and is effective as a live vaccine against the salmonid disease furunculosis. Infection and immunity. 1993; 61(5); 2172-2181. [PubMed: 8478107].
  6. Wiki: Aeromonas salmonicida: Aeromonas salmonicida [http://en.wikipedia.org/wiki/Aeromonas_salmonicida]

African Swine Fever Virus

  1. Argilaguet et al., 2011: Argilaguet JM, Pérez-Martín E, Gallardo C, Salguero FJ, Borrego B, Lacasta A, Accensi F, Díaz I, Nofrarías M, Pujols J, Blanco E, Pérez-Filgueira M, Escribano JM, Rodríguez F. Enhancing DNA immunization by targeting ASFV antigens to SLA-II bearing cells. Vaccine. 2011; 29(33); 5379-5385. [PubMed: 21679736].
  2. Lewis et al., 2000: Lewis T, Zsak L, Burrage TG, Lu Z, Kutish GF, Neilan JG, Rock DL. An African swine fever virus ERV1-ALR homologue, 9GL, affects virion maturation and viral growth in macrophages and viral virulence in swine. Journal of virology. 2000; 74(3); 1275-1285. [PubMed: 10627538].
  3. Sanchez-Vizcaino et al., 2012: Sanchez-Vizcaino JM, Mur L, Martinez-Lopez B. African Swine Fever: An Epidemiological Update. Transboundary and emerging diseases. 2012; ; . [PubMed: 22225967].

Allergy

  1. Ballantyne et al., 2007: Ballantyne SJ, Barlow JL, Jolin HE, Nath P, Williams AS, Chung KF, Sturton G, Wong SH, McKenzie AN. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. The Journal of allergy and clinical immunology. 2007; 120(6); 1324-1331. [PubMed: 17889290].
  2. Bilsborough et al., 2008: Bilsborough J, Chadwick E, Mudri S, Ye X, Henderson WR Jr, Waggie K, Hebb L, Shin J, Rixon M, Gross JA, Dillon SR. TACI-Ig prevents the development of airway hyperresponsiveness in a murine model of asthma. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2008; 38(12); 1959-1968. [PubMed: 19037968].
  3. Chuang et al., 2006: Chuang YH, Suen JL, Chiang BL. Fas-ligand-expressing adenovirus-transfected dendritic cells decrease allergen-specific T cells and airway inflammation in a murine model of asthma. Journal of molecular medicine (Berlin, Germany). 2006; 84(7); 595-603. [PubMed: 16565865].
  4. Edwan and Agrawal, 2007: Edwan JH, Agrawal DK. Flt3-ligand plasmid prevents the development of pathophysiological features of chronic asthma in a mouse model. Immunologic research. 2007; 37(2); 147-159. [PubMed: 17695249].
  5. Eigenmann et al., 2008: Eigenmann PA, Asigbetse KE, Frossard CP. Avirulant Salmonella typhimurium strains prevent food allergy in mice. Clinical and experimental immunology. 2008; 151(3); 546-553. [PubMed: 18190606].
  6. Focke et al., 2001: Focke M, Mahler V, Ball T, Sperr WR, Majlesi Y, Valent P, Kraft D, Valenta R. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2001; 15(11); 2042-2044. [PubMed: 11511525].
  7. Gómez et al., 2008: Gómez S, Gamazo C, San Roman B, Ferrer M, Sanz ML, Espuelas S, Irache JM. Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2008; 70(3); 711-717. [PubMed: 18582571].
  8. Keane-Myers et al., 1998: Keane-Myers AM, Gause WC, Finkelman FD, Xhou XD, Wills-Karp M. Development of murine allergic asthma is dependent upon B7-2 costimulation. Journal of immunology (Baltimore, Md. : 1950). 1998; 160(2); 1036-1043. [PubMed: 9551945].
  9. Liu et al., 2009: Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochemical and biophysical research communications. 2009; 386(1); 181-185. [PubMed: 19508862].
  10. Maecker et al., 2001: Maecker HT, Hansen G, Walter DM, DeKruyff RH, Levy S, Umetsu DT. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. Journal of immunology (Baltimore, Md. : 1950). 2001; 166(2); 959-965. [PubMed: 11145673].
  11. Nagashima et al., 2008: Nagashima O, Harada N, Usui Y, Yamazaki T, Yagita H, Okumura K, Takahashi K, Akiba H. B7-H3 contributes to the development of pathogenic Th2 cells in a murine model of asthma. Journal of immunology (Baltimore, Md. : 1950). 2008; 181(6); 4062-4071. [PubMed: 18768862].
  12. Peng et al., 2004: Peng HJ, Tsai LC, Su SN, Chang ZN, Shen HD, Chao PL, Kuo SW, Tsao IY, Hung MW. Comparison of different adjuvants of protein and DNA vaccination for the prophylaxis of IgE antibody formation. Vaccine. 2004; 22(5-6); 755-761. [PubMed: 14741169].
  13. Polte et al., 2006: Polte T, Foell J, Werner C, Hoymann HG, Braun A, Burdach S, Mittler RS, Hansen G. CD137-mediated immunotherapy for allergic asthma. The Journal of clinical investigation. 2006; 116(4); 1025-1036. [PubMed: 16528411].
  14. Simoes et al., 2008: Simoes DC, Vassilakopoulos T, Toumpanakis D, Petrochilou K, Roussos C, Papapetropoulos A. Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma. American journal of respiratory and critical care medicine. 2008; 177(12); 1314-1321. [PubMed: 18356565].
  15. Wang et al., 2008: Wang SY, Yang M, Xu XP, Qiu GF, Ma J, Wang SJ, Huang XX, Xu HX. Intranasal delivery of T-bet modulates the profile of helper T cell immune responses in experimental asthma. Journal of investigational allergology & clinical immunology : official organ of the International Association of Asthmology (INTERASMA) and Sociedad Latinoamericana de Alergia e Inmunologia. 2008; 18(5); 357-365. [PubMed: 18973099].
  16. Westritschnig et al., 2004: Westritschnig K, Focke M, Verdino P, Goessler W, Keller W, Twardosz A, Mari A, Horak F, Wiedermann U, Hartl A, Thalhamer J, Sperr WR, Valent P, Valenta R. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. Journal of immunology (Baltimore, Md. : 1950). 2004; 172(9); 5684-5692. [PubMed: 15100313].
  17. Westritschnig et al., 2007: Westritschnig K, Linhart B, Focke-Tejkl M, Pavkov T, Keller W, Ball T, Mari A, Hartl A, Stöcklinger A, Scheiblhofer S, Thalhamer J, Ferreira F, Vieths S, Vogel L, Böhm A, Valent P, Valenta R. A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin. Journal of immunology (Baltimore, Md. : 1950). 2007; 179(11); 7624-7634. [PubMed: 18025208].
  18. Wiki: Allergy: Allergy [http://en.wikipedia.org/wiki/Allergy]

Arthritis

  1. Ho et al., 2006: Ho PP, Higgins JP, Kidd BA, Tomooka B, Digennaro C, Lee LY, de Vegvar HE, Steinman L, Robinson WH. Tolerizing DNA vaccines for autoimmune arthritis. Autoimmunity. 2006; 39(8); 675-682. [PubMed: 17178564].
  2. Mayo Clinic - Arthritis: Arthritis [http://www.mayoclinic.com/health/arthritis/DS01122]
  3. Quintana et al., 2002: Quintana FJ, Carmi P, Mor F, Cohen IR. Inhibition of adjuvant arthritis by a DNA vaccine encoding human heat shock protein 60. Journal of immunology (Baltimore, Md. : 1950). 2002; 169(6); 3422-3428. [PubMed: 12218165].
  4. Ragno et al., 1997: Ragno S, Colston MJ, Lowrie DB, Winrow VR, Blake DR, Tascon R. Protection of rats from adjuvant arthritis by immunization with naked DNA encoding for mycobacterial heat shock protein 65. Arthritis and rheumatism. 1997; 40(2); 277-283. [PubMed: 9041939].
  5. Santos-Junior et al., 2005: Santos-Junior RR, Sartori A, De Franco M, Filho OG, Coelho-Castelo AA, Bonato VL, Cabrera WH, Ibañez OM, Silva CL. Immunomodulation and protection induced by DNA-hsp65 vaccination in an animal model of arthritis. Human gene therapy. 2005; 16(11); 1338-1345. [PubMed: 16259568].
  6. Song et al., 2009: Song X, Liang F, Liu N, Luo Y, Xue H, Yuan F, Tan L, Sun Y, Xi C, Xi Y. Construction and characterization of a novel DNA vaccine that is potent antigen-specific tolerizing therapy for experimental arthritis by increasing CD4+CD25+Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Vaccine. 2009; 27(5); 690-700. [PubMed: 19095031].
  7. Xue et al., 2011: Xue H, Liang F, Liu N, Song X, Yuan F, Luo Y, Zhao X, Long J, Sun Y, Xi Y. Potent antirheumatic activity of a new DNA vaccine targeted to B7-2/CD28 costimulatory signaling pathway in autoimmune arthritis. Human gene therapy. 2011; 22(1); 65-76. [PubMed: 20695769].

Atherosclerosis

  1. Chyu et al., 2005: Chyu KY, Zhao X, Reyes OS, Babbidge SM, Dimayuga PC, Yano J, Cercek B, Fredrikson GN, Nilsson J, Shah PK. Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice. Biochemical and biophysical research communications. 2005; 338(4); 1982-1989. [PubMed: 16288717].
  2. Fredrikson et al., 2005: Fredrikson GN, Andersson L, Söderberg I, Dimayuga P, Chyu KY, Shah PK, Nilsson J. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity. 2005; 38(2); 171-179. [PubMed: 16040338].
  3. Jan et al., 2010: Jan M, Meng S, Chen NC, Mai J, Wang H, Yang XF. Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics. Journal of biomedicine & biotechnology. 2010; 2010; 459798. [PubMed: 20414374].

Avian Encephalomyelitis Virus

  1. AE-Poxine: AE-Poxine vaccine website [https://online.zoetis.com/US/EN/Products/Pages/AE_Poxine.aspx]
  2. Calneck, B. W., 2003: Bruce N. Calneck. Avian Encephalomyelitis. 271-281. Diseases of poultry, 11th ed. 2003. Iowa State University Press, Ames, IA.
  3. Marvil et al., 1999: Marvil P, Knowles NJ, Mockett AP, Britton P, Brown TD, Cavanagh D. Avian encephalomyelitis virus is a picornavirus and is most closely related to hepatitis A virus. The Journal of general virology. 1999; 80 ( Pt 3); 653-662. [PubMed: 10092005].

Avian Paramyxovirus

  1. Beck et al., 2003: Beck I, Gerlach H, Burkhardt E, Kaleta EF. Investigation of several selected adjuvants regarding their efficacy and side effects for the production of a vaccine for parakeets to prevent a disease caused by a paramyxovirus type 3. Vaccine. 2003; 21(9-10); 1006-1022. [PubMed: 12547615].
  2. Wiki: Avain paramyxovirus: Wiki: Avain paramyxovirus [http://en.wikipedia.org/wiki/Avian_paramyxovirus]

Avian pneumovirus

  1. Kapczynski and Sellers, 2003: Kapczynski DR, Sellers HS. Immunization of turkeys with a DNA vaccine expressing either the F or N gene of avian metapneumovirus. Avian diseases. 2003; 47(4); 1376-1383. [PubMed: 14708985].
  2. Merck Vet Manual: Avian Pneumovirus: Merck Vet Manual: Avian Pneumovirus [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/206300.htm]

Avian Polyomavirus

  1. Merck Vet Manual: Avian Polyomavirus: Merck Vet Manual: Avian Polyomavirus [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/170221.htm]

Avian Reovirus

  1. Avian Reovirus Infections: Avian Reovirus Infections [http://www.thepoultrysite.com/articles/96/avian-reovirus-infections]
  2. Wan et al., 2011: Wan J, Wang C, Wen X, Huang X, Ling S, Huang Y, Cao S. Immunogenicity of a DNA vaccine of Avian Reovirus orally delivered by attenuated Salmonella typhimurium. Research in veterinary science. 2011; 91(3); 382-383. [PubMed: 20947110].
  3. Wan et al., 2012: Wan J, Wen X, Huang X, Tang Y, Huang Y, Yan Q, Zhao Q, Cao S. Immunogenic analysis of two DNA vaccines of avian reovirus mediated by attenuated Salmonella typhimurium in chickens. Veterinary immunology and immunopathology. 2012; 147(3-4); 154-160. [PubMed: 22575372].

Babesia bovis

  1. Brown et al., 1993: Brown WC, Palmer GH, McElwain TF, Hines SA, Dobbelaere DA. Babesia bovis: characterization of the T helper cell response against the 42-kDa merozoite surface antigen (MSA-1) in cattle. Experimental parasitology. 1993; 77(1); 97-9110. [PubMed: 8344411].
  2. Brown et al., 1996: Brown WC, McElwain TF, Ruef BJ, Suarez CE, Shkap V, Chitko-McKown CG, Tuo W, Rice-Ficht AC, Palmer GH. Babesia bovis rhoptry-associated protein 1 is immunodominant for T helper cells of immune cattle and contains T-cell epitopes conserved among geographically distant B. bovis strains. Infection and immunity. 1996; 64(8); 3341-3350. [PubMed: 8757873].
  3. de and Combrink, 2006: de Waal DT, Combrink MP. Live vaccines against bovine babesiosis. Veterinary parasitology. 2006; 138(1-2); 88-96. [PubMed: 16504404].
  4. Norimine et al., 2004: Norimine J, Mosqueda J, Palmer GH, Lewin HA, Brown WC. Conservation of Babesia bovis small heat shock protein (Hsp20) among strains and definition of T helper cell epitopes recognized by cattle with diverse major histocompatibility complex class II haplotypes. Infection and immunity. 2004; 72(2); 1096-1106. [PubMed: 14742557].
  5. Wiki: Babesia bovis: Babesia bovis [http://en.wikipedia.org/wiki/Babesia_bovis]
  6. Wright et al., 1992: Wright IG, Casu R, Commins MA, Dalrymple BP, Gale KR, Goodger BV, Riddles PW, Waltisbuhl DJ, Abetz I, Berrie DA. The development of a recombinant Babesia vaccine. Veterinary parasitology. 1992; 44(1-2); 3-13. [PubMed: 1441189].

Babesia canis

  1. Moreau et al., 1989: Moreau Y, Vidor E, Bissuel G, Dubreuil N. Vaccination against canine babesiosis: an overview of field observations. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1989; 83 Suppl; 95-96. [PubMed: 2623757].
  2. Pet Education.com: Babesia canis: Babesia canis: The Cause of Piroplasmosis [http://www.peteducation.com/article.cfm?c=2+2101&aid=720]

Bacillus anthracis

  1. Bielinska et al., 2007: Bielinska AU, Janczak KW, Landers JJ, Makidon P, Sower LE, Peterson JW, Baker JR Jr. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infection and immunity. 2007; 75(8); 4020-4029. [PubMed: 17502384].
  2. Brey, 2005: Brey RN. Molecular basis for improved anthrax vaccines. Advanced drug delivery reviews. 2005 Jun 17; 57(9); 1266-92. [PubMed: 15935874].
  3. CDC, 2000: Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) [http://www.cdc.gov/mmwr/PDF/rr/rr4915.pdf]
  4. Chabot et al., 2004: Chabot DJ, Scorpio A, Tobery SA, Little SF, Norris SL, Friedlander AM. Anthrax capsule vaccine protects against experimental infection. Vaccine. 2004 Nov 15; 23(1); 43-7. [PubMed: 15519706].
  5. Chekanov et al., 2006: Chekanov AV, Remacle AG, Golubkov VS, Akatov VS, Sikora S, Savinov AY, Fugere M, Day R, Rozanov DV, Strongin AY. Both PA63 and PA83 are endocytosed within an anthrax protective antigen mixed heptamer: a putative mechanism to overcome a furin deficiency. Archives of biochemistry and biophysics. 2006 Feb 1; 446(1); 52-9. [PubMed: 16384550].
  6. Chitlaru et al., 2007: Chitlaru T, Gat O, Grosfeld H, Inbar I, Gozlan Y, Shafferman A. Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome. Infection and immunity. 2007; 75(6); 2841-2852. [PubMed: 17353282].
  7. Coeshott et al., 2004: Coeshott CM, Smithson SL, Verderber E, Samaniego A, Blonder JM, Rosenthal GJ, Westerink MA. Pluronic F127-based systemic vaccine delivery systems. Vaccine. 2004 Jun 23; 22(19); 2396-405. [PubMed: 15193401].
  8. Coker et al., 2003: Coker PR, Smith KL, Fellows PF, Rybachuck G, Kousoulas KG, Hugh-Jones ME. Bacillus anthracis virulence in Guinea pigs vaccinated with anthrax vaccine adsorbed is linked to plasmid quantities and clonality. Journal of clinical microbiology. 2003 Mar; 41(3); 1212-8. [PubMed: 12624053].
  9. Cui et al., 2006: Cui Z, Sloat BR. Topical immunization onto mouse skin using a microemulsion incorporated with an anthrax protective antigen protein-encoding plasmid. International journal of pharmaceutics. 2006 Jul 24; 317(2); 187-91. [PubMed: 16730934 ].
  10. FDA: Anthrax Vaccine Adsorbed: FDA: Anthrax Vaccine Adsorbed for Bacillus anthracis [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093863.htm]
  11. Flick-Smith et al., 2002: Flick-Smith HC, Walker NJ, Gibson P, Bullifent H, Hayward S, Miller J, Titball RW, Williamson ED. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infection and immunity. 2002 Mar; 70(3); 1653-6. [PubMed: 11854261].
  12. Galloway et al., 2004: Galloway D, Liner A, Legutki J, Mateczun A, Barnewall R, Estep J. Genetic immunization against anthrax. Vaccine. 2004 Apr 16; 22(13-14); 1604-8. [PubMed: 15068841].
  13. Gat et al., 2005: Gat O, Mendelson I, Chitlaru T, Ariel N, Altboum Z, Levy H, Weiss S, Grosfeld H, Cohen S, Shafferman A. The solute-binding component of a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence determinant. Molecular microbiology. 2005; 58(2); 533-551. [PubMed: 16194238].
  14. Glomski et al., 2007: Glomski IJ, Corre JP, Mock M, Goossens PL. Cutting Edge: IFN-gamma-producing CD4 T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis. Journal of immunology (Baltimore, Md. : 1950). 2007 Mar 1; 178(5); 2646-50. [PubMed: 17312104 ].
  15. Gu et al., 1999: Gu ML, Leppla SH, Klinman DM. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine. 1999 Jan 28; 17(4); 340-4. [PubMed: 9987172].
  16. Hahn et al., 2004: Hahn UK, Alex M, Czerny CP, Bohm R, Beyer W. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination. International journal of medical microbiology : IJMM. 2004 Jul; 294(1); 35-44. [PubMed: 15293452].
  17. Hanna et al., 1999: Hanna PC, Ireland JA. Understanding Bacillus anthracis pathogenesis. Trends in microbiology. 1999 May; 7(5); 180-2. [PubMed: 10383221].
  18. Hermanson et al., 2004: Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, Lalor P, Komai M, Mere R, Bell M, Brenneman K, Mateczun A, Evans T, Kaslow D, Galloway D, Hobart P. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proceedings of the National Academy of Sciences of the United States of America. 2004 Sep 14; 101(37); 13601-6. [PubMed: 15342913].
  19. Hirsh et al, 2004: Hirsh DC, Biberstrein EL.. Bacillus. . 170-174.. Veterinary Microbiology, 2nd Ed.. 2004. Blackwell Publishing, Ames, Iowa...
  20. Ivins et al., 1992: Ivins BE, Welkos SL, Little SF, Crumrine MH, Nelson GO. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infection and immunity. 1992; 60(2); 662-668. [PubMed: 1730501].
  21. Ivins et al., 1995: Ivins B, Fellows P, Pitt L, Estep J, Farchaus J, Friedlander A, Gibbs P. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine. 1995; 13(18); 1779-1784. [PubMed: 8701593].
  22. Klaschik et al., 2007: Klaschik S, Gursel I, Klinman DM. CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis. Molecular immunology. 2007 Feb; 44(6); 1095-104. [PubMed: 16930709].
  23. Klinman et al., 2004: Klinman DM, Xie H, Little SF, Currie D, Ivins BE. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine. 2004 Jul 29; 22(21-22); 2881-6. [PubMed: 15246624 ].
  24. Kutsenko et al., 2002: Kutsenko AS, Gizatullin RZ, Al-Amin AN, Wang F, Kvasha SM, Podowski RM, Matushkin YG, Gyanchandani A, Muravenko OV, Levitsky VG, Kolchanov NA, Protopopov AI, Kashuba VI, Kisselev LL, Wasserman W, Wahlestedt C, Zabarovsky ER. NotI flanking sequences: a tool for gene discovery and verification of the human genome. Nucleic acids research. 2002 Jul 15; 30(14); 3163-70. [PubMed: 12136098].
  25. Leppla et al., 2002: Leppla SH, Robbins JB, Schneerson R, Shiloach J. Development of an improved vaccine for anthrax. The Journal of clinical investigation. 2002 Jul; 110(2); 141-4. [PubMed: 12122102].
  26. Little et al., 1986: Little SF, Knudson GB. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infection and immunity. 1986 May; 52(2); 509-12. [PubMed: 3084385].
  27. Livingston et al., 2010: Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine. 2010; 28(4); 1056-1061. [PubMed: 19896452].
  28. Luxembourg et al., 2008: Luxembourg A, Hannaman D, Nolan E, Ellefsen B, Nakamura G, Chau L, Tellez O, Little S, Bernard R. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine. 2008; 26(40); 5216-5222. [PubMed: 18462850].
  29. McConnell et al., 2006: McConnell MJ, Hanna PC, Imperiale MJ. Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4. Infection and immunity. 2006; 74(2); 1009-1015. [PubMed: 16428747].
  30. Midha and Bhatnagar, 2009: Midha S, Bhatnagar R. Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses. European journal of immunology. 2009; 39(1); 159-177. [PubMed: 19130551].
  31. PathPort: Virginia Bioinformatics Institute [http://pathport.vbi.vt.edu/pathinfo/pathogens/Bacillus-anthracis_Info.shtml]
  32. Pittman et al., 2006: Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT Jr. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine. 2006 Apr 24; 24(17); 3654-60. [PubMed: 16497418].
  33. Price et al., 2001: Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infection and immunity. 2001 Jul; 69(7); 4509-15. [PubMed: 11401993].
  34. Rhie et al., 2003: Rhie GE, Roehrl MH, Mourez M, Collier RJ, Mekalanos JJ, Wang JY. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proceedings of the National Academy of Sciences of the United States of America. 2003 Sep 16; 100(19); 10925-30. [PubMed: 12960361].
  35. Rhie et al., 2005: Rhie GE, Park YM, Chun JH, Yoo CK, Seong WK, Oh HB. Expression and secretion of the protective antigen of Bacillus anthracis in Bacillus brevis. FEMS immunology and medical microbiology. 2005; 45(2); 331-339. [PubMed: 16009541].
  36. Ribeiro et al., 2007: Ribeiro S, Rijpkema SG, Durrani Z, Florence AT. PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice. International journal of pharmaceutics. 2007; 331(2); 228-232. [PubMed: 17258876].
  37. Ribot et al., 2006: Ribot WJ, Powell BS, Ivins BE, Little SF, Johnson WM, Hoover TA, Norris SL, Adamovicz JJ, Friedlander AM, Andrews GP. Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits. Vaccine. 2006 Apr 24; 24(17); 3469-76. [PubMed: 16519970].
  38. Riemenschneider et al., 2003: Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, Custer D, Bray M, Ruff A, Ivins B, Bassett A, Rossi C, Schmaljohn C. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003; 21(25-26); 4071-4080. [PubMed: 12922144].
  39. Schneerson et al., 2003: Schneerson R, Kubler-Kielb J, Liu TY, Dai ZD, Leppla SH, Yergey A, Backlund P, Shiloach J, Majadly F, Robbins JB. Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proceedings of the National Academy of Sciences of the United States of America. 2003 Jul 22; 100(15); 8945-50. [PubMed: 12857944].
  40. Sloat and Cui, 2006: Sloat BR, Cui Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharmaceutical research. 2006; 23(6); 1217-1226. [PubMed: 16718616].
  41. Smith et al., 2006: Smith ME, Koser M, Xiao S, Siler C, McGettigan JP, Calkins C, Pomerantz RJ, Dietzschold B, Schnell MJ. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology. 2006 Sep 30; 353(2); 344-56. [PubMed: 16820183].
  42. Spore vaccine: Anthrax Spore Vaccine [http://www.atozvetsupply.com/Anthrax-Vaccine-p/313-csav.htm]
  43. Tucker et al., 2003: Tucker SN, Lin K, Stevens S, Scollay R, Bennett MJ, Olson DC. Systemic and mucosal antibody responses following retroductal gene transfer to the salivary gland. Molecular therapy : the journal of the American Society of Gene Therapy. 2003; 8(3); 392-399. [PubMed: 12946312].
  44. Vilalta et al., 2005: Vilalta A, Mahajan RK, Hartikka J, Leamy V, Martin T, Rusalov D, Bozoukova V, Lalor P, Hall K, Kaslow DC, Rolland A. II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential. Human gene therapy. 2005; 16(10); 1151-1156. [PubMed: 16218776].
  45. Wang et al., 2004: Wang TT, Fellows PF, Leighton TJ, Lucas AH. Induction of opsonic antibodies to the gamma-D-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate. FEMS immunology and medical microbiology. 2004 Apr 9; 40(3); 231-7. [PubMed: 15039099].
  46. Xie et al., 2005: Xie H, Gursel I, Ivins BE, Singh M, O'Hagan DT, Ulmer JB, Klinman DM. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infection and immunity. 2005 Feb; 73(2); 828-33. [PubMed: 15664922].

Bluetongue virus

  1. Maclachlan et al., 2009: Maclachlan NJ, Drew CP, Darpel KE, Worwa G. The pathology and pathogenesis of bluetongue. Journal of comparative pathology. 2009; 141(1); 1-16. [PubMed: 19476953].
  2. Wiki: Bluetongue: Wiki: Bluetongue [http://en.wikipedia.org/wiki/Bluetongue]

Bordetella avium

  1. HealthGene Corp: Bordetella avium: D417 - Bordetella avium [http://www.healthgene.com/avian/d417.asp]
  2. Jackwood and Saif, 1985: Jackwood MW, Saif YM. Efficacy of a commercial turkey coryza vaccine (Art-Vax) in turkey poults. Avian diseases. 1985; 29(4); 1130-1139. [PubMed: 3833219].

Bordetella bronchiseptica

  1. Goodnow, 1980: Goodnow RA. Biology of Bordetella bronchiseptica. Microbiological reviews. 1980; 44(4); 722-738. [PubMed: 7010115].
  2. Mann et al., 2007: Mann P, Goebel E, Barbarich J, Pilione M, Kennett M, Harvill E. Use of a genetically defined double mutant strain of Bordetella bronchiseptica lacking adenylate cyclase and type III secretion as a live vaccine. Infection and immunity. 2007; 75(7); 3665-3672. [PubMed: 17452472].
  3. Mattoo et al., 2001: Mattoo S, Foreman-Wykert AK, Cotter PA, Miller JF. Mechanisms of Bordetella pathogenesis. Frontiers in bioscience : a journal and virtual library. 2001; 6; E168-186. [PubMed: 11689354].
  4. McArthur et al., 2003: McArthur JD, West NP, Cole JN, Jungnitz H, Guzmán CA, Chin J, Lehrbach PR, Djordjevic SP, Walker MJ. An aromatic amino acid auxotrophic mutant of Bordetella bronchiseptica is attenuated and immunogenic in a mouse model of infection. FEMS microbiology letters. 2003; 221(1); 7-16. [PubMed: 12694904].
  5. Nagano et al., 1988: Nagano H, Nakai T, Horiguchi Y, Kume K. Isolation and characterization of mutant strains of Bordetella bronchiseptica lacking dermonecrotic toxin-producing ability. Journal of clinical microbiology. 1988; 26(10); 1983-1987. [PubMed: 3182989].
  6. Register et al., 2007: Register KB, Sacco RE, Brockmeier SL. Immune response in mice and swine to DNA vaccines derived from the Pasteurella multocida toxin gene. Vaccine. 2007; 25(32); 6118-6128. [PubMed: 17590484].
  7. Scheiblhofer et al., 2003: Scheiblhofer S, Weiss R, Dürnberger H, Mostböck S, Breitenbach M, Livey I, Thalhamer J. A DNA vaccine encoding the outer surface protein C from Borrelia burgdorferi is able to induce protective immune responses. Microbes and infection / Institut Pasteur. 2003; 5(11); 939-946. [PubMed: 12941385].
  8. Stevenson and Roberts, 2002: Stevenson A, Roberts M. Use of a rationally attenuated Bordetella bronchiseptica as a live mucosal vaccine and vector for heterologous antigens. Vaccine. 2002; 20(17-18); 2325-2335. [PubMed: 12009288].

Bordetella pertussis

  1. Bruss and Siber, 2002: Bruss JB, Siber GR. Quantitative priming with inactivated pertussis toxoid vaccine in the aerosol challenge model. Infection and immunity. 2002; 70(8); 4600-4608. [PubMed: 12117973].
  2. Cainelli et al., 2007: Cainelli Gebara VC, Risoléo L, Lopes AP, Ferreira VR, Quintilio W, Lépine F, Silva WD, Raw I. Adjuvant and immunogenic activities of the 73kDa N-terminal alpha-domain of BrkA autotransporter and Cpn60/60kDa chaperonin of Bordetella pertussis. Vaccine. 2007; 25(4); 621-629. [PubMed: 17011680].
  3. Chen et al., 1998: Chen I, Finn TM, Yanqing L, Guoming Q, Rappuoli R, Pizza M. A recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor. Infection and immunity. 1998; 66(4); 1648-1653. [PubMed: 9529093].
  4. FDA: Adacel: FDA: Adacel [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172481.htm]
  5. FDA: Boostrix: FDA: Boostrix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172925.htm]
  6. FDA: DAPTACEL: FDA: DAPTACEL [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101572.htm]
  7. FDA: Infanrix: FDA: Infanrix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101568.htm]
  8. FDA: Pediarix: FDA: Pediarix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm146759.htm]
  9. FDA: Pentacel: FDA: Pentacel [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172502.htm]
  10. FDA: Tripedia: FDA: Tripedia [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101565.htm]
  11. Fennelly et al., 2008: Fennelly NK, Sisti F, Higgins SC, Ross PJ, van der Heide H, Mooi FR, Boyd A, Mills KH. Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infection and immunity. 2008; 76(3); 1257-1266. [PubMed: 18195025].
  12. Feunou et al., 2008: Feunou PF, Ismaili J, Debrie AS, Huot L, Hot D, Raze D, Lemoine Y, Locht C. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine. 2008; 26(45); 5722-5727. [PubMed: 18762220].
  13. Guiso et al., 1989: Guiso N, Rocancourt M, Szatanik M, Alonso JM. Bordetella adenylate cyclase is a virulence associated factor and an immunoprotective antigen. Microbial pathogenesis. 1989; 7(5); 373-380. [PubMed: 2622329].
  14. Kamachi et al., 2003: Kamachi K, Konda T, Arakawa Y. DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice. Vaccine. 2003; 21(31); 4609-4615. [PubMed: 14575775].
  15. Kinnear et al., 2001: Kinnear SM, Marques RR, Carbonetti NH. Differential regulation of Bvg-activated virulence factors plays a role in Bordetella pertussis pathogenicity. Infection and immunity. 2001; 69(4); 1983-1993. [PubMed: 11254549].
  16. Komatsu et al., 2010: Komatsu E, Yamaguchi F, Abe A, Weiss AA, Watanabe M. Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model. Clinical and vaccine immunology : CVI. 2010; 17(5); 807-812. [PubMed: 20357056].
  17. Merkel et al., 1998: Merkel TJ, Stibitz S, Keith JM, Leef M, Shahin R. Contribution of regulation by the bvg locus to respiratory infection of mice by Bordetella pertussis. Infection and immunity. 1998; 66(9); 4367-4373. [PubMed: 9712789].
  18. Mielcarek et al., 2006: Mielcarek N, Debrie AS, Raze D, Quatannens J, Engle J, Goldman WE, Locht C. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation. Vaccine. 2006; 24 Suppl 2; S2-54-5. [PubMed: 16823926].
  19. Novotny et al., 1985: Novotny P, Chubb AP, Cownley K, Montaraz JA, Beesley JE. Bordetella adenylate cyclase: a genus specific protective antigen and virulence factor. Developments in biological standardization. 1985; 61; 27-41. [PubMed: 2872113].
  20. Novotny et al., 1991: Novotny P, Chubb AP, Cownley K, Charles IG. Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine. The Journal of infectious diseases. 1991; 164(1); 114-122. [PubMed: 2056199].
  21. Roberts et al., 1990: Roberts M, Maskell D, Novotny P, Dougan G. Construction and characterization in vivo of Bordetella pertussis aroA mutants. Infection and immunity. 1990; 58(3); 732-739. [PubMed: 2407655].
  22. Salyers and Whitt., 2002: Abigail A. Salyers, Dixie D. Whitt. Bordetella pertussis. 263-73. Bacterial Pathogenesis: A Molecular Approach. 2002. ASM Press, Washington D.C. USA.
  23. Sato and Sato, 1984: Sato H, Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infection and immunity. 1984; 46(2); 415-421. [PubMed: 6542069].
  24. Sukumar et al., 2007: Sukumar N, Mishra M, Sloan GP, Ogi T, Deora R. Differential Bvg phase-dependent regulation and combinatorial role in pathogenesis of two Bordetella paralogs, BipA and BcfA. Journal of bacteriology. 2007; 189(10); 3695-3704. [PubMed: 17351043].
  25. Wiki: Bordetella pertussis: Bordetella pertussis [http://en.wikipedia.org/wiki/Bordetella_pertussis]

Borrelia burgdorferi

  1. Hanson et al., 1998: Hanson MS, Cassatt DR, Guo BP, Patel NK, McCarthy MP, Dorward DW, Höök M. Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infection and immunity. 1998; 66(5); 2143-2153. [PubMed: 9573101].
  2. Hanson et al., 2000: Hanson MS, Patel NK, Cassatt DR, Ulbrandt ND. Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of lyme borreliosis. Infection and immunity. 2000; 68(11); 6457-6460. [PubMed: 11035759].
  3. Luke et al., 1997: Luke CJ, Carner K, Liang X, Barbour AG. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. The Journal of infectious diseases. 1997; 175(1); 91-97. [PubMed: 8985201].
  4. Probert and LeFebvre, 1994: Probert WS, LeFebvre RB. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infection and immunity. 1994; 62(5); 1920-1926. [PubMed: 8168958].
  5. Sadziene et al., 1996: Sadziene A, Thompson PA, Barbour AG. A flagella-less mutant of Borrelia burgdorferi as a live attenuated vaccine in the murine model of Lyme disease. The Journal of infectious diseases. 1996; 173(5); 1184-1193. [PubMed: 8627071].
  6. Salyers and Whitt., 2002: Abigail A. Salyers, Dixie D. Whitt. The Spirochetes: Borrelia burgdorferi and Treponema pallidum. 187-199. Bacterial Pathogenesis: A Molecular Approach. 2002. ASM Press, Washington D.C. USA.
  7. Scheiblhofer et al., 2003: Scheiblhofer S, Weiss R, Dürnberger H, Mostböck S, Breitenbach M, Livey I, Thalhamer J. A DNA vaccine encoding the outer surface protein C from Borrelia burgdorferi is able to induce protective immune responses. Microbes and infection / Institut Pasteur. 2003; 5(11); 939-946. [PubMed: 12941385].
  8. Weiss et al., 1999: Weiss R, Dürnberger J, Mostböck S, Scheiblhofer S, Hartl A, Breitenbach M, Strasser P, Dorner F, Livey I, Crowe B, Thalhamer J. Improvement of the immune response against plasmid DNA encoding OspC of Borrelia by an ER-targeting leader sequence. Vaccine. 1999; 18(9-10); 815-824. [PubMed: 10580194].
  9. Wiki: B. burgdorferi: Wiki: Borrelia burgdorferi [http://en.wikipedia.org/wiki/Borrelia_burgdorferi]

Bovine coronavirus

  1. Liu et al., 2006: Liu L, Hägglund S, Hakhverdyan M, Alenius S, Larsen LE, Belák S. Molecular epidemiology of bovine coronavirus on the basis of comparative analyses of the S gene. Journal of clinical microbiology. 2006; 44(3); 957-960. [PubMed: 16517883].

Bovine herpesvirus 1

  1. Babiuk et al., 1987: Babiuk LA, L'Italien J, van Drunen Littel-van den Hurk S, Zamb T, Lawman JP, Hughes G, Gifford GA. Protection of cattle from bovine herpesvirus type I (BHV-1) infection by immunization with individual viral glycoproteins. Virology. 1987; 159(1); 57-66. [PubMed: 3037783].
  2. Caselli et al., 2005: Caselli E, Boni M, Di Luca D, Salvatori D, Vita A, Cassai E. A combined bovine herpesvirus 1 gB-gD DNA vaccine induces immune response in mice. Comparative immunology, microbiology and infectious diseases. 2005; 28(2); 155-166. [PubMed: 15582691].
  3. Castrucci et al., 2004: Castrucci G, Ferrari M, Marchini C, Salvatori D, Provinciali M, Tosini A, Petrini S, Sardonini Q, Lo Dico M, Frigeri F, Amici A. Immunization against bovine herpesvirus-1 infection. Preliminary tests in calves with a DNA vaccine. Comparative immunology, microbiology and infectious diseases. 2004; 27(3); 171-179. [PubMed: 15001312].
  4. Cox et al., 1993: Cox GJ, Zamb TJ, Babiuk LA. Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. Journal of virology. 1993; 67(9); 5664-5667. [PubMed: 8350420].
  5. Deshpande et al., 2002: Deshpande MS, Ambagala TC, Hegde NR, Hariharan MJ, Navaratnam M, Srikumaran S. Induction of cytotoxic T-lymphocytes specific for bovine herpesvirus-1 by DNA immunization. Vaccine. 2002; 20(31-32); 3744-3751. [PubMed: 12399204].
  6. Gao et al., 1994: Gao Y, Leary TP, Eskra L, Splitter GA. Truncated bovine herpesvirus-1 glycoprotein I (gpI) initiates a protective local immune response in its natural host. Vaccine. 1994; 12(2); 145-152. [PubMed: 8147097].
  7. Gogev et al., 2002: Gogev S, Vanderheijden N, Lemaire M, Schynts F, D'Offay J, Deprez I, Adam M, Eloit M, Thiry E. Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal administration of replication-defective human adenovirus type 5 expressing glycoprotein gC or gD. Vaccine. 2002; 20(9-10); 1451-1465. [PubMed: 11818166].
  8. Gupta et al., 2001: Gupta PK, Saini M, Gupta LK, Rao VD, Bandyopadhyay SK, Butchaiah G, Garg GK, Garg SK. Induction of immune responses in cattle with a DNA vaccine encoding glycoprotein C of bovine herpesvirus-1. Veterinary microbiology. 2001; 78(4); 293-305. [PubMed: 11182496].
  9. Huang et al., 2005: Huang Y, Babiuk LA, van Drunen Littel-van den Hurk S. Immunization with a bovine herpesvirus 1 glycoprotein B DNA vaccine induces cytotoxic T-lymphocyte responses in mice and cattle. The Journal of general virology. 2005; 86(Pt 4); 887-898. [PubMed: 15784883].
  10. Kaashoek et al., 1994: Kaashoek MJ, Moerman A, Madić J, Rijsewijk FA, Quak J, Gielkens AL, van Oirschot JT. A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine. Vaccine. 1994; 12(5); 439-444. [PubMed: 8023552].
  11. Kaashoek et al., 1995: Kaashoek MJ, Moerman A, Madić J, Weerdmeester K, Maris-Veldhuis M, Rijsewijk FA, van Oirschot JT. An inactivated vaccine based on a glycoprotein E-negative strain of bovine herpesvirus 1 induces protective immunity and allows serological differentiation. Vaccine. 1995; 13(4); 342-346. [PubMed: 7793128].
  12. Kaashoek et al., 1998: Kaashoek MJ, Rijsewijk FA, Ruuls RC, Keil GM, Thiry E, Pastoret PP, Van Oirschot JT. Virulence, immunogenicity and reactivation of bovine herpesvirus 1 mutants with a deletion in the gC, gG, gI, gE, or in both the gI and gE gene. Vaccine. 1998; 16(8); 802-809. [PubMed: 9627937].
  13. Khattar et al., 2010: Khattar SK, Collins PL, Samal SK. Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine. 2010; 28(18); 3159-3170. [PubMed: 20189484].
  14. Kit et al., 1985: Kit S, Qavi H, Gaines JD, Billingsley P, McConnell S. Thymidine kinase-negative bovine herpesvirus type 1 mutant is stable and highly attenuated in calves. Archives of virology. 1985; 86(1-2); 63-83. [PubMed: 2994602].
  15. Langellotti et al., 2011: Langellotti CA, Pappalardo JS, Quattrocchi V, Mongini C, Zamorano P. Induction of specific cytotoxic activity for bovine herpesvirus-1 by DNA immunization with different adjuvants. Antiviral research. 2011; 90(3); 134-142. [PubMed: 21443903].
  16. Petrini et al., 2011: Petrini S, Ramadori G, Corradi A, Borghetti P, Lombardi G, Villa R, Bottarelli E, Guercio A, Amici A, Ferrari M. Evaluation of safety and efficacy of DNA vaccines against bovine herpesvirus-1 (BoHV-1) in calves. Comparative immunology, microbiology and infectious diseases. 2011; 34(1); 3-10. [PubMed: 19906427].
  17. Pontarollo et al., 2002: Pontarollo RA, Babiuk LA, Hecker R, Van Drunen Littel-Van Den Hurk S. Augmentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by vaccination with CpG-enhanced plasmid vectors. The Journal of general virology. 2002; 83(Pt 12); 2973-2981. [PubMed: 12466473].
  18. Schrijver et al., 1997: Schrijver RS, Langedijk JP, Keil GM, Middel WG, Maris-Veldhuis M, Van Oirschot JT, Rijsewijk FA. Immunization of cattle with a BHV1 vector vaccine or a DNA vaccine both coding for the G protein of BRSV. Vaccine. 1997; 15(17-18); 1908-1916. [PubMed: 9413101].
  19. van et al., 1996: van Oirschot JT, Kaashoek MJ, Rijsewijk FA. Advances in the development and evaluation of bovine herpesvirus 1 vaccines. Veterinary microbiology. 1996; 53(1-2); 43-54. [PubMed: 9010997].
  20. van et al., 1997: van Drunen Littel-van den Hurk S, Tikoo SK, van den Hurk JV, Babiuk LA, Van Donkersgoed J. Protective immunity in cattle following vaccination with conventional and marker bovine herpesvirus-1 (BHV1) vaccines. Vaccine. 1997; 15(1); 36-44. [PubMed: 9041664].
  21. Wiki: Bovine herpesvirus 1: Bovine herpesvirus 1 [http://en.wikipedia.org/wiki/Bovine_herpesvirus_1]
  22. Zheng et al., 2005: Zheng C, Babiuk LA, van Drunen Littel-van den Hurk S. Bovine herpesvirus 1 VP22 enhances the efficacy of a DNA vaccine in cattle. Journal of virology. 2005; 79(3); 1948-1953. [PubMed: 15650221].

Bovine Leukemia virus

  1. Brillowska et al., 1999: Brillowska A, Dabrowski S, Rułka J, Kubiś P, Buzała E, Kur J. Protection of cattle against bovine leukemia virus (BLV) infection could be attained by DNA vaccination. Acta biochimica Polonica. 1999; 46(4); 971-976. [PubMed: 10824867].
  2. Usui et al., 2003: Usui T, Konnai S, Tajima S, Watarai S, Aida Y, Ohashi K, Onuma M. Protective effects of vaccination with bovine leukemia virus (BLV) Tax DNA against BLV infection in sheep. The Journal of veterinary medical science / the Japanese Society of Veterinary Science. 2003; 65(11); 1201-1205. [PubMed: 14665749].
  3. Wiki: Bovine leukemia virus: Bovine leukemia virus [http://en.wikipedia.org/wiki/Bovine_leukemia_virus]

Bovine papillomavirus

  1. Wiki: Bovine papillomavirus: Wiki: Bovine papillomavirus [http://en.wikipedia.org/wiki/Bovine_papillomavirus]

Bovine Parainfluenza 3 Virus (BPIV-3)

  1. Merck Vet Manual: Parainfluenza-3 Virus: Merck Veterinary Manual: Parainfluenza-3 Virus [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/121210.htm]

Bovine Respiratory Syncytial Virus

  1. Merck Vet Manual: BRSV: Merck Veterinary Manual-Bovine Respiratory Syncytial Virus [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/121211.htm]
  2. Schmidt et al., 2002: Schmidt U, Beyer J, Polster U, Gershwin LJ, Buchholz UJ. Mucosal immunization with live recombinant bovine respiratory syncytial virus (BRSV) and recombinant BRSV lacking the envelope glycoprotein G protects against challenge with wild-type BRSV. Journal of virology. 2002; 76(23); 12355-12359. [PubMed: 12414977].
  3. Schrijver et al., 1997: Schrijver RS, Langedijk JP, Keil GM, Middel WG, Maris-Veldhuis M, Van Oirschot JT, Rijsewijk FA. Immunization of cattle with a BHV1 vector vaccine or a DNA vaccine both coding for the G protein of BRSV. Vaccine. 1997; 15(17-18); 1908-1916. [PubMed: 9413101].
  4. Taylor et al., 2005: Taylor G, Bruce C, Barbet AF, Wyld SG, Thomas LH. DNA vaccination against respiratory syncytial virus in young calves. Vaccine. 2005; 23(10); 1242-1250. [PubMed: 15652666].

Bovine viral diarrhea virus 1

  1. Beer et al., 2000: Beer M, Hehnen HR, Wolfmeyer A, Poll G, Kaaden OR, Wolf G. A new inactivated BVDV genotype I and II vaccine. An immunisation and challenge study with BVDV genotype I. Veterinary microbiology. 2000; 77(1-2); 195-208. [PubMed: 11042413].
  2. Merck Vet Manual: Bovine Viral Diarrhea: Merck Vet Manual: Bovine Viral Diarrhea and Mucosal Disease Complex [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/22103.htm]
  3. Petrini et al., 2011: Petrini S, Ramadori G, Corradi A, Borghetti P, Lombardi G, Villa R, Bottarelli E, Guercio A, Amici A, Ferrari M. Evaluation of safety and efficacy of DNA vaccines against bovine herpesvirus-1 (BoHV-1) in calves. Comparative immunology, microbiology and infectious diseases. 2011; 34(1); 3-10. [PubMed: 19906427].

Bovine viral diarrhea virus 2

  1. Liang et al., 2008: Liang R, van den Hurk JV, Landi A, Lawman Z, Deregt D, Townsend H, Babiuk LA, van Drunen Littel-van den Hurk S. DNA prime protein boost strategies protect cattle from bovine viral diarrhea virus type 2 challenge. The Journal of general virology. 2008; 89(Pt 2); 453-466. [PubMed: 18198376].
  2. Merck Vet Manual: Bovine Viral Diarrhea: Merck Vet Manual: Bovine Viral Diarrhea and Mucosal Disease Complex [http://www.merckmanuals.com/vet/digestive_system/intestinal_diseases_in_ruminants/intestinal_diseases_in_cattle.html#v3263133?qt=&sc=&alt=]
  3. van et al., 2013: van Drunen Littel-van den Hurk S, Lawman Z, Snider M, Wilson D, van den Hurk JV, Ellefsen B, Hannaman D. Two doses of bovine viral diarrhea virus DNA vaccine delivered by electroporation induce long-term protective immune responses. Clinical and vaccine immunology : CVI. 2013; 20(2); 166-173. [PubMed: 23220999].

Brucella spp.

  1. Abtahi et al., 2008: Abtahi H, Salmanian AH, Rafati S, Nejad GB, Saffari M, Ghazavi A, Mosayebi G. The profile of cytokines and IgG subclasses in BALB/c mice after immunization with Brucella ribosomal gene. Pakistan journal of biological sciences: PJBS. 2008; 11(21); 2472-2477. [PubMed: 19205266].
  2. Adone et al., 2005: Adone R, Ciuchini F, Marianelli C, Tarantino M, Pistoia C, Marcon G, Petrucci P, Francia M, Riccardi G, Pasquali P. Protective properties of rifampin-resistant rough mutants of Brucella melitensis. Infection and immunity. 2005; 73(7); 4198-4204. [PubMed: 15972510].
  3. Al-Mariri et al., 2001: Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J, Walravens K, Letesson JJ. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infection and immunity. 2001 Aug; 69(8); 4816-22. [PubMed: 11447155 ].
  4. Al-Mariri et al., 2001: Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godfroid J, Walravens K, Letesson JJ. Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp. Infection and immunity. 2001; 69(10); 6264-6270. [PubMed: 11553569].
  5. Al-Mariri et al., 2002: Al-Mariri A, Tibor A, Lestrate P, Mertens P, De Bolle X, Letesson JJ. Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infection and immunity. 2002; 70(4); 1915-1923. [PubMed: 11895955].
  6. Arenas-Gamboa et al., 2008: Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Rice-Ficht AC. Immunization with a Single Dose of a Microencapsulated Brucella melitensis Mutant Enhances Protection Against Wild-type Challenge. Infection and immunity. 2008; ; . [PubMed: 18362129].
  7. Arenas-Gamboa et al., 2009: Arenas-Gamboa AM, Ficht TA, Davis DS, Elzer PH, Wong-Gonzalez A, Rice-Ficht AC. Enhanced immune response of red deer (Cervus elaphus) to live rb51 vaccine strain using composite microspheres. Journal of wildlife diseases. 2009; 45(1); 165-173. [PubMed: 19204345].
  8. Arenas-Gamboa et al., 2009: Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Gomez G, Rice-Ficht AC. The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infection and immunity. 2009; 77(2); 877-884. [PubMed: 19047401].
  9. Arenas-Gamboa et al., 2011: Arenas-Gamboa AM, Rice-Ficht AC, Kahl-McDonagh MM, Ficht TA. The protective efficacy and safety of 16M{Delta}mucR against intraperitoneal and aerosol challenge in BALB/c mice. Infection and immunity. 2011; ; . [PubMed: 21708998].
  10. Banai, 2002: Banai M. Control of small ruminant brucellosis by use of Brucella melitensis Rev.1 vaccine: laboratory aspects and field observations. Veterinary microbiology. 2002 Dec 20; 90(1-4); 497-519. [PubMed: 12414167].
  11. Bhattacharjee et al., 2002: Bhattacharjee AK, Van de Verg L, Izadjoo MJ, Yuan L, Hadfield TL, Zollinger WD, Hoover DL. Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein. Infection and immunity. 2002; 70(7); 3324-3329. [PubMed: 12065469].
  12. Bhattacharjee et al., 2006: Bhattacharjee AK, Izadjoo MJ, Zollinger WD, Nikolich MP, Hoover DL. Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine. Infection and immunity. 2006 Oct; 74(10); 5820-5. [PubMed: 16988260].
  13. Blasco et al., 1993: Blasco JM, Gamazo C, Winter AJ, Jimenez de Bagues MP, Marin C, Barberan M, Moriyon I, Alonso-Urmeneta B, Diaz R. Evaluation of whole cell and subcellular vaccines against Brucella ovis in rams. Veterinary immunology and immunopathology. 1993 Aug; 37(3-4); 257-70. [PubMed: 8236802].
  14. Bosseray, 1991: Bosseray N. Brucella melitensis Rev. 1 living attenuated vaccine: stability of markers, residual virulence and immunogenicity in mice. Biologicals : journal of the International Association of Biological Standardization. 1991 Oct; 19(4); 355-63. [PubMed: 1797046].
  15. Cassataro et al., 2002: Cassataro J, Velikovsky CA, Giambartolomei GH, Estein S, Bruno L, Cloeckaert A, Bowden RA, Spitz M, Fossati CA. Immunogenicity of the Brucella melitensis recombinant ribosome recycling factor-homologous protein and its cDNA. Vaccine. 2002; 20(11-12); 1660-1669. [PubMed: 11858876].
  16. Cassataro et al., 2004: Cassataro J, Pasquevich K, Bruno L, Wallach JC, Fossati CA, Baldi PC. Antibody reactivity to Omp31 from Brucella melitensis in human and animal infections by smooth and rough Brucellae. Clinical and diagnostic laboratory immunology. 2004 Jan; 11(1); 111-4. [PubMed: 14715555].
  17. Cassataro et al., 2005: Cassataro J, Velikovsky CA, de la Barrera S, Estein SM, Bruno L, Bowden R, Pasquevich KA, Fossati CA, Giambartolomei GH. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infection and immunity. 2005 Oct; 73(10); 6537-46. [PubMed: 16177328].
  18. Cassataro et al., 2007: Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Zwerdling A, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA. A DNA vaccine coding for the quimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine. 2007 Jun 12; ; . [PubMed: 17600596].
  19. Cassataro et al., 2007: Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Velikovsky CA, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine. 2007 May 30; 25(22); 4437-46. [PubMed: 17442465].
  20. Cassataro et al., 2007: Cassataro J, Velikovsky CA, Bruno L, Estein SM, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH. Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting. Clinical and vaccine immunology : CVI. 2007; 14(7); 869-874. [PubMed: 17428946].
  21. Cheville, 2000: Cheville NF. Development, testing and commercialization of a new brucellosis vaccine for cattle. Annals of the New York Academy of Sciences. 2000; 916; 147-53. [PubMed: 11193615].
  22. Cloeckaert et al., 2002: Cloeckaert A, Grayon M, Grepinet O. Identification of Brucella melitensis vaccine strain Rev.1 by PCR-RFLP based on a mutation in the rpsL gene. Vaccine. 2002 Jun 7; 20(19-20); 2546-50. [PubMed: 12057611].
  23. Cloeckaert et al., 2004: Cloeckaert A, Jacques I, Grilló MJ, Marín CM, Grayon M, Blasco JM, Verger JM. Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis. Vaccine. 2004; 22(21-22); 2827-2835. [PubMed: 15246618].
  24. Colby et al., 2002: Colby LA, Schurig GG, Elzer PH. An indirect ELISA to detect the serologic response of elk (Cervus elaphus nelsoni) inoculated with Brucella abortus strain RB51. Journal of wildlife diseases. 2002; 38(4); 752-759. [PubMed: 12528442].
  25. Commander et al., 2007: Commander NJ, Spencer SA, Wren BW, MacMillan AP. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Vaccine. 2007; 25(1); 43-54. [PubMed: 17049676].
  26. Cook et al., 2001: Cook WE, Williams ES, Thorne ET, Taylor SK, Anderson S. Safety of Brucella abortus strain RB51 in deer mice. Journal of wildlife diseases. 2001; 37(3); 621-625. [PubMed: 11504238].
  27. Corbel, 1997: Corbel MJ. Recent advances in brucellosis. Journal of medical microbiology. 1997 Feb; 46(2); 101-3. [PubMed: 9060868 ].
  28. Crawford et al., 1996: Crawford RM, Van De Verg L, Yuan L, Hadfield TL, Warren RL, Drazek ES, Houng HH, Hammack C, Sasala K, Polsinelli T, Thompson J, Hoover DL. Deletion of purE attenuates Brucella melitensis infection in mice. Infection and immunity. 1996; 64(6); 2188-2192. [PubMed: 8675325].
  29. Delpino et al., 2007a: Delpino MV, Estein SM, Fossati CA, Baldi PC. Partial protection against Brucella infection in mice by immunization with nonpathogenic alphaproteobacteria. Clinical and vaccine immunology : CVI. 2007; 14(10); 1296-1301. [PubMed: 17715332].
  30. Delpino et al., 2007b: Delpino MV, Estein SM, Fossati CA, Baldi PC, Cassataro J. Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine. 2007; 25(37-38); 6721-6729. [PubMed: 17686554].
  31. Drazek et al., 1995: Drazek ES, Houng HS, Crawford RM, Hadfield TL, Hoover DL, Warren RL. Deletion of purE attenuates Brucella melitensis 16M for growth in human monocyte-derived macrophages. Infection and immunity. 1995; 63(9); 3297-3301. [PubMed: 7642258].
  32. Edmonds et al., 2002: Edmonds MD, Cloeckaert A, Elzer PH. Brucella species lacking the major outer membrane protein Omp25 are attenuated in mice and protect against Brucella melitensis and Brucella ovis. Veterinary microbiology. 2002; 88(3); 205-221. [PubMed: 12151196].
  33. ELBERG and FAUNCE, 1957: ELBERG SS, FAUNCE K Jr. Immunization against Brucella infection. VI. Immunity conferred on goats by a nondependent mutant from a streptomycin-dependent mutant strain of Brucella melitensis. Journal of bacteriology. 1957; 73(2); 211-217. [PubMed: 13416171].
  34. Estein et al., 2003: Estein SM, Cassataro J, Vizcaino N, Zygmunt MS, Cloeckaert A, Bowden RA. The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice. Microbes and infection / Institut Pasteur. 2003 Feb; 5(2); 85-93. [PubMed: 12650766].
  35. Estevan et al., 2006: Estevan M, Gamazo C, Grilló MJ, Del Barrio GG, Blasco JM, Irache JM. Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice. Vaccine. 2006; 24(19); 4179-4187. [PubMed: 16481077].
  36. Fernandes et al., 1996: Fernandes DM, Jiang X, Jung JH, Baldwin CL. Comparison of T cell cytokines in resistant and susceptible mice infected with virulent Brucella abortus strain 2308. FEMS immunology and medical microbiology. 1996 Dec 31; 16(3-4); 193-203. [PubMed: 9116636 ].
  37. Fu et al., 2012: Fu S, Xu J, Li X, Xie Y, Qiu Y, Du X, Yu S, Bai Y, Chen Y, Wang T, Wang Z, Yu Y, Peng G, Huang K, Huang L, Wang Y, Chen Z. Immunization of Mice with Recombinant Protein CobB or AsnC Confers Protection against Brucella abortus Infection. PloS one. 2012; 7(2); e29552. [PubMed: 22383953].
  38. Galindo et al., 2009: Galindo RC, Muñoz PM, de Miguel MJ, Marin CM, Blasco JM, Gortazar C, Kocan KM, de la Fuente J. Characterization of possible correlates of protective response against Brucella ovis infection in rams immunized with the B. melitensis Rev 1 vaccine. Vaccine. 2009; 27(23); 3039-3044. [PubMed: 19428917].
  39. Gee et al., 2005: Gee JM, Valderas MW, Kovach ME, Grippe VK, Robertson GT, Ng WL, Richardson JM, Winkler ME, Roop RM 2nd. The Brucella abortus Cu,Zn superoxide dismutase is required for optimal resistance to oxidative killing by murine macrophages and wild-type virulence in experimentally infected mice. Infection and immunity. 2005 May; 73(5); 2873-80. [PubMed: 15845493].
  40. Geong et al., 2000: Geong M, Robertson ID. Response of Bali cattle (Bos javanicus) to vaccination with Brucella abortus strain 19 in West Timor. Preventive veterinary medicine. 2000 Nov 16; 47(3); 177-86. [PubMed: 11058778].
  41. Goldbaum et al., 1999: Goldbaum FA, Velikovsky CA, Baldi PC, Mortl S, Bacher A, Fossati CA. The 18-kDa cytoplasmic protein of Brucella species --an antigen useful for diagnosis--is a lumazine synthase. Journal of medical microbiology. 1999 Sep; 48(9); 833-9. [PubMed: 10482294 ].
  42. Guilloteau et al., 2006: Guilloteau LA, Laroucau K, Olivier M, Grillo MJ, Marin CM, Verger JM, Blasco JM. Residual virulence and immunogenicity of CGV26 and CGV2631 B. melitensis Rev. 1 deletion mutant strains in sheep after subcutaneous or conjunctival vaccination. Vaccine. 2006; 24(17); 3461-3468. [PubMed: 16519974].
  43. Gupta et al., 2007: Gupta VK, Rout PK, Vihan VS. Induction of immune response in mice with a DNA vaccine encoding outer membrane protein (omp31) of Brucella melitensis 16M. Research in veterinary science. 2007; 82(3); 305-313. [PubMed: 17014873].
  44. Hamdy et al., 2002: Hamdy ME, El-Gibaly SM, Montasser AM. Comparison between immune responses and resistance induced in BALB/c mice vaccinated with RB51 and Rev. 1 vaccines and challenged with Brucella melitensis bv. 3. Veterinary microbiology. 2002; 88(1); 85-94. [PubMed: 12119140].
  45. He et al., 2001: He Y, Vemulapalli R, Zeytun A, Schurig GG. Induction of specific cytotoxic lymphocytes in mice vaccinated with Brucella abortus RB51. Infection and immunity. 2001 Sep; 69(9); 5502-8. [PubMed: 11500423 ].
  46. He et al., 2002: He Y, Vemulapalli R, Schurig GG. Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu,Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type. Infection and immunity. 2002 May; 70(5); 2535-43. [PubMed: 11953393].
  47. Hemmen et al., 1995: Hemmen F, Weynants V, Scarcez T, Letesson JJ, Saman E. Cloning and sequence analysis of a newly identified Brucella abortus gene and serological evaluation of the 17-kilodalton antigen that it encodes. Clinical and diagnostic laboratory immunology. 1995 May; 2(3); 263-7. [PubMed: 7664168 ].
  48. High et al., 2007: High KP, Prasad R, Marion CR, Schurig GG, Boyle SM, Sriranganathan N. Outcome and immune responses after Brucella abortus infection in young adult and aged mice. Biogerontology. 2007; 8(5); 583-593. [PubMed: 17653832].
  49. Hoover et al., 1999: Hoover DL, Crawford RM, Van De Verg LL, Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, Warren RL, Nikolich MP, Hadfield TL. Protection of mice against brucellosis by vaccination with Brucella melitensis WR201(16MDeltapurEK). Infection and immunity. 1999; 67(11); 5877-5884. [PubMed: 10531243].
  50. Hu et al., 2010: Hu XD, Chen ST, Li JY, Yu DH, Yi-Zhang, Cai H. An IL-15 adjuvant enhances the efficacy of a combined DNA vaccine against Brucella by increasing the CD8+ cytotoxic T cell response. Vaccine. 2010; 28(12); 2408-2415. [PubMed: 20064480].
  51. Izadjoo et al., 2004: Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, Hadfield TL, Hoover DL. Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M. Infection and immunity. 2004; 72(7); 4031-4039. [PubMed: 15213148].
  52. Jacques et al., 2007: Jacques I, Verger JM, Laroucau K, Grayon M, Vizcaino N, Peix A, Cortade F, Carreras F, Guilloteau LA. Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep. Vaccine. 2007 Jan 15; 25(5); 794-805. [PubMed: 17070627].
  53. Januszewski et al., 2001: Januszewski MC, Olsen SC, McLean RG, Clark L, Rhyan JC. Experimental infection of nontarget species of rodents and birds with Brucella abortus strain RB51 vaccine. Journal of wildlife diseases. 2001; 37(3); 532-537. [PubMed: 11504226].
  54. Jensen and Halling, 2008: Jensen AE, Halling SM. Effect of polymyxin B and environmental conditions on isolation of Brucella species and the vaccine strain RB51. Comparative immunology, microbiology and infectious diseases. 2008; ; . [PubMed: 18814911].
  55. Jiménez et al., 1994: Jiménez de Bagüés MP, Elzer PH, Jones SM, Blasco JM, Enright FM, Schurig GG, Winter AJ. Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis. Infection and immunity. 1994; 62(11); 4990-4996. [PubMed: 7927779].
  56. Kahl-McDonagh and Ficht, 2006: Kahl-McDonagh MM, Ficht TA. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infection and immunity. 2006; 74(7); 4048-4057. [PubMed: 16790778].
  57. Kahl-McDonagh et al., 2007: Kahl-McDonagh MM, Arenas-Gamboa AM, Ficht TA. Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge. Infection and immunity. 2007; 75(10); 4923-4932. [PubMed: 17664263].
  58. Ko et al., 2002: Ko J, Gendron-Fitzpatrick A, Ficht TA, Splitter GA. Virulence criteria for Brucella abortus strains as determined by interferon regulatory factor 1-deficient mice. Infection and immunity. 2002; 70(12); 7004-7012. [PubMed: 12438380].
  59. Kohler et al., 2002: Kohler S, Foulongne V, Ouahrani-Bettache S, Bourg G, Teyssier J, Ramuz M, Liautard JP. The analysis of the intramacrophagic virulome of Brucella suis deciphers the environment encountered by the pathogen inside the macrophage host cell. Proceedings of the National Academy of Sciences of the United States of America. 2002 Nov 26; 99(24); 15711-6. [PubMed: 12438693 ].
  60. Kurar and Splitter, 1997: Kurar E, Splitter GA. Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response. Vaccine. 1997; 15(17-18); 1851-1857. [PubMed: 9413093].
  61. Laplagne et al., 2004: Laplagne DA, Zylberman V, Ainciart N, Steward MW, Sciutto E, Fossati CA, Goldbaum FA. Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides. Proteins. 2004 Dec 1; 57(4); 820-8. [PubMed: 15390265].
  62. Leclerq et al., 2002: Leclerq S, Harms JS, Rosinha GM, Azevedo V, Oliveira SC. Induction of a th1-type of immune response but not protective immunity by intramuscular DNA immunisation with Brucella abortus GroEL heat-shock gene. Journal of medical microbiology. 2002; 51(1); 20-26. [PubMed: 11803949].
  63. Lee et al., 1999: Lee IK, Olsen SC, Kehrli M, Bolin CA. The adjuvant effect of a single dose of interleukin-12 on murine immune responses to live or killed Brucella abortus strain RB51. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 1999; 63(4); 284-287. [PubMed: 10534009].
  64. Lee et al., 2001: Lee IK, Olsen SC, Bolin CA. Effects of exogenous recombinant interleukin-12 on immune responses and protection against Brucella abortus in a murine model. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 2001; 65(4); 223-228. [PubMed: 11768128].
  65. Letesson et al., 1997: Letesson JJ, Tibor A, van Eynde G, Wansard V, Weynants V, Denoel P, Saman E. Humoral immune responses of Brucella-infected cattle, sheep, and goats to eight purified recombinant Brucella proteins in an indirect enzyme-linked immunosorbent assay. Clinical and diagnostic laboratory immunology. 1997 Sep; 4(5); 556-64. [PubMed: 9302205].
  66. Li, 1991: Li HZ. [A pathohistological study on experimental brucellosis in inbred mice]. Zhonghua bing li xue za zhi Chinese journal of pathology. 1991 Jun; 20(2); 134-6. [PubMed: 1914022 ].
  67. Longo et al., 2009: Longo M, Mallardo K, Montagnaro S, De Martino L, Gallo S, Fusco G, Galiero G, Guarino A, Pagnini U, Iovane G. Shedding of Brucella abortus rough mutant strain RB51 in milk of water buffalo (Bubalus bubalis). Preventive veterinary medicine. 2009; 90(1-2); 113-118. [PubMed: 19362381].
  68. Luo et al., 2006a: Luo DY, Li P, Xing L, Zhao GY, Shi W, Zhang SL, Wang XL. DNA vaccine encoding L7/L12-P39 of Brucella abortus induces protective immunity in BALB/c mice. Chinese medical journal. 2006 Feb 20; 119(4); 331-4. [PubMed: 16537031].
  69. Luo et al., 2006b: Luo D, Ni B, Li P, Shi W, Zhang S, Han Y, Mao L, He Y, Wu Y, Wang X. Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice. Infection and immunity. 2006; 74(5); 2734-2741. [PubMed: 16622210].
  70. Makar et al., 1975: Makar AB, McMartin KE, Palese M, Tephly TR. Formate assay in body fluids: application in methanol poisoning. Biochemical medicine. 1975; 13(2); 117-126. [PubMed: 1].
  71. Mallick et al., 2007: Mallick AI, Singha H, Khan S, Anwar T, Ansari MA, Khalid R, Chaudhuri P, Owais M. Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis. Vaccine. 2007; 25(46); 7873-7884. [PubMed: 17931756].
  72. Martins et al., 2009: Martins H, Garin-Bastuji B, Lima F, Flor L, Pina Fonseca A, Boinas F. Eradication of bovine brucellosis in the Azores, Portugal-Outcome of a 5-year programme (2002-2007) based on test-and-slaughter and RB51 vaccination. Preventive veterinary medicine. 2009; 90(1-2); 80-89. [PubMed: 19439382].
  73. Montaraz et al., 1986: Montaraz JA, Winter AJ. Comparison of living and nonliving vaccines for Brucella abortus in BALB/c mice. Infection and immunity. 1986 Aug; 53(2); 245-51. [PubMed: 3089933 ].
  74. Moriyon et al., 2004: Moriyon I, Grillo MJ, Monreal D, Gonzalez D, Marin C, Lopez-Goni I, Mainar-Jaime RC, Moreno E, Blasco JM. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Veterinary research. 2004 Jan-Feb; 35(1); 1-38. [PubMed: 15099501].
  75. Munoz-Montesino et al., 2004: Munoz-Montesino C, Andrews E, Rivers R, Gonzalez-Smith A, Moraga-Cid G, Folch H, Cespedes S, Onate AA. Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. Infection and immunity. 2004 Apr; 72(4); 2081-7. [PubMed: 15039330].
  76. Nol et al., 2009: Nol P, Olsen SC, Rhyan JC. Experimental infection of Richardson's ground squirrels (Spermophilus richardsonii) with attenuated and virulent strains of Brucella abortus. Journal of wildlife diseases. 2009; 45(1); 189-195. [PubMed: 19204348].
  77. Oliveira et al., 1994: Oliveira SC, Zhu Y, Splitter G. Sequences of the rplJL operon containing the L10 and L7/L12 genes from Brucella abortus. Gene. 1994 Mar 11; 140(1); 137-8. [PubMed: 8125331 ].
  78. Oliveira et al., 1996: Oliveira SC, Splitter GA. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine. 1996 Jul; 14(10); 959-62. [PubMed: 8873388 ].
  79. Olsen et al., 2004: Olsen SC, Rhyan J, Gidlewski T, Goff J, Stoffregen WC. Safety of Brucella abortus strain RB51 in black bears. Journal of wildlife diseases. 2004; 40(3); 429-433. [PubMed: 15465709].
  80. Olsen et al., 2007: Olsen SC, Waters WR, Stoffregen WS. An aerosolized Brucella spp. challenge model for laboratory animals. Zoonoses and public health. 2007; 54(8); 281-285. [PubMed: 17894637].
  81. Olsen et al., 2009: Olsen SC, Boyle SM, Schurig GG, Sriranganathan NN. Immune responses and protection against experimental challenge after vaccination of bison with Brucella abortus strain RB51 or RB51 overexpressing superoxide dismutase and glycosyltransferase genes. Clinical and vaccine immunology : CVI. 2009; 16(4); 535-540. [PubMed: 19176693].
  82. Onate et al., 2003: Onate AA, Cespedes S, Cabrera A, Rivers R, Gonzalez A, Munoz C, Folch H, Andrews E. A DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. Infection and immunity. 2003 Sep; 71(9); 4857-61. [PubMed: 12933826].
  83. Palmer et al., 1996: Palmer MV, Cheville NF, Tatum FM. Morphometric and histopathologic analysis of lymphoid depletion in murine spleens following infection with Brucella abortus strains 2308 or RB51 or an htrA deletion mutant. Veterinary pathology. 1996; 33(3); 282-289. [PubMed: 8740701].
  84. Paranavitana et al., 2005: Paranavitana C, Zelazowska E, Izadjoo M, Hoover D. Interferon-gamma associated cytokines and chemokines produced by spleen cells from Brucella-immune mice. Cytokine. 2005; 30(2); 86-92. [PubMed: 15804600].
  85. Parent et al., 2007: Parent MA, Goenka R, Murphy E, Levier K, Carreiro N, Golding B, Ferguson G, Roop RM 2nd, Walker GC, Baldwin CL. Brucella abortus bacA mutant induces greater pro-inflammatory cytokines than the wild-type parent strain. Microbes and infection / Institut Pasteur. 2007; 9(1); 55-62. [PubMed: 17196866].
  86. Pasquali et al., 2001: Pasquali P, Adone R, Gasbarre LC, Pistoia C, Ciuchini F. Mouse cytokine profiles associated with Brucella abortus RB51 vaccination or B. abortus 2308 infection. Infection and immunity. 2001; 69(10); 6541-6544. [PubMed: 11553603].
  87. Pasquali et al., 2003: Pasquali P, Rosanna A, Pistoia C, Petrucci P, Ciuchini F. Brucella abortus RB51 induces protection in mice orally infected with the virulent strain B. abortus 2308. Infection and immunity. 2003; 71(5); 2326-2330. [PubMed: 12704101].
  88. Pasquevich et al., 2009: Pasquevich KA, Estein SM, García Samartino C, Zwerdling A, Coria LM, Barrionuevo P, Fossati CA, Giambartolomei GH, Cassataro J. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infection and immunity. 2009; 77(1); 436-445. [PubMed: 18981242].
  89. Poester et al., 2006: Poester FP, Gonçalves VS, Paixão TA, Santos RL, Olsen SC, Schurig GG, Lage AP. Efficacy of strain RB51 vaccine in heifers against experimental brucellosis. Vaccine. 2006; 24(25); 5327-5334. [PubMed: 16713034].
  90. Rajasekaran et al., 2008: Rajasekaran P, Seleem MN, Contreras A, Purwantini E, Schurig GG, Sriranganathan N, Boyle SM. Brucella abortus strain RB51 leucine auxotroph as an environmentally safe vaccine for plasmid maintenance and antigen overexpression. Applied and environmental microbiology. 2008; 74(22); 7051-7055. [PubMed: 18836016].
  91. Ramamoorthy et al., 2007: Ramamoorthy S, Sanakkayala N, Vemulapalli R, Duncan RB, Lindsay DS, Schurig GS, Boyle SM, Kasimanickam R, Sriranganathan N. Prevention of lethal experimental infection of C57BL/6 mice by vaccination with Brucella abortus strain RB51 expressing Neospora caninum antigens. International journal for parasitology. 2007; 37(13); 1521-1529. [PubMed: 17568587].
  92. Roop et al., 2004: Roop RM 2nd, Bellaire BH, Valderas MW, Cardelli JA. Adaptation of the Brucellae to their intracellular niche. Molecular microbiology. 2004 May; 52(3); 621-30. [PubMed: 15101970 ].
  93. Rosinha et al., 2002a: Rosinha GM, Freitas DA, Miyoshi A, Azevedo V, Campos E, Cravero SL, Rossetti O, Splitter G, Oliveira SC. Identification and characterization of a Brucella abortus ATP-binding cassette transporter homolog to Rhizobium meliloti ExsA and its role in virulence and protection in mice. Infection and immunity. 2002; 70(9); 5036-5044. [PubMed: 12183550].
  94. Rosinha et al., 2002b: Rosinha GM, Myioshi A, Azevedo V, Splitter GA, Oliveira SC. Molecular and immunological characterisation of recombinant Brucella abortus glyceraldehyde-3-phosphate-dehydrogenase, a T- and B-cell reactive protein that induces partial protection when co-administered with an interleukin-12-expressing plasmid in a DNA vaccine formulation. Journal of medical microbiology. 2002; 51(8); 661-671. [PubMed: 12171297].
  95. Schurig et al., 1991: Schurig GG, Roop RM 2nd, Bagchi T, Boyle S, Buhrman D, Sriranganathan N. Biological properties of RB51; a stable rough strain of Brucella abortus. Veterinary microbiology. 1991 Jul; 28(2); 171-88. [PubMed: 1908158].
  96. Schurig et al., 2002: Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. Veterinary microbiology. 2002 Dec 20; 90(1-4); 479-96. [PubMed: 12414166].
  97. Sislema-Egas et al., 2012: Sislema-Egas F, Céspedes S, Fernández P, Retamal-Díaz A, Sáez D, Oñate A. Evaluation of protective effect of DNA vaccines encoding the BAB1_0263 and BAB1_0278 open reading frames of Brucella abortus in BALB/c mice. Vaccine. 2012; 30(50); 7286-7291. [PubMed: 23026687].
  98. Stevens et al., 1994a: Stevens MG, Olsen SC, Pugh GW Jr. Lymphocyte proliferation in response to Brucella abortus 2308 or RB51 antigens in mice infected with strain 2308, RB51, or 19. Infection and immunity. 1994; 62(10); 4659-4663. [PubMed: 7927736].
  99. Stevens et al., 1994b: Stevens MG, Olsen SC, Pugh GW Jr, Palmer MV. Immune and pathologic responses in mice infected with Brucella abortus 19, RB51, or 2308. Infection and immunity. 1994 Aug; 62(8); 3206-12. [PubMed: 8039890].
  100. Stevens et al., 1995a: Stevens MG, Olsen SC, Pugh GW Jr. Comparison of spleen cell proliferation in response to Brucella abortus 2308 lipopolysaccharide or proteins in mice vaccinated with strain 19 or RB51. Infection and immunity. 1995; 63(8); 3199-3205. [PubMed: 7622248].
  101. Stevens et al., 1995b: Stevens MG, Olsen SC, Pugh GW Jr, Brees D. Comparison of immune responses and resistance to brucellosis in mice vaccinated with Brucella abortus 19 or RB51. Infection and immunity. 1995; 63(1); 264-270. [PubMed: 7806364].
  102. Stevens et al., 1996: Stevens MG, Olsen SC, Palmer MV, Pugh GW Jr. Immune responses and resistance to brucellosis in mice vaccinated orally with Brucella abortus RB51. Infection and immunity. 1996; 64(11); 4534-4541. [PubMed: 8890203].
  103. Stoffregen et al., 2006: Stoffregen WC, Olsen SC, Bricker BJ. Parenteral vaccination of domestic pigs with Brucella abortus strain RB51. American journal of veterinary research. 2006; 67(10); 1802-1808. [PubMed: 17014337].
  104. Tibor et al., 1998: Tibor A, Jacques I, Guilloteau L, Verger JM, Grayon M, Wansard V, Letesson JJ. Effect of P39 gene deletion in live Brucella vaccine strains on residual virulence and protective activity in mice. Infection and immunity. 1998; 66(11); 5561-5564. [PubMed: 9784574].
  105. Tobias et al., 1992: Tobias L, Schurig GG, Cordes DO. Comparative behaviour of Brucella abortus strains 19 and RB51 in the pregnant mouse. Research in veterinary science. 1992; 53(2); 179-183. [PubMed: 1439207].
  106. Trant et al., 2010: Trant CG, Lacerda TL, Carvalho NB, Azevedo V, Rosinha GM, Salcedo SP, Gorvel JP, Oliveira SC. The Brucella abortus phosphoglycerate kinase mutant is highly attenuated and induces protection superior to that of vaccine strain 19 in immunocompromised and immunocompetent mice. Infection and immunity. 2010; 78(5); 2283-2291. [PubMed: 20194591].
  107. Ugalde et al., 2003: Ugalde JE, Comerci DJ, Leguizamón MS, Ugalde RA. Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine. Infection and immunity. 2003; 71(11); 6264-6269. [PubMed: 14573645].
  108. Velikovsky et al., 2002: Velikovsky CA, Cassataro J, Giambartolomei GH, Goldbaum FA, Estein S, Bowden RA, Bruno L, Fossati CA, Spitz M. A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infection and immunity. 2002 May; 70(5); 2507-11. [PubMed: 11953389 ].
  109. Vemulapalli et al., 2000a: Vemulapalli R, He Y, Cravero S, Sriranganathan N, Boyle SM, Schurig GG. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infection and immunity. 2000 Jun; 68(6); 3286-9. [PubMed: 10816475].
  110. Vemulapalli et al., 2000b: Vemulapalli R, He Y, Buccolo LS, Boyle SM, Sriranganathan N, Schurig GG. Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation. Infection and immunity. 2000 Jul; 68(7); 3927-32. [PubMed: 10858205].
  111. Vemulapalli et al., 2004: Vemulapalli R, Contreras A, Sanakkayala N, Sriranganathan N, Boyle SM, Schurig GG. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice. Veterinary microbiology. 2004 Sep 8; 102(3-4); 237-45. [PubMed: 15327798].
  112. Wang et al., 2011: Wang Y, Bai Y, Qu Q, Xu J, Chen Y, Zhong Z, Qiu Y, Wang T, Du X, Wang Z, Yu S, Fu S, Yuan J, Zhen Q, Yu Y, Chen Z, Huang L. The 16MΔvjbR as an ideal live attenuated vaccine candidate for differentiation between Brucella vaccination and infection. Veterinary microbiology. 2011; ; . [PubMed: 21530111].
  113. Winter et al., 1988: Winter AJ, Rowe GE, Duncan JR, Eis MJ, Widom J, Ganem B, Morein B. Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice. Infection and immunity. 1988; 56(11); 2808-2817. [PubMed: 2844673].
  114. Winter et al., 1996: Winter AJ, Schurig GG, Boyle SM, Sriranganathan N, Bevins JS, Enright FM, Elzer PH, Kopec JD. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4. American journal of veterinary research. 1996 May; 57(5); 677-83. [PubMed: 8723881].
  115. Xin, 1986: Xin X. Orally administrable brucellosis vaccine: Brucella suis strain 2 vaccine. Vaccine. 1986; 4(4); 212-216. [PubMed: 3541425].
  116. Yang et al., 2006: Yang X, Becker T, Walters N, Pascual DW. Deletion of znuA virulence factor attenuates Brucella abortus and confers protection against wild-type challenge. Infection and immunity. 2006; 74(7); 3874-3879. [PubMed: 16790759].
  117. Yang et al., 2007: Yang X, Walters N, Robison A, Trunkle T, Pascual DW. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. Vaccine. 2007; 25(12); 2261-2268. [PubMed: 17239499].
  118. Yu et al., 2007: Yu DH, Hu XD, Cai H. A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. DNA and cell biology. 2007 Jun; 26(6); 435-43. [PubMed: 17570767].
  119. Yu et al., 2007: Yu DH, Li M, Hu XD, Cai H. A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector. Vaccine. 2007; 25(37-38); 6744-6754. [PubMed: 17681650].

Burkholderia pseudomallei

  1. Breitbach et al., 2008: Breitbach K, Köhler J, Steinmetz I. Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008; 102 Suppl 1; S89-94. [PubMed: 19121696].
  2. Chen et al., 2006: Chen YS, Hsiao YS, Lin HH, Yen CM, Chen SC, Chen YL. Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellin. Vaccine. 2006; 24(6); 750-758. [PubMed: 16169637].
  3. Harland et al., 2007: Harland DN, Chu K, Haque A, Nelson M, Walker NJ, Sarkar-Tyson M, Atkins TP, Moore B, Brown KA, Bancroft G, Titball RW, Atkins HS. Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infection and immunity. 2007; 75(8); 4173-4180. [PubMed: 17517877].
  4. Nelson et al., 2004: Nelson M, Prior JL, Lever MS, Jones HE, Atkins TP, Titball RW. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. Journal of medical microbiology. 2004; 53(Pt 12); 1177-1182. [PubMed: 15585494].
  5. Norris et al., 2011: Norris MH, Propst KL, Kang Y, Dow SW, Schweizer HP, Hoang TT. The Burkholderia pseudomallei {Delta}asd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice. Infection and immunity. 2011; ; . [PubMed: 21807903].
  6. Srilunchang et al., 2009: Srilunchang T, Proungvitaya T, Wongratanacheewin S, Strugnell R, Homchampa P. Construction and characterization of an unmarked aroC deletion mutant of Burkholderia pseudomallei strain A2. The Southeast Asian journal of tropical medicine and public health. 2009; 40(1); 123-130. [PubMed: 19323044].
  7. Wiki: B. pseudomallei: Wiki: B. pseudomallei [http://en.wikipedia.org/wiki/Burkholderia_pseudomallei]

Campylobacter fetus

  1. Thompson, 2002: Thompson SA. Campylobacter surface-layers (S-layers) and immune evasion. Annals of periodontology / the American Academy of Periodontology. 2002; 7(1); 43-53. [PubMed: 16013216].

Campylobacter jejuni

  1. Abimiku et al., 1989: Abimiku AG, Dolby JM, Borriello SP. Comparison of different vaccines and induced immune response against Campylobacter jejuni colonization in the infant mouse. Epidemiology and infection. 1989 Apr; 102(2); 271-80. [PubMed: 2703020 ].
  2. Abulreesh et al., 2006: Abulreesh HH, Paget TA, Goulder R. Campylobacter in waterfowl and aquatic environments: incidence and methods of detection. Environmental science & technology. 2006 Dec 1; 40(23); 7122-31. [PubMed: 17180958].
  3. Andrews, 1998: Andrews GP. The enteric Campylobacter: they are everywhere. Clinical laboratory science : journal of the American Society for Medical Technology. 1998 Sep-Oct; 11(5); 305-8. [PubMed: 10186956].
  4. Baqar et al., 1995a: Baqar S, Bourgeois AL, Schultheiss PJ, Walker RI, Rollins DM, Haberberger RL, Pavlovskis OR. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine. 1995 Jan; 13(1); 22-8. [PubMed: 7539199].
  5. Baqar et al., 1995b: Baqar S, Applebee LA, Bourgeois AL. Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice. Infection and immunity. 1995 Sep; 63(9); 3731-5. [PubMed: 7642317].
  6. Baqar et al., 2008: Baqar S, Applebee LA, Gilliland TC Jr, Lee LH, Porter CK, Guerry P. Immunogenicity and protective efficacy of recombinant Campylobacter jejuni flagellum-secreted proteins in mice. Infection and immunity. 2008; 76(7); 3170-3175. [PubMed: 18426878].
  7. Buckley et al., 2010: Buckley AM, Wang J, Hudson DL, Grant AJ, Jones MA, Maskell DJ, Stevens MP. Evaluation of live-attenuated Salmonella vaccines expressing Campylobacter antigens for control of C. jejuni in poultry. Vaccine. 2010; 28(4); 1094-1105. [PubMed: 19853682].
  8. Burr et al., 2005: Burr DH, Rollins D, Lee LH, Pattarini DL, Walz SS, Tian JH, Pace JL, Bourgeois AL, Walker RI. Prevention of disease in ferrets fed an inactivated whole cell Campylobacter jejuni vaccine. Vaccine. 2005 Jul 29; 23(34); 4315-21. [PubMed: 16005742 ].
  9. Dolby et al., 1986: Dolby JM, Newell DG. The protection of infant mice from colonization with Campylobacter jejuni by vaccination of the dams. The Journal of hygiene. 1986 Apr; 96(2); 143-51. [PubMed: 3701036 ].
  10. Engberg, 2006: Engberg J. Contributions to the epidemiology of Campylobacter infections. A review of clinical and microbiological studies. Danish medical bulletin. 2006 Nov; 53(4); 361-89. [PubMed: 17150145].
  11. Huang et al., 2007: Huang S, Sahin O, Zhang Q. Infection-induced antibodies against the major outer membrane protein of Campylobacter jejuni mainly recognize conformational epitopes. FEMS microbiology letters. 2007 Jul; 272(2); 137-43. [PubMed: 17521366].
  12. Islam et al., 2010: Islam A, Raghupathy R, Albert MJ. Recombinant PorA, the major outer membrane protein of Campylobacter jejuni, provides heterologous protection in an adult mouse intestinal colonization model. Clinical and vaccine immunology : CVI. 2010; 17(11); 1666-1671. [PubMed: 20861330].
  13. Jagusztyn-Krynicka et al., 2004: Jagusztyn-Krynicka EK, Wyszynska A, Raczko A. New approaches to development of mucosal vaccine against enteric bacterial pathogens; preventing campylobacteriosis. Polish journal of microbiology / Polskie Towarzystwo Mikrobiologow = The Polish Society of Microbiologists. 2004; 53 Suppl; 7-15. [PubMed: 15787191].
  14. Khoury et al., 1995: Khoury CA, Meinersmann RJ. A genetic hybrid of the Campylobacter jejuni flaA gene with LT-B of Escherichia coli and assessment of the efficacy of the hybrid protein as an oral chicken vaccine. Avian diseases. 1995 Oct-Dec; 39(4); 812-20. [PubMed: 8719215 ].
  15. Kopecko, 1997: Kopecko DJ. Regulatory considerations for Campylobacter vaccine development. The Journal of infectious diseases. 1997 Dec; 176 Suppl 2; S189-91. [PubMed: 9396709].
  16. Lee et al., 1999: Lee LH, Burg E 3rd, Baqar S, Bourgeois AL, Burr DH, Ewing CP, Trust TJ, Guerry P. Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni. Infection and immunity. 1999 Nov; 67(11); 5799-805. [PubMed: 10531231].
  17. Martin et al., 1999: Martin PR, Mulks MH. Cloning and characterization of a gene encoding an antigenic membrane protein from Actinobacillus pleuropneumoniae with homology to ABC transporters. FEMS immunology and medical microbiology. 1999 Aug 15; 25(3); 245-54. [PubMed: 10459579].
  18. Nelson et al., 2007: Nelson JM, Chiller TM, Powers JH, Angulo FJ. Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Apr 1; 44(7); 977-80. [PubMed: 17342653].
  19. Pawelec et al., 1997: Pawelec D, Rozynek E, Popowski J, Jagusztyn-Krynicka EK. Cloning and characterization of a Campylobacter jejuni 72Dz/92 gene encoding a 30 kDa immunopositive protein, component of the ABC transport system; expression of the gene in avirulent Salmonella typhimurium. FEMS immunology and medical microbiology. 1997 Oct; 19(2); 137-50. [PubMed: 9395059].
  20. Pawelec et al., 2000: Pawelec DP, Korsak D, Wyszynska AK, Rozynek E, Popowski J, Jagusztyn-Krynicka EK. Genetic diversity of the Campylobacter genes coding immunodominant proteins. FEMS microbiology letters. 2000 Apr 1; 185(1); 43-9. [PubMed: 10731605].
  21. Prokhorova et al., 2006: Prokhorova TA, Nielsen PN, Petersen J, Kofoed T, Crawford JS, Morsczeck C, Boysen A, Schrotz-King P. Novel surface polypeptides of Campylobacter jejuni as traveller's diarrhoea vaccine candidates discovered by proteomics. Vaccine. 2006 Sep 29; 24(40-41); 6446-55. [PubMed: 16824653].
  22. Rice et al., 1997: Rice BE, Rollins DM, Mallinson ET, Carr L, Joseph SW. Campylobacter jejuni in broiler chickens: colonization and humoral immunity following oral vaccination and experimental infection. Vaccine. 1997 Dec; 15(17-18); 1922-32. [PubMed: 9413103 ].
  23. Scott, 1997: Scott DA. Vaccines against Campylobacter jejuni. The Journal of infectious diseases. 1997 Dec; 176 Suppl 2; S183-8. [PubMed: 9396708].
  24. Shoaf-Sweeney et al., 2008: Shoaf-Sweeney KD, Larson CL, Tang X, Konkel ME. Identification of Campylobacter jejuni proteins recognized by maternal antibodies of chickens. Applied and environmental microbiology. 2008; 74(22); 6867-6875. [PubMed: 18805999].
  25. Sizemore et al., 2006: Sizemore DR, Warner B, Lawrence J, Jones A, Killeen KP. Live, attenuated Salmonella typhimurium vectoring Campylobacter antigens. Vaccine. 2006 May 1; 24(18); 3793-803. [PubMed: 16135393].
  26. Smibert, 1978: Smibert RM. The genus Campylobacter. Annual review of microbiology. 1978; 32; 673-709. [PubMed: 360978].
  27. Walker, 2005: Walker RI. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. Vaccine. 2005 May 16; 23(26); 3369-85. [PubMed: 15837361].
  28. Wallis, 2004: Wallis TS. Vaccination against salmonella, enterohaemorrhagic E. coli and Campylobacter in food-producing animals. Developments in biologicals. 2004; 119; 343-50. [PubMed: 15742645].
  29. White et al., 1997: White PL, Baker AR, James WO. Strategies to control Salmonella and Campylobacter in raw poultry products. Revue scientifique et technique (International Office of Epizootics). 1997 Aug; 16(2); 525-41. [PubMed: 9501366].
  30. Wilkinson et al., 2003: Wilkinson J, Rood D, Minior D, Guillard K, Darre M, Silbart LK. Immune response to a mucosally administered aflatoxin B1 vaccine. Poultry science. 2003 Oct; 82(10); 1565-72. [PubMed: 14601734].
  31. Wyszynska et al., 2004: Wyszynska A, Raczko A, Lis M, Jagusztyn-Krynicka EK. Oral immunization of chickens with avirulent Salmonella vaccine strain carrying C. jejuni 72Dz/92 cjaA gene elicits specific humoral immune response associated with protection against challenge with wild-type Campylobacter. Vaccine. 2004 Mar 29; 22(11-12); 1379-89. [PubMed: 15063560 ].
  32. Zeng et al., 2009: Zeng X, Xu F, Lin J. Molecular, antigenic, and functional characteristics of ferric enterobactin receptor CfrA in Campylobacter jejuni. Infection and immunity. 2009; 77(12); 5437-5448. [PubMed: 19737895].
  33. Zheng et al., 2007: Zheng H, Cai FC, Zhong M, Deng B, Li X, Zhang XP. [Experimental study on the chitosan-DNA vaccines against campylobacter jejuni invasion]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. 2007; 41(5); 375-379. [PubMed: 18206008].

Canarypox virus

  1. Tulman et al., 2004: Tulman ER, Afonso CL, Lu Z, Zsak L, Kutish GF, Rock DL. The genome of canarypox virus. Journal of virology. 2004; 78(1); 353-366. [PubMed: 14671117].

Cancer

  1. Aarntzen et al., 2012: Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, van Rossum MM, Blokx WA, Jacobs JF, Duiveman-de Boer T, Schuurhuis DH, Mus R, Thielemans K, de Vries IJ, Figdor CG, Punt CJ, Adema GJ. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012; 18(19); 5460-5470. [PubMed: 22896657].
  2. Aarntzen et al., 2013: Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, van de Rakt M, Lesterhuis WJ, van Riel M, Punt CJ, Adema GJ, Heerschap A, Figdor CG, Oyen WJ, de Vries IJ. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19(6); 1525-1533. [PubMed: 23382117].
  3. Abkin et al., 2013: Abkin SV, Pankratova KM, Komarova EY, Guzhova IV, Margulis BA. Hsp70 chaperone-based gel composition as a novel immunotherapeutic anti-tumor tool. Cell stress & chaperones. 2013; 18(3); 391-396. [PubMed: 23233202].
  4. Adams et al., 2008: Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, Shapiro RL, Berman RS, Berner N, Shao Y, Manches O, Pan L, Venhaus RR, Hoffman EW, Jungbluth A, Gnjatic S, Old L, Pavlick AC, Bhardwaj N. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. Journal of immunology (Baltimore, Md. : 1950). 2008; 181(1); 776-784. [PubMed: 18566444].
  5. Agarwala et al., 2004: Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004; 100(8); 1692-1698. [PubMed: 15073858].
  6. Ahmad et al., 2009: Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Molecular therapy : the journal of the American Society of Gene Therapy. 2009; 17(6); 1101-1108. [PubMed: 19337234].
  7. Ahmad et al., 2010: Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genetic vaccines and therapy. 2010; 8(1); 1. [PubMed: 20181099].
  8. Bae et al., 2009: Bae MY, Cho NH, Seong SY. Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli. Clinical and experimental immunology. 2009; 157(1); 128-138. [PubMed: 19659778].
  9. Baghdadi et al., 2013: Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, Jinushi M. Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer immunology, immunotherapy : CII. 2013; 62(4); 629-637. [PubMed: 23143694].
  10. Baird et al., 2013: Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. Journal of immunology (Baltimore, Md. : 1950). 2013; 190(1); 469-478. [PubMed: 23225891].
  11. Baldueva et al., 2012: Baldueva IA, Novik AV, Moiseenko VM, Nekhaeva TL, Danilova AB, Danilov AO, Protsenko SA, Petrova TIu, UleÄ­skaia GI, Shchekina LA, Semenova AI, MikhaÄ­lichenko TD, Teletaeva GM, Zhabina AS, Volkov NV, Komarov IuI. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients]. Voprosy onkologii. 2012; 58(2); 212-221. [PubMed: 22774527].
  12. Basak et al., 2000: Basak S, Eck S, Gutzmer R, Smith AJ, Birebent B, Purev E, Staib L, Somasundaram R, Zaloudik J, Li W, Jacob L, Mitchell E, Speicher D, Herlyn D. Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector. Annals of the New York Academy of Sciences. 2000; 910; 237-252. [PubMed: 10911917].
  13. Becker et al., 2010: Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010; 33(6); 639-647. [PubMed: 20551832].
  14. Benteyn et al., 2013: Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A. Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). BioMed research international. 2013; 2013; 976383. [PubMed: 23509826].
  15. Benvenuti et al., 2000: Benvenuti F, Burrone OR, Efremov DG. Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection. Gene therapy. 2000; 7(7); 605-611. [PubMed: 10819576].
  16. Berd et al., 1997: Berd D, Maguire HC Jr, Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997; 15(6); 2359-2370. [PubMed: 9196151].
  17. Bergman et al., 2003: Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, Segal N, Gregor P, Engelhorn M, Riviere I, Houghton AN, Wolchok JD. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(4); 1284-1290. [PubMed: 12684396].
  18. Bernhardt et al., 2006: Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, Buanes T, Gaudernack G. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. British journal of cancer. 2006; 95(11); 1474-1482. [PubMed: 17060934].
  19. Bettinotti et al., 2003: Bettinotti MP, Panelli MC, Ruppe E, Mocellin S, Phan GQ, White DE, Marincola FM. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178. International journal of cancer. Journal international du cancer. 2003; 105(2); 210-216. [PubMed: 12673681].
  20. Bilgi et al., 1979: Bilgi C, Brown NE, McPherson TA, Lentle B. Pulmonary manifestations in patients with malignant melanoma during BCG immunotherapy. A preliminary report. Chest. 1979; 75(6); 685-687. [PubMed: 436519].
  21. Brockstedt et al., 2004: Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(38); 13832-13837. [PubMed: 15365184].
  22. Brockstedt et al., 2005: Brockstedt DG, Bahjat KS, Giedlin MA, Liu W, Leong M, Luckett W, Gao Y, Schnupf P, Kapadia D, Castro G, Lim JY, Sampson-Johannes A, Herskovits AA, Stassinopoulos A, Bouwer HG, Hearst JE, Portnoy DA, Cook DN, Dubensky TW Jr. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nature medicine. 2005; 11(8); 853-860. [PubMed: 16041382].
  23. Broder et al., 2000: Broder H, Anderson A, Odesa SK, Kremen TJ, Liau LM. Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor. Neurosurgical focus. 2000; 9(6); e6. [PubMed: 16817689].
  24. Buchan et al., 2005: Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. Journal of immunology (Baltimore, Md. : 1950). 2005; 174(10); 6292-6298. [PubMed: 15879128].
  25. Byrne et al., 1983: Byrne MJ, Van Hazel G, Reynolds PM, Lemish WM, Holman CD. Adjuvant immunotherapy with BCG in stage II malignant melanoma. Journal of surgical oncology. 1983; 23(2); 114-116. [PubMed: 6343725].
  26. Campbell et al., 2000: Campbell I, Moyana T, Carlsen S, Zheng C, Xiang J. Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth. Cancer gene therapy. 2000; 7(1); 37-44. [PubMed: 10678354].
  27. Campisano et al., 2013: Campisano S, Mac Keon S, Gazzaniga S, Ruiz MS, Traian MD, Mordoh J, Wainstok R. Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors. Vaccine. 2013; 31(2); 354-361. [PubMed: 23146677].
  28. Carpentier et al., 1998: Carpentier AF, Rosenfeld MR, Delattre JY, Whalen RG, Posner JB, Dalmau J. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998; 4(11); 2819-2824. [PubMed: 9829748].
  29. Carreno et al., 2013: Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, Aft RL, Cornelius LA, Trinkaus KM, Linette GP. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. The Journal of clinical investigation. 2013; 123(8); 3383-3394. [PubMed: 23867552].
  30. Cassel et al., 1983: Cassel WA, Murray DR, Phillips HS. A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer. 1983; 52(5); 856-860. [PubMed: 6871827].
  31. Castel et al., 1991: Castel T, Estapé J, Viñolas N, Mascaró JM, Castro J, Vilalta A, Gratacós R, Daniels M, Palou J, Grau JJ. Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy. Dermatologica. 1991; 183(1); 25-30. [PubMed: 1769411].
  32. Chen et al., 1994: Chen L, McGowan P, Ashe S, Johnston JV, Hellström I, Hellström KE. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer research. 1994; 54(20); 5420-5423. [PubMed: 7522958].
  33. Chen et al., 1997: Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Wiebke EA, Gaddy J, Sledge G, Broxmeyer HE, Cornetta K. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer research. 1997; 57(16); 3511-3516. [PubMed: 9270021].
  34. Chen et al., 2012: Chen J, Zhang L, Wen W, Hao J, Zeng P, Qian X, Zhang Y, Yin Y. Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice. PloS one. 2012; 7(10); e47219. [PubMed: 23071764].
  35. Choi et al., 2007: Choi Y, Jeon YH, Kang JH, Chung JK, Schmidt M, Kim AC. MIDGE/hNIS vaccination generates antigen-associated CD8+IFN-gamma+ T cells and enhances protective antitumor immunity. International journal of cancer. Journal international du cancer. 2007; 120(9); 1942-1950. [PubMed: 17266027].
  36. Chudley et al., 2012: Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, Creak A, Dobbyn J, Johnson B, Bass P, Heath C, Kerr P, Mathiesen I, Dearnaley D, Stevenson F, Ottensmeier C. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer immunology, immunotherapy : CII. 2012; ; . [PubMed: 22729556].
  37. Clunie et al., 1980: Clunie GJ, Gough IR, Dury M, Furnival CM, Bolton PM. A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results. Cancer. 1980; 46(3); 475-479. [PubMed: 6994866].
  38. Cochlovius et al., 2002: Cochlovius B, Stassar MJ, Schreurs MW, Benner A, Adema GJ. Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity. Immunology letters. 2002; 80(2); 89-96. [PubMed: 11750039].
  39. Cochran et al., 1981: Cochran AJ, Buyse ME, Lejeune FJ, Macher E, Revuz J, Rümke P. Adjuvant reactivity predicts survival in patients with "high-risk" primary malignant melanoma treated with systemic BCG. EORTC Malignant Melanoma Cooperative Group Writing Committee. International journal of cancer. Journal international du cancer. 1981; 28(5); 543-550. [PubMed: 7309294].
  40. Cohen et al., 1978: Cohen MH, Jessup JM, Felix EL, Weese JL, Herberman RB. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer. 1978; 41(6); 2456-2463. [PubMed: 657108].
  41. Cohen et al., 2006: Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer research. 2006; 66(9); 4904-4912. [PubMed: 16651447].
  42. Conry et al., 2002: Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, Shaw DR, LoBuglio AF. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002; 8(9); 2782-2787. [PubMed: 12231517].
  43. Culos and Cuellar, 2013: Culos KA, Cuellar S. Novel targets in the treatment of advanced melanoma: new first-line treatment options. The Annals of pharmacotherapy. 2013; 47(4); 519-526. [PubMed: 23548648].
  44. Currie and McElwain, 1975: Currie GA, McElwain TJ. Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study. British journal of cancer. 1975; 31(2); 143-156. [PubMed: 1164466].
  45. Drake, 2011: Drake CG. Update on prostate cancer vaccines. Cancer journal (Sudbury, Mass.). 2011; 17(5); 294-299. [PubMed: 21952278].
  46. Duan et al., 2007: Duan HF, Hu XW, Chen JL, Gao LH, Xi YY, Lu Y, Li JF, Zhao SR, Xu JJ, Chen HP, Chen W, Wu CT. Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8. Journal of the National Cancer Institute. 2007; 99(20); 1551-1555. [PubMed: 17925540].
  47. Durán-Aniotz et al., 2013: Durán-Aniotz C, Segal G, Salazar L, Pereda C, Falcón C, Tempio F, Aguilera R, González R, Pérez C, Tittarelli A, Catalán D, Nervi B, Larrondo M, Salazar-Onfray F, López MN. The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses. Cancer immunology, immunotherapy : CII. 2013; 62(4); 761-772. [PubMed: 23242374].
  48. El-Domeiri et al., 1978: El-Domeiri AA, Das Gupta TK, Trippon M, Simo C, Sabet TY, Crispen R. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma. Surgery, gynecology & obstetrics. 1978; 146(2); 230-232. [PubMed: 622668].
  49. Elias et al., 1997: Elias EG, Suter CM, Fabian DS. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. Journal of surgical oncology. 1997; 64(1); 17-22. [PubMed: 9040795].
  50. Eschenburg et al., 2010: Eschenburg G, Stermann A, Preissner R, Meyer HA, Lode HN. DNA vaccination: using the patient's immune system to overcome cancer. Clinical & developmental immunology. 2010; 2010; 169484. [PubMed: 21197271].
  51. Eton et al., 2010: Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. Journal of translational medicine. 2010; 8; 9. [PubMed: 20109236].
  52. Fang et al., 2009: Fang J, Lu Y, Ouyang K, Wu G, Zhang H, Liu Y, Chen Y, Lin M, Wang H, Jin L, Cao R, Roque RS, Zong L, Liu J, Li T. Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo. Clinical and vaccine immunology : CVI. 2009; 16(7); 1033-1039. [PubMed: 19458203].
  53. Faries et al., 2009: Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(22); 7029-7035. [PubMed: 19903777].
  54. FDA: TICE BCG: FDA TICE BCG information [http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM163039.pdf]
  55. Fenton et al., 1993: Fenton RG, Taub DD, Kwak LW, Smith MR, Longo DL. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. Journal of the National Cancer Institute. 1993; 85(16); 1294-1302. [PubMed: 8340941].
  56. Fernando et al., 1998: Fernando GJ, Stewart TJ, Tindle RW, Frazer IH. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. Journal of immunology (Baltimore, Md. : 1950). 1998; 161(5); 2421-2427. [PubMed: 9725239].
  57. Filipazzi et al., 2012: Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, Di Florio A, Asioli M, Frati P, Sovena G, Squarcina P, Maio M, Danielli R, Chiarion-Sileni V, Villa A, Lombardo C, Tragni G, Santinami M, Parmiani G, Rivoltini L. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012; 18(23); 6485-6496. [PubMed: 23032742].
  58. Finocchiaro and Glikin, 2012: Finocchiaro LM, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up. Cancer gene therapy. 2012; 19(12); 852-861. [PubMed: 23059870].
  59. Fontana et al., 2009: Fontana R, Bregni M, Cipponi A, Raccosta L, Rainelli C, Maggioni D, Lunghi F, Ciceri F, Mukenge S, Doglioni C, Colau D, Coulie PG, Bordignon C, Traversari C, Russo V. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood. 2009; 113(8); 1651-1660. [PubMed: 19074732].
  60. Fourcade et al., 2008: Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008; 31(8); 781-791. [PubMed: 18779741].
  61. Garcia-Hernandez et al., 2007: Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer research. 2007; 67(3); 1344-1351. [PubMed: 17283172].
  62. Garcia-Hernandez et al., 2008: Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer research. 2008; 68(3); 861-869. [PubMed: 18245488].
  63. Gomez et al., 2013: Gomez B, He L, Tsai YC, Wu TC, Viscidi RP, Hung CF. Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen. Cell & bioscience. 2013; 3(1); 29. [PubMed: 23856459].
  64. Gribben et al., 2005: Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005; 11(12); 4430-4436. [PubMed: 15958627].
  65. Grossmann et al., 1997: Grossmann ME, Brown MP, Brenner MK. Antitumor responses induced by transgenic expression of CD40 ligand. Human gene therapy. 1997; 8(16); 1935-1943. [PubMed: 9382959].
  66. Guinn et al., 2001: Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cellular immunology. 2001; 210(1); 56-65. [PubMed: 11485353].
  67. Hailemichael et al., 2013: Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, Sowell RT, Schluns KS, Davis RE, Hwu P, Overwijk WW. Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. Nature medicine. 2013; 19(4); 465-472. [PubMed: 23455713].
  68. Hanwell et al., 2013: Hanwell DG, McNeil B, Visan L, Rodrigues L, Dunn P, Shewen PE, Macallum GE, Turner PV, Vogel TU. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4. Journal of immunotherapy (Hagerstown, Md. : 1997). 2013; 36(4); 238-247. [PubMed: 23603858].
  69. Harrop et al., 2006: Harrop R, Ryan MG, Myers KA, Redchenko I, Kingsman SM, Carroll MW. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer immunology, immunotherapy : CII. 2006; 55(9); 1081-1090. [PubMed: 16311730].
  70. Hawkins et al., 2002: Hawkins WG, Gold JS, Blachere NE, Bowne WB, Hoos A, Lewis JJ, Houghton AN. Xenogeneic DNA immunization in melanoma models for minimal residual disease. The Journal of surgical research. 2002; 102(2); 137-143. [PubMed: 11796010].
  71. He et al., 2013: He X, Wang J, Zhao F, Chen D, Chen J, Zhang H, Yang C, Liu Y, Dou J. ESAT-6-gpi DNA vaccine augmented the specific antitumour efficacy induced by the tumour vaccine B16F10-ESAT-6-gpi/IL-21 in a mouse model. Scandinavian journal of immunology. 2013; 78(1); 69-78. [PubMed: 23679337].
  72. Henz et al., 1996: Henz BM, Macher E, Bröcker EB, Suciu S, Steerenberg PA, Jung E, Rümke P. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781). Dermatology (Basel, Switzerland). 1996; 193(2); 105-109. [PubMed: 8884144].
  73. Hersey et al., 2002: Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, Gill PG, Coventry BJ, McMullen A, Dillon H, Simes RJ. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002; 20(20); 4181-4190. [PubMed: 12377961].
  74. Hersey et al., 2005: Hersey P, Menzies SW, Coventry B, Nguyen T, Farrelly M, Collins S, Hirst D, Johnson H. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer immunology, immunotherapy : CII. 2005; 54(3); 208-218. [PubMed: 15449035].
  75. Hersey, 1992: Hersey P. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World journal of surgery. 1992; 16(2); 251-260. [PubMed: 1561807].
  76. Hirschowitz et al., 1998: Hirschowitz EA, Leonard S, Song W, Ferris B, Leopold PL, Lewis JJ, Bowne WB, Wang S, Houghton AN, Crystal RG. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene therapy. 1998; 5(7); 975-983. [PubMed: 9813669].
  77. Hodi, 2010: Hodi FS. Overcoming immunological tolerance to melanoma: Targeting CTLA-4. Asia-Pacific journal of clinical oncology. 2010; 6 Suppl 1; S16-23. [PubMed: 20482528].
  78. Hsueh and Morton, 2003: Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Seminars in cancer biology. 2003; 13(6); 401-407. [PubMed: 15001158].
  79. Hsueh et al., 2002: Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O'Day SJ, Boasberg PD, Stern SL, Ye X, Morton DL. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002; 20(23); 4549-4554. [PubMed: 12454111].
  80. Huebener et al., 2008: Huebener N, Fest S, Strandsby A, Michalsky E, Preissner R, Zeng Y, Gaedicke G, Lode HN. A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity. Molecular cancer therapeutics. 2008; 7(7); 2241-2251. [PubMed: 18645033].
  81. Hunter-Craig et al., 1970: Hunter-Craig I, Newton KA, Westbury G, Lacey BW. Use of vaccinia virus in the treatment of metastatic malignant melanoma. British medical journal. 1970; 2(5708); 512-515. [PubMed: 4913781].
  82. Irie et al., 2004: Irie RF, Ollila DW, O'Day S, Morton DL. Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer immunology, immunotherapy : CII. 2004; 53(2); 110-117. [PubMed: 14564483].
  83. Jha et al., 2012: Jha G, Miller JS, Curtsinger JM, Zhang Y, Mescher MF, Dudek AZ. Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen Vaccine for the Treatment of Stage IV Melanoma. American journal of clinical oncology. 2012; ; . [PubMed: 23241505].
  84. Johnson et al., 2006: Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, McNeel DG. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine. 2006; 24(3); 293-303. [PubMed: 16115700].
  85. Jones et al., 1996: Jones RC, Kelley M, Gupta RK, Nizze JA, Yee R, Leopoldo Z, Qi K, Stern S, Morton DL. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Annals of surgical oncology. 1996; 3(5); 437-445. [PubMed: 8876885].
  86. Kalli et al., 2013: Kalli F, Machiorlatti R, Battaglia F, Parodi A, Conteduca G, Ferrera F, Proietti M, Tardito S, Sanguineti M, Millo E, Fenoglio D, De Palma R, Inghirami G, Filaci G. Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice. Journal of translational medicine. 2013; 11; 120. [PubMed: 23663506].
  87. Kamata et al., 2002: Kamata M, Denda-Nagai K, Kubota N, Aida S, Takeda K, Irimura T. Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases. Clinical & experimental metastasis. 2002; 19(8); 689-696. [PubMed: 12553374].
  88. Kaplan et al., 2006: Kaplan CD, Krüger JA, Zhou H, Luo Y, Xiang R, Reisfeld RA. A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. Vaccine. 2006; 24(47-48); 6994-7002. [PubMed: 17050049].
  89. Kim and Sin, 2005: Kim MS, Sin JI. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology. 2005; 116(2); 255-266. [PubMed: 16162274].
  90. Kim et al., 2001: Kim JJ, Yang JS, Nottingham LK, Tang W, Dang K, Manson KH, Wyand MS, Wilson DM, Weiner DB. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. Oncogene. 2001; 20(33); 4497-4506. [PubMed: 11494145].
  91. Kim et al., 2001: Kim JJ, Yang JS, Dang K, Manson KH, Weiner DB. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001; 7(3 Suppl); 882s-889s. [PubMed: 11300487].
  92. Koido et al., 2000: Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. Journal of immunology (Baltimore, Md. : 1950). 2000; 165(10); 5713-5719. [PubMed: 11067929].
  93. Kolarić et al., 1979: Kolarić K, Malenica B, Roth A. A preliminary report of a pilot trial in adjuvant chemotherapy of primary melanoma. Tumori. 1979; 65(2); 229-236. [PubMed: 462575].
  94. Komatsu et al., 2013: Komatsu N, Jackson HM, Chan KF, Oveissi S, Cebon J, Itoh K, Chen W. Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein. Molecular immunology. 2013; 54(3-4); 465-471. [PubMed: 23454162].
  95. Krown et al., 1978: Krown SE, Hilal EY, Pinsky CM, Hirshaut Y, Wanebo HJ, Hansen JA, Huvos AG, Oettgen HF. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma. Cancer. 1978; 42(6); 2648-2660. [PubMed: 728866].
  96. Kruit et al., 2013: Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31(19); 2413-2420. [PubMed: 23715572].
  97. Lee et al., 2005: Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer research. 2005; 65(23); 11156-11163. [PubMed: 16322266].
  98. Leitner et al., 2003: Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nature medicine. 2003; 9(1); 33-39. [PubMed: 12496961].
  99. Leslie et al., 2007: Leslie MC, Zhao YJ, Lachman LB, Hwu P, Wu GJ, Bar-Eli M. Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis. Gene therapy. 2007; 14(4); 316-323. [PubMed: 17024104].
  100. Liao et al., 2006: Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer immunity. 2006; 6; 8. [PubMed: 16626110].
  101. Lieberman et al., 1975: Lieberman R, Wybran J, Epstein W. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma. Cancer. 1975; 35(3); 756-777. [PubMed: 234295].
  102. Lienard et al., 2009: Lienard D, Avril MF, Le Gal FA, Baumgaertner P, Vermeulen W, Blom A, Geldhof C, Rimoldi D, Pagliusi S, Romero P, Dietrich PY, Corvaia N, Speiser DE. Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009; 32(8); 875-883. [PubMed: 19752746].
  103. Lindencrona et al., 2004: Lindencrona JA, Preiss S, Kammertoens T, Schüler T, Piechocki M, Wei WZ, Seliger B, Blankenstein T, Kiessling R. CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. International journal of cancer. Journal international du cancer. 2004; 109(2); 259-264. [PubMed: 14750178].
  104. Lipton et al., 1983: Lipton A, Harvey HA, Lawrence B, Gottlieb R, Kukrika M, Dixon R, Graham W, Miller S, Heckard R, Schelzel D, White DS. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. Cancer. 1983; 51(1); 57-60. [PubMed: 6821809].
  105. Lipton et al., 1991: Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R, Bartolucci AA. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991; 9(7); 1151-1156. [PubMed: 2045856].
  106. Liu et al., 2013: Liu H, Geng S, Feng C, Xie X, Wu B, Chen X, Zou Q, Wang S, Cui J, Xing R, Li W, Lu Y, Wang B. A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8+T lymphocytes in a murine melanoma model. Human vaccines & immunotherapeutics. 2013; 9(10); 2196-2202. [PubMed: 24051432].
  107. Lladser et al., 2010: Lladser A, Ljungberg K, Tufvesson H, Tazzari M, Roos AK, Quest AF, Kiessling R. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer immunology, immunotherapy : CII. 2010; 59(1); 81-92. [PubMed: 19526360].
  108. Lode et al., 2000: Lode HN, Pertl U, Xiang R, Gaedicke G, Reisfeld RA. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Medical and pediatric oncology. 2000; 35(6); 641-646. [PubMed: 11107137].
  109. Lotem et al., 2004: Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, Isacson R, Kaduri L, Merims S, Frankenburg S, Peretz T. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. British journal of cancer. 2004; 90(4); 773-780. [PubMed: 14970852].
  110. Ly et al., 2013: Ly LV, Sluijter M, van der Burg SH, Jager MJ, van Hall T. Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma. Journal of immunology (Baltimore, Md. : 1950). 2013; 190(1); 489-496. [PubMed: 23203930].
  111. MacGregor et al., 1977: MacGregor AB, Falk RE, Landi S, Ambus U, Samuel ES, Langer B. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin. Canadian journal of surgery. Journal canadien de chirurgie. 1977; 20(1); 25-30. [PubMed: 832200].
  112. Manley et al., 2011: Manley CA, Leibman NF, Wolchok JD, Rivière IC, Bartido S, Craft DM, Bergman PJ. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine. 2011; 25(1); 94-99. [PubMed: 21143299].
  113. Maraskovsky et al., 2004: Maraskovsky E, Sjölander S, Drane DP, Schnurr M, Le TT, Mateo L, Luft T, Masterman KA, Tai TY, Chen Q, Green S, Sjölander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004; 10(8); 2879-2890. [PubMed: 15102697].
  114. Maruyama et al., 2000: Maruyama H, Zaloudik J, Li W, Sperlagh M, Koido T, Somasundaram R, Scheck S, Prewett M, Herlyn D. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. Cancer immunology, immunotherapy : CII. 2000; 49(3); 123-132. [PubMed: 10881691].
  115. Mattarollo et al., 2013: Mattarollo SR, Steegh K, Li M, Duret H, Foong Ngiow S, Smyth MJ. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. Immunology and cell biology. 2013; 91(1); 105-114. [PubMed: 23090488].
  116. McNeel et al., 2009: McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009; 27(25); 4047-4054. [PubMed: 19636017].
  117. Meyer et al., 2005: Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, Weigle B, Schmitz M, Mateo L, Schmidt B, Bernhard H, Jakob T, Hein R, Schuler G, Schuler-Thurner B, Wagner SN, Drexler I, Sutter G, Arndtz N, Chaplin P, Metz J, Enk A, Huber C, Wölfel T. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer immunology, immunotherapy : CII. 2005; 54(5); 453-467. [PubMed: 15627214].
  118. Miguel et al., 2012: Miguel A, Herrero MJ, Sendra L, Botella R, Algás R, Sánchez M, Aliño SF. Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine model. Toxins. 2012; 4(11); 1058-1081. [PubMed: 23202306].
  119. Miguel et al., 2013: Miguel A, Herrero MJ, Sendra L, Botella R, Algás R, Sánchez M, Aliño SF. Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines. Cancer gene therapy. 2013; 20(10); 576-581. [PubMed: 23969885].
  120. Mincheff et al., 2000: Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. European urology. 2000; 38(2); 208-217. [PubMed: 10895014].
  121. Mincheff et al., 2006: Mincheff M, Zoubak S, Makogonenko Y. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals. Cancer gene therapy. 2006; 13(4); 436-444. [PubMed: 16276349].
  122. Mittelman et al., 1995: Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S, Ferrone S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 1995; 1(7); 705-713. [PubMed: 9816036].
  123. Mohanty et al., 2007: Mohanty K, Saha A, Pal S, Mallick P, Chatterjee SK, Foon KA, Bhattacharya-Chatterjee M. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu. Breast cancer research and treatment. 2007; 104(1); 1-11. [PubMed: 17004107].
  124. Mordoh et al., 2013: Mordoh J, Tapia IJ, Barrio MM. A word of caution: do not wake sleeping dogs; micrometastases of melanoma suddenly grew after progesterone treatment. BMC cancer. 2013; 13; 132. [PubMed: 23510193].
  125. Morera et al., 2008: Morera Y, Bequet-Romero M, Ayala M, Lamdán H, Agger EM, Andersen P, Gavilondo JV. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis. 2008; 11(4); 381-393. [PubMed: 19034678].
  126. Morton et al., 1992: Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Annals of surgery. 1992; 216(4); 463-482. [PubMed: 1417196].
  127. Narayanan et al., 2004: Narayanan K, Jaramillo A, Benshoff ND, Campbell LG, Fleming TP, Dietz JR, Mohanakumar T. Response of established human breast tumors to vaccination with mammaglobin-A cDNA. Journal of the National Cancer Institute. 2004; 96(18); 1388-1396. [PubMed: 15367572].
  128. Nicholaou et al., 2009: Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, Tan B, Maraskovsky E, Miloradovic L, Hopkins W, Pan L, Venhaus R, Hoffman EW, Chen W, Cebon J. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(6); 2166-2173. [PubMed: 19276262].
  129. Nicholson et al., 2003: Nicholson S, Guile K, John J, Clarke IA, Diffley J, Donnellan P, Michael A, Szlosarek P, Dalgleish AG. A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma research. 2003; 13(4); 389-393. [PubMed: 12883365].
  130. Niethammer et al., 2002: Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nature medicine. 2002; 8(12); 1369-1375. [PubMed: 12415261].
  131. Nigro et al., 2009: Nigro EA, Brini AT, Soprana E, Ambrosi A, Dombrowicz D, Siccardi AG, Vangelista L. Antitumor IgE adjuvanticity: key role of Fc epsilon RI. Journal of immunology (Baltimore, Md. : 1950). 2009; 183(7); 4530-4536. [PubMed: 19748979].
  132. O'Connor et al., 1978: O'Connor TP, Labandter HP, Hiles RW, Bodenham DC. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma. British journal of plastic surgery. 1978; 31(4); 317-322. [PubMed: 361132].
  133. Odin et al., 2001: Odin L, Favrot M, Poujol D, Michot JP, Moingeon P, Tartaglia J, Puisieux I. Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53. Cancer gene therapy. 2001; 8(2); 87-98. [PubMed: 11263530].
  134. Oka et al., 2006: Oka Y, Tsuboi A, Kawakami M, Elisseeva OA, Nakajima H, Udaka K, Kawase I, Oji Y, Sugiyama H. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Current medicinal chemistry. 2006; 13(20); 2345-2352. [PubMed: 16918359].
  135. Overwijk et al., 1999: Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(6); 2982-2987. [PubMed: 10077623].
  136. Pavlenko et al., 2004: Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellström M, Kiessling R, Masucci G, Wersäll P, Nilsson S, Pisa P. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. British journal of cancer. 2004; 91(4); 688-694. [PubMed: 15280930].
  137. Pertl et al., 2003: Pertl U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA. Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood. 2003; 101(2); 649-654. [PubMed: 12393580].
  138. Pope et al., 1994: Pope BL, Sigindere J, Chourmouzis E, MacIntyre P, Goodman MG. 7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine. Cancer immunology, immunotherapy : CII. 1994; 38(2); 83-91. [PubMed: 8306370].
  139. Pullarkat et al., 2003: Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(4); 1301-1312. [PubMed: 12684398].
  140. Qin et al., 2005: Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Immunology letters. 2005; 99(1); 85-93. [PubMed: 15894116].
  141. Quirt et al., 1991: Quirt IC, Shelley WE, Pater JL, Bodurtha AJ, McCulloch PB, McPherson TA, Paterson AH, Prentice R, Silver HK, Willan AR. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991; 9(5); 729-735. [PubMed: 2016615].
  142. Rakhmilevich et al., 2001: Rakhmilevich AL, Imboden M, Hao Z, Macklin MD, Roberts T, Wright KM, Albertini MR, Yang NS, Sondel PM. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001; 7(4); 952-961. [PubMed: 11309346].
  143. Reali et al., 2001: Reali E, Greiner JW, Corti A, Gould HJ, Bottazzoli F, Paganelli G, Schlom J, Siccardi AG. IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. Cancer research. 2001; 61(14); 5517-5522. [PubMed: 11454701].
  144. Reid et al., 2004: Reid Y, Storts D, Riss T, Minor L. Authentication of Human Cell Lines by STR DNA Profiling Analysis. . 2004; ; . [PubMed: 23805434].
  145. Ribas et al., 2010: Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, Rodriguez MJ, Prieto VG, Glaspy JA, Oseguera DK, Hernandez J, Villanueva A, Chmielowski B, Mitsky P, Bercovici N, Wasserman E, Landais D, Ross MI. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. Journal of translational medicine. 2010; 8; 89. [PubMed: 20875102].
  146. Rice et al., 2004: Rice J, Buchan S, Dewchand H, Simpson E, Stevenson FK. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire. Journal of immunology (Baltimore, Md. : 1950). 2004; 173(7); 4492-4499. [PubMed: 15383580].
  147. Ricupito et al., 2013: Ricupito A, Grioni M, Calcinotto A, Hess Michelini R, Longhi R, Mondino A, Bellone M. Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings. Cancer research. 2013; 73(12); 3545-3554. [PubMed: 23539449].
  148. Rinaldi et al., 2008: Rinaldi M, Fioretti D, Iurescia S, Signori E, Pierimarchi P, Seripa D, Tonon G, Fazio VM. Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model. Biochemical and biophysical research communications. 2008; 370(2); 279-284. [PubMed: 18364239].
  149. Robert et al., 2013: Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19(8); 2232-2239. [PubMed: 23444228].
  150. Roos et al., 2005: Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. The Prostate. 2005; 62(3); 217-223. [PubMed: 15389792].
  151. Rosenberg et al., 1998: Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature medicine. 1998; 4(3); 321-327. [PubMed: 9500606].
  152. Ruan et al., 2009: Ruan Z, Yang Z, Wang Y, Wang H, Chen Y, Shang X, Yang C, Guo S, Han J, Liang H, Wu Y. DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009; 32(5); 486-491. [PubMed: 19609240].
  153. Russo et al., 2007: Russo V, Cipponi A, Raccosta L, Rainelli C, Fontana R, Maggioni D, Lunghi F, Mukenge S, Ciceri F, Bregni M, Bordignon C, Traversari C. Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity. The Journal of clinical investigation. 2007; 117(10); 3087-3096. [PubMed: 17885685].
  154. Russo et al., 2013: Russo V, Pilla L, Lunghi F, Crocchiolo R, Greco R, Ciceri F, Maggioni D, Fontana R, Mukenge S, Rivoltini L, Rigamonti G, Mercuri SR, Nicoletti R, Maschio AD, Gianolli L, Fazio F, Marchianò A, Florio AD, Maio M, Salomoni M, Gallo-Stampino C, Fiacco MD, Lambiase A, Coulie PG, Patuzzo R, Parmiani G, Traversari C, Bordignon C, Santinami M, Bregni M. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. International journal of cancer. Journal international du cancer. 2013; 132(11); 2557-2566. [PubMed: 23151995].
  155. Saha et al., 2004: Saha A, Chatterjee SK, Foon KA, Primus FJ, Sreedharan S, Mohanty K, Bhattacharya-Chatterjee M. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer research. 2004; 64(14); 4995-5003. [PubMed: 15256474].
  156. Salerno et al., 2013: Salerno EP, Shea SM, Olson WC, Petroni GR, Smolkin ME, McSkimming C, Chianese-Bullock KA, Slingluff CL Jr. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer immunology, immunotherapy : CII. 2013; 62(7); 1149-1159. [PubMed: 23657629].
  157. Sawada et al., 2012: Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T. Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012; 18(13); 3686-3696. [PubMed: 22577059].
  158. Schwartzentruber et al., 2011: Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. The New England journal of medicine. 2011; 364(22); 2119-2127. [PubMed: 21631324].
  159. Seavey et al., 2009: Seavey MM, Maciag PC, Al-Rawi N, Sewell D, Paterson Y. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model. Journal of immunology (Baltimore, Md. : 1950). 2009; 182(9); 5537-5546. [PubMed: 19380802].
  160. Seino et al., 1997: Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nature medicine. 1997; 3(2); 165-170. [PubMed: 9018234].
  161. Slingluff et al., 2003: Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003; 21(21); 4016-4026. [PubMed: 14581425].
  162. Slingluff et al., 2008: Slingluff CL Jr, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, Chianese-Bullock KA, Neese PY, Deacon DH, Nail C, Merrill P, Fink R, Patterson JW, Rehm PK. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008; 26(30); 4973-4980. [PubMed: 18809608].
  163. Slingluff et al., 2011: Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, von Mehren M, Grosh WW. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29(21); 2924-2932. [PubMed: 21690475].
  164. Slingluff et al., 2013: Slingluff CL Jr, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, Whiteside TL, Leming PD, Kirkwood JM. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19(15); 4228-4238. [PubMed: 23653149].
  165. Smith et al., 2005: Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC, Coulie P, Schneider J, Hoffman E, Hawkins R, Harris AL, Cerundolo V. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. International journal of cancer. Journal international du cancer. 2005; 113(2); 259-266. [PubMed: 15386406].
  166. Soares et al., 2001: Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. Journal of immunology (Baltimore, Md. : 1950). 2001; 166(11); 6555-6563. [PubMed: 11359807].
  167. Sondak and Sosman, 2003: Sondak VK, Sosman JA. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Seminars in cancer biology. 2003; 13(6); 409-415. [PubMed: 15001159].
  168. Speiser et al., 2010: Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W, Walden P, Zippelius A, Conzett KB, Senti G, Voelter V, Cerottini JP, Guggisberg D, Willers J, Geldhof C, Romero P, Kündig T, Knuth A, Dummer R, Trefzer U, Bachmann MF. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010; 33(8); 848-858. [PubMed: 20842051].
  169. Stebbing et al., 2012: Stebbing J, Dalgleish A, Gifford-Moore A, Martin A, Gleeson C, Wilson G, Brunet LR, Grange J, Mudan S. An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012; 23(5); 1314-1319. [PubMed: 21930686].
  170. Steitz and Tüting, 2013: Steitz J, Tüting T. Biolistic DNA vaccination against melanoma. Methods in molecular biology (Clifton, N.J.). 2013; 940; 317-337. [PubMed: 23104352].
  171. Stevenson et al., 2004: Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ, Roddick JS, King AT, McNicholl F, Savelyeva N, Rice J. DNA vaccines to attack cancer. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101 Suppl 2; 14646-14652. [PubMed: 15292504].
  172. Storm et al., 1979: Storm FK, Sparks FC, Morton DL. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion. Surgery, gynecology & obstetrics. 1979; 149(1); 17-21. [PubMed: 451822].
  173. Sun et al., 2002: Sun X, Hodge LM, Jones HP, Tabor L, Simecka JW. Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. Vaccine. 2002; 20(9-10); 1466-1474. [PubMed: 11818167].
  174. Suriano et al., 2013: Suriano R, Rajoria S, L George A, Geliebter J, Wallack M, Tiwari RK. Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines. Journal of Cancer. 2013; 4(5); 371-382. [PubMed: 23833682].
  175. Syrengelas et al., 1996: Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nature medicine. 1996; 2(9); 1038-1041. [PubMed: 8782465].
  176. Tagawa et al., 2003: Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer. 2003; 98(1); 144-154. [PubMed: 12833467].
  177. Tan et al., 2007: Tan GH, Li YN, Huang FY, Wang H, Bai RZ, Jang J. Combination of recombinant xenogeneic endoglin DNA and protein vaccination enhances anti-tumor effects. Immunological investigations. 2007; 36(4); 423-440. [PubMed: 17691024].
  178. Tan et al., 2013: Tan C, Reddy V, Dannull J, Ding E, Nair SK, Tyler DS, Pruitt SK, Lee WT. Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. Journal of translational medicine. 2013; 11; 148. [PubMed: 23768240].
  179. Tanaka et al., 2011: Tanaka A, Jensen JD, Prado R, Riemann H, Shellman YG, Norris DA, Chin L, Yee C, Fujita M. Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene therapy. 2011; 18(8); 827-834. [PubMed: 21390072].
  180. Tanaka et al., 2012: Tanaka K, Ishikawa S, Matsui Y, Kawanishi T, Tamesada M, Harashima N, Harada M. Combining a peptide vaccine with oral ingestion of Lentinula edodes mycelia extract enhances anti-tumor activity in B16 melanoma-bearing mice. Cancer immunology, immunotherapy : CII. 2012; ; . [PubMed: 22588648].
  181. Tarhini et al., 2012: Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. Journal of immunotherapy (Hagerstown, Md. : 1997). 2012; 35(9); 702-710. [PubMed: 23090079].
  182. Thatcher and Crowther, 1977: Thatcher N, Crowther D. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients. Developments in biological standardization. 1977; 38; 449-453. [PubMed: 608536].
  183. Thirdborough et al., 2002: Thirdborough SM, Radcliffe JN, Friedmann PS, Stevenson FK. Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma. Cancer research. 2002; 62(6); 1757-1760. [PubMed: 11912151].
  184. Timmerman et al., 2002: Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer research. 2002; 62(20); 5845-5852. [PubMed: 12384547].
  185. Trepiakas et al., 2010: Trepiakas R, Berntsen A, Hadrup SR, Bjørn J, Geertsen PF, Straten PT, Andersen MH, Pedersen AE, Soleimani A, Lorentzen T, Johansen JS, Svane IM. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy. 2010; 12(6); 721-734. [PubMed: 20429791].
  186. Varella et al., 1981: Varella AD, Bandiera DC, de Amorim AR Sr, Calvis LA, Santos IO, Escaleira N, Gentil F. Treatment of disseminated malignant melanoma with high-dose oral BCG. Cancer. 1981; 48(6); 1353-1362. [PubMed: 7023654].
  187. Vence et al., 2013: Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. Journal of immunotherapy (Hagerstown, Md. : 1997). 2013; 36(4); 276-286. [PubMed: 23603862].
  188. Vollmer et al., 1999: Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Economou JS. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer research. 1999; 59(13); 3064-3067. [PubMed: 10397245].
  189. Wagner et al., 2000: Wagner SN, Wagner C, Lührs P, Weimann TK, Kutil R, Goos M, Stingl G, Schneeberger A. Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo. The Journal of investigative dermatology. 2000; 115(6); 1082-1087. [PubMed: 11121145].
  190. Wagner et al., 2007: Wagner S, Jasinska J, Breiteneder H, Kundi M, Pehamberger H, Scheiner O, Zielinski CC, Wiedermann U. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast cancer research and treatment. 2007; 106(1); 29-38. [PubMed: 17203384].
  191. Wallack et al., 1986: Wallack MK, McNally K, Michaelides M, Bash J, Bartolucci A, Siegler H, Balch C, Wanebo H. A phase I/II SECSG (Southeastern Cancer Study Group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO). The American surgeon. 1986; 52(3); 148-151. [PubMed: 3513682].
  192. Wang et al., 2008: Wang YJ, Hou Y, Huang H, Liu GR, White AP, Liu SL. Two oral HBx vaccines delivered by live attenuated Salmonella: both eliciting effective anti-tumor immunity. Cancer letters. 2008; 263(1); 67-76. [PubMed: 18226855].
  193. Wang et al., 2013: Wang J, Wang X, Chen Y, Wan M, Xiang Z, Wu X, Wei H, Wang L, Zhang P, Wang L, Yu Y. Immunization with a HSP65-HER2 fusion peptide selectively eliminates HER2(+) B16 melanoma cells in a xenograft tumor mouse model. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34(1); 193-201. [PubMed: 23055194].
  194. Wang et al., 2013: Wang Z, You H, Song S. [Inhibiting effect of IL-10 in tumor microenvironment on anti-tumor activity of SOCS1-silenced DC vaccine]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology. 2013; 29(4); 379-383. [PubMed: 23643168].
  195. Watson and Gilliam, 2001: Watson SA, Gilliam AD. G17DT--a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert opinion on biological therapy. 2001; 1(2); 309-317. [PubMed: 11727538].
  196. Wätzig and Knopf, 1979: Wätzig V, Knopf B. [Clinical administration of BCG-immunotherapy in malignant melanoma (author's transl)]. Archiv fur Geschwulstforschung. 1979; 49(2); 140-145. [PubMed: 475550].
  197. Weber et al., 1998: Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ, Houghton AN. Tumor immunity and autoimmunity induced by immunization with homologous DNA. The Journal of clinical investigation. 1998; 102(6); 1258-1264. [PubMed: 9739060].
  198. Weber et al., 2008: Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, Miles S, Liu X, Obrocea M, Qiu Z, Bot A. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008; 31(2); 215-223. [PubMed: 18481391].
  199. Wiki: Cancer: Cancer [http://en.wikipedia.org/wiki/Cancer]
  200. Wilgenhof et al., 2011: Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, De Coninck A, Van Riet I, Verfaillie G, Vandeloo J, Bonehill A, Thielemans K, Neyns B. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. Journal of immunotherapy (Hagerstown, Md. : 1997). 2011; 34(5); 448-456. [PubMed: 21577140].
  201. Williams et al., 2008: Williams BB, Wall M, Miao RY, Williams B, Bertoncello I, Kershaw MH, Mantamadiotis T, Haber M, Norris MD, Gautam A, Darcy PK, Ramsay RG. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer. Cancer immunology, immunotherapy : CII. 2008; 57(11); 1635-1645. [PubMed: 18386000].
  202. Wolchok et al., 2010: Wolchok JD, Weber JS, Hamid O, Lebbé C, Maio M, Schadendorf D, de Pril V, Heller K, Chen TT, Ibrahim R, Hoos A, O'Day SJ. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer immunity. 2010; 10; 9. [PubMed: 20957980].
  203. Wolfraim et al., 2013: Wolfraim LA, Takahara M, Viley AM, Shivakumar R, Nieda M, Maekawa R, Liu LN, Peshwa MV. Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL. International immunopharmacology. 2013; 15(3); 488-497. [PubMed: 23474736].
  204. Woods and Cebon, 2013: Woods K, Cebon J. Tumor-specific T-cell help is associated with improved survival in melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19(15); 4021-4023. [PubMed: 23864163].
  205. Wu et al., 2013: Wu H, Han Y, Qin Y, Cao C, Xia Y, Liu C, Wang Y. Whole-cell vaccine coated with recombinant calreticulin enhances activation of dendritic cells and induces tumour-specific immune responses. Oncology reports. 2013; 29(2); 529-534. [PubMed: 23166014].
  206. Xiang et al., 2008: Xiang R, Luo Y, Niethammer AG, Reisfeld RA. Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunological reviews. 2008; 222; 117-128. [PubMed: 18363997].
  207. Xie et al., 2013: Xie Y, Wang L, Freywald A, Qureshi M, Chen Y, Xiang J. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling. Cellular & molecular immunology. 2013; 10(1); 72-77. [PubMed: 23042534].
  208. Xu et al., 2013: Xu G, Smith T, Grey F, Hill AB. Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice. Biochemical and biophysical research communications. 2013; 437(2); 287-291. [PubMed: 23811402].
  209. Xu et al., 2013: Xu M, Xing Y, Zhou L, Yang X, Yao W, Xiao W, Ge C, Ma Y, Yang J, Wu J, Cao R, Li T, Liu J. Improved efficacy of therapeutic vaccination with viable human umbilical vein endothelial cells against murine melanoma by introduction of OK432 as adjuvant. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34(3); 1399-1408. [PubMed: 23456765].
  210. Yang et al., 1995: Yang G, Hellström KE, Hellström I, Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. Journal of immunology (Baltimore, Md. : 1950). 1995; 154(6); 2794-2800. [PubMed: 7533183].
  211. Yu et al., 2013: Yu X, Guo C, Yi H, Qian J, Fisher PB, Subjeck JR, Wang XY. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity. Cancer research. 2013; 73(7); 2093-2103. [PubMed: 23333935].
  212. Zhai et al., 1996: Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, Couture LA, Smith AE, Rosenberg SA. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. Journal of immunology (Baltimore, Md. : 1950). 1996; 156(2); 700-710. [PubMed: 8543823].
  213. Zhang et al., 2005: Zhang M, Obata C, Hisaeda H, Ishii K, Murata S, Chiba T, Tanaka K, Li Y, Furue M, Chou B, Imai T, Duan X, Himeno K. A novel DNA vaccine based on ubiquitin-proteasome pathway targeting 'self'-antigens expressed in melanoma/melanocyte. Gene therapy. 2005; 12(13); 1049-1057. [PubMed: 15800663].
  214. Zhang et al., 2007: Zhang X, Yu C, Zhao J, Fu L, Yi S, Liu S, Yu T, Chen W. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. The journal of gene medicine. 2007; 9(8); 715-726. [PubMed: 17595048].
  215. Zhang et al., 2012: Zhang H, Wang Y, Liu C, Zhang L, Xia Q, Zhang Y, Wu J, Jiang C, Chen Y, Wu Y, Zha X, Yu X, Kong W. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Cancer immunology, immunotherapy : CII. 2012; ; . [PubMed: 22706381].

Canine adenovirus type 1

  1. Merck Vet Manual: Infectious Canine Hepatitis: Merck Veterinary Manual- Infectious Canine Hepatitis: Introduction [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/57200.htm]

Canine Adenovirus Type 2

  1. Buonavoglia and Martella, 2007: Buonavoglia C, Martella V. Canine respiratory viruses. Veterinary research. 2007; 38(2); 355-373. [PubMed: 17296161].

Canine coronavirus

  1. Pardo et al., 1999: Pardo MC, M. Mackowiak. Efficacy of a new canine-origin, modified-live virus vaccine against canine coronavirus. Canine Practice. 1999; 24; 6-8.
  2. Wiki: Canine coronavirus: Canine coronavirus [http://en.wikipedia.org/wiki/Canine_coronavirus]

Canine distemper virus

  1. Fischer et al., 2002: Fischer L, Tronel JP, Pardo-David C, Tanner P, Colombet G, Minke J, Audonnet JC. Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge. Vaccine. 2002; 20(29-30); 3485-3497. [PubMed: 12297394].
  2. Jensen et al., 2009: Jensen TH, Nielsen L, Aasted B, Blixenkrone-Møller M. Early life DNA vaccination with the H gene of Canine distemper virus induces robust protection against distemper. Vaccine. 2009; 27(38); 5178-5183. [PubMed: 19596418].
  3. Wiki: Canine distemper virus: Canine distemper virus [http://en.wikipedia.org/wiki/Canine_distemper_virus]

Canine parainfluenza virus

  1. Buonavoglia and Martella, 2007: Buonavoglia C, Martella V. Canine respiratory viruses. Veterinary research. 2007; 38(2); 355-373. [PubMed: 17296161].

Canine parvovirus

  1. Jiang et al., 1998: Jiang W, Baker HJ, Swango LJ, Schorr J, Self MJ, Smith BF. Nucleic acid immunization protects dogs against challenge with virulent canine parvovirus. Vaccine. 1998; 16(6); 601-607. [PubMed: 9569471].
  2. Langeveld et al., 2001: Langeveld JP, Brennan FR, Martínez-Torrecuadrada JL, Jones TD, Boshuizen RS, Vela C, Casal JI, Kamstrup S, Dalsgaard K, Meloen RH, Bendig MM, Hamilton WD. Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus. Vaccine. 2001; 19(27); 3661-3670. [PubMed: 11395200].
  3. Wiki: Canine parvovirus: Canine parvovirus [http://en.wikipedia.org/wiki/Canine_parvovirus]

Chicken Anemia Virus

  1. Merck Vet Manual: Chicken Anemia Virus Infection: Merck Vet Manual: Chicken Anemia Virus Infection [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/200200.htm]

Chlamydia muridarum

  1. Faludi et al., 2009: Faludi I, Burian K, Csanadi A, Miczak A, Lu X, Kakkar VV, Gonczol E, Endresz V. Adjuvant modulation of the immune response of mice against the LcrE protein of Chlamydophila pneumoniae. International journal of medical microbiology : IJMM. 2009; 299(7); 520-528. [PubMed: 19451031].
  2. McNeilly et al., 2007: McNeilly CL, Beagley KW, Moore RJ, Haring V, Timms P, Hafner LM. Expression library immunization confers partial protection against Chlamydia muridarum genital infection. Vaccine. 2007; 25(14); 2643-2655. [PubMed: 17239501].
  3. Skelding et al., 2006: Skelding KA, Hickey DK, Horvat JC, Bao S, Roberts KG, Finnie JM, Hansbro PM, Beagley KW. Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection. Vaccine. 2006; 24(3); 355-366. [PubMed: 16153755].
  4. Wang et al., 2009: Wang J, Chen L, Chen F, Zhang X, Zhang Y, Baseman J, Perdue S, Yeh IT, Shain R, Holland M, Bailey R, Mabey D, Yu P, Zhong G. A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice. Vaccine. 2009; 27(22); 2967-2980. [PubMed: 19428908].
  5. Wiki: Chlamydia muridarum: Chlamydia muridarum [http://en.wikipedia.org/wiki/Chlamydia_muridarum]
  6. Yu et al., 2009: Yu H, Jiang X, Shen C, Karunakaran KP, Brunham RC. Novel Chlamydia muridarum T cell antigens induce protective immunity against lung and genital tract infection in murine models. Journal of immunology (Baltimore, Md. : 1950). 2009; 182(3); 1602-1608. [PubMed: 19155509].
  7. Yu et al., 2010: Yu H, Jiang X, Shen C, Karunakaran KP, Jiang J, Rosin NL, Brunham RC. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells. Infection and immunity. 2010; 78(5); 2272-2282. [PubMed: 20231405].

Chlamydia trachomatis

  1. Darville and Hiltke, 2010: Darville T, Hiltke TJ. Pathogenesis of genital tract disease due to Chlamydia trachomatis. The Journal of infectious diseases. 2010; 201 Suppl 2; S114-125. [PubMed: 20524234].
  2. Schautteet et al., 2011: Schautteet K, Stuyven E, Beeckman DS, Van Acker S, Carlon M, Chiers K, Cox E, Vanrompay D. Protection of pigs against Chlamydia trachomatis challenge by administration of a MOMP-based DNA vaccine in the vaginal mucosa. Vaccine. 2011; 29(7); 1399-1407. [PubMed: 21195805].
  3. Zhong et al., 1993: Zhong G, Toth I, Reid R, Brunham RC. Immunogenicity evaluation of a lipidic amino acid-based synthetic peptide vaccine for Chlamydia trachomatis. Journal of immunology (Baltimore, Md. : 1950). 1993; 151(7); 3728-3736. [PubMed: 7690812].

Chlamydophila abortus

  1. Chalmers et al., 1997: Chalmers WS, Simpson J, Lee SJ, Baxendale W. Use of a live chlamydial vaccine to prevent ovine enzootic abortion. The Veterinary record. 1997; 141(3); 63-67. [PubMed: 9257434].
  2. Héchard et al., 2002: Héchard C, Grépinet O, Rodolakis A. Protection evaluation against Chlamydophila abortus challenge by DNA vaccination with a dnaK-encoding plasmid in pregnant and non-pregnant mice. Veterinary research. 2002; 33(3); 313-326. [PubMed: 12056482].
  3. Héchard et al., 2003: Héchard C, Grépinet O, Rodolakis A. Evaluation of protection against Chlamydophila abortus challenge after DNA immunization with the major outer-membrane protein-encoding gene in pregnant and non-pregnant mice. Journal of medical microbiology. 2003; 52(Pt 1); 35-40. [PubMed: 12488563].
  4. Stemke-Hale et al., 2005: Stemke-Hale K, Kaltenboeck B, DeGraves FJ, Sykes KF, Huang J, Bu CH, Johnston SA. Screening the whole genome of a pathogen in vivo for individual protective antigens. Vaccine. 2005; 23(23); 3016-3025. [PubMed: 15811648].
  5. Wiki: Chlamydophila abortus: Chlamydophila abortus [http://en.wikipedia.org/wiki/Chlamydophila_abortus]

Chlamydophila pneumoniae

  1. Faludi et al., 2009: Faludi I, Burian K, Csanadi A, Miczak A, Lu X, Kakkar VV, Gonczol E, Endresz V. Adjuvant modulation of the immune response of mice against the LcrE protein of Chlamydophila pneumoniae. International journal of medical microbiology : IJMM. 2009; 299(7); 520-528. [PubMed: 19451031].
  2. Li et al., 2006: Li D, Borovkov A, Vaglenov A, Wang C, Kim T, Gao D, Sykes KF, Kaltenboeck B. Mouse model of respiratory Chlamydia pneumoniae infection for a genomic screen of subunit vaccine candidates. Vaccine. 2006; 24(15); 2917-2927. [PubMed: 16434129].
  3. Penttilä et al., 2000: Penttilä T, Vuola JM, Puurula V, Anttila M, Sarvas M, Rautonen N, Mäkelä PH, Puolakkainen M. Immunity to Chlamydia pneumoniae induced by vaccination with DNA vectors expressing a cytoplasmic protein (Hsp60) or outer membrane proteins (MOMP and Omp2). Vaccine. 2000; 19(9-10); 1256-1265. [PubMed: 11137265].
  4. Svanholm et al., 2000: Svanholm C, Bandholtz L, Castaños-Velez E, Wigzell H, Rottenberg ME. Protective DNA immunization against Chlamydia pneumoniae. Scandinavian journal of immunology. 2000; 51(4); 345-353. [PubMed: 10736106].
  5. Tammiruusu et al., 2007: Tammiruusu A, Penttilä T, Lahesmaa R, Sarvas M, Puolakkainen M, Vuola JM. Intranasal administration of chlamydial outer protein N (CopN) induces protection against pulmonary Chlamydia pneumoniae infection in a mouse model. Vaccine. 2007; 25(2); 283-290. [PubMed: 16949182].
  6. Wiki: Chlamydophila pneumoniae: Chlamydophila pneumoniae [http://en.wikipedia.org/wiki/Chlamydophila_pneumoniae]

Chlamydophila psittaci

  1. Harkinezhad et al., 2009: Harkinezhad T, Schautteet K, Vanrompay D. Protection of budgerigars (Melopsittacus undulatus) against Chlamydophila psittaci challenge by DNA vaccination. Veterinary research. 2009; 40(6); 61. [PubMed: 19640395].
  2. Verminnen et al., 2010: Verminnen K, Beeckman DS, Sanders NN, De Smedt S, Vanrompay DC. Vaccination of turkeys against Chlamydophila psittaci through optimised DNA formulation and administration. Vaccine. 2010; 28(18); 3095-3105. [PubMed: 20199760].
  3. Wiki: Chlamydophila psittaci: Chlamydophila psittaci [http://en.wikipedia.org/wiki/Chlamydophila_psittaci]
  4. Zhang et al., 2009: Zhang X, Yuan Z, Duan Q, Zhu H, Yu H, Wang Q. Mucosal immunity in mice induced by orally administered transgenic rice. Vaccine. 2009; 27(10); 1596-1600. [PubMed: 19146896].

Classical swine fever virus

  1. Fernandez-Sainz et al., 2009: Fernandez-Sainz I, Holinka LG, Gavrilov BK, Prarat MV, Gladue D, Lu Z, Jia W, Risatti GR, Borca MV. Alteration of the N-linked glycosylation condition in E1 glycoprotein of Classical Swine Fever Virus strain Brescia alters virulence in swine. Virology. 2009; 386(1); 210-216. [PubMed: 19203774].
  2. Hammond et al., 2001: Hammond JM, Jansen ES, Morrissy CJ, Goff WV, Meehan GC, Williamson MM, Lenghaus C, Sproat KW, Andrew ME, Coupar BE, Johnson MA. A prime-boost vaccination strategy using naked DNA followed by recombinant porcine adenovirus protects pigs from classical swine fever. Veterinary microbiology. 2001; 80(2); 101-119. [PubMed: 11295331].
  3. Hulst et al., 1993: Hulst MM, Westra DF, Wensvoort G, Moormann RJ. Glycoprotein E1 of hog cholera virus expressed in insect cells protects swine from hog cholera. Journal of virology. 1993; 67(9); 5435-5442. [PubMed: 8350404].
  4. König et al., 1995: König M, Lengsfeld T, Pauly T, Stark R, Thiel HJ. Classical swine fever virus: independent induction of protective immunity by two structural glycoproteins. Journal of virology. 1995; 69(10); 6479-6486. [PubMed: 7666549].
  5. Lin et al., 2009: Lin GJ, Liu TY, Tseng YY, Chen ZW, You CC, Hsuan SL, Chien MS, Huang C. Yeast-expressed classical swine fever virus glycoprotein E2 induces a protective immune response. Veterinary microbiology. 2009; 139(3-4); 369-374. [PubMed: 19625145].
  6. Maurer et al., 2005: Maurer R, Stettler P, Ruggli N, Hofmann MA, Tratschin JD. Oronasal vaccination with classical swine fever virus (CSFV) replicon particles with either partial or complete deletion of the E2 gene induces partial protection against lethal challenge with highly virulent CSFV. Vaccine. 2005; 23(25); 3318-3328. [PubMed: 15837238].
  7. Moormann et al., 2000: Moormann RJ, Bouma A, Kramps JA, Terpstra C, De Smit HJ. Development of a classical swine fever subunit marker vaccine and companion diagnostic test. Veterinary microbiology. 2000; 73(2-3); 209-219. [PubMed: 10785329].
  8. Sainz et al., 2008: Sainz IF, Holinka LG, Lu Z, Risatti GR, Borca MV. Removal of a N-linked glycosylation site of classical swine fever virus strain Brescia Erns glycoprotein affects virulence in swine. Virology. 2008; 370(1); 122-129. [PubMed: 17904607].
  9. Tarradas et al., 2011: Tarradas J, Álvarez B, Fraile L, Rosell R, Muñoz M, Galindo-Cardiel I, Domingo M, Dominguez J, Ezquerra A, Sobrino F, Ganges L. Immunomodulatory effect of swine CCL20 chemokine in DNA vaccination against CSFV. Veterinary immunology and immunopathology. 2011; 142(3-4); 243-251. [PubMed: 21684019].
  10. van, 2003: van Aarle P. Suitability of an E2 subunit vaccine of classical swine fever in combination with the E(rns)-marker-test for eradication through vaccination. Developments in biologicals. 2003; 114; 193-200. [PubMed: 14677689].
  11. Wan et al., 2010: Wan C, Yi L, Yang Z, Yang J, Shao H, Zhang C, Pan Z. The Toll-like receptor adaptor molecule TRIF enhances DNA vaccination against classical swine fever. Veterinary immunology and immunopathology. 2010; 137(1-2); 47-53. [PubMed: 20466439].
  12. Wiki: Classical swine fever: Classical swine fever [http://en.wikipedia.org/wiki/Classical_swine_fever_virus]

Clostridium botulinum

  1. Arimitsu et al., 2004: Arimitsu H, Lee JC, Sakaguchi Y, Hayakawa Y, Hayashi M, Nakaura M, Takai H, Lin SN, Mukamoto M, Murphy T, Oguma K. Vaccination with recombinant whole heavy chain fragments of Clostridium botulinum Type C and D neurotoxins. Clinical and diagnostic laboratory immunology. 2004 May; 11(3); 496-502. [PubMed: 15138174].
  2. Arnon et al., 2001: Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K. Botulinum toxin as a biological weapon: medical and public health management. JAMA : the journal of the American Medical Association. 2001 Feb 28; 285(8); 1059-70. [PubMed: 11209178 ].
  3. Baldwin et al., 2005: Baldwin MR, Tepp WH, Pier CL, Bradshaw M, Ho M, Wilson BA, Fritz RB, Johnson EA, Barbieri JT. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infection and immunity. 2005; 73(10); 6998-7005. [PubMed: 16177380].
  4. Bennett et al., 2003: Bennett AM, Perkins SD, Holley JL. DNA vaccination protects against botulinum neurotoxin type F. Vaccine. 2003 Jul 4; 21(23); 3110-7. [PubMed: 12804837 ].
  5. Boles et al., 2006: Boles J, West M, Montgomery V, Tammariello R, Pitt ML, Gibbs P, Smith L, LeClaire RD. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon : official journal of the International Society on Toxinology. 2006 Jun 15; 47(8); 877-84. [PubMed: 16730042 ].
  6. Byrne et al., 1998: Byrne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infection and immunity. 1998 Oct; 66(10); 4817-22. [PubMed: 9746584].
  7. Byrne et al., 2000: Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie. 2000 Sep-Oct; 82(9-10); 955-66. [PubMed: 11086225].
  8. Clayton et al., 1995: Clayton MA, Clayton JM, Brown DR, Middlebrook JL. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infection and immunity. 1995; 63(7); 2738-2742. [PubMed: 7790092].
  9. Jathoul et al., 2004: Jathoul AP, Holley JL, Garmory HS. Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters. Vaccine. 2004 Sep 28; 22(29-30); 3942-6. [PubMed: 15364442].
  10. Johnson, 1997: Johnson S. Antibody responses to clostridial infection in humans. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1997 Sep; 25 Suppl 2; S173-7. [PubMed: 9310668].
  11. Lee et al., 2006: Lee JS, Groebner JL, Hadjipanayis AG, Negley DL, Schmaljohn AL, Welkos SL, Smith LA, Smith JF. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine. 2006 Nov 17; 24(47-48); 6886-92. [PubMed: 16828936].
  12. Lohenry et al., 2006: Lohenry K, Foulke K. Botulism: rare, but deadly. JAAPA : official journal of the American Academy of Physician Assistants. 2006 Nov; 19(11); 41-5. [PubMed: 17124790 ].
  13. Martinez et al., 1999: Martinez R, Wobeser G. Immunization of ducks for type C botulism. Journal of wildlife diseases. 1999 Oct; 35(4); 710-5. [PubMed: 10574530 ].
  14. NCBI: Entrez Gene [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=gene]
  15. PathPort: Virginia Bioinformatics Institute [http://pathport.vbi.vt.edu/pathinfo/pathogens/Clostridium_botulinum_Info.shtml]
  16. Rubin et al., 1982: Rubin LG, Dezfulian M, Yolken RH. Serum antibody response to Clostridium botulinum toxin in infant botulism. Journal of clinical microbiology. 1982 Oct; 16(4); 770-1. [PubMed: 7153329].
  17. Siegel, 1988: Siegel LS. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. Journal of clinical microbiology. 1988 Nov; 26(11); 2351-6. [PubMed: 3235662].
  18. Webb et al., 2009: Webb RP, Smith TJ, Wright P, Brown J, Smith LA. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine. 2009; 27(33); 4490-4497. [PubMed: 19450643].
  19. Yu et al., 2008: Yu YZ, Li N, Wang RL, Zhu HQ, Wang S, Yu WY, Sun ZW. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clinical and vaccine immunology : CVI. 2008; 15(12); 1819-1823. [PubMed: 18845829].
  20. Yu et al., 2009: Yu Y, Yu J, Li N, Wang S, Yu W, Sun Z. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors. Vaccine. 2009; 27(44); 6148-6153. [PubMed: 19712769].
  21. Zeng et al., 2007: Zeng M, Xu Q, Elias M, Pichichero ME, Simpson LL, Smith LA. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine. 2007; 25(43); 7540-7548. [PubMed: 17897756].

Clostridium perfringens

  1. Songer, 2010: Songer JG. Clostridia as agents of zoonotic disease. Veterinary microbiology. 2010; 140(3-4); 399-404. [PubMed: 19682805].
  2. Wiki: C. perfringens: Wiki: C. perfringens [http://en.wikipedia.org/wiki/C._perfringens]

Clostridium tetani

  1. Anderson et al., 1997: Anderson R, Gao XM, Papakonstantinopoulou A, Fairweather N, Roberts M, Dougan G. Immunization of mice with DNA encoding fragment C of tetanus toxin. Vaccine. 1997; 15(8); 827-829. [PubMed: 9234525].
  2. Brook, 2008: Brook I. Current concepts in the management of Clostridium tetani infection. Expert review of anti-infective therapy. 2008; 6(3); 327-336. [PubMed: 18588497].
  3. FDA Boostrix: FDA Boostrix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172925.htm]
  4. FDA Decavac: FDA Decavac [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094067.htm]
  5. FDA Infanrix: FDA Infanrix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101568.htm]
  6. FDA: Adacel: FDA: Adacel [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172481.htm]
  7. FDA: DAPTACEL: FDA: DAPTACEL [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101572.htm]
  8. FDA: dttadLB: FDA: Diphtheria and Tetanus Toxoids Adsorbed USP [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094012.htm]
  9. FDA: KINRIX: FDA: KINRIX [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172495.htm]
  10. FDA: Pediarix: FDA: Pediarix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm146759.htm]
  11. FDA: Pentacel: FDA: Pentacel Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172502.htm]
  12. FDA: Tenivac: FDA: Tenivac [http://www.fda.gov/BiologicsBloodVaccines/ucm152800.htm]
  13. FDA: Tetanus Toxoid: FDA: Tetanus Toxoid [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm166863.htm]
  14. FDA: Tetanus Toxoid Adsorbed by Sanofi Pasteur Inc: FDA: Tetanus Toxoid Adsorbed by Sanofi Pasteur Inc [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094068.htm]
  15. FDA: Tripedia: FDA: Tripedia [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101565.htm]
  16. Gupta and Siber, 1994: Gupta RK, Siber GR. Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. Biologicals : journal of the International Association of Biological Standardization. 1994; 22(1); 53-63. [PubMed: 8068314].
  17. He et al., 2000: He HJ, He ZY, Shi HJ, Zhu W, Yang GZ, Yuan QS, Wu XF. Cloning and Expression of Tetanus Toxin Fragment C in E.coli. Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica. 2000; 32(4); 322-326. [PubMed: 12075415].

Coccidioides spp.

  1. Awasthi et al., 2005: Awasthi S, Awasthi V, Magee DM, Coalson JJ. Efficacy of antigen 2/proline-rich antigen cDNA-transfected dendritic cells in immunization of mice against Coccidioides posadasii. Journal of immunology (Baltimore, Md. : 1950). 2005; 175(6); 3900-3906. [PubMed: 16148136].
  2. Delgado et al., 2003: Delgado N, Xue J, Yu JJ, Hung CY, Cole GT. A recombinant beta-1,3-glucanosyltransferase homolog of Coccidioides posadasii protects mice against coccidioidomycosis. Infection and immunity. 2003; 71(6); 3010-3019. [PubMed: 12761077].
  3. Hung et al., 2007: Hung CY, Xue J, Cole GT. Virulence mechanisms of coccidioides. Annals of the New York Academy of Sciences. 2007; 1111; 225-235. [PubMed: 17513466].
  4. Ivey et al., 2003: Ivey FD, Magee DM, Woitaske MD, Johnston SA, Cox RA. Identification of a protective antigen of Coccidioides immitis by expression library immunization. Vaccine. 2003; 21(27-30); 4359-4367. [PubMed: 14505918].
  5. Kirkland et al., 1998: Kirkland TN, Thomas PW, Finley F, Cole GT. Immunogenicity of a 48-kilodalton recombinant T-cell-reactive protein of Coccidioides immitis. Infection and immunity. 1998; 66(2); 424-431. [PubMed: 9453590].
  6. Li et al., 2001: Li K, Yu JJ, Hung CY, Lehmann PF, Cole GT. Recombinant urease and urease DNA of Coccidioides immitis elicit an immunoprotective response against coccidioidomycosis in mice. Infection and immunity. 2001; 69(5); 2878-2887. [PubMed: 11292702].
  7. Orsborn et al., 2006: Orsborn KI, Shubitz LF, Peng T, Kellner EM, Orbach MJ, Haynes PA, Galgiani JN. Protein expression profiling of Coccidioides posadasii by two-dimensional differential in-gel electrophoresis and evaluation of a newly recognized peroxisomal matrix protein as a recombinant vaccine candidate. Infection and immunity. 2006; 74(3); 1865-1872. [PubMed: 16495561].
  8. Tarcha et al., 2006a: Tarcha EJ, Basrur V, Hung CY, Gardner MJ, Cole GT. A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice. Infection and immunity. 2006; 74(1); 516-527. [PubMed: 16369008].
  9. Tarcha et al., 2006b: Tarcha EJ, Basrur V, Hung CY, Gardner MJ, Cole GT. Multivalent recombinant protein vaccine against coccidioidomycosis. Infection and immunity. 2006; 74(10); 5802-5813. [PubMed: 16988258].

Corynebacterium diphtheriae

  1. Adacel: Adacel [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172481.htm]
  2. Boostrix: Boostrix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172925.htm]
  3. CDC: Diphtheria: CDC: Diphtheria general information [http://www.cdc.gov/ncidod/dbmd/diseaseinfo/diptheria_t.htm]
  4. FDA: DAPTACEL: FDA: DAPTACEL Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101572.htm]
  5. FDA: Decavac: Decavac [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094067.htm]
  6. FDA: Diphtheria and Tetanus Toxoids Adsorbed USP: FDA: Diphtheria and Tetanus Toxoids Adsorbed USP [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094012.htm]
  7. FDA: INFANRIX: FDA: INFANRIX [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101568.htm]
  8. FDA: KINRIX: FDA: KINRIX Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172495.htm]
  9. FDA: Menactra: FDA: Menactra Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm176044.htm]
  10. FDA: Pediarix: FDA: Pediarix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm146759.htm]
  11. FDA: Pentacel: FDA: Pentacel Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172502.htm]
  12. FDA: Tripedia: FDA: Tripedia [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101565.htm]
  13. Holmes, 2000: Holmes RK. Biology and molecular epidemiology of diphtheria toxin and the tox gene. The Journal of infectious diseases. 2000; 181 Suppl 1; S156-167. [PubMed: 10657208].
  14. MicrobeWiki: C. diphtheriae: MicrobeWiki: C. diphtheriae [http://microbewiki.kenyon.edu/index.php/Corynebacterium_diphtheriae]
  15. Tenivac: Tenivac [http://www.fda.gov/cber/label/tenivaclb.pdf]
  16. Textbook of Bacteriology: Diphtheria [http://textbookofbacteriology.net/diphtheria]

Coxiella burnetii

  1. Ackland et al., 1994: Ackland JR, Worswick DA, Marmion BP. Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vax (CSL) 1985-1990. The Medical journal of Australia. 1994; 160(11); 704-708. [PubMed: 8202006 ].
  2. Akporiaye and Baca, 1983: Akporiaye ET, Baca OG. Superoxide anion production and superoxide dismutase and catalase activities in Coxiella burnetii. Journal of bacteriology. 1983; 154(1); 520-523. [PubMed: 6300038 ].
  3. Arricau-Bouvery et al., 2005: Arricau-Bouvery N, Souriau A, Bodier C, Dufour P, Rousset E, Rodolakis A. Effect of vaccination with phase I and phase II Coxiella burnetii vaccines in pregnant goats. Vaccine. 2005; 23(35); 4392-4402. [PubMed: 16005747 ].
  4. Brennan et al., 2004: Brennan RE, Russell K, Zhang G, Samuel JE. Both inducible nitric oxide synthase and NADPH oxidase contribute to the control of virulent phase I Coxiella burnetii infections. Infection and immunity. 2004; 72(11); 6666-6675. [PubMed: 15501800].
  5. Burton et al., 1971: Burton PR, Kordova N, Paretsky D. Electron microscopic studies of the rickettsia Coxiella burneti: entry, lysosomal response, and fate of rickettsial DNA in L-cells. Canadian journal of microbiology. 1971; 17(2); 143-150. [PubMed: 4100953].
  6. Burton et al., 1978: Burton PR, Stueckemann J, Welsh RM, Paretsky D. Some ultrastructural effects of persistent infections by the rickettsia Coxiella burnetii in mouse L cells and green monkey kidney (Vero) cells. Infection and immunity. 1978; 21(2); 556-566. [PubMed: 99368].
  7. Capo et al., 1999: Capo C, Lindberg FP, Meconi S, Zaffran Y, Tardei G, Brown EJ, Raoult D, Mege JL. Subversion of monocyte functions by coxiella burnetii: impairment of the cross-talk between alphavbeta3 integrin and CR3. Journal of immunology (Baltimore, Md. : 1950). 1999; 163(11); 6078-6085. [PubMed: 10570297].
  8. Fries et al., 1993: Fries LF, Waag DM, Williams JC. Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever. Infection and immunity. 1993; 61(4); 1251-1258. [PubMed: 8454328 ].
  9. Hackstadt and Williams, 1981: Hackstadt T, Williams JC. Biochemical stratagem for obligate parasitism of eukaryotic cells by Coxiella burnetii. Proceedings of the National Academy of Sciences of the United States of America. 1981; 78(5); 3240-3244. [PubMed: 6942430].
  10. Hackstadt et al., 1985: Hackstadt T, Peacock MG, Hitchcock PJ, Cole RL. Lipopolysaccharide variation in Coxiella burnetti: intrastrain heterogeneity in structure and antigenicity. Infection and immunity. 1985; 48(2); 359-365. [PubMed: 3988339 ].
  11. Johnson et al., 1977: Johnson JW, McLeod CG, Stookey JL, Higbee GA, Pedersen CE Jr. Lesions in guinea pigs infected with Coxiella burnetii strain M-44. The Journal of infectious diseases. 1977; 135(6); 995-998. [PubMed: 864292 ].
  12. Langley et al., 2003: Langley JM, Marrie TJ, Leblanc JC, Almudevar A, Resch L, Raoult D. Coxiella burnetii seropositivity in parturient women is associated with adverse pregnancy outcomes. American journal of obstetrics and gynecology. 2003; 189(1); 228-232. [PubMed: 12861167 ].
  13. Li et al., 2005: Li Q, Niu D, Wen B, Chen M, Qiu L, Zhang J. Protective immunity against Q fever induced with a recombinant P1 antigen fused with HspB of Coxiella burnetii. Annals of the New York Academy of Sciences. 2005; 1063; 130-142. [PubMed: 16481504 ].
  14. Mege et al., 1997: Mege JL, Maurin M, Capo C, Raoult D. Coxiella burnetii: the 'query' fever bacterium. A model of immune subversion by a strictly intracellular microorganism. FEMS microbiology reviews. 1997; 19(4); 209-217. [PubMed: 9167255 ].
  15. Ohkuma and Poole, 1978: Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proceedings of the National Academy of Sciences of the United States of America. 1978; 75(7); 3327-3331. [PubMed: 28524].
  16. Ormsbee, 1969: Ormsbee RA. Rickettsiae (as organisms). Annual review of microbiology. 1969; 23; 275-292. [PubMed: 4899075].
  17. Palmer et al., 1983: Palmer NC, Kierstead M, Key DW, Williams JC, Peacock MG, Vellend H. Placentitis and Abortion in Goats and Sheep in Ontario Caused by Coxiella burnetii. The Canadian veterinary journal. La revue veterinaire canadienne. 1983; 24(2); 60-61. [PubMed: 17422227].
  18. Robinson and Hasty, 1974: Robinson DM, Hasty SE. Production of a potent vaccine from the attenuated M-44 strain of Coxiella burneti. Applied microbiology. 1974; 27(4); 777-783. [PubMed: 4825980 ].
  19. Shannon et al., 2005: Shannon JG, Howe D, Heinzen RA. Virulent Coxiella burnetii does not activate human dendritic cells: role of lipopolysaccharide as a shielding molecule. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(24); 8722-8727. [PubMed: 15939879 ].
  20. Stoker and Marmion, 1955: Stoker MG, Marmion BP. The spread of Q fever from animals to man; the natural history of a rickettsial disease. Bulletin of the World Health Organization. 1955; 13(5); 781-806. [PubMed: 13284558 ].
  21. Tigertt et al., 1961: Tigertt WD, Beneson AS, Gochenour WS. Airborne Q fever. Bacteriological reviews. 1961; 25; 285-293. [PubMed: 13921201].
  22. Turco et al., 1984: Turco J, Thompson HA, Winkler HH. Interferon-gamma inhibits growth of Coxiella burnetii in mouse fibroblasts. Infection and immunity. 1984; 45(3); 781-783. [PubMed: 6432701 ].
  23. Waag et al., 1997: Waag DM, England MJ, Pitt ML. Comparative efficacy of a Coxiella burnetii chloroform:methanol residue (CMR) vaccine and a licensed cellular vaccine (Q-Vax) in rodents challenged by aerosol. Vaccine. 1997; 15(16); 1779-1783. [PubMed: 9364683 ].
  24. Waag et al., 2002: Waag DM, England MJ, Tammariello RF, Byrne WR, Gibbs P, Banfield CM, Pitt ML. Comparative efficacy and immunogenicity of Q fever chloroform:methanol residue (CMR) and phase I cellular (Q-Vax) vaccines in cynomolgus monkeys challenged by aerosol. Vaccine. 2002; 20(19-20); 2623-2634. [PubMed: 12057622 ].
  25. Waag, 2007: Waag DM. Coxiella burnetii: Host and bacterial responses to infection. Vaccine. 2007; 25(42); 7288-7295. [PubMed: 17825460 ].
  26. Waldhalm et al., 1978: Waldhalm DG, Stoenner HG, Simmons RE, Thomas LA. Abortion associated with Coxiella burnetii infection in dairy goats. Journal of the American Veterinary Medical Association. 1978; 173(12); 1580-1581. [PubMed: 748297 ].
  27. Williams and Cantrell, 1982: Williams JC, Cantrell JL. Biological and immunological properties of Coxiella burnetii vaccines in C57BL/10ScN endotoxin-nonresponder mice. Infection and immunity. 1982; 35(3); 1091-1102. [PubMed: 7068212].
  28. Williams and Thompson, 1991: Williams JC, Thompson HA. Methods for isolation, amplification, and purification of Coxiella burnetii. 73-115. Q Fever: The Biology of Coxiella burnetii. 1991. CRC Press, .
  29. Williams et al., 1990: Williams JC, Hoover TA, Waag DM, Banerjee-Bhatnagar N, Bolt CR, Scott GH. Antigenic structure of Coxiella burnetii. A comparison of lipopolysaccharide and protein antigens as vaccines against Q fever. Annals of the New York Academy of Sciences. 1990; 590; 370-380. [PubMed: 2378463].
  30. Zamboni et al., 2004: Zamboni DS, Campos MA, Torrecilhas AC, Kiss K, Samuel JE, Golenbock DT, Lauw FN, Roy CR, Almeida IC, Gazzinelli RT. Stimulation of toll-like receptor 2 by Coxiella burnetii is required for macrophage production of pro-inflammatory cytokines and resistance to infection. The Journal of biological chemistry. 2004; 279(52); 54405-54415. [PubMed: 15485838 ].

Cryptosporidium parvum

  1. Ehigiator et al., 2007: Ehigiator HN, Romagnoli P, Priest JW, Secor WE, Mead JR. Induction of murine immune responses by DNA encoding a 23-kDa antigen of Cryptosporidium parvum. Parasitology research. 2007; 101(4); 943-950. [PubMed: 17487508].
  2. Jenkins et al., 1999: Jenkins MC, O'Brien C, Trout J, Guidry A, Fayer R. Hyperimmune bovine colostrum specific for recombinant Cryptosporidium parvum antigen confers partial protection against cryptosporidiosis in immunosuppressed adult mice. Vaccine. 1999; 17(19); 2453-2460. [PubMed: 10392628].
  3. Wiki: Cryptosporidium parvum: Cryptosporidium parvum [http://en.wikipedia.org/wiki/Cryptosporidium_parvum]

Dengue Virus

  1. Azevedo et al., 2011: Azevedo AS, Yamamura AM, Freire MS, Trindade GF, Bonaldo M, Galler R, Alves AM. DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III. PloS one. 2011; 6(7); e20528. [PubMed: 21779317].
  2. Bray and Lai, 1991: Bray M, Lai CJ. Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology. 1991; 185(1); 505-508. [PubMed: 1926792].
  3. Chen et al., 2007: Chen L, Ewing D, Subramanian H, Block K, Rayner J, Alterson KD, Sedegah M, Hayes C, Porter K, Raviprakash K. A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques. Journal of virology. 2007; 81(21); 11634-11639. [PubMed: 17715224].
  4. Costa et al., 2006: Costa SM, Paes MV, Barreto DF, Pinhão AT, Barth OM, Queiroz JL, Armôa GR, Freire MS, Alves AM. Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence. Vaccine. 2006; 24(2); 195-205. [PubMed: 16122850].
  5. Delenda et al., 1994: Delenda C, Frenkiel MP, Deubel V. Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells. Archives of virology. 1994; 139(1-2); 197-207. [PubMed: 7826210].
  6. Konishi et al., 2000: Konishi E, Yamaoka M, Kurane I, Mason PW. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine. 2000; 18(11-12); 1133-1139. [PubMed: 10590335].
  7. Konishi et al., 2003: Konishi E, Terazawa A, Fujii A. Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and a relation to their immunogenicity in mice. Vaccine. 2003; 21(25-26); 3713-3720. [PubMed: 12922102].
  8. Konishi et al., 2006: Konishi E, Kosugi S, Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine. 2006; 24(12); 2200-2207. [PubMed: 16316713].
  9. Lima et al., 2011: Lima DM, de Paula SO, França RF, Palma PV, Morais FR, Gomes-Ruiz AC, de Aquino MT, da Fonseca BA. A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection. Vaccine. 2011; 29(4); 831-838. [PubMed: 21115054].
  10. Liu et al., 2006: Liu WT, Lin WT, Tsai CC, Chuang CC, Liao CL, Lin HC, Hung YW, Huang SS, Liang CC, Hsu HL, Wang HJ, Liu YT. Enhanced immune response by amphotericin B following NS1 protein prime-oral recombinant Salmonella vaccine boost vaccination protects mice from dengue virus challenge. Vaccine. 2006; 24(31-32); 5852-5861. [PubMed: 16759760].
  11. Martina et al., 2009: Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clinical microbiology reviews. 2009; 22(4); 564-581. [PubMed: 19822889].
  12. Porter et al., 1998: Porter KR, Kochel TJ, Wu SJ, Raviprakash K, Phillips I, Hayes CG. Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses. Archives of virology. 1998; 143(5); 997-991003. [PubMed: 9645204].
  13. Ramanathan et al., 2009: Ramanathan MP, Kuo YC, Selling BH, Li Q, Sardesai NY, Kim JJ, Weiner DB. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes. Vaccine. 2009; 27(46); 6444-6453. [PubMed: 19580892].
  14. Raviprakash et al., 2000: Raviprakash K, Porter KR, Kochel TJ, Ewing D, Simmons M, Phillips I, Murphy GS, Weiss WR, Hayes CG. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. The Journal of general virology. 2000; 81(Pt 7); 1659-1667. [PubMed: 10859370].
  15. Raviprakash et al., 2001: Raviprakash K, Marques E, Ewing D, Lu Y, Phillips I, Porter KR, Kochel TJ, August TJ, Hayes CG, Murphy GS. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology. 2001; 290(1); 74-82. [PubMed: 11883007].
  16. Raviprakash et al., 2006: Raviprakash K, Apt D, Brinkman A, Skinner C, Yang S, Dawes G, Ewing D, Wu SJ, Bass S, Punnonen J, Porter K. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology. 2006; 353(1); 166-173. [PubMed: 16814355].
  17. Wu et al., 2003: Wu SF, Liao CL, Lin YL, Yeh CT, Chen LK, Huang YF, Chou HY, Huang JL, Shaio MF, Sytwu HK. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine. 2003; 21(25-26); 3919-3929. [PubMed: 12922127].

Diabetes

  1. Balasa et al., 2001: Balasa B, Boehm BO, Fortnagel A, Karges W, Van Gunst K, Jung N, Camacho SA, Webb SR, Sarvetnick N. Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection. Clinical immunology (Orlando, Fla.). 2001; 99(2); 241-252. [PubMed: 11318596].
  2. Bot et al., 2001: Bot A, Smith D, Bot S, Hughes A, Wolfe T, Wang L, Woods C, von Herrath M. Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. Journal of immunology (Baltimore, Md. : 1950). 2001; 167(5); 2950-2955. [PubMed: 11509644].
  3. CDC - Basics about Diabetes: Basics about Diabetes [http://www.cdc.gov/diabetes/consumer/learn.htm]
  4. Filippova et al., 2001: Filippova M, Liu J, Escher A. Effects of plasmid DNA injection on cyclophosphamide-accelerated diabetes in NOD mice. DNA and cell biology. 2001; 20(3); 175-181. [PubMed: 11313020].
  5. Li et al., 2004: Li AF, Hough J, Henderson D, Escher A. Co-delivery of pro-apoptotic BAX with a DNA vaccine recruits dendritic cells and promotes efficacy of autoimmune diabetes prevention in mice. Vaccine. 2004; 22(13-14); 1751-1763. [PubMed: 15068859].
  6. Solvason et al., 2008: Solvason N, Lou YP, Peters W, Evans E, Martinez J, Ramirez U, Ocampo A, Yun R, Ahmad S, Liu E, Yu L, Eisenbarth G, Leviten M, Steinman L, Garren H. Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. Journal of immunology (Baltimore, Md. : 1950). 2008; 181(12); 8298-8307. [PubMed: 19050246].
  7. Tisch et al., 2001: Tisch R, Wang B, Weaver DJ, Liu B, Bui T, Arthos J, Serreze DV. Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. Journal of immunology (Baltimore, Md. : 1950). 2001; 166(3); 2122-2132. [PubMed: 11160264].
  8. Urbanek-Ruiz et al., 2001: Urbanek-Ruiz I, Ruiz PJ, Paragas V, Garren H, Steinman L, Fathman CG. Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice. Clinical immunology (Orlando, Fla.). 2001; 100(2); 164-171. [PubMed: 11465945].
  9. Wolfe et al., 2002: Wolfe T, Bot A, Hughes A, Möhrle U, Rodrigo E, Jaume JC, Baekkeskov S, von Herrath M. Endogenous expression levels of autoantigens influence success or failure of DNA immunizations to prevent type 1 diabetes: addition of IL-4 increases safety. European journal of immunology. 2002; 32(1); 113-121. [PubMed: 11754351].

Duck enteritis virus

  1. Field Manual of Wildlife Diseases: Field Manual of Wildlife Diseases- Chapter 16 Duck Plague [http://www.nwhc.usgs.gov/publications/field_manual/chapter_16.pdf]

Duck hepatitis virus 1

  1. Ding and Zhang, 2007: Ding C, Zhang D. Molecular analysis of duck hepatitis virus type 1. Virology. 2007; 361(1); 9-17. [PubMed: 17300822].
  2. Fu et al., 2012: Fu Y, Chen Z, Li C, Liu G. Protective immune responses in ducklings induced by a suicidal DNA vaccine of the VP1 gene of duck hepatitis virus type 1. Veterinary microbiology. 2012; 160(3-4); 314-318. [PubMed: 22819169].
  3. Merck Vet Manual: Duck Viral Hepatitis: Merck Vet Manual: Duck Viral Hepatitis [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/202100.htm]

Eastern Equine Encephalitis Virus

  1. Wiki: Eastern Equine Encephalitis: Wiki: Eastern Equine Encephalitis Virus [http://en.wikipedia.org/wiki/Eastern_equine_encephalitis_virus]

Ebola virus

  1. Bukreyev et al., 2006: Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, Murphy BR, Collins PL, Sanchez A. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. Journal of virology. 2006; 80(5); 2267-2279. [PubMed: 16474134].
  2. Feldmann et al., 2003: Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nature reviews. Immunology. 2003 Aug; 3(8); 677-85. [PubMed: 12974482].
  3. Garbutt et al., 2004: Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Möller P, Wagner R, Volchkov V, Klenk HD, Feldmann H, Ströher U. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. Journal of virology. 2004; 78(10); 5458-5465. [PubMed: 15113924].
  4. Geisbert et al., 2002: Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerging infectious diseases. 2002 May; 8(5); 503-7. [PubMed: 11996686].
  5. Hensley et al., 2010: Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, Stanley D, Fabozzi G, Nichol ST, Ksiazek TG, Rollin PE, Wahl-Jensen V, Bailey M, Jahrling PB, Roederer M, Koup RA, Sullivan NJ. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS pathogens. 2010; 6(5); e1000904. [PubMed: 20502688].
  6. Jones et al., 2005: Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature medicine. 2005; 11(7); 786-790. [PubMed: 15937495].
  7. Kobinger et al., 2006: Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, Jones S, Wilson JM. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006; 346(2); 394-401. [PubMed: 16356525].
  8. Martin et al., 2006: Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel GJ, Graham BS. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clinical and vaccine immunology : CVI. 2006; 13(11); 1267-1277. [PubMed: 16988008].
  9. Pratt et al., 2010: Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, Dye JM, Holman DH, Dong JY. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clinical and vaccine immunology : CVI. 2010; 17(4); 572-581. [PubMed: 20181765].
  10. Pushko et al., 2000: Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine. 2000 Aug 15; 19(1); 142-53. [PubMed: 10924796].
  11. Richardson et al., 2009: Richardson JS, Yao MK, Tran KN, Croyle MA, Strong JE, Feldmann H, Kobinger GP. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PloS one. 2009; 4(4); e5308. [PubMed: 19390586].
  12. Riemenschneider et al., 2003: Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, Custer D, Bray M, Ruff A, Ivins B, Bassett A, Rossi C, Schmaljohn C. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003; 21(25-26); 4071-4080. [PubMed: 12922144].
  13. Sheets et al., 2006: Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, Kong WP, Nabel GJ, Gomez PL. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicological sciences : an official journal of the Society of Toxicology. 2006; 91(2); 610-619. [PubMed: 16569729].
  14. Sullivan et al., 2000: Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000 Nov 30; 408(6812); 605-9. [PubMed: 11117750].
  15. Sullivan et al., 2003a: Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: implications for vaccines and therapies. Journal of virology. 2003 Sep; 77(18); 9733-7. [PubMed: 12941881].
  16. Sullivan et al., 2003b: Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003 Aug 7; 424(6949); 681-4. [PubMed: 12904795].
  17. Sullivan et al., 2006: Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, Roederer M, Koup RA, Goudsmit J, Jahrling PB, Nabel GJ. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS medicine. 2006; 3(6); e177. [PubMed: 16683867].
  18. Swenson et al., 2005: Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine. 2005; 23(23); 3033-3042. [PubMed: 15811650].
  19. Swenson et al., 2008: Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, Dong JY, Pratt WD. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clinical and vaccine immunology : CVI. 2008; 15(3); 460-467. [PubMed: 18216185].
  20. Vanderzanden et al., 1998: Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, Jahrling P, Huggins J, Schmaljohn A, Schmaljohn C. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 1998 Jun 20; 246(1); 134-44. [PubMed: 9657001].
  21. Warfield et al., 2005: Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, Hart MK, Bavari S. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. Journal of immunology (Baltimore, Md. : 1950). 2005; 175(2); 1184-1191. [PubMed: 16002721].
  22. Wilson et al., 2001: Wilson JA, Bray M, Bakken R, Hart MK. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology. 2001 Aug 1; 286(2); 384-90. [PubMed: 11485406].
  23. Xu et al., 1998: Xu L, Sanchez A, Yang Z, Zaki SR, Nabel EG, Nichol ST, Nabel GJ. Immunization for Ebola virus infection. Nature medicine. 1998 Jan; 4(1); 37-42. [PubMed: 9427604].

Edwardsiella ictaluri

  1. Microgen: Microgen:Edwardsiella ictaluri [http://microgen.ouhsc.edu/e_ictal/e_ictal_home.htm]
  2. Russo et al., 2009: Russo R, Shoemaker CA, Panangala VS, Klesius PH. In vitro and in vivo interaction of macrophages from vaccinated and non-vaccinated channel catfish (Ictalurus punctatus) to Edwardsiella ictaluri. Fish & shellfish immunology. 2009; 26(3); 543-552. [PubMed: 19233291].
  3. Santander et al., 2011: Santander J, Mitra A, Curtiss R 3rd. Phenotype, virulence and immunogenicity of Edwardsiella ictaluri cyclic adenosine 3',5'-monophosphate receptor protein (Crp) mutants in catfish host. Fish & shellfish immunology. 2011; ; . [PubMed: 22015784].

Edwardsiella tarda

  1. Jiao et al., 2009: Jiao XD, Zhang M, Hu YH, Sun L. Construction and evaluation of DNA vaccines encoding Edwardsiella tarda antigens. Vaccine. 2009; 27(38); 5195-5202. [PubMed: 19596416].
  2. Lan et al., 2007: Lan MZ, Peng X, Xiang MY, Xia ZY, Bo W, Jie L, Li XY, Jun ZP. Construction and characterization of a live, attenuated esrB mutant of Edwardsiella tarda and its potential as a vaccine against the haemorrhagic septicaemia in turbot, Scophthamus maximus (L.). Fish & shellfish immunology. 2007; 23(3); 521-530. [PubMed: 17478097].
  3. Microbe Wiki: E. tarda: Microbe Wiki: Edwardsiella tarda [http://microbewiki.kenyon.edu/index.php/Edwardsiella_tarda]
  4. Sun et al., 2011: Sun Y, Liu CS, Sun L. Construction and analysis of the immune effect of an Edwardsiella tarda DNA vaccine encoding a D15-like surface antigen. Fish & shellfish immunology. 2011; 30(1); 273-279. [PubMed: 21059395].
  5. Xiao et al., 2011: Xiao J, Chen T, Wang Q, Liu Q, Wang X, Lv Y, Wu H, Zhang Y. Search for live attenuated vaccine candidate against edwardsiellosis by mutating virulence-related genes of fish pathogen Edwardsiella tarda. Letters in applied microbiology. 2011; ; . [PubMed: 21777261].

Eimeria maxima

  1. Jang et al., 2010: Jang SI, Lillehoj HS, Lee SH, Lee KW, Park MS, Cha SR, Lillehoj EP, Subramanian BM, Sriraman R, Srinivasan VA. Eimeria maxima recombinant Gam82 gametocyte antigen vaccine protects against coccidiosis and augments humoral and cell-mediated immunity. Vaccine. 2010; 28(17); 2980-2985. [PubMed: 20178868].
  2. Smith et al., 1994: Smith NC, Wallach M, Miller CM, Morgenstern R, Braun R, Eckert J. Maternal transmission of immunity to Eimeria maxima: enzyme-linked immunosorbent assay analysis of protective antibodies induced by infection. Infection and immunity. 1994; 62(4); 1348-1357. [PubMed: 8132342].
  3. Smith et al., 2002: Smith AL, Hesketh P, Archer A, Shirley MW. Antigenic diversity in Eimeria maxima and the influence of host genetics and immunization schedule on cross-protective immunity. Infection and immunity. 2002; 70(5); 2472-2479. [PubMed: 11953384].
  4. Wallach, 1997: Wallach M. The importance of transmission-blocking immunity in the control of infections by apicomplexan parasites. International journal for parasitology. 1997; 27(10); 1159-1167. [PubMed: 9394186].
  5. Xu et al., 2013: Xu J, Zhang Y, Tao J. Efficacy of a DNA Vaccine Carrying Eimeria maxima Gam56 Antigen Gene against Coccidiosis in Chickens. The Korean journal of parasitology. 2013; 51(2); 147-154. [PubMed: 23710081].

Eimeria spp.

  1. Lillehoj et al., 2005: Lillehoj HS, Ding X, Quiroz MA, Bevensee E, Lillehoj EP. Resistance to intestinal coccidiosis following DNA immunization with the cloned 3-1E Eimeria gene plus IL-2, IL-15, and IFN-gamma. Avian diseases. 2005; 49(1); 112-117. [PubMed: 15839423].
  2. Min et al., 2001: Min W, Lillehoj HS, Burnside J, Weining KC, Staeheli P, Zhu JJ. Adjuvant effects of IL-1beta, IL-2, IL-8, IL-15, IFN-alpha, IFN-gamma TGF-beta4 and lymphotactin on DNA vaccination against Eimeria acervulina. Vaccine. 2001; 20(1-2); 267-274. [PubMed: 11567773].
  3. Shirley et al., 2005: Shirley MW, Smith AL, Tomley FM. The biology of avian Eimeria with an emphasis on their control by vaccination. Advances in parasitology. 2005; 60; 285-330. [PubMed: 16230106].
  4. Wiki: Eimeria: Eimeria [http://en.wikipedia.org/wiki/Eimeria]

Eimeria tenella

  1. Ding et al., 2005: Ding X, Lillehoj HS, Dalloul RA, Min W, Sato T, Yasuda A, Lillehoj EP. In ovo vaccination with the Eimeria tenella EtMIC2 gene induces protective immunity against coccidiosis. Vaccine. 2005; 23(28); 3733-3740. [PubMed: 15882535].
  2. Du and Wang, 2005: Du A, Wang S. Efficacy of a DNA vaccine delivered in attenuated Salmonella typhimurium against Eimeria tenella infection in chickens. International journal for parasitology. 2005; 35(7); 777-785. [PubMed: 15890351].
  3. Miller et al., 1989: Miller GA, Bhogal BS, McCandliss R, Strausberg RL, Jessee EJ, Anderson AC, Fuchs CK, Nagle J, Likel MH, Strasser JM. Characterization and vaccine potential of a novel recombinant coccidial antigen. Infection and immunity. 1989; 57(7); 2014-2020. [PubMed: 2659532].
  4. Song et al., 2009: Song X, Xu L, Yan R, Huang X, Shah MA, Li X. The optimal immunization procedure of DNA vaccine pcDNA-TA4-IL-2 of Eimeria tenella and its cross-immunity to Eimeria necatrix and Eimeria acervulina. Veterinary parasitology. 2009; 159(1); 30-36. [PubMed: 19019543].
  5. Wang et al., 2009: Wang Q, Li J, Zhang X, Liu Q, Liu C, Ma G, Cao L, Gong P, Cai Y, Zhang G. Protective immunity of recombinant Mycobacterium bovis BCG expressing rhomboid gene against Eimeria tenella challenge. Veterinary parasitology. 2009; 160(3-4); 198-203. [PubMed: 19117681].
  6. Wiki: Eimeria tenella: Eimeria tenella [http://en.wikipedia.org/wiki/Eimeria_tenella]
  7. Williams, 2002: Williams RB. Fifty years of anticoccidial vaccines for poultry (1952-2002). Avian diseases. 2002; 46(4); 775-802. [PubMed: 12495038].
  8. Xu et al., 2006: Xu SZ, Chen T, Wang M. Protective immunity enhanced by chimeric DNA prime-protein booster strategy against Eimeria tenella challenge. Avian diseases. 2006; 50(4); 579-585. [PubMed: 17274297].

Entamoeba histolytica

  1. Carrero et al., 2010: Carrero JC, Contreras-Rojas A, Sánchez-Hernández B, Petrosyan P, Bobes RJ, Ortiz-Ortiz L, Laclette JP. Protection against murine intestinal amoebiasis induced by oral immunization with the 29kDa antigen of Entamoeba histolytica and cholera toxin. Experimental parasitology. 2010; ; . [PubMed: 20303954].
  2. Houpt et al., 2004: Houpt E, Barroso L, Lockhart L, Wright R, Cramer C, Lyerly D, Petri WA. Prevention of intestinal amebiasis by vaccination with the Entamoeba histolytica Gal/GalNac lectin. Vaccine. 2004; 22(5-6); 611-617. [PubMed: 14741152].
  3. Petri and Ravdin, 1991: Petri WA Jr, Ravdin JI. Protection of gerbils from amebic liver abscess by immunization with the galactose-specific adherence lectin of Entamoeba histolytica. Infection and immunity. 1991; 59(1); 97-9101. [PubMed: 1987067].
  4. Wiki: Entamoeba histolytica: Entamoeba histolytica [http://en.wikipedia.org/wiki/Entamoeba_histolytica]
  5. Zhang and Stanley, 1996: Zhang T, Stanley SL Jr. Oral immunization with an attenuated vaccine strain of Salmonella typhimurium expressing the serine-rich Entamoeba histolytica protein induces an antiamebic immune response and protects gerbils from amebic liver abscess. Infection and immunity. 1996; 64(5); 1526-1531. [PubMed: 8613356].

Equid herpesvirus

  1. Patel and Heldens, 2005: Patel JR, Heldens J. Equine herpesviruses 1 (EHV-1) and 4 (EHV-4)--epidemiology, disease and immunoprophylaxis: a brief review. Veterinary journal (London, England : 1997). 2005; 170(1); 14-23. [PubMed: 15993786].
  2. Slater et al., 1993: Slater JD, Gibson JS, Field HJ. Pathogenicity of a thymidine kinase-deficient mutant of equine herpesvirus 1 in mice and specific pathogen-free foals. The Journal of general virology. 1993; 74 ( Pt 5); 819-828. [PubMed: 8388018].
  3. Tsujimura et al., 2006: Tsujimura K, Yamanaka T, Kondo T, Fukushi H, Matsumura T. Pathogenicity and immunogenicity of equine herpesvirus type 1 mutants defective in either gI or gE gene in murine and hamster models. The Journal of veterinary medical science / the Japanese Society of Veterinary Science. 2006; 68(10); 1029-1038. [PubMed: 17085880].

Equine arteritis virus

  1. Wiki: Equine viral arteritis: Wiki: Equine viral arteritis [http://en.wikipedia.org/wiki/Equine_viral_arteritis]

Equine rotavirus

  1. AAEP: Rotaviral Diarrhea: AAEP: Rotaviral Diarrhea [http://www.aaep.org/rotaviral_diarrhea.htm]

Erysipelothrix rhusiopathiae

  1. Brooke and Riley, 1999: Brooke CJ, Riley TV. Erysipelothrix rhusiopathiae: bacteriology, epidemiology and clinical manifestations of an occupational pathogen. Journal of medical microbiology. 1999; 48(9); 789-799. [PubMed: 10482289].
  2. Chen et al., 2009: Chen KX, Li YJ, Zhang FC, Cao WY, Li JW. [Enhancement of antibodies to protective domain of surface protective antigen A of Erysipelothrix rhusiopathiae by DNA immunization with plasmids expressing spaA-chimeras]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology. 2009; 25(11); 984-986. [PubMed: 19900362].
  3. Wang et al., 2010: Wang Q, Chang BJ, Riley TV. Erysipelothrix rhusiopathiae. Veterinary microbiology. 2010; 140(3-4); 405-417. [PubMed: 19733019].

Escherichia coli

  1. Acheson et al., 1996: Acheson DW, Levine MM, Kaper JB, Keusch GT. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infection and immunity. 1996; 64(1); 355-357. [PubMed: 8557364].
  2. Alteri et al., 2009: Alteri CJ, Hagan EC, Sivick KE, Smith SN, Mobley HL. Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS pathogens. 2009; 5(9); e1000586. [PubMed: 19806177].
  3. Berhanu et al., 2008: Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE. Vaccination of BALB/c Mice with Escherichia coli-expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus Challenge. Journal of virology. 2008; ; . [PubMed: 18199639].
  4. Bielaszewska et al., 1997: Bielaszewska M, Clarke I, Karmali MA, Petric M. Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits. Infection and immunity. 1997; 65(7); 2509-2516. [PubMed: 9199412].
  5. Billips et al., 2009: Billips BK, Yaggie RE, Cashy JP, Schaeffer AJ, Klumpp DJ. A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli. The Journal of infectious diseases. 2009; 200(2); 263-272. [PubMed: 19522648].
  6. Bozic et al., 2006: Bozic F, Lackovic G, Kovsca-Janjatovic A, Smolec O, Valpotic I. Levamisole synergizes experimental F4ac+ Escherichia coli oral vaccine in stimulating ileal Peyer's patch T cells in weaned pigs. Journal of veterinary pharmacology and therapeutics. 2006 Jun; 29(3); 199-204. [PubMed: 16669864].
  7. Butterton et al., 1997: Butterton JR, Ryan ET, Acheson DW, Calderwood SB. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains. Infection and immunity. 1997; 65(6); 2127-2135. [PubMed: 9169742 ].
  8. Byrd and Cassels, 2006: Byrd W, Cassels FJ. The encapsulation of enterotoxigenic Escherichia coli colonization factor CS3 in biodegradable microspheres enhances the murine antibody response following intranasal administration. Microbiology (Reading, England). 2006; 152(Pt 3); 779-786. [PubMed: 16514157].
  9. Chen et al., 1994: Chen L, McGowan P, Ashe S, Johnston JV, Hellström I, Hellström KE. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer research. 1994; 54(20); 5420-5423. [PubMed: 7522958].
  10. Daley et al., 2007: Daley A, Randall R, Darsley M, Choudhry N, Thomas N, Sanderson IR, Croft N, Kelly P. Genetically modified enterotoxigenic escherichia coli vaccines induce mucosal immune responses without inflammation. Gut. 2007 Jun 12; ; . [PubMed: 17566016].
  11. Dean-Nystrom et al., 2002: Dean-Nystrom EA, Gansheroff LJ, Mills M, Moon HW, O'Brien AD. Vaccination of pregnant dams with intimin(O157) protects suckling piglets from Escherichia coli O157:H7 infection. Infection and immunity. 2002; 70(5); 2414-2418. [PubMed: 11953378].
  12. Durant et al., 2007: Durant L, Metais A, Soulama-Mouze C, Genevard JM, Nassif X, Escaich S. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli. Infection and immunity. 2007 Apr; 75(4); 1916-25. [PubMed: 17145948 ].
  13. Durant et al., 2007: Durant L, Metais A, Soulama-Mouze C, Genevard JM, Nassif X, Escaich S. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli. Infection and immunity. 2007; 75(4); 1916-1925. [PubMed: 17145948].
  14. ELBERG and FAUNCE, 1957: ELBERG SS, FAUNCE K Jr. Immunization against Brucella infection. VI. Immunity conferred on goats by a nondependent mutant from a streptomycin-dependent mutant strain of Brucella melitensis. Journal of bacteriology. 1957; 73(2); 211-217. [PubMed: 13416171].
  15. Fan et al., 2011: Fan HY, Wang L, Luo J, Long BG. Protection against Escherichia coli O157:H7 challenge by immunization of mice with purified Tir proteins. Molecular biology reports. 2011; ; . [PubMed: 21567195].
  16. Fujii et al., 2012: Fujii J, Naito M, Yutsudo T, Matsumoto S, Heatherly DP, Yamada T, Kobayashi H, Yoshida S, Obrig T. Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice. Clinical and vaccine immunology : CVI. 2012; 19(12); 1932-1937. [PubMed: 23035176].
  17. Ghaem-Maghami et al., 2001: Ghaem-Maghami M, Simmons CP, Daniell S, Pizza M, Lewis D, Frankel G, Dougan G. Intimin-specific immune responses prevent bacterial colonization by the attaching-effacing pathogen Citrobacter rodentium. Infection and immunity. 2001; 69(9); 5597-5605. [PubMed: 11500434 ].
  18. Hagan and Mobley, 2007: Hagan EC, Mobley HL. Uropathogenic Escherichia coli outer membrane antigens expressed during urinary tract infection. Infection and immunity. 2007; 75(8); 3941-3949. [PubMed: 17517861].
  19. Hancock et al., 2008: Hancock V, Ferrières L, Klemm P. The ferric yersiniabactin uptake receptor FyuA is required for efficient biofilm formation by urinary tract infectious Escherichia coli in human urine. Microbiology (Reading, England). 2008; 154(Pt 1); 167-175. [PubMed: 18174135].
  20. Horne et al., 2002: Horne C, Vallance BA, Deng W, Finlay BB. Current progress in enteropathogenic and enterohemorrhagic Escherichia coli vaccines. Expert review of vaccines. 2002; 1(4); 483-493. [PubMed: 12901587 ].
  21. Hu et al., 2009: Hu CX, Xu ZR, Li WF, Niu D, Lu P, Fu LL. Secretory expression of K88 (F4) fimbrial adhesin FaeG by recombinant Lactococcus lactis for oral vaccination and its protective immune response in mice. Biotechnology letters. 2009; 31(7); 991-997. [PubMed: 19277476].
  22. Judge et al., 2004: Judge NA, Mason HS, O'Brien AD. Plant cell-based intimin vaccine given orally to mice primed with intimin reduces time of Escherichia coli O157:H7 shedding in feces. Infection and immunity. 2004 Jan; 72(1); 168-75. [PubMed: 14688094 ].
  23. Kwaga et al., 1994: Kwaga JK, Allan BJ, van der Hurk JV, Seida H, Potter AA. A carAB mutant of avian pathogenic Escherichia coli serogroup O2 is attenuated and effective as a live oral vaccine against colibacillosis in turkeys. Infection and immunity. 1994; 62(9); 3766-3772. [PubMed: 8063392].
  24. Langermann et al., 1997: Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science (New York, N.Y.). 1997; 276(5312); 607-611. [PubMed: 9110982].
  25. Leyten et al., 2005: Leyten EM, Soonawala D, Schultsz C, Herzog C, Ligthelm RJ, Wijnands S, Visser LG. Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study. Vaccine. 2005; 23(43); 5120-5126. [PubMed: 15982790].
  26. Liu et al., 2009: Liu J, Sun Y, Feng S, Zhu L, Guo X, Qi C. Towards an attenuated enterohemorrhagic Escherichia coli O157:H7 vaccine characterized by a deleted ler gene and containing apathogenic Shiga toxins. Vaccine. 2009; 27(43); 5929-5935. [PubMed: 19682616].
  27. Lynne et al., 2006: Lynne AM, Foley SL, Nolan LK. Immune response to recombinant Escherichia coli Iss protein in poultry. Avian diseases. 2006 Jun; 50(2); 273-6. [PubMed: 16863080].
  28. Marcato et al., 2001: Marcato P, Mulvey G, Read RJ, Vander Helm K, Nation PN, Armstrong GD. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. The Journal of infectious diseases. 2001; 183(3); 435-443. [PubMed: 11133375].
  29. Mason et al., 1998: Mason HS, Haq TA, Clements JD, Arntzen CJ. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine. 1998; 16(13); 1336-1343. [PubMed: 9682399 ].
  30. Melkebeek et al., 2007: Melkebeek V, Verdonck F, Goddeeris BM, Cox E. Comparison of immune responses in parenteral FaeG DNA primed pigs boosted orally with F4 protein or reimmunized with the DNA vaccine. Veterinary immunology and immunopathology. 2007 Apr 15; 116(3-4); 199-214. [PubMed: 17331591].
  31. Moravec et al., 2007: Moravec T, Schmidt MA, Herman EM, Woodford-Thomas T. Production of Escherichia coli heat labile toxin (LT) B subunit in soybean seed and analysis of its immunogenicity as an oral vaccine. Vaccine. 2007 Feb 19; 25(9); 1647-57. [PubMed: 17188785].
  32. Pascual et al., 1999: Pascual DW, Hone DM, Hall S, van Ginkel FW, Yamamoto M, Walters N, Fujihashi K, Powell RJ, Wu S, Vancott JL, Kiyono H, McGhee JR. Expression of recombinant enterotoxigenic Escherichia coli colonization factor antigen I by Salmonella typhimurium elicits a biphasic T helper cell response. Infection and immunity. 1999; 67(12); 6249-6256. [PubMed: 10569734 ].
  33. Pathport: Escherichia coli [http://pathport.vbi.vt.edu/pathinfo/]
  34. Potter et al., 2004: Potter AA, Klashinsky S, Li Y, Frey E, Townsend H, Rogan D, Erickson G, Hinkley S, Klopfenstein T, Moxley RA, Smith DR, Finlay BB. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine. 2004; 22(3-4); 362-369. [PubMed: 14670317].
  35. Pubmed: Protein search [http://www.ncbi.nlm.nih.gov.proxy.lib.umich.edu/sites/entrez?db=Protein]
  36. Russo et al., 2007: Russo TA, Beanan JM, Olson R, Genagon SA, MacDonald U, Cope JJ, Davidson BA, Johnston B, Johnson JR. A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate. Vaccine. 2007 May 10; 25(19); 3859-70. [PubMed: 17306426].
  37. Thankavel et al., 1997: Thankavel K, Madison B, Ikeda T, Malaviya R, Shah AH, Arumugam PM, Abraham SN. Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection. The Journal of clinical investigation. 1997; 100(5); 1123-1136. [PubMed: 9276729].
  38. Turner et al., 2006: Turner AK, Beavis JC, Stephens JC, Greenwood J, Gewert C, Thomas N, Deary A, Casula G, Daley A, Kelly P, Randall R, Darsley MJ. Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I. Infection and immunity. 2006 Feb; 74(2); 1062-71. [PubMed: 16428753].
  39. Van et al., 2005: Van Donkersgoed J, Hancock D, Rogan D, Potter AA. Escherichia coli O157:H7 vaccine field trial in 9 feedlots in Alberta and Saskatchewan. The Canadian veterinary journal. La revue veterinaire canadienne. 2005; 46(8); 724-728. [PubMed: 16187717].
  40. van et al., 2007: van Diemen PM, Dziva F, Abu-Median A, Wallis TS, van den Bosch H, Dougan G, Chanter N, Frankel G, Stevens MP. Subunit vaccines based on intimin and Efa-1 polypeptides induce humoral immunity in cattle but do not protect against intestinal colonisation by enterohaemorrhagic Escherichia coli O157:H7 or O26:H-. Veterinary immunology and immunopathology. 2007 Mar 15; 116(1-2); 47-58. [PubMed: 17258324].
  41. Walker et al., 2007: Walker RI, Steele D, Aguado T. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. Vaccine. 2007 Mar 30; 25(14); 2545-66. [PubMed: 17224212].
  42. Wen et al., 2006: Wen SX, Teel LD, Judge NA, O'Brien AD. A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proceedings of the National Academy of Sciences of the United States of America. 2006 May 2; 103(18); 7082-7. [PubMed: 16641102].
  43. Wennerås et al., 1992: Wennerås C, Svennerholm AM, Ahrén C, Czerkinsky C. Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine. Infection and immunity. 1992; 60(7); 2605-2611. [PubMed: 1612730].
  44. Zhang et al., 2006: Zhang J, Shi Z, Kong FK, Jex E, Huang Z, Watt JM, Van Kampen KR, Tang DC. Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. Infection and immunity. 2006 Jun; 74(6); 3607-17. [PubMed: 16714593].

Experimental autoimmune encephalomyelitis

  1. Bourquin et al., 2000: Bourquin C, Iglesias A, Berger T, Wekerle H, Linington C. Myelin oligodendrocyte glycoprotein-DNA vaccination induces antibody-mediated autoaggression in experimental autoimmune encephalomyelitis. European journal of immunology. 2000; 30(12); 3663-3671. [PubMed: 11169409].
  2. Lobell et al., 1999: Lobell A, Weissert R, Eltayeb S, Svanholm C, Olsson T, Wigzell H. Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis. Journal of immunology (Baltimore, Md. : 1950). 1999; 163(9); 4754-4762. [PubMed: 10528174].
  3. Lobell et al., 2003: Lobell A, Weissert R, Eltayeb S, de Graaf KL, Wefer J, Storch MK, Lassmann H, Wigzell H, Olsson T. Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response. Journal of immunology (Baltimore, Md. : 1950). 2003; 170(4); 1806-1813. [PubMed: 12574345].
  4. Ramshaw et al., 1997: Ramshaw IA, Fordham SA, Bernard CC, Maguire D, Cowden WB, Willenborg DO. DNA vaccines for the treatment of autoimmune disease. Immunology and cell biology. 1997; 75(4); 409-413. [PubMed: 9315486].
  5. Ruiz et al., 1999: Ruiz PJ, Garren H, Ruiz IU, Hirschberg DL, Nguyen LV, Karpuj MV, Cooper MT, Mitchell DJ, Fathman CG, Steinman L. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. Journal of immunology (Baltimore, Md. : 1950). 1999; 162(6); 3336-3341. [PubMed: 10092787].
  6. Selmaj et al., 2000: Selmaj K, Kowal C, Walczak A, Nowicka J, Raine CS. Naked DNA vaccination differentially modulates autoimmune responses in experimental autoimmune encephalomyelitis. Journal of neuroimmunology. 2000; 111(1-2); 34-44. [PubMed: 11063819].
  7. Tsunoda et al., 1998: Tsunoda I, Kuang LQ, Tolley ND, Whitton JL, Fujinami RS. Enhancement of experimental allergic encephalomyelitis (EAE) by DNA immunization with myelin proteolipid protein (PLP) plasmid DNA. Journal of neuropathology and experimental neurology. 1998; 57(8); 758-767. [PubMed: 9720491].
  8. Waisman et al., 1996: Waisman A, Ruiz PJ, Hirschberg DL, Gelman A, Oksenberg JR, Brocke S, Mor F, Cohen IR, Steinman L. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nature medicine. 1996; 2(8); 899-905. [PubMed: 8705860].
  9. Walczak et al., 2004: Walczak A, Szymanska B, Selmaj K. Differential prevention of experimental autoimmune encephalomyelitis with antigen-specific DNA vaccination. Clinical neurology and neurosurgery. 2004; 106(3); 241-245. [PubMed: 15177776].
  10. Weissert et al., 2000: Weissert R, Lobell A, de Graaf KL, Eltayeb SY, Andersson R, Olsson T, Wigzell H. Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(4); 1689-1694. [PubMed: 10677519].
  11. Wiki: Experimental autoimmune encephalomyelitis: Experimental autoimmune encephalomyelitis [http://en.wikipedia.org/wiki/Experimental_autoimmune_encephalomyelitis]

Experimental autoimmune uveitis

  1. Commodaro et al., 2010: Commodaro AG, Peron JP, Lopes CT, Arslanian C, Belfort R Jr, Rizzo LV, Bueno V. Evaluation of experimental autoimmune uveitis in mice treated with FTY720. Investigative ophthalmology & visual science. 2010; 51(5); 2568-2574. [PubMed: 20019358].
  2. Silver et al., 2007: Silver PB, Agarwal RK, Su SB, Suffia I, Grajewski RS, Luger D, Chan CC, Mahdi RM, Nickerson JM, Caspi RR. Hydrodynamic vaccination with DNA encoding an immunologically privileged retinal antigen protects from autoimmunity through induction of regulatory T cells. Journal of immunology (Baltimore, Md. : 1950). 2007; 179(8); 5146-5158. [PubMed: 17911600].

Feline calicivirus

  1. Radford et al., 2007: Radford AD, Coyne KP, Dawson S, Porter CJ, Gaskell RM. Feline calicivirus. Veterinary research. 2007; 38(2); 319-335. [PubMed: 17296159].

Feline herpesvirus 1

  1. Gaskell et al., 2007: Gaskell R, Dawson S, Radford A, Thiry E. Feline herpesvirus. Veterinary research. 2007; 38(2); 337-354. [PubMed: 17296160].
  2. Yokoyama et al., 1996: Yokoyama N, Maeda K, Tohya Y, Kawaguchi Y, Shin YS, Ono M, Ishiguro S, Fujikawa Y, Mikami T. Pathogenicity and vaccine efficacy of a thymidine kinase-deficient mutant of feline herpesvirus type 1 in cats. Archives of virology. 1996; 141(3-4); 481-494. [PubMed: 8645090].

Feline immunodeficiency virus

  1. Hosie et al., 1998: Hosie MJ, Flynn JN, Rigby MA, Cannon C, Dunsford T, Mackay NA, Argyle D, Willett BJ, Miyazawa T, Onions DE, Jarrett O, Neil JC. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies. Journal of virology. 1998; 72(9); 7310-7319. [PubMed: 9696827].
  2. Lockridge et al., 2000: Lockridge KM, Chien M, Dean GA, Stefano Cole K, Montelaro RC, Luciw PA, Sparger EE. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA. Virology. 2000; 273(1); 67-79. [PubMed: 10891409].
  3. Pistello et al., 2005: Pistello M, Bonci F, Isola P, Mazzetti P, Merico A, Zaccaro L, Matteucci D, Bendinelli M. Evaluation of feline immunodeficiency virus ORF-A mutants as candidate attenuated vaccine. Virology. 2005; 332(2); 676-690. [PubMed: 15680433].
  4. Wiki: Feline Immunodeficincy Virus: Wiki: Feline Immunodeficincy Virus [http://en.wikipedia.org/wiki/Feline_immunodeficiency_virus]

Feline infectious peritonitis virus

  1. Addie et al., 2009: Addie D, Belák S, Boucraut-Baralon C, Egberink H, Frymus T, Gruffydd-Jones T, Hartmann K, Hosie MJ, Lloret A, Lutz H, Marsilio F, Pennisi MG, Radford AD, Thiry E, Truyen U, Horzinek MC. Feline infectious peritonitis. ABCD guidelines on prevention and management. Journal of feline medicine and surgery. 2009; 11(7); 594-604. [PubMed: 19481039].
  2. Haijema et al., 2004: Haijema BJ, Volders H, Rottier PJ. Live, attenuated coronavirus vaccines through the directed deletion of group-specific genes provide protection against feline infectious peritonitis. Journal of virology. 2004; 78(8); 3863-3871. [PubMed: 15047802].

Feline leukemia virus

  1. Hanlon et al., 2001: Hanlon L, Argyle D, Bain D, Nicolson L, Dunham S, Golder MC, McDonald M, McGillivray C, Jarrett O, Neil JC, Onions DE. Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors. Journal of virology. 2001; 75(18); 8424-8433. [PubMed: 11507187].
  2. Poulet et al., 2003: Poulet H, Brunet S, Boularand C, Guiot AL, Leroy V, Tartaglia J, Minke J, Audonnet JC, Desmettre P. Efficacy of a canarypox virus-vectored vaccine against feline leukaemia. The Veterinary record. 2003; 153(5); 141-145. [PubMed: 12934796].
  3. Wiki: Feline leukemia virus: Feline leukemia virus [http://en.wikipedia.org/wiki/Feline_leukemia_virus]

Feline panleukopenia virus

  1. Truyen et al., 2009: Truyen U, Addie D, Belák S, Boucraut-Baralon C, Egberink H, Frymus T, Gruffydd-Jones T, Hartmann K, Hosie MJ, Lloret A, Lutz H, Marsilio F, Pennisi MG, Radford AD, Thiry E, Horzinek MC. Feline panleukopenia. ABCD guidelines on prevention and management. Journal of feline medicine and surgery. 2009; 11(7); 538-546. [PubMed: 19481033].
  2. Wiki: Feline Panleukopenia: Wiki: Feline Panleukopenia [http://en.wikipedia.org/wiki/Feline_Panleukopenia]

Flavobacterium columnare

  1. Dumpala et al., 2010: Dumpala PR, Gülsoy N, Lawrence ML, Karsi A. Proteomic analysis of the fish pathogen Flavobacterium columnare. Proteome science. 2010; 8; 26. [PubMed: 20525376].

Foot-and-mouth disease virus

  1. Dar et al., 2012: Dar PA, Ganesh K, Nagarajan G, Sarika S, Reddy GR, Suryanarayana VV. Sindbis virus replicase-based DNA vaccine construct encoding FMDV-specific multivalent epitope gene: studies on its immune responses in guinea pigs. Scandinavian journal of immunology. 2012; 76(4); 345-353. [PubMed: 22702835].
  2. Fowler et al., 2012: Fowler V, Robinson L, Bankowski B, Cox S, Parida S, Lawlor C, Gibson D, O'Brien F, Ellefsen B, Hannaman D, Takamatsu HH, Barnett PV. A DNA vaccination regime including protein boost and electroporation protects cattle against foot-and-mouth disease. Antiviral research. 2012; 94(1); 25-34. [PubMed: 22330893].
  3. Joyappa et al., 2009: Joyappa DH, Kumar CA, Banumathi N, Reddy GR, Suryanarayana VV. Calcium phosphate nanoparticle prepared with foot and mouth disease virus P1-3CD gene construct protects mice and guinea pigs against the challenge virus. Veterinary microbiology. 2009; 139(1-2); 58-66. [PubMed: 19505774].
  4. Reddy et al., 2012: Reddy KS, Rashmi BR, Dechamma HJ, Gopalakrishna S, Banumathi N, Suryanarayana VV, Reddy GR. Cationic microparticle [poly(D,L-lactide-co-glycolide)]-coated DNA vaccination induces a long-term immune response against foot and mouth disease in guinea pigs. The journal of gene medicine. 2012; 14(5); 348-352. [PubMed: 22438260].
  5. Shao et al., 2005: Shao HJ, Chen L, Su YB. DNA fragment encoding human IL-1beta 163-171 peptide enhances the immune responses elicited in mice by DNA vaccine against foot-and-mouth disease. Veterinary research communications. 2005; 29(1); 35-46. [PubMed: 15727290].
  6. Wang et al., 2006: Wang F, He XW, Jiang L, Ren D, He Y, Li DA, Sun SH. Enhanced immunogenicity of microencapsulated multiepitope DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice. Vaccine. 2006; 24(12); 2017-2026. [PubMed: 16414158].
  7. Ward et al., 1997: Ward G, Rieder E, Mason PW. Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine. Journal of virology. 1997; 71(10); 7442-7447. [PubMed: 9311823].
  8. Wiki: Foot and mouth disease: Wiki: Foot and mouth disease [http://en.wikipedia.org/wiki/Foot-and-mouth_disease]

Fowlpox virus

  1. Merck Vet Manual: Fowlpox: Merck Veterinary Manual- Fowlpox in Chickens and Turkeys [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/204801.htm]
  2. Wiki: Fowlpox: Wiki: Fowlpox [http://en.wikipedia.org/wiki/index.html?curid=6441791]

Francisella tularensis

  1. Bakshi et al., 2006: Bakshi CS, Malik M, Regan K, Melendez JA, Metzger DW, Pavlov VM, Sellati TJ. Superoxide dismutase B gene (sodB)-deficient mutants of Francisella tularensis demonstrate hypersensitivity to oxidative stress and attenuated virulence. Journal of bacteriology. 2006 Sep; 188(17); 6443-8. [PubMed: 16923916].
  2. Bakshi et al., 2008: Bakshi CS, Malik M, Mahawar M, Kirimanjeswara GS, Hazlett KR, Palmer LE, Furie MB, Singh R, Melendez JA, Sellati TJ, Metzger DW. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine. 2008; 26(41); 5276-5288. [PubMed: 18692537].
  3. Bokhari et al., 2008: Bokhari SM, Kim KJ, Pinson DM, Slusser J, Yeh HW, Parmely MJ. NK cells and gamma interferon coordinate the formation and function of hepatic granulomas in mice infected with the Francisella tularensis live vaccine strain. Infection and immunity. 2008; 76(4); 1379-1389. [PubMed: 18227174].
  4. Breitbach et al., 2008: Breitbach K, Köhler J, Steinmetz I. Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008; 102 Suppl 1; S89-94. [PubMed: 19121696].
  5. Cong et al., 2009: Cong Y, Yu JJ, Guentzel MN, Berton MT, Seshu J, Klose KE, Arulanandam BP. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine. 2009; 27(41); 5554-5561. [PubMed: 19651173].
  6. Conlan et al., 2010: Conlan JW, Shen H, Golovliov I, Zingmark C, Oyston PC, Chen W, House RV, Sjöstedt A. Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization. Vaccine. 2010; 28(7); 1824-1831. [PubMed: 20018266].
  7. Dreisbach et al., 2000: Dreisbach VC, Cowley S, Elkins KL. Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon. Infection and immunity. 2000 Apr; 68(4); 1988-96. [PubMed: 10722593].
  8. Elkins et al., 1996: Elkins KL, Rhinehart-Jones TR, Culkin SJ, Yee D, Winegar RK. Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infection and immunity. 1996 Aug; 64(8); 3288-93. [PubMed: 8757866].
  9. Gregory et al., 2010: Gregory SH, Chen WH, Mott S, Palardy JE, Parejo NA, Heninger S, Anderson CA, Artenstein AW, Opal SM, Cross AS. Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4. Vaccine. 2010; 28(16); 2908-2915. [PubMed: 20170768].
  10. Hartley et al., 2004: Hartley MG, Green M, Choules G, Rogers D, Rees DG, Newstead S, Sjostedt A, Titball RW. Protection afforded by heat shock protein 60 from Francisella tularensis is due to copurified lipopolysaccharide. Infection and immunity. 2004; 72(7); 4109-4113. [PubMed: 15213156].
  11. Hepburn et al., 2006: Hepburn MJ, Purcell BK, Lawler JV, Coyne SR, Petitt PL, Sellers KD, Norwood DA, Ulrich MP. Live vaccine strain Francisella tularensis is detectable at the inoculation site but not in blood after vaccination against tularemia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006 Sep 15; 43(6); 711-6. [PubMed: 16912944].
  12. Isherwood et al., 2005: Isherwood KE, Titball RW, Davies DH, Felgner PL, Morrow WJ. Vaccination strategies for Francisella tularensis. Advanced drug delivery reviews. 2005 Jun 17; 57(9); 1403-14. [PubMed: 15919131].
  13. Jayakar et al., 2011: Jayakar HR, Parvathareddy J, Fitzpatrick EA, Bina XR, Bina JE, Re F, Emery FD, Miller MA. A galU Mutant of Francisella tularensis is Attenuated for Virulence in a Murine Pulmonary Model of Tularemia. BMC microbiology. 2011; 11(1); 179. [PubMed: 21819572].
  14. Jia et al., 2009: Jia Q, Lee BY, Clemens DL, Bowen RA, Horwitz MA. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis. Vaccine. 2009; 27(8); 1216-1229. [PubMed: 19126421].
  15. Jia et al., 2010: Jia Q, Lee BY, Bowen R, Dillon BJ, Som SM, Horwitz MA. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge. Infection and immunity. 2010; 78(10); 4341-4355. [PubMed: 20643859].
  16. Lauriano et al., 2003: Lauriano CM, Barker JR, Nano FE, Arulanandam BP, Klose KE. Allelic exchange in Francisella tularensis using PCR products. FEMS microbiology letters. 2003 Dec 12; 229(2); 195-202. [PubMed: 14680699].
  17. Li et al., 2007: Li J, Ryder C, Mandal M, Ahmed F, Azadi P, Snyder DS, Pechous RD, Zahrt T, Inzana TJ. Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS. Microbiology (Reading, England). 2007; 153(Pt 9); 3141-3153. [PubMed: 17768257].
  18. Melillo et al., 2009: Melillo AA, Mahawar M, Sellati TJ, Malik M, Metzger DW, Melendez JA, Bakshi CS. Identification of Francisella tularensis live vaccine strain CuZn superoxide dismutase as critical for resistance to extracellularly generated reactive oxygen species. Journal of bacteriology. 2009; 191(20); 6447-6456. [PubMed: 19684141].
  19. Pammit et al., 2006: Pammit MA, Raulie EK, Lauriano CM, Klose KE, Arulanandam BP. Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infection and immunity. 2006 Apr; 74(4); 2063-71. [PubMed: 16552035].
  20. Pechous et al., 2006: Pechous R, Celli J, Penoske R, Hayes SF, Frank DW, Zahrt TC. Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain. Infection and immunity. 2006; 74(8); 4452-4461. [PubMed: 16861631].
  21. Quarry et al., 2007: Quarry JE, Isherwood KE, Michell SL, Diaper H, Titball RW, Oyston PC. A Francisella tularensis subspecies novicida purF mutant, but not a purA mutant, induces protective immunity to tularemia in mice. Vaccine. 2007; 25(11); 2011-2018. [PubMed: 17241711].
  22. Rodriguez et al., 2011: Rodriguez AR, Yu JJ, Murthy AK, Guentzel MN, Klose KE, Forsthuber TG, Chambers JP, Berton MT, Arulanandam BP. Mast cell/IL-4 control of Francisella tularensis replication and host cell death is associated with increased ATP production and phagosomal acidification. Mucosal immunology. 2011; 4(2); 217-226. [PubMed: 20861832].
  23. Rohmer et al., 2006: Rohmer L, Brittnacher M, Svensson K, Buckley D, Haugen E, Zhou Y, Chang J, Levy R, Hayden H, Forsman M, Olson M, Johansson A, Kaul R, Miller SI. Potential source of Francisella tularensis live vaccine strain attenuation determined by genome comparison. Infection and immunity. 2006 Sep 25; ; . [PubMed: 17000723].
  24. Sammons-Jackson et al., 2008: Sammons-Jackson WL, McClelland K, Manch-Citron JN, Metzger DW, Bakshi CS, Garcia E, Rasley A, Anderson BE. Generation and characterization of an attenuated mutant in a response regulator gene of Francisella tularensis live vaccine strain (LVS). DNA and cell biology. 2008; 27(7); 387-403. [PubMed: 18613792].
  25. Santiago et al., 2009: Santiago AE, Cole LE, Franco A, Vogel SN, Levine MM, Barry EM. Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes. Vaccine. 2009; 27(18); 2426-2436. [PubMed: 19368784].
  26. Savitt et al., 2009: Savitt AG, Mena-Taboada P, Monsalve G, Benach JL. Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy. Clinical and vaccine immunology : CVI. 2009; 16(3); 414-422. [PubMed: 19176692].
  27. Sebastian et al., 2007: Sebastian S, Dillon ST, Lynch JG, Blalock LT, Balon E, Lee KT, Comstock LE, Conlan JW, Rubin EJ, Tzianabos AO, Kasper DL. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity. Infection and immunity. 2007; 75(5); 2591-2602. [PubMed: 17296751].
  28. Sjöstedt et al., 1992: Sjöstedt A, Sandström G, Tärnvik A. Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium. Infection and immunity. 1992; 60(7); 2855-2862. [PubMed: 1612751].
  29. Tempel et al., 2006: Tempel R, Lai XH, Crosa L, Kozlowicz B, Heffron F. Attenuated Francisella novicida transposon mutants protect mice against wild-type challenge. Infection and immunity. 2006 Sep; 74(9); 5095-105. [PubMed: 16926401].
  30. Twine et al., 2005: Twine S, Bystrom M, Chen W, Forsman M, Golovliov I, Johansson A, Kelly J, Lindgren H, Svensson K, Zingmark C, Conlan W, Sjostedt A. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infection and immunity. 2005 Dec; 73(12); 8345-52. [PubMed: 16299332 ].
  31. Yu et al., 2010: Yu JJ, Goluguri T, Guentzel MN, Chambers JP, Murthy AK, Klose KE, Forsthuber TG, Arulanandam BP. Francisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice. Clinical and vaccine immunology : CVI. 2010; 17(2); 215-222. [PubMed: 20016043].

Gallid herpesvirus 1

  1. Chen et al., 2011: Chen HY, Zhang HY, Li XS, Cui BA, Wang SJ, Geng JW, Li K. Interleukin-18-mediated enhancement of the protective effect of an infectious laryngotracheitis virus glycoprotein B plasmid DNA vaccine in chickens. Journal of medical microbiology. 2011; 60(Pt 1); 110-116. [PubMed: 20829398].
  2. Fuchs et al., 2007: Fuchs W, Veits J, Helferich D, Granzow H, Teifke JP, Mettenleiter TC. Molecular biology of avian infectious laryngotracheitis virus. Veterinary research. 2007; 38(2); 261-279. [PubMed: 17296156].
  3. Han et al., 2002: Han MG, Kweon CH, Mo IP, Kim SJ. Pathogenicity and vaccine efficacy of a thymidine kinase gene deleted infectious laryngotracheitis virus expressing the green fluorescent protein gene. Archives of virology. 2002; 147(5); 1017-1031. [PubMed: 12021870].
  4. Helferich et al., 2007: Helferich D, Veits J, Teifke JP, Mettenleiter TC, Fuchs W. The UL47 gene of avian infectious laryngotracheitis virus is not essential for in vitro replication but is relevant for virulence in chickens. The Journal of general virology. 2007; 88(Pt 3); 732-742. [PubMed: 17325345].
  5. Veits et al., 2003: Veits J, Lüschow D, Kindermann K, Werner O, Teifke JP, Mettenleiter TC, Fuchs W. Deletion of the non-essential UL0 gene of infectious laryngotracheitis (ILT) virus leads to attenuation in chickens, and UL0 mutants expressing influenza virus haemagglutinin (H7) protect against ILT and fowl plague. The Journal of general virology. 2003; 84(Pt 12); 3343-3352. [PubMed: 14645915].

Giardia duodenalis

  1. Abdul-Wahid and Faubert, 2007: Abdul-Wahid A, Faubert G. Mucosal delivery of a transmission-blocking DNA vaccine encoding Giardia lamblia CWP2 by Salmonella typhimurium bactofection vehicle. Vaccine. 2007; 25(50); 8372-8383. [PubMed: 17996337].
  2. Lee et al., 2009: Lee P, Abdul-Wahid A, Faubert GM. Comparison of the local immune response against Giardia lamblia cyst wall protein 2 induced by recombinant Lactococcus lactis and Streptococcus gordonii. Microbes and infection / Institut Pasteur. 2009; 11(1); 20-28. [PubMed: 18992359].
  3. Olson et al., 2000: Olson ME, Ceri H, Morck DW. Giardia vaccination. Parasitology today (Personal ed.). 2000; 16(5); 213-217. [PubMed: 10782082].
  4. Wiki: Giardia lamblia: Giardia lamblia [http://en.wikipedia.org/wiki/Giardia_duodenalis]

Haemophilus influenzae

  1. AAPC 1991: American Academy of Pediatrics Committee. American Academy of Pediatrics Committee on Infectious Diseases: Haemophilus influenzae type b conjugate vaccines: recommendations for immunization of infants and children 2 months of age and older: update. Pediatrics. 1991; 88(1); 169-172. [PubMed: 2057256].
  2. ActHIB 2005: Haemophilus b conjugate vaccine ActHIB [http://www.acthib.com]
  3. Bakaletz et al., 1999: Bakaletz LO, Kennedy BJ, Novotny LA, Duquesne G, Cohen J, Lobet Y. Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Infection and immunity. 1999; 67(6); 2746-2762. [PubMed: 10338477].
  4. Barenkamp, 1986: Barenkamp SJ. Protection by serum antibodies in experimental nontypable Haemophilus influenzae otitis media. Infection and immunity. 1986; 52(2); 572-578. [PubMed: 3486158].
  5. Bertot et al., 2004: Bertot GM, Becker PD, Guzman CA, Grinstein S. Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae. The Journal of infectious diseases. 2004 Apr 1; 189(7); 1304-12. [PubMed: 15031801].
  6. Bolduc et al., 2000: Bolduc GR, Bouchet V, Jiang RZ, Geisselsoder J, Truong-Bolduc QC, Rice PA, Pelton SI, Goldstein R. Variability of outer membrane protein P1 and its evaluation as a vaccine candidate against experimental otitis media due to nontypeable Haemophilus influenzae: an unambiguous, multifaceted approach. Infection and immunity. 2000 Aug; 68(8); 4505-17. [PubMed: 10899849].
  7. Clancy et al., 1985: Clancy R, Cripps A, Murree-Allen K, Yeung S, Engel M. Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet. 1985 Dec 21-28; 2(8469-70); 1395-7. [PubMed: 2867396].
  8. Clancy et al., 1990: Clancy RL, Cripps AW, Gebski V. Protection against recurrent acute bronchitis after oral immunization with killed Haemophilus influenzae. The Medical journal of Australia. 1990 Apr 16; 152(8); 413-6. [PubMed: 2184330].
  9. Clancy et al., 1992: Clancy RL, Cripps AW. Specific protection against acute bronchitis associated with nontypeable Haemophilus influenzae. The Journal of infectious diseases. 1992 Jun; 165 Suppl 1; S194-5. [PubMed: 1588162].
  10. Comvax: Comvax [http://www.fda.gov/cber/products/comvax.htm]
  11. Decker et al., 1992: Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. The Journal of pediatrics. 1992 Feb; 120(2 Pt 1); 184-9. [PubMed: 1735812].
  12. FDA: ACTHIB: FDA: ACTHIB Vaccine for Haemophilus influenzae [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm174743.htm]
  13. FDA: COMVAX: FDA: COMVAX information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm174757.htm]
  14. FDA: MenHibrix: FDA: MenHibrix Package insert [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm308566.htm]
  15. FDA: Pentacel: FDA: Pentacel [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172502.htm]
  16. Forsgren et al., 2008: Forsgren A, Riesbeck K, Janson H. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008; 46(5); 726-731. [PubMed: 18230042].
  17. Foxwell et al., 2006: Foxwell AR, Cripps AW, Dear KB. Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane database of systematic reviews (Online). 2006 Oct 18; (4); CD001958. [PubMed: 17054150 ].
  18. Fritzell et al., 1992: Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. The Journal of pediatrics. 1992 Sep; 121(3); 355-62. [PubMed: 1517908].
  19. Green et al., 1991: Green BA, Farley JE, Quinn-Dey T, Deich RA, Zlotnick GW. The e (P4) outer membrane protein of Haemophilus influenzae: biologic activity of anti-e serum and cloning and sequencing of the structural gene. Infection and immunity. 1991 Sep; 59(9); 3191-8. [PubMed: 1715322 ].
  20. Gu et al., 1996: Gu XX, Tsai CM, Ueyama T, Barenkamp SJ, Robbins JB, Lim DJ. Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins. Infection and immunity. 1996 Oct; 64(10); 4047-53. [PubMed: 8926067 ].
  21. Gu et al., 1997: Gu XX, Sun J, Jin S, Barenkamp SJ, Lim DJ, Robbins JB, Battey J. Detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins confers protection against otitis media in chinchillas. Infection and immunity. 1997; 65(11); 4488-4493. [PubMed: 9353024].
  22. Gu et al., 2003: Gu XX, Rudy SF, Chu C, McCullagh L, Kim HN, Chen J, Li J, Robbins JB, Van Waes C, Battey JF. Phase I study of a lipooligosaccharide-based conjugate vaccine against nontypeable Haemophilus influenzae. Vaccine. 2003 May 16; 21(17-18); 2107-14. [PubMed: 12706701].
  23. HibTITER 2007: HAEMOPHILUS b CONJUGATE VACCINE (Diphtheria CRM197 Protein Conjugate) HibTITER® [http://www.wyeth.com/content/showlabeling.asp?id=105]
  24. Hotomi et al., 2005: Hotomi M, Ikeda Y, Suzumoto M, Yamauchi K, Green BA, Zlotnick G, Billal DS, Shimada J, Fujihara K, Yamanaka N. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization. Vaccine. 2005 Jan 26; 23(10); 1294-300. [PubMed: 15652672].
  25. Kayhty et al., 1984: Kayhty H, Karanko V, Peltola H, Makela PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics. 1984 Nov; 74(5); 857-65. [PubMed: 6387614].
  26. Kilian et al, 1991: Kilian, M. Haemophilus. 463-470. Manual of clinical microbiology, 5th ed. 1991. American Society for Microbiology, Washington, DC.
  27. Kurono et al., 1999: Kurono Y, Yamamoto M, Fujihashi K, Kodama S, Suzuki M, Mogi G, McGhee JR, Kiyono H. Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity. The Journal of infectious diseases. 1999 Jul; 180(1); 122-32. [PubMed: 10353870].
  28. Kyd and Cripps, 1998: Kyd JM, Cripps AW. Potential of a novel protein, OMP26, from nontypeable Haemophilus influenzae to enhance pulmonary clearance in a rat model. Infection and immunity. 1998; 66(5); 2272-2278. [PubMed: 9573117].
  29. Kyd et al., 2003: Kyd JM, Cripps AW, Novotny LA, Bakaletz LO. Efficacy of the 26-kilodalton outer membrane protein and two P5 fimbrin-derived immunogens to induce clearance of nontypeable Haemophilus influenzae from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx. Infection and immunity. 2003 Aug; 71(8); 4691-9. [PubMed: 12874350].
  30. Lehmann et al., 1991: Lehmann D, Coakley KJ, Coakley CA, Spooner V, Montgomery JM, Michael A, Riley ID, Smith T, Clancy RL, Cripps AW. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. The American review of respiratory disease. 1991 Aug; 144(2); 324-30. [PubMed: 1859055].
  31. Lepow et al., 1987: Lepow ML, Barkin RM, Berkowitz CD, Brunell PA, James D, Meier K, Ward J, Zahradnik JM, Samuelson J, McVerry PH. Safety and immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D) in infants. The Journal of infectious diseases. 1987 Oct; 156(4); 591-6. [PubMed: 3497990 ].
  32. Liu et al., 2004: Liu DF, Mason KW, Mastri M, Pazirandeh M, Cutter D, Fink DL, St Geme JW 3rd, Zhu D, Green BA. The C-terminal fragment of the internal 110-kilodalton passenger domain of the Hap protein of nontypeable Haemophilus influenzae is a potential vaccine candidate. Infection and immunity. 2004 Dec; 72(12); 6961-8. [PubMed: 15557618].
  33. Loosmore et al., 1996: Loosmore SM, Yang YP, Coleman DC, Shortreed JM, England DM, Harkness RE, Chong PS, Klein MH. Cloning and expression of the Haemophilus influenzae transferrin receptor genes. Molecular microbiology. 1996; 19(3); 575-586. [PubMed: 8830248].
  34. Loosmore et al., 1997: Loosmore SM, Yang YP, Coleman DC, Shortreed JM, England DM, Klein MH. Outer membrane protein D15 is conserved among Haemophilus influenzae species and may represent a universal protective antigen against invasive disease. Infection and immunity. 1997; 65(9); 3701-3707. [PubMed: 9284140].
  35. Loosmore et al., 1998: Loosmore SM, Yang YP, Oomen R, Shortreed JM, Coleman DC, Klein MH. The Haemophilus influenzae HtrA protein is a protective antigen. Infection and immunity. 1998; 66(3); 899-906. [PubMed: 9488373].
  36. Makwana et al., 2007: Makwana N, Riordan FA. Bacterial meningitis: the impact of vaccination. CNS drugs. 2007; 21(5); 355-66. [PubMed: 17447825].
  37. Marburg 1986: S. Marburg, D. Jorn, R. L. Tolman, B. Arison, J. McCauley, P. J. Kniskern, A. Hagopian, and P. P. Vella. Bimolecular chemistry of macromolecules: synthesis of bacterial polysaccharide conjugates with Neisseria meningitidis membrane protein. Journal of the American Chemical Society. 1986; 108; 5282-5287.
  38. Marrs et al., 2001: Marrs CF, Krasan GP, McCrea KW, Clemans DL, Gilsdorf JR. Haemophilus influenzae - human specific bacteria. Frontiers in bioscience : a journal and virtual library. 2001 Sep 1; 6; E41-60. [PubMed: 11532609].
  39. Mason et al., 2004: Mason KW, Zhu D, Scheuer CA, McMichael JC, Zlotnick GW, Green BA. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529. Vaccine. 2004 Sep 3; 22(25-26); 3449-56. [PubMed: 15308371].
  40. McMahon et al., 2005: McMahon M, Murphy TF, Kyd J, Thanavala Y. Role of an immunodominant T cell epitope of the P6 protein of nontypeable Haemophilus influenzae in murine protective immunity. Vaccine. 2005 May 20; 23(27); 3590-6. [PubMed: 15855018].
  41. Meekison et al., 1989: Meekison W, Hutcheon M, Guasparini R, Arnott M, Scheifele D, Grace M, Humphreys G, Barreto L. Post-marketing surveillance of adverse events following ProHIBit vaccine--British Columbia. Canada diseases weekly report = Rapport hebdomadaire des maladies au Canada. 1989 Jul 15; 15(28); 143-5. [PubMed: 2791073].
  42. Munson et al., 1983: Munson RS Jr, Shenep JL, Barenkamp SJ, Granoff DM. Purification and comparison of outer membrane protein P2 from Haemophilus influenzae type b isolates. The Journal of clinical investigation. 1983; 72(2); 677-684. [PubMed: 6603479].
  43. PedvasHIB: Liquid PedvaxHIB [http://www.merck.com/product/usa/pi_circulars/p/pedvax_hib]
  44. Peltola et al., 1977: Peltola H, Kayhty H, Sivonen A, Makela H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics. 1977 Nov; 60(5); 730-7. [PubMed: 335348].
  45. ProHIBiT 2007: Haemophilus b Conjugate Vaccine (Diphtheria Toxoid-Conjugate) [http://www.rxlist.com/cgi/generic/prohibit.htm]
  46. Reinholdt et al., 1997: Reinholdt J, Kilian M. Comparative analysis of immunoglobulin A1 protease activity among bacteria representing different genera, species, and strains. Infection and immunity. 1997 Nov; 65(11); 4452-9. [PubMed: 9353019].
  47. Riedmann et al., 2003: Riedmann EM, Kyd JM, Smith AM, Gomez-Gallego S, Jalava K, Cripps AW, Lubitz W. Construction of recombinant S-layer proteins (rSbsA) and their expression in bacterial ghosts--a delivery system for the nontypeable Haemophilus influenzae antigen Omp26. FEMS immunology and medical microbiology. 2003 Jul 15; 37(2-3); 185-92. [PubMed: 12832124].
  48. Rothstein et al., 1991: Rothstein EP, Madore DV, Long SS. Antibody persistence four years after primary immunization of infants and toddlers with Haemophilus influenzae type b CRM197 conjugate vaccine. The Journal of pediatrics. 1991 Oct; 119(4); 655-7. [PubMed: 1919902].
  49. Rubin and Rizvi, 1991: Rubin LG, Rizvi A. Antibody to a 145-kilodalton outer membrane protein has bactericidal activity and protective activity against experimental bacteremia caused by a Brazilian purpuric fever isolate of Haemophilus influenzae biogroup aegyptius. The Brazilian Purpuric Fever Study Group. Infection and immunity. 1991; 59(12); 4576-4582. [PubMed: 1937817].
  50. Sabirov et al., 2004: Sabirov A, Kodama S, Sabirova N, Mogi G, Suzuki M. Intranasal immunization with outer membrane protein P6 and cholera toxin induces specific sinus mucosal immunity and enhances sinus clearance of nontypeable Haemophilus influenzae. Vaccine. 2004 Aug 13; 22(23-24); 3112-21. [PubMed: 15297063].
  51. Talan et al., 1999: Talan DA, Moran GJ, Pinner RW. Progress toward eliminating Haemophilus influenzae type b disease among infants and children--United States, 1987-1997. Annals of emergency medicine. 1999 Jul; 34(1); 109-11. [PubMed: 10382005].
  52. Tandon et al., 1991: Tandon MK, Gebski V. A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand journal of medicine. 1991 Aug; 21(4); 427-32. [PubMed: 1953532].
  53. Tristram et al., 2007: Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clinical microbiology reviews. 2007 Apr; 20(2); 368-89. [PubMed: 17428889 ].
  54. Webb et al., 1999: Webb DC, Cripps AW. Immunization with recombinant transferrin binding protein B enhances clearance of nontypeable Haemophilus influenzae from the rat lung. Infection and immunity. 1999 May; 67(5); 2138-44. [PubMed: 10225866].
  55. Webb et al., 2000: Webb DC, Cripps AW. A P5 peptide that is homologous to peptide 10 of OprF from Pseudomonas aeruginosa enhances clearance of nontypeable Haemophilus influenzae from acutely infected rat lung in the absence of detectable peptide-specific antibody. Infection and immunity. 2000 Jan; 68(1); 377-81. [PubMed: 10603411].
  56. Weinberg et al., 1988: Weinberg GA, Granoff DM. Polysaccharide-protein conjugate vaccines for the prevention of Haemophilus influenzae type b disease. The Journal of pediatrics. 1988 Oct; 113(4); 621-31. [PubMed: 3050001 ].
  57. Wu et al., 2005: Wu T, Chen J, Murphy TF, Green BA, Gu XX. Investigation of non-typeable Haemophilus influenzae outer membrane protein P6 as a new carrier for lipooligosaccharide conjugate vaccines. Vaccine. 2005 Oct 25; 23(44); 5177-85. [PubMed: 16039021].
  58. Yang et al., 1997: Yang YP, Munson RS Jr, Grass S, Chong P, Harkness RE, Gisonni L, James O, Kwok Y, Klein MH. Effect of lipid modification on the physicochemical, structural, antigenic and immunoprotective properties of Haemophilus influenzae outer membrane protein P6. Vaccine. 1997; 15(9); 976-987. [PubMed: 9261944].
  59. Zagursky et al., 2000: Zagursky RJ, Ooi P, Jones KF, Fiske MJ, Smith RP, Green BA. Identification of a Haemophilus influenzae 5'-nucleotidase protein: cloning of the nucA gene and immunogenicity and characterization of the NucA protein. Infection and immunity. 2000 May; 68(5); 2525-34. [PubMed: 10768940].

Haemophilus parasuis

  1. Fu et al., 2012: Fu S, Zhang M, Ou J, Liu H, Tan C, Liu J, Chen H, Bei W. Construction and immune effect of Haemophilus parasuis DNA vaccine encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in mice. Vaccine. 2012; 30(48); 6839-6844. [PubMed: 23000128].
  2. Oliveira and Pijoan, 2004: Oliveira S, Pijoan C. Haemophilus parasuis: new trends on diagnosis, epidemiology and control. Veterinary microbiology. 2004; 99(1); 1-12. [PubMed: 15019107].

Haemophilus somnus

  1. Microbe Wiki: H. somnus: Microbe Wiki: Haemophilus somnus [http://microbewiki.kenyon.edu/index.php/Haemophilus_somnus]

Hantavirus

  1. Bharadwaj et al., 2002: Bharadwaj M, Mirowsky K, Ye C, Botten J, Masten B, Yee J, Lyons CR, Hjelle B. Genetic vaccines protect against Sin Nombre hantavirus challenge in the deer mouse (Peromyscus maniculatus). The Journal of general virology. 2002; 83(Pt 7); 1745-1751. [PubMed: 12075094].
  2. CDC Hantaviruses: CDC Hantaviruses [http://0-www.cdc.gov.mill1.sjlibrary.org/ncidod/diseases/hanta/hps/]
  3. Chu et al., 1995: Chu YK, Jennings GB, Schmaljohn CS. A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus. Journal of virology. 1995; 69(10); 6417-6423. [PubMed: 7666542].
  4. Custer et al., 2003: Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. Journal of virology. 2003 Sep; 77(18); 9894-905. [PubMed: 12941899 ].
  5. de Carvalho Nicacio et al., 2002: de Carvalho Nicacio C, Gonzalez Della Valle M, Padula P, Bjorling E, Plyusnin A, Lundkvist A. Cross-protection against challenge with Puumala virus after immunization with nucleocapsid proteins from different hantaviruses. Journal of virology. 2002 Jul; 76(13); 6669-77. [PubMed: 12050380].
  6. Hooper et al., 2001: Hooper JW, Custer DM, Thompson E, Schmaljohn CS. DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys. Journal of virology. 2001; 75(18); 8469-8477. [PubMed: 11507192].
  7. Klingstrom et al., 2004: Klingstrom J, Maljkovic I, Zuber B, Rollman E, Kjerrstrom A, Lundkvist A. Vaccination of C57/BL6 mice with Dobrava hantavirus nucleocapsid protein in Freund's adjuvant induced partial protection against challenge. Vaccine. 2004 Sep 28; 22(29-30); 4029-34. [PubMed: 15364453].
  8. Kruger et al., 2001: Kruger DH, Ulrich R, Lundkvist A A. Hantavirus infections and their prevention. Microbes and infection / Institut Pasteur. 2001 Nov; 3(13); 1129-44. [PubMed: 11709294 ].
  9. Lednicky, 2003: Lednicky JA. Hantaviruses. a short review. Archives of pathology & laboratory medicine. 2003 Jan; 127(1); 30-5. [PubMed: 12521363].
  10. Maes et al., 2006: Maes P, Keyaerts E, Bonnet V, Clement J, Avsic-Zupanc T, Robert A, Van Ranst M. Truncated recombinant Dobrava hantavirus nucleocapsid proteins induce strong, long-lasting immune responses in mice. Intervirology. 2006; 49(5); 253-60. [PubMed: 16714853].
  11. Safronetz et al., 2009: Safronetz D, Hegde NR, Ebihara H, Denton M, Kobinger GP, St Jeor S, Feldmann H, Johnson DC. Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus. Journal of virology. 2009; 83(14); 7285-7295. [PubMed: 19403663].
  12. Ulrich et al., 1998: Ulrich R, Lundkvist A, Meisel H, Koletzki D, Sjolander KB, Gelderblom HR, Borisova G, Schnitzler P, Darai G, Kruger DH. Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine. 1998 Jan-Feb; 16(2-3); 272-80. [PubMed: 9607042 ].
  13. Yoshimatsu et al., 1993: Yoshimatsu K, Yoo YC, Yoshida R, Ishihara C, Azuma I, Arikawa J. Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus-expressed proteins. Archives of virology. 1993; 130(3-4); 365-376. [PubMed: 8517793].
  14. Yuan et al., 2010: Yuan ZG, Luo SJ, Xu HJ, Wang XH, Li J, Yuan LG, He LT, Zhang XX. Generation of E3-deleted canine adenovirus type 2 expressing the Gc glycoprotein of Seoul virus by gene insertion of deletion of related terminal region sequences. The Journal of general virology. 2010; ; . [PubMed: 20181748].

Helicobacter pylori

  1. Chen et al., 2012: Chen J, Lin L, Li N, She F. Enhancement of Helicobacter pylori outer inflammatory protein DNA vaccine efficacy by co-delivery of interleukin-2 and B subunit heat-labile toxin gene encoded plasmids. Microbiology and immunology. 2012; 56(2); 85-92. [PubMed: 22150716].
  2. Dunkley et al., 1999: Dunkley ML, Harris SJ, McCoy RJ, Musicka MJ, Eyers FM, Beagley LG, Lumley PJ, Beagley KW, Clancy RL. Protection against Helicobacter pylori infection by intestinal immunisation with a 50/52-kDa subunit protein. FEMS immunology and medical microbiology. 1999; 24(2); 221-225. [PubMed: 10378424].
  3. Ferrero et al., 1995: Ferrero RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proceedings of the National Academy of Sciences of the United States of America. 1995; 92(14); 6499-6503. [PubMed: 7604021].
  4. Huang et al., 2005: Huang W, Bai Y, Wang JD, Wu JB, Li GF, Zhang WM, Zhou DY. [Preparation oral liposome-encapsulated recombinant Helicobacter pylori heat shock protein 60 vaccine for prevention of Hp infection]. Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA. 2005; 25(5); 531-534. [PubMed: 15897126].
  5. Manetti et al., 1997: Manetti R, Massari P, Marchetti M, Magagnoli C, Nuti S, Lupetti P, Ghiara P, Rappuoli R, Telford JL. Detoxification of the Helicobacter pylori cytotoxin. Infection and immunity. 1997; 65(11); 4615-4619. [PubMed: 9353041].
  6. Radcliff et al., 1997: Radcliff FJ, Hazell SL, Kolesnikow T, Doidge C, Lee A. Catalase, a novel antigen for Helicobacter pylori vaccination. Infection and immunity. 1997; 65(11); 4668-4674. [PubMed: 9353048].
  7. Salyers and Whitt., 2002: Abigail A. Salyers, Dixie D. Whitt. Helicobacter pylori, A Resourceful Gastric Pathogen. 339-49. Bacterial Pathogenesis: A Molecular Approach. 2002. ASM Press, Washington D.C. USA.
  8. Satin et al., 2000: Satin B, Del Giudice G, Della Bianca V, Dusi S, Laudanna C, Tonello F, Kelleher D, Rappuoli R, Montecucco C, Rossi F. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. The Journal of experimental medicine. 2000; 191(9); 1467-1476. [PubMed: 10790422].
  9. Smythies et al., 2005: Smythies LE, Novak MJ, Waites KB, Lindsey JR, Morrow CD, Smith PD. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine. 2005; 23(7); 901-909. [PubMed: 15603891].
  10. Todoroki et al., 2000: Todoroki I, Joh T, Watanabe K, Miyashita M, Seno K, Nomura T, Ohara H, Yokoyama Y, Tochikubo K, Itoh M. Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice. Biochemical and biophysical research communications. 2000; 277(1); 159-163. [PubMed: 11027657].
  11. Wiki: Helicobacter pylori: Helicobacter pylori [http://en.wikipedia.org/wiki/Helicobacter_pylori]
  12. Xu et al., 2007: Xu C, Li ZS, Du YQ, Gong YF, Yang H, Sun B, Jin J. Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2. World journal of gastroenterology : WJG. 2007; 13(6); 939-944. [PubMed: 17352028].

Hendra virus

  1. CDC: Hendra virus: Hendra Virus Disease and Nipah Virus Encephalitis [http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/nipah.htm]
  2. McEachern et al., 2008: McEachern JA, Bingham J, Crameri G, Green DJ, Hancock TJ, Middleton D, Feng YR, Broder CC, Wang LF, Bossart KN. A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine. 2008; 26(31); 3842-3852. [PubMed: 18556094].

Hepatitis A virus

  1. EMC: Avaxim: The electronic Medicines Compendium: Avaxim [http://emc.medicines.org.uk/medicine/17385/PIL/AVAXIM/]
  2. EMC: Epaxal: EMC: Epaxal Product Information [http://emc.medicines.org.uk/medicine/12742/SPC/Epaxal/]
  3. FDA: Havrix: FDA: Havrix vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm110016.htm]
  4. FDA: HAVRIX: FDA: HAVRIX Influenza Virus Vaccine [http://www.fda.gov/cber/label/havrixLB.pdf]
  5. FDA: TWINRIX: FDA: TWINRIX [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094035.htm]
  6. FDA: VAQTA: FDA: VAQTA vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm110017.htm]
  7. GSK: Twinrix: GSK: Twinrix Product information [http://www.gsk.ca/english/docs-pdf/Twinrix_PM_20080916_EN.pdf]
  8. Karayiannis et al., 1991: Karayiannis P, O'Rourke S, McGarvey MJ, Luther S, Waters J, Goldin R, Thomas HC. A recombinant vaccinia virus expressing hepatitis A virus structural polypeptides: characterization and demonstration of protective immunogenicity. The Journal of general virology. 1991; 72 ( Pt 9); 2167-2172. [PubMed: 1654376].
  9. SP: Avaxim Pediatrix: SP: Avaxim Pediatrix [https://www.vaccineshoppecanada.com/secure/pdfs/ca/Avaxim_Ped_E.pdf]
  10. Wiki: Hepatitis A: Wiki: Hepatitis A virus [http://en.wikipedia.org/wiki/Hepatitis_A_virus]

Hepatitis B virus

  1. Chen et al., 2011: Chen JH, Yu YS, Liu HH, Chen XH, Xi M, Zang GQ, Tang ZH. Ubiquitin conjugation of hepatitis B virus core antigen DNA vaccine leads to enhanced cell-mediated immune response in BALB/c mice. Hepatitis monthly. 2011; 11(8); 620-628. [PubMed: 22140385].
  2. Chow et al., 1998: Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, Chen YT, Tao MH. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. Journal of immunology (Baltimore, Md. : 1950). 1998; 160(3); 1320-1329. [PubMed: 9570550].
  3. Conry et al., 2002: Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, Shaw DR, LoBuglio AF. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002; 8(9); 2782-2787. [PubMed: 12231517].
  4. Davis et al., 1993: Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Human molecular genetics. 1993; 2(11); 1847-1851. [PubMed: 8281146].
  5. Davis et al., 1996: Davis HL, McCluskie MJ, Gerin JL, Purcell RH. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(14); 7213-7218. [PubMed: 8692971].
  6. FDA COMVAX: FDA COMVAX package insert information [http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM109869.pdf]
  7. FDA: COMVAX: FDA: COMVAX [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm174757.htm]
  8. FDA: ENGERIX-B: FDA: ENGERIX-B I [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm110102.htm]
  9. FDA: Pediarix: FDA: Pediarix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm146759.htm]
  10. FDA: RECOMBIVAX HB: FDA: RECOMBIVAX HB [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm110098.htm]
  11. FDA: TWINRIX: FDA: TWINRIX [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094035.htm]
  12. He et al., 2005: He X, Jiang L, Wang F, Xiao Z, Li J, Liu LS, Li D, Ren D, Jin X, Li K, He Y, Shi K, Guo Y, Zhang Y, Sun S. Augmented humoral and cellular immune responses to hepatitis B DNA vaccine adsorbed onto cationic microparticles. Journal of controlled release : official journal of the Controlled Release Society. 2005; 107(2); 357-372. [PubMed: 16099068].
  13. Hwang et al., 2002: Hwang YK, Kim NK, Park JM, Lee K, Han WK, Kim HI, Cheong HS. HLA-A2 1 restricted peptides from the HBx antigen induce specific CTL responses in vitro and in vivo. Vaccine. 2002; 20(31-32); 3770-3777. [PubMed: 12399208].
  14. Jain et al., 2009: Jain V, Vyas SP, Kohli DV. Well-defined and potent liposomal hepatitis B vaccines adjuvanted with lipophilic MDP derivatives. Nanomedicine : nanotechnology, biology, and medicine. 2009; 5(3); 334-344. [PubMed: 19523433].
  15. Khatri et al., 2008: Khatri K, Goyal AK, Gupta PN, Mishra N, Vyas SP. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. International journal of pharmaceutics. 2008; 354(1-2); 235-241. [PubMed: 18182259].
  16. Kuhröber et al., 1997: Kuhröber A, Wild J, Pudollek HP, Chisari FV, Reimann J. DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb- and Kd-restricted epitopes. International immunology. 1997; 9(8); 1203-1212. [PubMed: 9263018].
  17. Kwissa et al., 2003: Kwissa M, Kröger A, Hauser H, Reimann J, Schirmbeck R. Cytokine-facilitated priming of CD8+ T cell responses by DNA vaccination. Journal of molecular medicine (Berlin, Germany). 2003; 81(2); 91-9101. [PubMed: 12601525].
  18. Merck: Recombivax HB: Merck: Recombivax HB vaccine information [http://www.merck.com/product/usa/pi_circulars/r/recombivax_hb/recombivax_pi.pdf]
  19. Morrey et al., 2011: Morrey JD, Motter NE, Chang S, Fairman J. Breaking B and T cell tolerance using cationic lipid-DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV. Antiviral research. 2011; 90(3); 227-230. [PubMed: 21545812].
  20. Payette et al., 2006: Payette PJ, Ma X, Weeratna RD, McCluskie MJ, Shapiro M, Engle RE, Davis HL, Purcell RH. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge. Intervirology. 2006; 49(3); 144-151. [PubMed: 16428890].
  21. Qing et al., 2010: Qing Y, Chen M, Zhao J, Hu H, Xu H, Ling N, Peng M, Ren H. Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV-transgenic mice. Vaccine. 2010; 28(26); 4301-4307. [PubMed: 20430121].
  22. Quiroga et al., 1990: Quiroga JA, Castillo I, Porres JC, Casado S, Sáez F, Gracia Martínez M, Gómez M, Inglada L, Sánchez-Sicilia L, Mora A. Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology (Baltimore, Md.). 1990; 12(4 Pt 1); 661-663. [PubMed: 2145212].
  23. Schirmbeck et al., 1995: Schirmbeck R, Böhm W, Ando K, Chisari FV, Reimann J. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. Journal of virology. 1995; 69(10); 5929-5934. [PubMed: 7666497].
  24. Tacket et al., 1999: Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edelman R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine. 1999; 17(22); 2826-2829. [PubMed: 10438052].
  25. Thermet et al., 2003: Thermet A, Rollier C, Zoulim F, Trepo C, Cova L. Progress in DNA vaccine for prophylaxis and therapy of hepatitis B. Vaccine. 2003; 21(7-8); 659-662. [PubMed: 12531335].
  26. Triyatni et al., 1998: Triyatni M, Jilbert AR, Qiao M, Miller DS, Burrell CJ. Protective efficacy of DNA vaccines against duck hepatitis B virus infection. Journal of virology. 1998; 72(1); 84-94. [PubMed: 9420203].
  27. Wang et al., 2000: Wang S, Liu X, Fisher K, Smith JG, Chen F, Tobery TW, Ulmer JB, Evans RK, Caulfield MJ. Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate. Vaccine. 2000; 18(13); 1227-1235. [PubMed: 10649624].
  28. Wiki: Hepatitis B: Wiki: Hepatitis B virus [http://en.wikipedia.org/wiki/Hepatitis_B]
  29. Xu et al., 2005: Xu W, Chu Y, Zhang R, Xu H, Wang Y, Xiong S. Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine. Virology. 2005; 334(2); 255-263. [PubMed: 15780875].
  30. Zhang et al., 2001: Zhang Z, Torii N, Hu Z, Jacob J, Liang TJ. X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo. The Journal of clinical investigation. 2001; 108(10); 1523-1531. [PubMed: 11714744].
  31. Zhang et al., 2006: Zhang W, Dong SF, Sun SH, Wang Y, Li GD, Qu D. Coimmunization with IL-15 plasmid enhances the longevity of CD8 T cells induced by DNA encoding hepatitis B virus core antigen. World journal of gastroenterology : WJG. 2006; 12(29); 4727-4735. [PubMed: 16937447].
  32. Zhou et al., 2003: Zhou FJ, Hu ZL, Dai JX, Chen RW, Shi K, Lin Y, Sun SH. Protection of tree shrews by pVAX-PS DNA vaccine against HBV infection. DNA and cell biology. 2003; 22(7); 475-478. [PubMed: 12932306].
  33. Zhou et al., 2003: Zhou X, Zheng L, Liu L, Xiang L, Yuan Z. T helper 2 immunity to hepatitis B surface antigen primed by gene-gun-mediated DNA vaccination can be shifted towards T helper 1 immunity by codelivery of CpG motif-containing oligodeoxynucleotides. Scandinavian journal of immunology. 2003; 58(3); 350-357. [PubMed: 12950682].
  34. Zinckgraf and Silbart, 2003: Zinckgraf JW, Silbart LK. Modulating gene expression using DNA vaccines with different 3'-UTRs influences antibody titer, seroconversion and cytokine profiles. Vaccine. 2003; 21(15); 1640-1649. [PubMed: 12639485].

Hepatitis C virus

  1. CDC - Hepatitis C: Hepatitis C Information for Health Professionals [http://www.cdc.gov/hepatitis/hcv/]
  2. Geissler et al., 1997: Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. Journal of immunology (Baltimore, Md. : 1950). 1997; 158(3); 1231-1237. [PubMed: 9013964].
  3. Lang et al., 2012: Lang Kuhs KA, Ginsberg AA, Yan J, Wiseman RW, Khan AS, Sardesai NY, O'Connor DH, Weiner DB. Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses. Molecular therapy : the journal of the American Society of Gene Therapy. 2012; 20(3); 669-678. [PubMed: 21952169].

Hepatitis D virus

  1. A.D.A.M. Medical Encyclopedia: Delta agent (Hepatitis D) [http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001264/]
  2. Fiedler et al., 2013: Fiedler M, Kosinska A, Schumann A, Brovko O, Walker A, Lu M, Johrden L, Mayer A, Wildner O, Roggendorf M. Prime/Boost Immunization with DNA and Adenoviral Vectors Protects from Hepatitis D Virus (HDV) Infection after Simultaneous Infection with HDV and Woodchuck Hepatitis Virus. Journal of virology. 2013; ; . [PubMed: 23637419].

Hepatitis E virus

  1. CDC - Hepatitis E: Hepatitis E Information for Health Professionals [http://www.cdc.gov/hepatitis/HEV/]
  2. He et al., 1997: He J, Hoffman SL, Hayes CG. DNA inoculation with a plasmid vector carrying the hepatitis E virus structural protein gene induces immune response in mice. Vaccine. 1997; 15(4); 357-362. [PubMed: 9141205].

Herpes simplex virus type 1 and 2

  1. Awasthi et al., 2008: Awasthi S, Lubinski JM, Eisenberg RJ, Cohen GH, Friedman HM. An HSV-1 gD mutant virus as an entry-impaired live virus vaccine. Vaccine. 2008; 26(9); 1195-1203. [PubMed: 18243431].
  2. Awasthi et al., 2011: Awasthi S, Lubinski JM, Shaw CE, Barrett SM, Cai M, Wang F, Betts M, Kingsley S, Distefano DJ, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. Journal of virology. 2011; 85(20); 10472-10486. [PubMed: 21813597].
  3. Brittle et al., 2008: Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM. A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine. Journal of virology. 2008; 82(17); 8431-8441. [PubMed: 18562543].
  4. Burke et al., 1994: Burke RL, Goldbeck C, Ng P, Stanberry L, Ott G, Van Nest G. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. The Journal of infectious diseases. 1994; 170(5); 1110-1119. [PubMed: 7963702].
  5. Chlibek et al., 2013: Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC. Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of Age. The Journal of infectious diseases. 2013; ; . [PubMed: 23904292].
  6. Fan and Yang, 2010: Fan J, Yang H. Construction and immune response of HSV-2gD-Hsp70 DNA vaccine. Journal of dermatological science. 2010; 57(1); 64-66. [PubMed: 19942410].
  7. Farrell et al., 1994: Farrell HE, McLean CS, Harley C, Efstathiou S, Inglis S, Minson AC. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. Journal of virology. 1994; 68(2); 927-932. [PubMed: 8289395].
  8. Field and Wildy, 1978: Field HJ, Wildy P. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. The Journal of hygiene. 1978; 81(2); 267-277. [PubMed: 212476].
  9. GlaxoSmithKline, 2013: Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years [http://clinicaltrials.gov/ct2/show/study/NCT01165177]
  10. Goel et al., 2005: Goel N, Zimmerman DH, Rosenthal KS. Ligand epitope antigen presentation system vaccines against herpes simplex virus. Frontiers in bioscience : a journal and virtual library. 2005; 10; 966-974. [PubMed: 15569635].
  11. Grabowska et al., 2000: Grabowska AM, Jennings R, Laing P, Darsley M, Jameson CL, Swift L, Irving WL. Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2. Virology. 2000; 269(1); 47-53. [PubMed: 10725197].
  12. Halford et al., 2011: Halford WP, Püschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PloS one. 2011; 6(3); e17748. [PubMed: 21412438].
  13. Hariharan et al., 1998: Hariharan MJ, Driver DA, Townsend K, Brumm D, Polo JM, Belli BA, Catton DJ, Hsu D, Mittelstaedt D, McCormack JE, Karavodin L, Dubensky TW Jr, Chang SM, Banks TA. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. Journal of virology. 1998; 72(2); 950-958. [PubMed: 9444987].
  14. Haynes et al., 2006: Haynes JR, Arrington J, Dong L, Braun RP, Payne LG. Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin. Vaccine. 2006; 24(23); 5016-5026. [PubMed: 16621198].
  15. Heineman et al., 1995: Heineman TC, Connelly BL, Bourne N, Stanberry LR, Cohen J. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. Journal of virology. 1995; 69(12); 8109-8113. [PubMed: 7494331].
  16. Hu et al., 2011: Hu K, Dou J, Yu F, He X, Yuan X, Wang Y, Liu C, Gu N. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice. Vaccine. 2011; 29(7); 1455-1462. [PubMed: 21185849].
  17. Huilan et al., 2010: Huilan Y, Cui Z, Jianyong F, Lei G, Wei Q. Construction of, and T-helper (Th)1/Th2 immune responses to, a herpes simplex virus type 2 glycoprotein D-cytotoxic T-lymphocyte epitope DNA vaccine. Clinical and experimental dermatology. 2010; ; . [PubMed: 20497188].
  18. Jamali et al., 2009: Jamali A, Mahdavi M, Hassan ZM, Sabahi F, Farsani MJ, Bamdad T, Soleimanjahi H, Motazakker M, Shahabi S. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. International immunology. 2009; 21(3); 217-225. [PubMed: 19174474].
  19. Kim et al., 2009: Kim SB, Han YW, Rahman MM, Kim SJ, Yoo DJ, Kang SH, Kim K, Eo SK. Modulation of protective immunity against herpes simplex virus via mucosal genetic co-transfer of DNA vaccine with beta2-adrenergic agonist. Experimental & molecular medicine. 2009; 41(11); 812-823. [PubMed: 19641376].
  20. Manickan et al., 1997: Manickan E, Kanangat S, Rouse RJ, Yu Z, Rouse BT. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. Journal of leukocyte biology. 1997; 61(2); 125-132. [PubMed: 9021916].
  21. McClements et al., 1996: McClements WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(21); 11414-11420. [PubMed: 8876149].
  22. McClements et al., 1997: McClements WL, Armstrong ME, Keys RD, Liu MA. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs. Vaccine. 1997; 15(8); 857-860. [PubMed: 9234533].
  23. Mester et al., 1999: Mester JC, Twomey TA, Tepe ET, Bernstein DI. Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C. Vaccine. 1999; 18(9-10); 875-883. [PubMed: 10580201].
  24. Morrison and Knipe, 1994: Morrison LA, Knipe DM. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. Journal of virology. 1994; 68(2); 689-696. [PubMed: 8289372].
  25. Nass et al., 1998: Nass PH, Elkins KL, Weir JP. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins. The Journal of infectious diseases. 1998; 178(3); 611-617. [PubMed: 9728527].
  26. Orr et al., 2007: Orr MT, Orgun NN, Wilson CB, Way SS. Cutting edge: recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. Journal of immunology (Baltimore, Md. : 1950). 2007; 178(8); 4731-4735. [PubMed: 17404252].
  27. Osorio et al., 2004: Osorio Y, Cohen J, Ghiasi H. Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines. Investigative ophthalmology & visual science. 2004; 45(2); 506-514. [PubMed: 14744892].
  28. Shlapobersky et al., 2012: Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, Chu A, Rolland A, Sullivan S, Koelle DM. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. The Journal of general virology. 2012; 93(Pt 6); 1305-1315. [PubMed: 22398318].
  29. Sin et al., 2001: Sin JI, Kim JJ, Zhang D, Weiner DB. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Human gene therapy. 2001; 12(9); 1091-1102. [PubMed: 11399230].
  30. Tirabassi et al., 2011: Tirabassi RS, Ace CI, Levchenko T, Torchilin VP, Selin LK, Nie S, Guberski DL, Yang K. A mucosal vaccination approach for herpes simplex virus type 2. Vaccine. 2011; 29(5); 1090-1098. [PubMed: 21134447].
  31. Toka and Rouse, 2005: Toka FN, Rouse BT. Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-Herpes simplex virus immunity. Journal of leukocyte biology. 2005; 78(1); 178-186. [PubMed: 15817700].
  32. Veselenak et al., 2012: Veselenak RL, Shlapobersky M, Pyles RB, Wei Q, Sullivan SM, Bourne N. A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine. 2012; 30(49); 7046-7051. [PubMed: 23041125].
  33. Wiki: Herpes simplex virus: Herpes simplex virus [http://en.wikipedia.org/wiki/Herpes_simplex_virus]

Hirame rhabdovirus

  1. Borzym et al., 2012: First detection of Hirame rhabdovirus (HIRRV) in Europe [http://orbit.dtu.dk/fedora/objects/orbit:112698/datastreams/file_9708708/content]
  2. Seo et al., 2006: Seo JY, Kim KH, Kim SG, Oh MJ, Nam SW, Kim YT, Choi TJ. Protection of flounder against hirame rhabdovirus (HIRRV) with a DNA vaccine containing the glycoprotein gene. Vaccine. 2006; 24(7); 1009-1015. [PubMed: 16176849].
  3. Yasuike et al., 2007: Yasuike M, Kondo H, Hirono I, Aoki T. Difference in Japanese flounder, Paralichthys olivaceus gene expression profile following hirame rhabdovirus (HIRRV) G and N protein DNA vaccination. Fish & shellfish immunology. 2007; 23(3); 531-541. [PubMed: 17449275].

Human coxsackievirus

  1. Henke et al., 2004: Henke A, Chiang CS, Zell R, Stelzner A. Co-expression of interleukin-2 to increase the efficacy of DNA vaccine-mediated protection in coxsackievirus B3-infected mice. Antiviral research. 2004; 64(2); 131-136. [PubMed: 15498609].
  2. MedicineNet - Coxsackievirus: Coxsackie Virus [http://www.medicinenet.com/coxsackie_virus/article.htm]

Human cytomegalovirus

  1. Hwang et al., 1999: Hwang ES, Kwon KB, Park JW, Kim DJ, Park CG, Cha CY. Induction of neutralizing antibody against human cytomegalovirus (HCMV) with DNA-mediated immunization of HCMV glycoprotein B in mice. Microbiology and immunology. 1999; 43(3); 307-310. [PubMed: 10338203].
  2. Mayo Clinic - CMV: Cytomegalovirus (CMV) infection [http://www.mayoclinic.com/health/cmv/DS00938]
  3. Schleiss, 2009: Schleiss MR. VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Current opinion in molecular therapeutics. 2009; 11(5); 572-578. [PubMed: 19806506].
  4. Temperton et al., 2003: Temperton NJ, Quenelle DC, Lawson KM, Zuckerman JN, Kern ER, Griffiths PD, Emery VC. Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides. Journal of medical virology. 2003; 70(1); 86-90. [PubMed: 12629648].
  5. Wang et al., 2013: Wang H, Yao Y, Huang C, Chen Q, Chen J, Chen Z. Immunization with cytomegalovirus envelope glycoprotein M and glycoprotein N DNA vaccines can provide mice with complete protection against a lethal murine cytomegalovirus challenge. Virologica Sinica. 2013; 28(3); 174-182. [PubMed: 23715998].

Human Immunodeficiency Virus

  1. Aggarwal et al., 2005: Aggarwal P, Kumar S, Vajpayee M, Seth P. Adjuvant action of murine IL-2/Ig plasmid after intramuscular immunization with Indian HIV-1 subtype C recombinant env.gp 120 construct. Viral immunology. 2005; 18(4); 649-656. [PubMed: 16359231].
  2. Ami et al., 2005: Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, Yoshino N, Sakai K, Shinohara K, Matsumoto S, Yamada T, Yamazaki S, Yamamoto N, Honda M. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. Journal of virology. 2005; 79(20); 12871-12879. [PubMed: 16188989].
  3. Ara et al., 2001: Ara Y, Saito T, Takagi T, Hagiwara E, Miyagi Y, Sugiyama M, Kawamoto S, Ishii N, Yoshida T, Hanashi D, Koshino T, Okada H, Okuda K. Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system. Immunology. 2001; 103(1); 98-9105. [PubMed: 11380697].
  4. Ayyavoo et al., 2002: Ayyavoo V, Muthumani K, Kudchodkar S, Zhang D, Ramanathan P, Dayes NS, Kim JJ, Sin JI, Montaner LJ, Weiner DB. HIV-1 viral protein R compromises cellular immune function in vivo. International immunology. 2002 Jan; 14(1); 13-22. [PubMed: 11751747].
  5. Bagley et al., 2003: Bagley KC, Shata MT, Onyabe DY, DeVico AL, Fouts TR, Lewis GK, Hone DM. Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin. Vaccine. 2003; 21(23); 3335-3341. [PubMed: 12804865].
  6. Barouch et al., 2012: Barouch DH, Klasse PJ, Dufour J, Veazey RS, Moore JP. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(22); 8694-8698. [PubMed: 22586094].
  7. Barrett et al., 1989: Barrett N, Mitterer A, Mundt W, Eibl J, Eibl M, Gallo RC, Moss B, Dorner F. Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity. AIDS research and human retroviruses. 1989; 5(2); 159-171. [PubMed: 2713166].
  8. Bielinska et al., 2008: Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR Jr. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS research and human retroviruses. 2008; 24(2); 271-281. [PubMed: 18260780].
  9. Bomford et al., 1992: Bomford R, Stapleton M, Winsor S, McKnight A, Andronova T. The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS research and human retroviruses. 1992; 8(10); 1765-1771. [PubMed: 1457190].
  10. Bower et al., 2004: Bower JF, Yang X, Sodroski J, Ross TM. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. Journal of virology. 2004; 78(9); 4710-4719. [PubMed: 15078953].
  11. Boyer et al., 1997: Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, Chattergoon M, Frost P, Javadian A, Williams WV, Refaeli Y, Ciccarelli RB, McCallus D, Coney L, Weiner DB. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature medicine. 1997; 3(5); 526-532. [PubMed: 9142121].
  12. Bråve et al., 2007: Bråve A, Hinkula J, Cafaro A, Eriksson LE, Srivastava IK, Magnani M, Ensoli B, Barnett SW, Wahren B, Rollman E. Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. Vaccine. 2007; 25(39-40); 6882-6890. [PubMed: 17707956].
  13. Bråve et al., 2005: Bråve A, Ljungberg K, Boberg A, Rollman E, Isaguliants M, Lundgren B, Blomberg P, Hinkula J, Wahren B. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Molecular therapy : the journal of the American Society of Gene Therapy. 2005; 12(6); 1197-1205. [PubMed: 16112909].
  14. Buchbinder et al., 1994: Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. AIDS (London, England). 1994 Aug; 8(8); 1123-8. [PubMed: 7986410].
  15. Calarota et al., 1998: Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandström E, Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet. 1998; 351(9112); 1320-1325. [PubMed: 9643795].
  16. Calarota et al., 2008: Calarota SA, Dai A, Trocio JN, Weiner DB, Lori F, Lisziewicz J. IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. Vaccine. 2008; 26(40); 5188-5195. [PubMed: 18462844].
  17. Caley et al., 1999: Caley IJ, Betts MR, Davis NL, Swanstrom R, Frelinger JA, Johnston RE. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine. 1999 Aug 6; 17(23-24); 3124-35. [PubMed: 10462249].
  18. Caputo et al., 2003: Caputo A, Gavioli R, Altavilla G, Brocca-Cofano E, Boarini C, Betti M, Castaldello A, Lorenzini F, Micheletti F, Cafaro A, Sparnacci K, Laus M, Tondelli L, Ensoli B. Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. Vaccine. 2003; 21(11-12); 1103-1111. [PubMed: 12559787].
  19. Casimiro et al., 2003: Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. Journal of virology. 2003; 77(11); 6305-6313. [PubMed: 12743287].
  20. Chan et al., 1997: Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997 Apr 18; 89(2); 263-73. [PubMed: 9108481].
  21. Chen et al., 2005: Chen X, Rock MT, Hammonds J, Tartaglia J, Shintani A, Currier J, Slike B, Crowe JE Jr, Marovich M, Spearman P. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. Journal of virology. 2005 May; 79(9); 5537-47. [PubMed: 15827168].
  22. Chin'ombe et al., 2009: Chin'ombe N, Bourn WR, Williamson AL, Shephard EG. Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice. Virology journal. 2009; 6; 87. [PubMed: 19555490].
  23. Coakley et al., 2005: Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine co-receptor usage in HIV. Current opinion in infectious diseases. 2005 Feb; 18(1); 9-15. [PubMed: 15647694].
  24. Coffin et al., 1986: Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H, Toyoshima K, Varmus H, Vogt P. What to call the AIDS virus?. Nature. 1986 May 1-7; 321(6065); 10. [PubMed: 3010128].
  25. Cristillo et al., 2011: Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, Bowen B, Thompson D, Petrovsky N, Markham P, Pal R. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. The Journal of general virology. 2011; 92(Pt 1); 128-140. [PubMed: 21169215].
  26. Dale et al., 2004: Dale CJ, De Rose R, Stratov I, Chea S, Montefiori DC, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Law M, Kent SJ. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. Journal of virology. 2004; 78(24); 13819-13828. [PubMed: 15564490].
  27. Davis et al., 2002: Davis NL, West A, Reap E, MacDonald G, Collier M, Dryga S, Maughan M, Connell M, Walker C, McGrath K, Cecil C, Ping LH, Frelinger J, Olmsted R, Keith P, Swanstrom R, Williamson C, Johnson P, Montefiori D, Johnston RE. Alphavirus replicon particles as candidate HIV vaccines. IUBMB life. 2002 Apr-May; 53(4-5); 209-11. [PubMed: 12120997].
  28. Deng et al., 1996: Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996 Jun 20; 381(6584); 661-6. [PubMed: 8649511].
  29. Denis-Mize et al., 2000: Denis-Mize KS, Dupuis M, MacKichan ML, Singh M, Doe B, O'Hagan D, Ulmer JB, Donnelly JJ, McDonald DM, Ott G. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene therapy. 2000; 7(24); 2105-2112. [PubMed: 11223992].
  30. Duerr et al., 2012: Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, Del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN. Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study). The Journal of infectious diseases. 2012; 206(2); 258-266. [PubMed: 22561365].
  31. Durier et al., 2006: Durier C, Launay O, Meiffredy V, Saidi Y, Salmon D, Levy Y, Guillet JG, Pialoux G, Aboulker JP. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS (London, England). 2006 Apr 24; 20(7); 1039-49. [PubMed: 16603857].
  32. Flatz et al., 2012: Flatz L, Cheng C, Wang L, Foulds KE, Ko SY, Kong WP, Roychoudhuri R, Shi W, Bao S, Todd JP, Asmal M, Shen L, Donaldson M, Schmidt SD, Gall JG, Pinschewer DD, Letvin NL, Rao S, Mascola JR, Roederer M, Nabel GJ. Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates. Journal of virology. 2012; 86(15); 7760-7770. [PubMed: 22593152].
  33. Gudmundsdotter et al., 2009: Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandström E, Wahren B. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine. 2009; 27(33); 4468-4474. [PubMed: 19450644].
  34. Hammer et al., 2009: Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men [http://www.clinicaltrials.gov/ct2/show/NCT00865566?term=Ad5+DNA&rank=3]
  35. Hanke et al., 2002: Hanke T, McMichael AJ, Samuel RV, Powell LA, McLoughlin L, Crome SJ, Edlin A. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine. 2002; 21(1-2); 108-114. [PubMed: 12443668].
  36. Harris et al., 1996: Harris SJ, Woodrow SA, Gearing AJ, Adams SE, Kingsman AJ, Layton GT. The effects of adjuvants on CTL induction by V3:Ty-virus-like particles (V3-VLPs) in mice. Vaccine. 1996; 14(10); 971-976. [PubMed: 8873390].
  37. Harro et al., 2009: Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, Mulligan MJ, Priddy FH, Dubey SA, Kierstead LS, Sun X, Casimiro DR, DiNubile MJ, Shiver JW, Leavitt RY, Mehrotra DV. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS research and human retroviruses. 2009; 25(1); 103-114. [PubMed: 19108693].
  38. Hawkins et al., 2003: Hawkins WG, Trcka J, Segal N, Blachere NE, Gold JS, Moroi Y, Bowne WB, Lewis JJ, Wolchok JD, Houghton AN. The role of lipopolysaccharide in T-cell responses following DNA vaccination. Vaccine. 2003; 21(13-14); 1548-1553. [PubMed: 12615452].
  39. Hejdeman et al., 2004: Hejdeman B, Boström AC, Matsuda R, Calarota S, Lenkei R, Fredriksson EL, Sandström E, Bratt G, Wahren B. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy. AIDS research and human retroviruses. 2004; 20(8); 860-870. [PubMed: 15320990].
  40. Hirao et al., 2008: Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A, Betts MR, Draghia-Akli R, Weiner DB. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine. 2008; 26(25); 3112-3120. [PubMed: 18430495].
  41. Johnson et al., 2012: Johnson MJ, Petrovas C, Yamamoto T, Lindsay RW, Loré K, Gall JG, Gostick E, Lefebvre F, Cameron MJ, Price DA, Haddad E, Sekaly RP, Seder RA, Koup RA. Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. Journal of immunology (Baltimore, Md. : 1950). 2012; 188(12); 6109-6118. [PubMed: 22586038].
  42. Kaneko et al., 2000: Kaneko H, Bednarek I, Wierzbicki A, Kiszka I, Dmochowski M, Wasik TJ, Kaneko Y, Kozbor D. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology. 2000; 267(1); 8-16. [PubMed: 10648178].
  43. Kang et al., 2003: Kang KK, Choi SM, Choi JH, Lee DS, Kim CY, Ahn BO, Kim BM, Kim WB. Safety evaluation of GX-12, a new HIV therapeutic vaccine: investigation of integration into the host genome and expression in the reproductive organs. Intervirology. 2003; 46(5); 270-276. [PubMed: 14555847].
  44. Kent et al., 2007: Kent S, De Rose R, Rollman E. Drug evaluation: DNA/MVA prime-boost HIV vaccine. Current opinion in investigational drugs (London, England : 2000). 2007 Feb; 8(2); 159-67. [PubMed: 17328232].
  45. Kim et al., 1998: Kim JJ, Trivedi NN, Nottingham LK, Morrison L, Tsai A, Hu Y, Mahalingam S, Dang K, Ahn L, Doyle NK, Wilson DM, Chattergoon MA, Chalian AA, Boyer JD, Agadjanyan MG, Weiner DB. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. European journal of immunology. 1998; 28(3); 1089-1103. [PubMed: 9541605].
  46. Kim et al., 2000: Kim JJ, Yang JS, VanCott TC, Lee DJ, Manson KH, Wyand MS, Boyer JD, Ugen KE, Weiner DB. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants. Journal of virology. 2000; 74(7); 3427-3429. [PubMed: 10708463].
  47. Kim et al., 2001: Kim JJ, Yang JS, Manson KH, Weiner DB. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine. 2001; 19(17-19); 2496-2505. [PubMed: 11257383].
  48. Knight et al., 1990: Knight SC, Macatonia SE, Patterson S. HIV I infection of dendritic cells. International reviews of immunology. 1990; 6(2-3); 163-75. [PubMed: 2152500].
  49. Kutzler et al., 2005: Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, Sidhu M, Roopchand V, Kim JJ, Pavlakis GN, Felber BK, Waldmann TA, Boyer JD, Weiner DB. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. Journal of immunology (Baltimore, Md. : 1950). 2005; 175(1); 112-123. [PubMed: 15972637].
  50. Leclerc et al., 1997: Leclerc C, Dériaud E, Rojas M, Whalen RG. The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cellular immunology. 1997; 179(2); 97-9106. [PubMed: 9268493].
  51. Lekutis et al., 1997: Lekutis C, Shiver JW, Liu MA, Letvin NL. HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha. Journal of immunology (Baltimore, Md. : 1950). 1997; 158(9); 4471-4477. [PubMed: 9127013].
  52. Lena et al., 2002: Lena P, Villinger F, Giavedoni L, Miller CJ, Rhodes G, Luciw P. Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus. Vaccine. 2002; 20 Suppl 4; A69-79. [PubMed: 12477432].
  53. Li et al., 2008: Li W, Li S, Hu Y, Tang B, Cui L, He W. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting. Vaccine. 2008; 26(26); 3282-3290. [PubMed: 18472194].
  54. Liu et al., 2004: Liu YZ, Zhou L, Wang Q, Ye SQ, Li HX, Zeng Y. [Immune response induced by HIV DNA vaccine combined with recombinant adeno-associated virus]. Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology. 2004 Sep; 18(3); 251-4. [PubMed: 15640860].
  55. Liu et al., 2006: Liu J, Wyatt LS, Amara RR, Moss B, Robinson HL. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine. Vaccine. 2006 Apr 12; 24(16); 3332-9. [PubMed: 16472543].
  56. Locher et al., 2004: Locher CP, Witt SA, Ashlock BM, Polacino P, Hu SL, Shiboski S, Schmidt AM, Agy MB, Anderson DM, Staprans SI, zur Megede J, Levy JA. Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine. 2004; 22(17-18); 2261-2272. [PubMed: 15149785].
  57. Lu et al., 2000: Lu Y, Friedman R, Kushner N, Doling A, Thomas L, Touzjian N, Starnbach M, Lieberman J. Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity. Proceedings of the National Academy of Sciences of the United States of America. 2000 Jul 5; 97(14); 8027-32. [PubMed: 10884430].
  58. MacGregor et al., 1998: MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. The Journal of infectious diseases. 1998; 178(1); 92-9100. [PubMed: 9652427].
  59. MacGregor et al., 2005: MacGregor RR, Boyer JD, Ugen KE, Tebas P, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, Weiner DB. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine. 2005; 23(17-18); 2066-2073. [PubMed: 15755572].
  60. Malm et al., 2005: Malm M, Rollman E, Ustav M, Hinkula J, Krohn K, Wahren B, Blazevic V. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral immunology. 2005; 18(4); 678-88. [PubMed: 16359234].
  61. Mascola et al., 2005: Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. Journal of virology. 2005; 79(2); 771-779. [PubMed: 15613305].
  62. McElrath et al., 2008: McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008; 372(9653); 1894-1905. [PubMed: 19012957].
  63. McEvers et al., 2005: McEvers K, Elrefaei M, Norris P, Deeks S, Martin J, Lu Y, Cao H. Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways. Vaccine. 2005 Jul 14; 23(32); 4128-35. [PubMed: 15964481].
  64. Moore et al., 2002: Moore AC, Kong WP, Chakrabarti BK, Nabel GJ. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. Journal of virology. 2002; 76(1); 243-250. [PubMed: 11739689].
  65. O'Hagan et al., 2001: O'Hagan D, Singh M, Ugozzoli M, Wild C, Barnett S, Chen M, Schaefer M, Doe B, Otten GR, Ulmer JB. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. Journal of virology. 2001; 75(19); 9037-9043. [PubMed: 11533167].
  66. Otero et al., 2004: Otero M, Calarota SA, Felber B, Laddy D, Pavlakis G, Boyer JD, Weiner DB. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine. 2004; 22(13-14); 1782-1790. [PubMed: 15068862].
  67. Otten et al., 2005: Otten GR, Schaefer M, Doe B, Liu H, Srivastava I, Megede J, Kazzaz J, Lian Y, Singh M, Ugozzoli M, Montefiori D, Lewis M, Driver DA, Dubensky T, Polo JM, Donnelly J, O'Hagan DT, Barnett S, Ulmer JB. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. Journal of virology. 2005 Jul; 79(13); 8189-200. [PubMed: 15956564].
  68. Ozpolat et al., 1998: Ozpolat B, Rao XM, Powell MF, Lachman LB. Immunoliposomes containing antibodies to costimulatory molecules as adjuvants for HIV subunit vaccines. AIDS research and human retroviruses. 1998; 14(5); 409-417. [PubMed: 9546800].
  69. Pal et al., 2005: Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Cristillo A, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Lu S, Markham P. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. Journal of medical primatology. 2005; 34(5-6); 226-236. [PubMed: 16128917].
  70. Pal et al., 2006: Pal R, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Markham P, Lu S. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology. 2006; 348(2); 341-353. [PubMed: 16460776].
  71. Palella et al., 1998: Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England journal of medicine. 1998 Mar 26; 338(13); 853-60. [PubMed: 9516219].
  72. Parker, 2007: Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults [http://clinicaltrials.gov/ct2/show/NCT00528489]
  73. Peters et al., 2007: Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa-Manyonyi G, Dally L, Klavinskis L, Farah B, Tarragona T, Bart PA, Robinson A, Pieterse C, Stevens W, Thomas R, Barin B, McMichael AJ, McIntyre JA, Pantaleo G, Hanke T, Bwayo J. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine. 2007; 25(11); 2120-2127. [PubMed: 17250931].
  74. Qiu et al., 1999: Qiu JT, Song R, Dettenhofer M, Tian C, August T, Felber BK, Pavlakis GN, Yu XF. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. Journal of virology. 1999; 73(11); 9145-9152. [PubMed: 10516021].
  75. Rerks-Ngarm et al., 2009: Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. The New England journal of medicine. 2009; 361(23); 2209-2220. [PubMed: 19843557].
  76. Reynolds et al., 2012: Reynolds MR, Weiler AM, Piaskowski SM, Piatak M Jr, Robertson HT, Allison DB, Bett AJ, Casimiro DR, Shiver JW, Wilson NA, Lifson JD, Koff WC, Watkins DI. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine. 2012; 30(30); 4465-4475. [PubMed: 22569124].
  77. Robinson et al., 2006: Robinson HL, Montefiori DC, Villinger F, Robinson JE, Sharma S, Wyatt LS, Earl PL, McClure HM, Moss B, Amara RR. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology. 2006; 352(2); 285-294. [PubMed: 16740288].
  78. Santra et al., 2004: Santra S, Barouch DH, Korioth-Schmitz B, Lord CI, Krivulka GR, Yu F, Beddall MH, Gorgone DA, Lifton MA, Miura A, Philippon V, Manson K, Markham PD, Parrish J, Kuroda MJ, Schmitz JE, Gelman RS, Shiver JW, Montefiori DC, Panicali D, Letvin NL. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proceedings of the National Academy of Sciences of the United States of America. 2004 Jul 27; 101(30); 11088-93. [PubMed: 15258286].
  79. Sheets et al., 2006: Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, Kong WP, Nabel GJ, Gomez PL. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicological sciences : an official journal of the Society of Toxicology. 2006; 91(2); 610-619. [PubMed: 16569729].
  80. Shiver et al., 2002: Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002 Jan 17; 415(6869); 331-5. [PubMed: 11797011].
  81. Sizemore et al., 1995: Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science (New York, N.Y.). 1995; 270(5234); 299-302. [PubMed: 7569980].
  82. Song et al., 2006: Song R, Liu S, Adams RJ, Leong KW. Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2006; 26(6); 380-389. [PubMed: 16734558].
  83. Stieneker et al., 1991: Stieneker F, Kreuter J, Löwer J. High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines. AIDS (London, England). 1991; 5(4); 431-435. [PubMed: 2059385].
  84. Takehisa et al., 2001: Takehisa J, Harada Y, Ndembi N, Mboudjeka I, Taniguchi Y, Ngansop C, Kuate S, Zekeng L, Ibuki K, Shimada T, Bikandou B, Yamaguchi-Kabata Y, Miura T, Ikeda M, Ichimura H, Kaptue L, Hayami M. Natural infection of wild-born mandrills (Mandrillus sphinx) with two different types of simian immunodeficiency virus. AIDS research and human retroviruses. 2001 Aug 10; 17(12); 1143-54. [PubMed: 11522184].
  85. Tatalick et al., 2005: Tatalick LM, Gerard CJ, Takeya R, Price DN, Thorne BA, Wyatt LM, Anklesaria P. Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine. Vaccine. 2005 Apr 8; 23(20); 2628-38. [PubMed: 15780446].
  86. Vecino et al., 2002: Vecino WH, Morin PM, Agha R, Jacobs WR Jr, Fennelly GJ. Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV. Immunology letters. 2002; 82(3); 197-204. [PubMed: 12036602].
  87. Vinner et al., 1999: Vinner L, Nielsen HV, Bryder K, Corbet S, Nielsen C, Fomsgaard A. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons. Vaccine. 1999; 17(17); 2166-2175. [PubMed: 10367950].
  88. Wang et al., 1993: Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90(9); 4156-4160. [PubMed: 8483929].
  89. Wang et al., 1993: Wang B, Boyer J, Srikantan V, Coney L, Carrano R, Phan C, Merva M, Dang K, Agadjanan M, Gilbert L. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. DNA and cell biology. 1993; 12(9); 799-805. [PubMed: 8216851].
  90. Wang et al., 2006: Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, Lu S. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine. 2006; 24(21); 4531-4540. [PubMed: 16140431].
  91. Weber et al., 2001: Weber R, Bossart W, Cone R, Luethy R, Moelling K. Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2001; 20(11); 800-803. [PubMed: 11783696].
  92. Xin et al., 2005: Xin KQ, Jounai N, Someya K, Honma K, Mizuguchi H, Naganawa S, Kitamura K, Hayakawa T, Saha S, Takeshita F, Okuda K, Honda M, Klinman DM, Okuda K. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene therapy. 2005 Dec; 12(24); 1769-77. [PubMed: 16079886].
  93. Yoshino et al., 2004: Yoshino N, Lü FX, Fujihashi K, Hagiwara Y, Kataoka K, Lu D, Hirst L, Honda M, van Ginkel FW, Takeda Y, Miller CJ, Kiyono H, McGhee JR. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. Journal of immunology (Baltimore, Md. : 1950). 2004; 173(11); 6850-6857. [PubMed: 15557179].
  94. Zhang et al., 2009: Zhang H, Hong H, Li D, Ma S, Di Y, Stoten A, Haig N, Di Gleria K, Yu Z, Xu XN, McMichael A, Jiang S. Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells. The Journal of biological chemistry. 2009; 284(14); 9184-9191. [PubMed: 19193636].

Human metapneumovirus

  1. Biacchesi et al., 2005: Biacchesi S, Pham QN, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. Journal of virology. 2005; 79(19); 12608-12613. [PubMed: 16160190].
  2. Kapczynski and Sellers, 2003: Kapczynski DR, Sellers HS. Immunization of turkeys with a DNA vaccine expressing either the F or N gene of avian metapneumovirus. Avian diseases. 2003; 47(4); 1376-1383. [PubMed: 14708985].
  3. Schickli et al., 2008: Schickli JH, Kaur J, Macphail M, Guzzetta JM, Spaete RR, Tang RS. Deletion of human metapneumovirus M2-2 increases mutation frequency and attenuates growth in hamsters. Virology journal. 2008; 5; 69. [PubMed: 18519001].
  4. Wiki: Metapneumovirus: Metapneumovirus [http://en.wikipedia.org/wiki/Metapneumovirus]

Human Papillomavirus

  1. Brinkman et al., 2007: Brinkman JA, Xu X, Kast WM. The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. Vaccine. 2007; 25(17); 3437-3444. [PubMed: 17241713].
  2. Cheng et al., 2001: Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. The Journal of clinical investigation. 2001; 108(5); 669-678. [PubMed: 11544272].
  3. Chu et al., 2011: Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 [http://www.clinicaltrials.gov/ct2/show/NCT00685412?term=vgx&rank=1]
  4. Donnelly et al., 1996: Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA. Protection against papillomavirus with a polynucleotide vaccine. The Journal of infectious diseases. 1996; 173(2); 314-320. [PubMed: 8568291].
  5. FDA: Cevarix: FDA: Cervarix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186957.htm]
  6. FDA: Gardasil: FDA: Gardasil information [http://www.fda.gov/Cber/products/gardasil.htm]
  7. Garcia et al., 2004: Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, Magill M, Silverman M, Urban RG, Hedley ML, Beach KJ. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and gynecology. 2004; 103(2); 317-326. [PubMed: 14754702].
  8. Henken et al., 2012: Henken FE, Oosterhuis K, Ohlschläger P, Bosch L, Hooijberg E, Haanen JB, Steenbergen RD. Preclinical safety evaluation of DNA vaccines encoding modified HPV16 E6 and E7. Vaccine. 2012; 30(28); 4259-4266. [PubMed: 22554465].
  9. Huang, 2008: Huang CM. Human papillomavirus and vaccination. Mayo Clinic proceedings. Mayo Clinic. 2008; 83(6); 701-706; quiz 706-706. [PubMed: 18533087].
  10. Jagu et al., 2009: Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. Journal of the National Cancer Institute. 2009; 101(11); 782-792. [PubMed: 19470949].
  11. Karanam et al., 2009: Karanam B, Gambhira R, Peng S, Jagu S, Kim DJ, Ketner GW, Stern PL, Adams RJ, Roden RB. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine. 2009; 27(7); 1040-1049. [PubMed: 19095032].
  12. Kim et al., 2008: Kim D, Gambhira R, Karanam B, Monie A, Hung CF, Roden R, Wu TC. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine. 2008; 26(3); 351-360. [PubMed: 18096279].
  13. Klencke et al., 2002: Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N, Da Costa M, Palefsky JM. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002; 8(5); 1028-1037. [PubMed: 12006515].
  14. Lin et al., 2006: Lin CT, Tsai YC, He L, Calizo R, Chou HH, Chang TC, Soong YK, Hung CF, Lai CH. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. Journal of biomedical science. 2006; 13(4); 481-488. [PubMed: 16649071].
  15. Nieto et al., 2009: Nieto K, Kern A, Leuchs B, Gissmann L, Müller M, Kleinschmidt JA. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors. Antiviral therapy. 2009; 14(8); 1125-1137. [PubMed: 20032542].
  16. Ohlschläger et al., 2011: Ohlschläger P, Spies E, Alvarez G, Quetting M, Groettrup M. The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. International journal of cancer. Journal international du cancer. 2011; 128(2); 473-481. [PubMed: 20309939].
  17. Osen et al., 2001: Osen W, Peiler T, Ohlschläger P, Caldeira S, Faath S, Michel N, Müller M, Tommasino M, Jochmus I, Gissmann L. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine. 2001; 19(30); 4276-4286. [PubMed: 11457555].
  18. Panagiotis et al., 2008: Panagiotis C, Efthimios D, Konstantinos P, George C. Human papilloma virus: diagnostic, treatment and preventive issues. Akusherstvo i ginekologiia. 2008; 47(1); 35-38. [PubMed: 18642576].
  19. Qin et al., 2005: Qin Y, Wang XH, Cui HL, Cheung YK, Hu MH, Zhu SG, Xie Y. Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice. Gynecologic oncology. 2005; 96(2); 475-483. [PubMed: 15661238].
  20. Rocha-Zavaleta et al., 2002: Rocha-Zavaleta L, Alejandre JE, Garcia-Carranca A. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses. Journal of medical virology. 2002; 66(1); 86-95. [PubMed: 11748663].
  21. Sin, 2009: Sin JI. Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression. Immunology. 2009; 128(1 Suppl); e707-717. [PubMed: 19740332].
  22. Trimble et al., 2009: Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(1); 361-367. [PubMed: 19118066].
  23. Wiki: HPV: Wiki: Human papillomavirus [http://en.wikipedia.org/wiki/Human_papillomavirus]

Human Respiratory Syncytial Virus

  1. Jin et al., 2003: Jin H, Cheng X, Traina-Dorge VL, Park HJ, Zhou H, Soike K, Kemble G. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine. 2003; 21(25-26); 3647-3652. [PubMed: 12922094].
  2. Miller et al., 2002: Miller M, Cho JY, Baek KJ, Castaneda D, Nayar J, Rodriguez M, Roman M, Raz E, Broide DH. Plasmid DNA encoding the respiratory syncytial virus G protein protects against RSV-induced airway hyperresponsiveness. Vaccine. 2002; 20(23-24); 3023-3033. [PubMed: 12126916].
  3. Wiki: Human respiratory syncytial virus: Human respiratory syncytial virus [http://microbewiki.kenyon.edu/index.php/Human_respiratory_syncytial_virus]
  4. Wu et al., 2009: Wu H, Dennis VA, Pillai SR, Singh SR. RSV fusion (F) protein DNA vaccine provides partial protection against viral infection. Virus research. 2009; 145(1); 39-47. [PubMed: 19540885].

Infectious Bronchitis Virus (IBV)

  1. Guo et al., 2010: Guo Z, Wang H, Yang T, Wang X, Lu D, Li Y, Zhang Y. Priming with a DNA vaccine and boosting with an inactivated vaccine enhance the immune response against infectious bronchitis virus. Journal of virological methods. 2010; 167(1); 84-89. [PubMed: 20307574].
  2. Infectious-bronchitis.net: Information about Infectious Bronchitis in chickens and control of disease [http://www.infectious-bronchitis.com]
  3. Merck Vet Manual: Infectious Bronchitis: Merck Veterinary Manual: Infectious Bronchitis [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/206500.htm]
  4. Tan et al., 2009: Tan B, Wang H, Shang L, Yang T. Coadministration of chicken GM-CSF with a DNA vaccine expressing infectious bronchitis virus (IBV) S1 glycoprotein enhances the specific immune response and protects against IBV infection. Archives of virology. 2009; 154(7); 1117-1124. [PubMed: 19543689].
  5. Wiki: Infectious Bronchitis Virus: Wiki: Infectious Bronchitis Virus [http://en.wikipedia.org/wiki/Avian_infectious_bronchitis_virus]
  6. Yan et al., 2013: Yan F, Zhao Y, Hu Y, Qiu J, Lei W, Ji W, Li X, Wu Q, Shi X, Li Z. Protection of chickens against infectious bronchitis virus with a multivalent DNA vaccine and boosting with an inactivated vaccine. Journal of veterinary science. 2013; 14(1); 53-60. [PubMed: 23388447].
  7. Yang et al., 2009: Yang T, Wang HN, Wang X, Tang JN, Gao R, Li J, Guo ZC, Li YL. Multivalent DNA vaccine enhanced protection efficacy against infectious bronchitis virus in chickens. The Journal of veterinary medical science / the Japanese Society of Veterinary Science. 2009; 71(12); 1585-1590. [PubMed: 20046025].

Infectious Bursal Disease Virus (IBDV)

  1. Gao et al., 2013: Gao H, Li K, Gao L, Qi X, Gao Y, Qin L, Wang Y, Wang X. DNA prime-protein boost vaccination enhances protective immunity against infectious bursal disease virus in chickens. Veterinary microbiology. 2013; 164(1-2); 9-17. [PubMed: 23419823].
  2. Kumar et al., 2009: Kumar S, Ahi YS, Salunkhe SS, Koul M, Tiwari AK, Gupta PK, Rai A. Effective protection by high efficiency bicistronic DNA vaccine against infectious bursal disease virus expressing VP2 protein and chicken IL-2. Vaccine. 2009; 27(6); 864-869. [PubMed: 19111591].
  3. Li et al., 2013: Li K, Gao H, Gao L, Qi X, Gao Y, Qin L, Wang Y, Wang X. Adjuvant effects of interleukin-18 in DNA vaccination against infectious bursal disease virus in chickens. Vaccine. 2013; 31(14); 1799-1805. [PubMed: 23395585].
  4. Wiki: Infectious Bursal Disease: Wiki: Infectious Bursal Disease [http://en.wikipedia.org/wiki/Infectious_bursal_disease]

Infectious Hematopoietic Necrosis Virus

  1. Anderson et al., 1996: Anderson ED, Mourich DV, Fahrenkrug SC, LaPatra S, Shepherd J, Leong JA. Genetic immunization of rainbow trout (Oncorhynchus mykiss) against infectious hematopoietic necrosis virus. Molecular marine biology and biotechnology. 1996; 5(2); 114-122. [PubMed: 8680524].
  2. Corbeil et al., 1999: Corbeil S, Lapatra SE, Anderson ED, Jones J, Vincent B, Hsu YL, Kurath G. Evaluation of the protective immunogenicity of the N, P, M, NV and G proteins of infectious hematopoietic necrosis virus in rainbow trout oncorhynchus mykiss using DNA vaccines. Diseases of aquatic organisms. 1999; 39(1); 29-36. [PubMed: 11407402].
  3. Corbeil et al., 2000: Corbeil S, LaPatra SE, Anderson ED, Kurath G. Nanogram quantities of a DNA vaccine protect rainbow trout fry against heterologous strains of infectious hematopoietic necrosis virus. Vaccine. 2000; 18(25); 2817-2824. [PubMed: 10812224].
  4. Einer-Jensen et al., 2009: Einer-Jensen K, Delgado L, Lorenzen E, Bovo G, Evensen Ø, Lapatra S, Lorenzen N. Dual DNA vaccination of rainbow trout (Oncorhynchus mykiss) against two different rhabdoviruses, VHSV and IHNV, induces specific divalent protection. Vaccine. 2009; 27(8); 1248-1253. [PubMed: 19118593].
  5. Kurath et al., 2006: Kurath G, Garver KA, Corbeil S, Elliott DG, Anderson ED, LaPatra SE. Protective immunity and lack of histopathological damage two years after DNA vaccination against infectious hematopoietic necrosis virus in trout. Vaccine. 2006; 24(3); 345-354. [PubMed: 16154239].
  6. Lorenzen et al., 2002: Lorenzen N, Lorenzen E, Einer-Jensen K, LaPatra SE. Immunity induced shortly after DNA vaccination of rainbow trout against rhabdoviruses protects against heterologous virus but not against bacterial pathogens. Developmental and comparative immunology. 2002; 26(2); 173-179. [PubMed: 11696382].
  7. Thoulouze et al., 2004: Thoulouze MI, Bouguyon E, Carpentier C, Brémont M. Essential role of the NV protein of Novirhabdovirus for pathogenicity in rainbow trout. Journal of virology. 2004; 78(8); 4098-4107. [PubMed: 15047826].
  8. Wiki: Infectious Hematopoietic Necrosis Virus: Infectious Hematopoietic Necrosis Virus [http://en.wikipedia.org/wiki/Infectious_hematopoietic_necrosis_virus]

Infectious pancreatic necrosis virus

  1. Merck - Infectious Pancreatic Necrosis Virus: Infectious Pancreatic Necrosis [http://aqua.merck-animal-health.com/diseases/infectious-pancreatic-necrosis/productadditional_127_113313.aspx]
  2. Mikalsen et al., 2004: Mikalsen AB, Torgersen J, Aleström P, Hellemann AL, Koppang EO, Rimstad E. Protection of atlantic salmon Salmo salar against infectious pancreatic necrosis after DNA vaccination. Diseases of aquatic organisms. 2004; 60(1); 11-20. [PubMed: 15352520].

Infectious salmon anemia virus

  1. Rimstad and Mjaaland, 2002: Rimstad E, Mjaaland S. Infectious salmon anaemia virus. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 2002; 110(4); 273-282. [PubMed: 12076262].
  2. Wiki: Infectious Salmon anemia virus: Wiki: Infectious Salmon anemia virus [http://en.wikipedia.org/wiki/Infectious_salmon_anemia_virus]

Influenza virus

  1. Abe et al., 2003: Abe T, Takahashi H, Hamazaki H, Miyano-Kurosaki N, Matsuura Y, Takaku H. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. Journal of immunology (Baltimore, Md. : 1950). 2003; 171(3); 1133-1139. [PubMed: 12874198].
  2. Aflunov Product Info: Aflunov Product Information [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002094/WC500101080.pdf]
  3. Afluria webpage: Afluria official web page [http://www.afluria.com/]
  4. Andrew et al., 1986: Andrew ME, Coupar BE, Ada GL, Boyle DB. Cell-mediated immune responses to influenza virus antigens expressed by vaccinia virus recombinants. Microbial pathogenesis. 1986; 1(5); 443-452. [PubMed: 3509883].
  5. Berglund et al., 1998: Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljeström P. Enhancing immune responses using suicidal DNA vaccines. Nature biotechnology. 1998; 16(6); 562-565. [PubMed: 9624688].
  6. Bins et al., 2005: Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC, Schumacher TN, Haanen JB. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nature medicine. 2005; 11(8); 899-904. [PubMed: 15965482].
  7. Block et al., 2008: Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine. 2008; 26(38); 4940-4946. [PubMed: 18662737].
  8. Bot et al., 1996: Bot A, Bot S, Garcia-Sastre A, Bona C. DNA immunization of newborn mice with a plasmid-expressing nucleoprotein of influenza virus. Viral immunology. 1996; 9(4); 207-210. [PubMed: 8978016].
  9. Bright et al., 2008: Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PloS one. 2008; 3(1); e1501. [PubMed: 18231588].
  10. Bublot et al., 2006: Bublot M, Pritchard N, Swayne DE, Selleck P, Karaca K, Suarez DL, Audonnet JC, Mickle TR. Development and use of fowlpox vectored vaccines for avian influenza. Annals of the New York Academy of Sciences. 2006; 1081; 193-201. [PubMed: 17135511].
  11. Bublot et al., 2010: Bublot M, Manvell RJ, Shell W, Brown IH. High level of protection induced by two fowlpox vector vaccines against a highly pathogenic avian influenza H5N1 challenge in specific-pathogen-free chickens. Avian diseases. 2010; 54(1 Suppl); 257-261. [PubMed: 20521642].
  12. Caillet et al., 2010: Caillet C, Piras F, Bernard MC, de Montfort A, Boudet F, Vogel FR, Hoffenbach A, Moste C, Kusters I. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. Vaccine. 2010; 28(18); 3076-3079. [PubMed: 20193791].
  13. Chen et al., 1999: Chen Z, Yoshikawa T, Kadowaki S, Hagiwara Y, Matsuo K, Asanuma H, Aizawa C, Kurata T, Tamura S. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. The Journal of general virology. 1999; 80 ( Pt 10); 2559-2564. [PubMed: 10573147].
  14. Chen et al., 2001: Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Sata T, Kurata T, Tamura S. Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine. 2001; 19(11-12); 1446-1455. [PubMed: 11163667].
  15. Chen et al., 2009: Chen Q, Kuang H, Wang H, Fang F, Yang Z, Zhang Z, Zhang X, Chen Z. Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus genes. 2009; 38(1); 30-38. [PubMed: 19067149].
  16. Cox et al., 2009: Cox RJ, Major D, Hauge S, Madhun AS, Brokstad KA, Kuhne M, Smith J, Vogel FR, Zambon M, Haaheim LR, Wood J. A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza and other respiratory viruses. 2009; 3(3); 107-117. [PubMed: 19453487].
  17. Deliyannis et al., 1998: Deliyannis G, Jackson DC, Dyer W, Bates J, Coulter A, Harling-McNabb L, Brown LE. Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Vaccine. 1998; 16(20); 2058-2068. [PubMed: 9796065].
  18. Donnelly et al., 1997: Donnelly JJ, Friedman A, Ulmer JB, Liu MA. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine. 1997; 15(8); 865-868. [PubMed: 9234535].
  19. el et al., 1989: el Guink N, Kris RM, Goodman-Snitkoff G, Small PA Jr, Mannino RJ. Intranasal immunization with proteoliposomes protects against influenza. Vaccine. 1989; 7(2); 147-151. [PubMed: 2546328].
  20. Eliasson et al., 2008: Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine. 2008; 26(9); 1243-1252. [PubMed: 18243429].
  21. EMA Pandemrix Suppl, 2013: EMA Pandemrix Summary of Product Characteristics [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000832/WC500038121.pdf]
  22. EMA Pandemrix, 2013: European Medicines Agency (EMA) Pandemrix [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000832/human_med_000965.jsp&mid=WC0b01ac058001d124]
  23. Epstein et al., 2002: Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, Renshaw M, Sambhara S, Katz JM. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerging infectious diseases. 2002; 8(8); 796-801. [PubMed: 12141964].
  24. Epstein et al., 2005: Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, Nabel GJ. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine. 2005; 23(46-47); 5404-5410. [PubMed: 16011865].
  25. Fattal-German et al., 1988: Fattal-German M, German A, Bizzini B. Potentiating the effectiveness of influenza vaccination by a combined immunostimulation with P40 immunomodulator: an experimental study in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 1988; 42(1); 73-78. [PubMed: 3408809].
  26. FDA: Afluria: FDA: Afluria influenza virus vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094043.htm]
  27. FDA: Agriflu: FDA: Agriflu [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm192126.htm]
  28. FDA: CSL H1N1 vaccine: FDA: the H1N1 influenza vaccine from CSL [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181975.htm]
  29. FDA: Fluarix: FDA: Fluarix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112850.htm]
  30. FDA: FluLaval: FDA FluLaval information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112845.htm]
  31. FDA: Flulaval Approval: FDA: Flulaval approval information [http://www.fda.gov/cber/products/flulaval.htm]
  32. FDA: Flulaval old: FDA Flulaval information [http://www.fda.gov/CbER/label/flulavalLB.pdf]
  33. FDA: Flumist: FDA: Flumist Influenza Virus Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094047.htm]
  34. FDA: Fluvirin: FDA: Fluvirin Influenza Virus Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112852.htm]
  35. FDA: Fluzone: FDA: Fluzone influenza vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112854.htm]
  36. FDA: Fluzone HD: FDA: Fluzone High-dose [http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM195479.pdf]
  37. FDA: H1N1 Novartis Vaccine: FDA H1N1 Influenza Vaccine from Novartis Vaccines and Diagnostics Ltd [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181973.htm]
  38. FDA: H1N1 Vaccine Sanofi Pasteur: FDA: H1N1 Influenza virus vaccine from Sanofi Pasteur [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181971.htm]
  39. FDA: MedImmune H1N1 vaccine: Influenza A (H1N1) 2009 Monovalent Vaccine (MedImmune LLC) [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181970.htm]
  40. FDA: Sanofi Pasteur H5N1: FDA: Sanofi Pasteur H5N1Influenza virus vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094044.htm]
  41. Feltquate et al., 1997: Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. Journal of immunology (Baltimore, Md. : 1950). 1997; 158(5); 2278-2284. [PubMed: 9036975].
  42. Fluad Press Release: Fluad Press Release from Novartis [http://www.novartisvaccines.com/downloads/newsroom/media-releases/20071019_FluadVACCINEpublication.pdf]
  43. Fluad Product Monograph: Fluad Product Monograph [http://www.novartis.ca/products/en/vaccines-f.shtml]
  44. FluMist website: FluMist official website [http://www.flumist.com/]
  45. Focetria Product Information: Focetria Summary of Product Characteristics [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000710/WC500023749.pdf]
  46. Fu et al., 1999: Fu TM, Guan L, Friedman A, Schofield TL, Ulmer JB, Liu MA, Donnelly JJ. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. Journal of immunology (Baltimore, Md. : 1950). 1999; 162(7); 4163-4170. [PubMed: 10201942].
  47. Fynan et al., 1993: Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90(24); 11478-11482. [PubMed: 8265577].
  48. Ge et al., 2010: Ge J, Tian G, Zeng X, Jiang Y, Chen H, Bua Z. Generation and evaluation of a Newcastle disease virus-based H9 avian influenza live vaccine. Avian diseases. 2010; 54(1 Suppl); 294-296. [PubMed: 20521648].
  49. GSK: Fluviral S/F: Fluviral Product Monograph [http://www.gsk.ca/english/docs-pdf/Fluviral_2009_PM.pdf]
  50. GSK: US Fluarix: GSK: US Fluarix vaccine information [http://us.gsk.com/products/assets/us_fluarix.pdf]
  51. Health Canada DPD: Health Canada Drug Product Database [http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php]
  52. Henke et al., 2006: Henke A, Rohland N, Zell R, Wutzler P. Co-expression of interleukin-2 by a bicistronic plasmid increases the efficacy of DNA immunization to prevent influenza virus infections. Intervirology. 2006; 49(4); 249-252. [PubMed: 16601357].
  53. Huber et al., 2006: Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DR, Macdonald GH, McCullers JA. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clinical and vaccine immunology : CVI. 2006; 13(9); 981-990. [PubMed: 16960108].
  54. Intanza Product Monograph: Intanza Protduct Monograph [http://www.sanofipasteur.com/sanofi-pasteur2/sp-media/SP_CA/EN/75/1215/415%20416%20INTANZA%20R0-0510%20En.pdf]
  55. Jazayeri et al., 2012: Jazayeri SD, Ideris A, Zakaria Z, Omar AR. Attenuated Salmonella typhimurium SV4089 as a Potential Carrier of Oral DNA Vaccine in Chickens. Journal of biomedicine & biotechnology. 2012; 2012; 264986. [PubMed: 22701301].
  56. Jiang et al., 2007: Jiang Y, Yu K, Zhang H, Zhang P, Li C, Tian G, Li Y, Wang X, Ge J, Bu Z, Chen H. Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector. Antiviral research. 2007; 75(3); 234-241. [PubMed: 17451817].
  57. Jimenez et al., 2007: Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, Lalor P, Leamy V, Vahle R, Luke CJ, Rolland A, Kaslow DC, Smith LR. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Human vaccines. 2007; 3(5); 157-164. [PubMed: 17637571].
  58. Kao et al., 2010: Kao RY, Yang D, Lau LS, Tsui WH, Hu L, Dai J, Chan MP, Chan CM, Wang P, Zheng BJ, Sun J, Huang JD, Madar J, Chen G, Chen H, Guan Y, Yuen KY. Identification of influenza A nucleoprotein as an antiviral target. Nature biotechnology. 2010; 28(6); 600-605. [PubMed: 20512121].
  59. Kayamuro et al., 2010: Kayamuro H, Yoshioka Y, Abe Y, Arita S, Katayama K, Nomura T, Yoshikawa T, Kubota-Koketsu R, Ikuta K, Okamoto S, Mori Y, Kunisawa J, Kiyono H, Itoh N, Nagano K, Kamada H, Tsutsumi Y, Tsunoda S. Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. Journal of virology. 2010; 84(24); 12703-12712. [PubMed: 20881038].
  60. Kodihalli et al., 1999: Kodihalli S, Goto H, Kobasa DL, Krauss S, Kawaoka Y, Webster RG. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. Journal of virology. 1999; 73(3); 2094-2098. [PubMed: 9971791].
  61. Kodihalli et al., 2000: Kodihalli S, Kobasa DL, Webster RG. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine. 2000; 18(23); 2592-2599. [PubMed: 10775793].
  62. Laddy et al., 2008: Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, Khan AS, Greenhouse J, Sardesai NY, Draghia-Akli R, Weiner DB. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PloS one. 2008; 3(6); e2517. [PubMed: 18575608].
  63. Lalor et al., 2008: Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, Rolland A, Smith LR. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. The Journal of infectious diseases. 2008; 197(12); 1643-1652. [PubMed: 18513153].
  64. Le et al., 2007: Le Gall-Reculé G, Cherbonnel M, Pelotte N, Blanchard P, Morin Y, Jestin V. Importance of a prime-boost DNA/protein vaccination to protect chickens against low-pathogenic H7 avian influenza infection. Avian diseases. 2007; 51(1 Suppl); 490-494. [PubMed: 17494616].
  65. Ledgerwood et al., 2011: Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Pearce MB, Yassine HM, Boyington JC, Bailer R, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. The Lancet infectious diseases. 2011; 11(12); 916-924. [PubMed: 21975270].
  66. Lena et al., 2002: Lena P, Villinger F, Giavedoni L, Miller CJ, Rhodes G, Luciw P. Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus. Vaccine. 2002; 20 Suppl 4; A69-79. [PubMed: 12477432].
  67. Liljebjelke et al., 2010: Liljebjelke KA, Petkov DI, Kapczynski DR. Mucosal vaccination with a codon-optimized hemagglutinin gene expressed by attenuated Salmonella elicits a protective immune response in chickens against highly pathogenic avian influenza. Vaccine. 2010; 28(27); 4430-4437. [PubMed: 20406663].
  68. Loudon et al., 2010: Loudon PT, Yager EJ, Lynch DT, Narendran A, Stagnar C, Franchini AM, Fuller JT, White PA, Nyuandi J, Wiley CA, Murphey-Corb M, Fuller DH. GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PloS one. 2010; 5(6); e11021. [PubMed: 20544035].
  69. Lunn et al., 1999: Lunn DP, Soboll G, Schram BR, Quass J, McGregor MW, Drape RJ, Macklin MD, McCabe DE, Swain WF, Olsen CW. Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Vaccine. 1999; 17(18); 2245-2258. [PubMed: 10403592].
  70. Luo et al., 2008: Luo M, Tao P, Li J, Zhou S, Guo D, Pan Z. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice. Journal of virological methods. 2008; 154(1-2); 121-127. [PubMed: 18789973].
  71. Minke et al., 2004: Minke JM, Audonnet JC, Fischer L. Equine viral vaccines: the past, present and future. Veterinary research. 2004; 35(4); 425-443. [PubMed: 15236675].
  72. Muller et al., 1990: Muller S, Plaué S, Samama JP, Valette M, Briand JP, Van Regenmortel MH. Antigenic properties and protective capacity of a cyclic peptide corresponding to site A of influenza virus haemagglutinin. Vaccine. 1990; 8(4); 308-314. [PubMed: 2396470].
  73. Nakaya et al., 2011: Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, Means AR, Kasturi SP, Khan N, Li GM, McCausland M, Kanchan V, Kokko KE, Li S, Elbein R, Mehta AK, Aderem A, Subbarao K, Ahmed R, Pulendran B. Systems biology of vaccination for seasonal influenza in humans. Nature immunology. 2011; 12(8); 786-795. [PubMed: 21743478].
  74. Oh et al., 2010: Oh HL, Akerstrom S, Shen S, Bereczky S, Karlberg H, Klingström J, Lal SK, Mirazimi A, Tan YJ. An antibody against a novel and conserved epitope in the HA1 subunit neutralizes numerous H5N1 influenza viruses. Journal of virology. 2010; ; . [PubMed: 20519402].
  75. Olsen et al., 1997: Olsen CW, McGregor MW, Dybdahl-Sissoko N, Schram BR, Nelson KM, Lunn DP, Macklin MD, Swain WF, Hinshaw VS. Immunogenicity and efficacy of baculovirus-expressed and DNA-based equine influenza virus hemagglutinin vaccines in mice. Vaccine. 1997; 15(10); 1149-1156. [PubMed: 9269061].
  76. Park et al., 2006: Park MS, Steel J, García-Sastre A, Swayne D, Palese P. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(21); 8203-8208. [PubMed: 16717196].
  77. Pertmer et al., 1995: Pertmer TM, Eisenbraun MD, McCabe D, Prayaga SK, Fuller DH, Haynes JR. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine. 1995; 13(15); 1427-1430. [PubMed: 8578820].
  78. Pertmer et al., 2001: Pertmer TM, Oran AE, Madorin CA, Robinson HL. Th1 genetic adjuvants modulate immune responses in neonates. Vaccine. 2001; 19(13-14); 1764-1771. [PubMed: 11166902].
  79. Prabakaran et al., 2010: Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. Journal of virology. 2010; 84(7); 3201-3209. [PubMed: 20071572].
  80. Pushko et al., 2010: Pushko P, Kort T, Nathan M, Pearce MB, Smith G, Tumpey TM. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine. 2010; ; . [PubMed: 20470801].
  81. Rao et al., 2010: Rao SS, Kong WP, Wei CJ, Van Hoeven N, Gorres JP, Nason M, Andersen H, Tumpey TM, Nabel GJ. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PloS one. 2010; 5(3); e9812. [PubMed: 20352112].
  82. Raz et al., 1994: Raz E, Carson DA, Parker SE, Parr TB, Abai AM, Aichinger G, Gromkowski SH, Singh M, Lew D, Yankauckas MA. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91(20); 9519-9523. [PubMed: 7937799].
  83. Reichert and Mauler, 1975: Reichert E, Mauler R. Effect of neuraminidase on potency of inactivated influenza virus vaccines in mice. Developments in biological standardization. 1975; 28; 319-323. [PubMed: 1126575].
  84. Richt and García-Sastre, 2009: Richt JA, García-Sastre A. Attenuated influenza virus vaccines with modified NS1 proteins. Current topics in microbiology and immunology. 2009; 333; 177-195. [PubMed: 19768406].
  85. Rieger, 1975: Rieger HJ. [Commitment of hospital physicians to obligatory treatment of prisoners]. Deutsche medizinische Wochenschrift (1946). 1975; 100(15); 847-849. [PubMed: 1122836].
  86. Roberts et al., 1999: Roberts A, Buonocore L, Price R, Forman J, Rose JK. Attenuated vesicular stomatitis viruses as vaccine vectors. Journal of virology. 1999; 73(5); 3723-3732. [PubMed: 10196265].
  87. Robinson et al., 1993: Robinson HL, Hunt LA, Webster RG. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine. 1993; 11(9); 957-960. [PubMed: 8212843].
  88. Rota et al., 1987: Rota PA, Shaw MW, Kendal AP. Comparison of the immune response to variant influenza type B hemagglutinins expressed in vaccinia virus. Virology. 1987; 161(2); 269-275. [PubMed: 3318092].
  89. Roy et al., 2007: Roy S, Kobinger GP, Lin J, Figueredo J, Calcedo R, Kobasa D, Wilson JM. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine. 2007; 25(39-40); 6845-6851. [PubMed: 17728024].
  90. Sanofi Pasteur: Intanza: Sanofi Pasteur: Intanza [http://www.sanofipasteur.ca/sanofi-pasteur2/sp-media/SP_CA/EN/75/1215/415%20416%20INTANZA%20R0-0510%20En.pdf]
  91. Smith et al., 2010: Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, Chaplin JA, Rusalov D, Rolland AP, Fisher CL, Al-Ibrahim MS, Kabongo ML, Steigbigel R, Belshe RB, Kitt ER, Chu AH, Moss RB. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine. 2010; 28(13); 2565-2572. [PubMed: 20117262].
  92. Solvay Website: Influvac Manufacter Website [http://www.solvay-influenza.com/aboutvaccination/faqs/0,,2659-2-0,00.htm#7]
  93. Song et al., 2008: Song L, Nakaar V, Kavita U, Price A, Huleatt J, Tang J, Jacobs A, Liu G, Huang Y, Desai P, Maksymiuk G, Takahashi V, Umlauf S, Reiserova L, Bell R, Li H, Zhang Y, McDonald WF, Powell TJ, Tussey L. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PloS one. 2008; 3(5); e2257. [PubMed: 18493310].
  94. Song et al., 2009: Song L, Zhang Y, Yun NE, Poussard AL, Smith JN, Smith JK, Borisevich V, Linde JJ, Zacks MA, Li H, Kavita U, Reiserova L, Liu X, Dumuren K, Balasubramanian B, Weaver B, Parent J, Umlauf S, Liu G, Huleatt J, Tussey L, Paessler S. Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine. 2009; 27(42); 5875-5884. [PubMed: 19654064].
  95. Tamura et al., 1989: Tamura SI, Samegai Y, Kurata H, Kikuta K, Nagamine T, Aizawa C, Kurata T. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine. Vaccine. 1989; 7(3); 257-262. [PubMed: 2781859].
  96. Tamura et al., 1996: Tamura S, Miyata K, Matsuo K, Asanuma H, Takahashi H, Nakajima K, Suzuki Y, Aizawa C, Kurata T. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. Journal of immunology (Baltimore, Md. : 1950). 1996; 156(10); 3892-3900. [PubMed: 8621928].
  97. Tao et al., 2009: Tao P, Luo M, Pan R, Ling D, Zhou S, Tien P, Pan Z. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice. Antiviral research. 2009; 81(3); 253-260. [PubMed: 19135483].
  98. Tite et al., 1990: Tite JP, Hughes-Jenkins C, O'Callaghan D, Dougan G, Russell SM, Gao XM, Liew FY. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection. Immunology. 1990; 71(2); 202-207. [PubMed: 2172156].
  99. Tompkins et al., 2007: Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging infectious diseases. 2007; 13(3); 426-435. [PubMed: 17552096].
  100. Vaxigrip Package Insert: Vaxigrip Package Insert [https://www.vaccineshoppecanada.com/secure/pdfs/ca/vaxigrip_e.pdf]
  101. Veits et al., 2006: Veits J, Wiesner D, Fuchs W, Hoffmann B, Granzow H, Starick E, Mundt E, Schirrmeier H, Mebatsion T, Mettenleiter TC, Römer-Oberdörfer A. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(21); 8197-8202. [PubMed: 16717197].
  102. Watanabe et al., 2009: Watanabe S, Watanabe T, Kawaoka Y. Influenza A virus lacking M2 protein as a live attenuated vaccine. Journal of virology. 2009; 83(11); 5947-5950. [PubMed: 19321619].
  103. Wiki: Influenza: Wiki: Influenza [http://en.wikipedia.org/wiki/Influenza]

Japanese encephalitis virus

  1. FDA: Ixiaro: FDA: Ixiaro [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm179132.htm]
  2. FDA: JE-Vax: FDA: JE-Vax vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094048.htm]
  3. Konishi et al., 2003: Konishi E, Ajiro N, Nukuzuma C, Mason PW, Kurane I. Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice. Vaccine. 2003; 21(25-26); 3675-3683. [PubMed: 12922097].
  4. Kulkarni et al., 2012: Kulkarni R, Sapkal G, Gore M. Evaluation of Japanese encephalitis virus polytope DNA vaccine candidate in BALB/c mice. Virus research. 2012; 170(1-2); 118-125. [PubMed: 23007095].
  5. Li et al., 2009: Li Y, Ye J, Cao S, Xiao S, Zhao Q, Liu X, Jin M, Chen H. Immunization with pseudotype baculovirus expressing envelope protein of Japanese encephalitis virus elicits protective immunity in mice. The journal of gene medicine. 2009; 11(1); 57-65. [PubMed: 19006097].
  6. Sheets et al., 2006: Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, Kong WP, Nabel GJ, Gomez PL. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicological sciences : an official journal of the Society of Toxicology. 2006; 91(2); 610-619. [PubMed: 16569729].
  7. Wiki: Japanese encephalitis: Wiki: Japanese encephalitis [http://en.wikipedia.org/wiki/Japanese_encephalitis]
  8. Wu et al., 2006: Wu CJ, Li TL, Huang HW, Tao MH, Chan YL. Development of an effective Japanese encephalitis virus-specific DNA vaccine. Microbes and infection / Institut Pasteur. 2006; 8(11); 2578-2586. [PubMed: 16949850].
  9. Xu et al., 2004: Xu G, Xu X, Li Z, He Q, Wu B, Sun S, Chen H. Construction of recombinant pseudorabies virus expressing NS1 protein of Japanese encephalitis (SA14-14-2) virus and its safety and immunogenicity. Vaccine. 2004; 22(15-16); 1846-1853. [PubMed: 15121294].
  10. Yasuda et al., 1990: Yasuda A, Kimura-Kuroda J, Ogimoto M, Miyamoto M, Sata T, Sato T, Takamura C, Kurata T, Kojima A, Yasui K. Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virus. Journal of virology. 1990; 64(6); 2788-2795. [PubMed: 2159544].
  11. Zhao et al., 2003: Zhao Z, Wakita T, Yasui K. Inoculation of plasmids encoding Japanese encephalitis virus PrM-E proteins with colloidal gold elicits a protective immune response in BALB/c mice. Journal of virology. 2003; 77(7); 4248-4260. [PubMed: 12634382].

Lassa Fever Virus

  1. Auperin et al., 1988: Auperin DD, Esposito JJ, Lange JV, Bauer SP, Knight J, Sasso DR, McCormick JB. Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus research. 1988 Feb; 9(2-3); 233-48. [PubMed: 3354260].
  2. Botten et al., 2006: Botten J, Alexander J, Pasquetto V, Sidney J, Barrowman P, Ting J, Peters B, Southwood S, Stewart B, Rodriguez-Carreno MP, Mothe B, Whitton JL, Sette A, Buchmeier MJ. Identification of protective Lassa virus epitopes that are restricted by HLA-A2. Journal of virology. 2006 Sep; 80(17); 8351-61. [PubMed: 16912286].
  3. Bredenbeek et al., 2006: Bredenbeek PJ, Molenkamp R, Spaan WJ, Deubel V, Marianneau P, Salvato MS, Moshkoff D, Zapata J, Tikhonov I, Patterson J, Carrion R, Ticer A, Brasky K, Lukashevich IS. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology. 2006 Feb 20; 345(2); 299-304. [PubMed: 16412488].
  4. Fisher-Hoch et al., 2000: Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB. Effective vaccine for lassa fever. Journal of virology. 2000 Aug; 74(15); 6777-83. [PubMed: 10888616].
  5. Fisher-Hoch et al., 2001: Fisher-Hoch SP, McCormick JB. Towards a human Lassa fever vaccine. Reviews in medical virology. 2001 Sep-Oct; 11(5); 331-41. [PubMed: 11590670].
  6. Geisbert et al., 2005: Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, Grolla A, Stroher U, Fernando L, Daddario KM, Guttieri MC, Mothe BR, Larsen T, Hensley LE, Jahrling PB, Feldmann H. Development of a new vaccine for the prevention of Lassa fever. PLoS medicine. 2005 Jun; 2(6); e183. [PubMed: 15971954].
  7. Jiang et al., 2011: Jiang X, Dalebout TJ, Bredenbeek PJ, Carrion R Jr, Brasky K, Patterson J, Goicochea M, Bryant J, Salvato MS, Lukashevich IS. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine. 2011; 29(6); 1248-1257. [PubMed: 21145373].
  8. Lukashevich et al., 2005: Lukashevich IS, Patterson J, Carrion R, Moshkoff D, Ticer A, Zapata J, Brasky K, Geiger R, Hubbard GB, Bryant J, Salvato MS. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. Journal of virology. 2005 Nov; 79(22); 13934-42. [PubMed: 16254329].
  9. Morrison et al., 1989: Morrison HG, Bauer SP, Lange JV, Esposito JJ, McCormick JB, Auperin DD. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. Virology. 1989; 171(1); 179-188. [PubMed: 2741340].
  10. Rodriguez-Carreno et al., 2005: Rodriguez-Carreno MP, Nelson MS, Botten J, Smith-Nixon K, Buchmeier MJ, Whitton JL. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology. 2005; 335(1); 87-98. [PubMed: 15823608].

Lawsonia intracellularis

  1. Guedes and Gebhart, 2003: Guedes RM, Gebhart CJ. Onset and duration of fecal shedding, cell-mediated and humoral immune responses in pigs after challenge with a pathogenic isolate or attenuated vaccine strain of Lawsonia intracellularis. Veterinary microbiology. 2003; 91(2-3); 135-145. [PubMed: 12458163].
  2. Kroll et al., 2004: Kroll JJ, Roof MB, McOrist S. Evaluation of protective immunity in pigs following oral administration of an avirulent live vaccine of Lawsonia intracellularis. American journal of veterinary research. 2004; 65(5); 559-565. [PubMed: 15141873].
  3. MicrobeWiki: Lawsonia intracellularis: Lawsonia intracellularis [http://microbewiki.kenyon.edu/index.php/Lawsonia_intracellularis]

Leishmania amazonensis

  1. Campbell et al., 2003: Campbell K, Diao H, Ji J, Soong L. DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous Leishmaniasis. Infection and immunity. 2003; 71(11); 6270-6278. [PubMed: 14573646].
  2. Campbell et al., 2004: Campbell K, Popov V, Soong L. Identification and molecular characterization of a gene encoding a protective Leishmania amazonensis Trp-Asp (WD) protein. Infection and immunity. 2004; 72(4); 2194-2202. [PubMed: 15039343].
  3. Champsi and McMahon-Pratt, 1988: Champsi J, McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infection and immunity. 1988; 56(12); 3272-3279. [PubMed: 3182080].
  4. Dumonteil et al., 2000: Dumonteil E, Andrade-Narvarez F, Escobedo-Ortegon J, Ramirez-Sierra MJ, Valencia-Pacheco G, Flores-Serrano A, Canto-Lara S, Arjona-Torres A. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana. Developments in biologicals. 2000; 104; 135-141. [PubMed: 11713811].
  5. Fedeli et al., 2010: Fedeli CE, Ferreira JH, Mussalem JS, Longo-Maugéri IM, Gentil LG, dos Santos MR, Katz S, Barbiéri CL. Partial protective responses induced by a recombinant cysteine proteinase from Leishmania (Leishmania) amazonensis in a murine model of cutaneous leishmaniasis. Experimental parasitology. 2010; 124(2); 153-158. [PubMed: 19735658].

Leishmania donovani

  1. Aguilar-Be et al., 2005: Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut-Martin M, García-Miss Mdel R, Palatnik de Sousa CB, Dumonteil E. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infection and immunity. 2005; 73(2); 812-819. [PubMed: 15664920].
  2. Arora et al., 2011: Arora SK, Masih S, Vasishta RK. Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis. Experimental parasitology. 2011; ; . [PubMed: 21640106].
  3. Bhaumik et al., 2009: Bhaumik S, Basu R, Sen S, Naskar K, Roy S. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine. 2009; 27(9); 1306-1316. [PubMed: 19162111].
  4. Bhowmick and Ali, 2009: Bhowmick S, Ali N. Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. PloS one. 2009; 4(6); e5820. [PubMed: 19503834].
  5. Bhowmick et al., 2008: Bhowmick S, Ravindran R, Ali N. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infection and immunity. 2008; 76(3); 1003-1015. [PubMed: 18195029].
  6. Borja-Cabrera et al., 2002: Borja-Cabrera GP, Correia Pontes NN, da Silva VO, Paraguai de Souza E, Santos WR, Gomes EM, Luz KG, Palatnik M, Palatnik de Sousa CB. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine. 2002; 20(27-28); 3277-3284. [PubMed: 12213397].
  7. Chakravarty et al., 2011: Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. 2011; 29(19); 3531-3537. [PubMed: 21414377].
  8. Henriquez et al., 2010: Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection. The Journal of parasitology. 2010; 96(5); 929-936. [PubMed: 20950100].
  9. Merck Manual: Leishmaniasis: Leishmaniasis [http://www.merck.com/mmpe/sec14/ch186/ch186f.html]
  10. Mizbani et al., 2009: Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, Papadopoulou B, Rafati S. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine. 2009; 28(1); 53-62. [PubMed: 19818721].
  11. Nagill and Kaur, 2010: Nagill R, Kaur S. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis. Vaccine. 2010; 28(23); 4002-4012. [PubMed: 20093205].
  12. Selvapandiyan et al., 2009: Selvapandiyan A, Dey R, Nylen S, Duncan R, Sacks D, Nakhasi HL. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. Journal of immunology (Baltimore, Md. : 1950). 2009; 183(3); 1813-1820. [PubMed: 19592661].
  13. Stäger et al., 2000: Stäger S, Smith DF, Kaye PM. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. Journal of immunology (Baltimore, Md. : 1950). 2000; 165(12); 7064-7071. [PubMed: 11120835].
  14. Sukumaran and Madhubala, 2004: Sukumaran B, Madhubala R. Leishmaniasis: current status of vaccine development. Current molecular medicine. 2004; 4(6); 667-679. [PubMed: 15357215].
  15. Tewary et al., 2006: Tewary P, Saxena S, Madhubala R. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis. Vaccine. 2006; 24(13); 2409-2416. [PubMed: 16413950].
  16. WD: Leishmania donovani: Leishmania donovani [http://www.wrongdiagnosis.com/medical/leishmania_donovani.htm]

Leishmania infantum

  1. Carrion et al., 2011: Carrion J, Folgueira C, Soto M, Fresno M, Requena JM. Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation. Parasites & vectors. 2011; 4(1); 150. [PubMed: 21794145].
  2. Gonzalo et al., 2001: Gonzalo RM, Rodríguez JR, Rodríguez D, González-Aseguinolaza G, Larraga V, Esteban M. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes and infection / Institut Pasteur. 2001; 3(9); 701-711. [PubMed: 11489418].
  3. Goto et al., 2007: Goto Y, Bogatzki LY, Bertholet S, Coler RN, Reed SG. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine. 2007; 25(42); 7450-7458. [PubMed: 17804125].
  4. Iborra et al., 2003: Iborra S, Soto M, Carrión J, Nieto A, Fernández E, Alonso C, Requena JM. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infection and immunity. 2003; 71(11); 6562-6572. [PubMed: 14573678].
  5. Moreno et al., 2007: Moreno J, Nieto J, Masina S, Cañavate C, Cruz I, Chicharro C, Carrillo E, Napp S, Reymond C, Kaye PM, Smith DF, Fasel N, Alvar J. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine. 2007; 25(29); 5290-5300. [PubMed: 17576026].
  6. Wiki: Leishmania infantum: Leishmania infantum [http://en.wikipedia.org/wiki/Leishmania_infantum]

Leishmania major

  1. Ahmed et al., 2009: Ahmed SB, Touihri L, Chtourou Y, Dellagi K, Bahloul C. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice. Vaccine. 2009; 27(1); 99-9106. [PubMed: 18951941].
  2. Ameen, 2010: Ameen M. Cutaneous leishmaniasis: advances in disease pathogenesis, diagnostics and therapeutics. Clinical and experimental dermatology. 2010; 35(7); 699-705. [PubMed: 20831602].
  3. Bhaumik et al., 2009: Bhaumik S, Basu R, Sen S, Naskar K, Roy S. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine. 2009; 27(9); 1306-1316. [PubMed: 19162111].
  4. Chenik et al., 2006: Chenik M, Louzir H, Ksontini H, Dilou A, Abdmouleh I, Dellagi K. Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB/c mice against a virulent challenge with Leishmania major. Vaccine. 2006; 24(14); 2521-2529. [PubMed: 16417957].
  5. Handman et al., 1995: Handman E, Symons FM, Baldwin TM, Curtis JM, Scheerlinck JP. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infection and immunity. 1995; 63(11); 4261-4267. [PubMed: 7591056].
  6. Hezarjaribi et al., 2013: Hezarjaribi HZ, Ghaffarifar F, Dalimi A, Sharifi Z, Jorjani O. Effect of IL-22 on DNA vaccine encoding LACK gene of Leishmania major in BALB/c mice. Experimental parasitology. 2013; 134(3); 341-348. [PubMed: 23541883].
  7. Rafati et al., 2002: Rafati S, Kariminia A, Seyde-Eslami S, Narimani M, Taheri T, Lebbatard M. Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation. Vaccine. 2002; 20(19-20); 2439-2447. [PubMed: 12057598].
  8. Rafati et al., 2006: Rafati S, Ghaemimanesh F, Zahedifard F. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice. Vaccine. 2006; 24(16); 3290-3297. [PubMed: 16481076].
  9. Reithinger et al., 2007: Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. The Lancet infectious diseases. 2007; 7(9); 581-596. [PubMed: 17714672].
  10. Solioz et al., 1999: Solioz N, Blum-Tirouvanziam U, Jacquet R, Rafati S, Corradin G, Mauël J, Fasel N. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis. Vaccine. 1999; 18(9-10); 850-859. [PubMed: 10580198].
  11. Walker et al., 1998: Walker PS, Scharton-Kersten T, Rowton ED, Hengge U, Bouloc A, Udey MC, Vogel JC. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Human gene therapy. 1998; 9(13); 1899-1907. [PubMed: 9741428].

Leptospira spp.

  1. Forster et al., 2013: Forster KM, Hartwig DD, Seixas FK, Bacelo KL, Amaral M, Hartleben CP, Dellagostin OA. A Conserved Region of Leptospiral Immunoglobulin-Like A and B Proteins as a DNA Vaccine Elicits a Prophylactic Immune Response against Leptospirosis. Clinical and vaccine immunology : CVI. 2013; 20(5); 725-731. [PubMed: 23486420].
  2. Maneewatch et al., 2007: Maneewatch S, Tapchaisri P, Sakolvaree Y, Klaysing B, Tongtawe P, Chaisri U, Songserm T, Wongratanacheewin S, Srimanote P, Chongsa-nguanz M, Chaicumpa W. OmpL1 DNA vaccine cross-protects against heterologous Leptospira spp. challenge. Asian Pacific journal of allergy and immunology / launched by the Allergy and Immunology Society of Thailand. 2007; 25(1); 75-82. [PubMed: 17891923].
  3. Wiki: Leptospirosis: Wiki: Leptospirosis [http://en.wikipedia.org/wiki/Leptospirosis]

Listeria monocytogenes

  1. Brockstedt et al., 2004: Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(38); 13832-13837. [PubMed: 15365184].
  2. Brockstedt et al., 2005: Brockstedt DG, Bahjat KS, Giedlin MA, Liu W, Leong M, Luckett W, Gao Y, Schnupf P, Kapadia D, Castro G, Lim JY, Sampson-Johannes A, Herskovits AA, Stassinopoulos A, Bouwer HG, Hearst JE, Portnoy DA, Cook DN, Dubensky TW Jr. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nature medicine. 2005; 11(8); 853-860. [PubMed: 16041382].
  3. Cornell et al., 1999: Cornell KA, Bouwer HG, Hinrichs DJ, Barry RA. Genetic immunization of mice against Listeria monocytogenes using plasmid DNA encoding listeriolysin O. Journal of immunology (Baltimore, Md. : 1950). 1999; 163(1); 322-329. [PubMed: 10384131].
  4. Darji et al., 2003: Darji A, Mohamed W, Domann E, Chakraborty T. Induction of immune responses by attenuated isogenic mutant strains of Listeria monocytogenes. Vaccine. 2003; 21 Suppl 2; S102-109. [PubMed: 12763691].
  5. Grenningloh et al., 2008: Grenningloh R, Darj A, Bauer H, zur Lage S, Chakraborty T, Jacobs T, Weiss S. Liposome-encapsulated antigens induce a protective CTL response against Listeria monocytogenes independent of CD4+ T cell help. Scandinavian journal of immunology. 2008; 67(6); 594-602. [PubMed: 18433404].
  6. Jiang et al., 2007: Jiang S, Rasmussen RA, Nolan KM, Frankel FR, Lieberman J, McClure HM, Williams KM, Babu US, Raybourne RB, Strobert E, Ruprecht RM. Live attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys. Vaccine. 2007; 25(42); 7470-7479. [PubMed: 17854955].
  7. Ramaswamy et al., 2007: Ramaswamy V, Cresence VM, Rejitha JS, Lekshmi MU, Dharsana KS, Prasad SP, Vijila HM. Listeria--review of epidemiology and pathogenesis. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2007; 40(1); 4-13. [PubMed: 17332901].
  8. Wiki: L. monocytogenes: Wiki: Listeria monocytogenes [http://en.wikipedia.org/wiki/Listeria_monocytogenes]

Lymphocytic choriomeningitis virus

  1. CDC - LCMV: Lymphocytic Choriomeningitis [http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/lcmv/qa.htm]
  2. Coon et al., 1999: Coon B, An LL, Whitton JL, von Herrath MG. DNA immunization to prevent autoimmune diabetes. The Journal of clinical investigation. 1999; 104(2); 189-194. [PubMed: 10411548].
  3. Hassett et al., 2000: Hassett DE, Slifka MK, Zhang J, Whitton JL. Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization. Journal of virology. 2000; 74(18); 8286-8291. [PubMed: 10954526].
  4. Petrini et al., 2011: Petrini S, Ramadori G, Corradi A, Borghetti P, Lombardi G, Villa R, Bottarelli E, Guercio A, Amici A, Ferrari M. Evaluation of safety and efficacy of DNA vaccines against bovine herpesvirus-1 (BoHV-1) in calves. Comparative immunology, microbiology and infectious diseases. 2011; 34(1); 3-10. [PubMed: 19906427].
  5. Rottembourg et al., 2010: Rottembourg D, Filippi CM, Bresson D, Ehrhardt K, Estes EA, Oldham JE, von Herrath MG. Essential role for TLR9 in prime but not prime-boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infection. Journal of immunology (Baltimore, Md. : 1950). 2010; 184(12); 7100-7107. [PubMed: 20483769].

Mannheimia haemolytica

  1. Homchampa et al., 1994: Homchampa P, Strugnell RA, Adler B. Construction and vaccine potential of an aroA mutant of Pasteurella haemolytica. Veterinary microbiology. 1994; 42(1); 35-44. [PubMed: 7839583].
  2. Rice et al., 2007: Rice JA, Carrasco-Medina L, Hodgins DC, Shewen PE. Mannheimia haemolytica and bovine respiratory disease. Animal health research reviews / Conference of Research Workers in Animal Diseases. 2007; 8(2); 117-128. [PubMed: 18218156].

Marburg Virus

  1. Bausch et al., 2007: Bausch DG, Geisbert TW. Development of vaccines for Marburg hemorrhagic fever. Expert review of vaccines. 2007 Feb; 6(1); 57-74. [PubMed: 17280479].
  2. Daddario-DiCaprio et al., 2006: Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Stroher U, Hensley LE, Grolla A, Fritz EA, Feldmann F, Feldmann H, Jones SM. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. Journal of virology. 2006; 80(19); 9659-9666. [PubMed: 16973570].
  3. Geisbert et al., 2010: Geisbert TW, Bailey M, Geisbert JB, Asiedu C, Roederer M, Grazia-Pau M, Custers J, Jahrling P, Goudsmit J, Koup R, Sullivan NJ. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. Journal of virology. 2010; 84(19); 10386-10394. [PubMed: 20660192].
  4. Hevey et al., 1997: Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology. 1997 Dec 8; 239(1); 206-16. [PubMed: 9426460 ].
  5. Hevey et al., 1998: Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 1998 Nov 10; 251(1); 28-37. [PubMed: 9813200 ].
  6. Jones et al., 2005: Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature medicine. 2005; 11(7); 786-790. [PubMed: 15937495].
  7. Mohamadzadeh et al., 2007: Mohamadzadeh M, Chen L, Schmaljohn AL. How Ebola and Marburg viruses battle the immune system. Nature reviews. Immunology. 2007; 7(7); 556-567. [PubMed: 17589545].
  8. Riemenschneider et al., 2003: Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, Custer D, Bray M, Ruff A, Ivins B, Bassett A, Rossi C, Schmaljohn C. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003; 21(25-26); 4071-4080. [PubMed: 12922144 ].
  9. Swenson et al., 2005: Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine. 2005; 23(23); 3033-3042. [PubMed: 15811650].
  10. Swenson et al., 2008: Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, Dong JY, Pratt WD. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clinical and vaccine immunology : CVI. 2008; 15(3); 460-467. [PubMed: 18216185].
  11. Wang et al., 2006: Wang D, Schmaljohn AL, Raja NU, Trubey CM, Juompan LY, Luo M, Deitz SB, Yu H, Woraratanadharm J, Holman DH, Moore KM, Swain BM, Pratt WD, Dong JY. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine. 2006 Apr 5; 24(15); 2975-86. [PubMed: 16530297 ].
  12. Warfield et al., 2004: Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine. 2004 Sep 3; 22(25-26); 3495-502. [PubMed: 15308377 ].

Marek's disease virus

  1. Darteil et al., 1995: Darteil R, Bublot M, Laplace E, Bouquet JF, Audonnet JC, Rivière M. Herpesvirus of turkey recombinant viruses expressing infectious bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV virulent challenge in chickens. Virology. 1995; 211(2); 481-490. [PubMed: 7645252].
  2. Hughes and Rivailler, 2007: Hughes AL, Rivailler P. Phylogeny and recombination history of gallid herpesvirus 2 (Marek's disease virus) genomes. Virus research. 2007; 130(1-2); 28-33. [PubMed: 17566585].
  3. Lee et al., 2003: Lee LE, Witter RL, Reddy SM, Wu P, Yanagida N, Yoshida S. Protection and synergism by recombinant fowl pox vaccines expressing multiple genes from Marek's disease virus. Avian diseases. 2003; 47(3); 549-558. [PubMed: 14562881].

Measles virus

  1. Brinckmann et al., 1991: Brinckmann UG, Bankamp B, Reich A, ter Meulen V, Liebert UG. Efficacy of individual measles virus structural proteins in the protection of rats from measles encephalitis. The Journal of general virology. 1991; 72 ( Pt 10); 2491-2500. [PubMed: 1833505].
  2. Drillien et al., 1988: Drillien R, Spehner D, Kirn A, Giraudon P, Buckland R, Wild F, Lecocq JP. Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion protein. Proceedings of the National Academy of Sciences of the United States of America. 1988; 85(4); 1252-1256. [PubMed: 3422488].
  3. FDA: Attenuvax: FDA: Attenuvax information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm203032.htm]
  4. FDA: MMR-II: FDA: MMR-II [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094050.htm]
  5. FDA: ProQuad: FDA: ProQuad Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094051.htm]
  6. Griffin et al., 2008: Griffin DE, Pan CH, Moss WJ. Measles vaccines. Frontiers in bioscience : a journal and virtual library. 2008; 13; 1352-1370. [PubMed: 17981635].
  7. GSK: Priorix: GSK: Priorix Product Information [http://www.gsk.ca/english/docs-pdf/Priorix_PM_20081103_EN.pdf]
  8. GSK: Priorix-Tetra: GSK: Priorix-Tetra Product Information [http://www.gsk.ca/english/docs-pdf/Priorix-Tetra_PM_20090908_EN.pdf]
  9. Martinez et al., 1997: Martinez X, Brandt C, Saddallah F, Tougne C, Barrios C, Wild F, Dougan G, Lambert PH, Siegrist CA. DNA immunization circumvents deficient induction of T helper type 1 and cytotoxic T lymphocyte responses in neonates and during early life. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94(16); 8726-8731. [PubMed: 9238045].
  10. Pan et al., 2010: Pan CH, Greer CE, Hauer D, Legg HS, Lee EY, Bergen MJ, Lau B, Adams RJ, Polo JM, Griffin DE. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. Journal of virology. 2010; 84(8); 3798-3807. [PubMed: 20130066].
  11. Spreng et al., 2000: Spreng S, Gentschev I, Goebel W, Weidinger G, ter Meulen V, Niewiesk S. Salmonella vaccines secreting measles virus epitopes induce protective immune responses against measles virus encephalitis. Microbes and infection / Institut Pasteur. 2000; 2(14); 1687-1692. [PubMed: 11137042].
  12. Wiki: Measles: Wiki: Measles [http://en.wikipedia.org/wiki/Measles]
  13. Yanagi et al., 2006: Yanagi Y, Takeda M, Ohno S. Measles virus: cellular receptors, tropism and pathogenesis. The Journal of general virology. 2006; 87(Pt 10); 2767-2779. [PubMed: 16963735].

Mink enteritis virus

  1. Wki: Mink enteritis virus: Wki: Mink enteritis virus [http://en.wikipedia.org/wiki/Mink_enteritis_virus]

Mumps virus

  1. FDA: MMR-II: FDA: MMR-II [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094050.htm]
  2. FDA: ProQuad: FDA: ProQuad Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094051.htm]
  3. Hviid et al., 2008: Hviid A, Rubin S, Mühlemann K. Mumps. Lancet. 2008; 371(9616); 932-944. [PubMed: 18342688].
  4. Liang et al., 2008: Liang Y, Ma S, Yang Z, Liu L, Wang L, Wang J, Jiang L, Shi C, Dong C, Li Q. Immunogenicity and safety of a novel formalin-inactivated and alum-adjuvanted candidate subunit vaccine for mumps. Vaccine. 2008; 26(33); 4276-4283. [PubMed: 18597904].
  5. Merck: Mumpsvax: Merck: Mumpsvax information [http://www.merck.com/product/usa/pi_circulars/m/mumpsvax/mumpsvax_pi.pdf]

Murine Cytomegalovirus

  1. González et al., 1996: González Armas JC, Morello CS, Cranmer LD, Spector DH. DNA immunization confers protection against murine cytomegalovirus infection. Journal of virology. 1996; 70(11); 7921-7928. [PubMed: 8892915].
  2. Krmpotic et al., 2003: Krmpotic A, Bubic I, Polic B, Lucin P, Jonjic S. Pathogenesis of murine cytomegalovirus infection. Microbes and infection / Institut Pasteur. 2003; 5(13); 1263-1277. [PubMed: 14623023].
  3. Wang et al., 2013: Wang H, Yao Y, Huang C, Chen Q, Chen J, Chen Z. Immunization with cytomegalovirus envelope glycoprotein M and glycoprotein N DNA vaccines can provide mice with complete protection against a lethal murine cytomegalovirus challenge. Virologica Sinica. 2013; ; . [PubMed: 23715998].

Murine leukemia virus

  1. MicrobeWiki - Murine Leukemia Virus: Murine Leukemia Virus (MuLV) [http://microbewiki.kenyon.edu/index.php/Murine_Leukemia_Virus_(MuLV)]
  2. Sarzotti et al., 1997: Sarzotti M, Dean TA, Remington MP, Ly CD, Furth PA, Robbins DS. Induction of cytotoxic T cell responses in newborn mice by DNA immunization. Vaccine. 1997; 15(8); 795-797. [PubMed: 9234516].

Mycobacterium avium

  1. Martin et al., 2003: Martin E, Kamath AT, Briscoe H, Britton WJ. The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guèrin) in protecting against systemic Mycobacterim avium infection. Immunology. 2003; 109(2); 308-314. [PubMed: 12757627].
  2. Park et al., 2011: Park KT, Allen AJ, Bannantine JP, Seo KS, Hamilton MJ, Abdellrazeq GS, Rihan HM, Grimm A, Davis WC. Evaluation of two mutants of Mycobacterium avium subsp. paratuberculosis as candidates for a live attenuated vaccine for Johne's disease. Vaccine. 2011; ; . [PubMed: 21565243].
  3. WebMD - Mycobacterium avium complex: HIV, AIDS, and Mycobacterium Avium Complex [http://www.webmd.com/hiv-aids/guide/aids-hiv-opportunistic-infections-mycobacterium-avium-complex]

Mycobacterium marinum

  1. Medscape - Mycobacterium marinum: Mycobacterium Marinum [http://emedicine.medscape.com/article/223363-overview]
  2. Pasnik and Smith, 2005: Pasnik DJ, Smith SA. Immunogenic and protective effects of a DNA vaccine for Mycobacterium marinum in fish. Veterinary immunology and immunopathology. 2005; 103(3-4); 195-206. [PubMed: 15621306].

Mycobacterium tuberculosis

  1. Aagaard et al., 2011: Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nature medicine. 2011; 17(2); 189-194. [PubMed: 21258338].
  2. Agger et al., 2002: Agger EM, Andersen P. A novel TB vaccine; towards a strategy based on our understanding of BCG failure. Vaccine. 2002 Nov 22; 21(1-2); 7-14. [PubMed: 12443657 ].
  3. Aguilar et al., 2006: Aguilar LD, Infante E, Bianco MV, Cataldi A, Bigi F, Pando RH. Immunogenicity and protection induced by Mycobacterium tuberculosis mce-2 and mce-3 mutants in a Balb/c mouse model of progressive pulmonary tuberculosis. Vaccine. 2006; 24(13); 2333-2342. [PubMed: 16388878].
  4. Buddle et al., 1995: Buddle BM, Keen D, Thomson A, Jowett G, McCarthy AR, Heslop J, De Lisle GW, Stanford JL, Aldwell FE. Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae. Research in veterinary science. 1995; 59(1); 10-16. [PubMed: 8525078].
  5. Cai et al., 2005: Cai H, Yu DH, Tian X, Zhu YX. Coadministration of interleukin 2 plasmid DNA with combined DNA vaccines significantly enhances the protective efficacy against Mycobacterium tuberculosis. DNA and cell biology. 2005; 24(10); 605-613. [PubMed: 16225391].
  6. Chandra et al., 2006: Chandra S, Kaur M, Midha S, Bhatnagar R, Banerjee-Bhatnagar N. Evaluation of the ability of N-terminal fragment of lethal factor of Bacillus anthracis for delivery of Mycobacterium T cell antigen ESAT-6 into cytosol of antigen presenting cells to elicit effective cytotoxic T lymphocyte response. Biochemical and biophysical research communications. 2006 Dec 22; 351(3); 702-7. [PubMed: 17084814 ].
  7. Chiong et al., 2011: Chiong E, Kesavan A, Mahendran R, Chan YH, Sng JH, Lim YK, Kamaraj R, Tan TM, Esuvaranathan K. NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guérin therapy for bladder cancer. European urology. 2011; 59(3); 430-437. [PubMed: 21163569].
  8. Collins et al., 2005: Collins DM, Skou B, White S, Bassett S, Collins L, For R, Hurr K, Hotter G, de Lisle GW. Generation of attenuated Mycobacterium bovis strains by signature-tagged mutagenesis for discovery of novel vaccine candidates. Infection and immunity. 2005 Apr; 73(4); 2379-86. [PubMed: 15784584].
  9. De et al., 1999: De Lisle GW, Wilson T, Collins DM, Buddle BM. Vaccination of guinea pigs with nutritionally impaired avirulent mutants of Mycobacterium bovis protects against tuberculosis. Infection and immunity. 1999 May; 67(5); 2624-6. [PubMed: 10225931 ].
  10. Dillon et al., 1999: Dillon DC, Alderson MR, Day CH, Lewinsohn DM, Coler R, Bement T, Campos-Neto A, Skeiky YA, Orme IM, Roberts A, Steen S, Dalemans W, Badaro R, Reed SG. Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infection and immunity. 1999; 67(6); 2941-2950. [PubMed: 10338503].
  11. Dou et al., 2010: Dou J, Tang Q, Yu F, Yang H, Zhao F, Xu W, Wang J, Hu W, Hu K, Liou C, Feng He X, Wang Y. Investigation of immunogenic effect of the BCG priming and Ag85A- GM-CSF boosting in Balb/c mice model. Immunobiology. 2010; 215(2); 133-142. [PubMed: 19450898].
  12. Ducati et al., 2006: Ducati RG, Ruffino-Netto A, Basso LA, Santos DS. The resumption of consumption-- a review on tuberculosis. Memorias do Instituto Oswaldo Cruz. 2006 Nov; 101(7); 697-714. [PubMed: 17160276].
  13. Ernst et al., 2007: Ernst JD, Trevejo-Nunez G, Banaiee N. Genomics and the evolution, pathogenesis, and diagnosis of tuberculosis. The Journal of clinical investigation. 2007 Jul; 117(7); 1738-45. [PubMed: 17607348].
  14. Falero-Diaz et al., 2000: Falero-Diaz G, Challacombe S, Banerjee D, Douce G, Boyd A, Ivanyi J. Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine. 2000; 18(28); 3223-3229. [PubMed: 10869767].
  15. Fletcher, 2007: Fletcher HA. Correlates of immune protection from tuberculosis. Current molecular medicine. 2007 May; 7(3); 319-25. [PubMed: 17504116].
  16. Fonseca et al., 2001: Fonseca DP, Benaissa-Trouw B, van Engelen M, Kraaijeveld CA, Snippe H, Verheul AF. Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein. Infection and immunity. 2001 Aug; 69(8); 4839-45. [PubMed: 11447158].
  17. Fontán et al., 2008: Fontán PA, Aris V, Alvarez ME, Ghanny S, Cheng J, Soteropoulos P, Trevani A, Pine R, Smith I. Mycobacterium tuberculosis sigma factor E regulon modulates the host inflammatory response. The Journal of infectious diseases. 2008; 198(6); 877-885. [PubMed: 18657035].
  18. Gartner et al., 2008: Gartner T, Romano M, Suin V, Kalai M, Korf H, De Baetselier P, Huygen K. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine co-expressing pro-apoptotic caspase-3. Vaccine. 2008; 26(11); 1458-1470. [PubMed: 18280621].
  19. Geiman et al., 2004: Geiman DE, Kaushal D, Ko C, Tyagi S, Manabe YC, Schroeder BG, Fleischmann RD, Morrison NE, Converse PJ, Chen P, Bishai WR. Attenuation of late-stage disease in mice infected by the Mycobacterium tuberculosis mutant lacking the SigF alternate sigma factor and identification of SigF-dependent genes by microarray analysis. Infection and immunity. 2004; 72(3); 1733-1745. [PubMed: 14977982].
  20. Goldstone et al., 2009: Goldstone RM, Goonesekera SD, Bloom BR, Sampson SL. The transcriptional regulator Rv0485 modulates the expression of a pe and ppe gene pair and is required for Mycobacterium tuberculosis virulence. Infection and immunity. 2009; 77(10); 4654-4667. [PubMed: 19651861].
  21. Grode et al., 2005: Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, Mann P, Goosmann C, Bandermann S, Smith D, Bancroft GJ, Reyrat JM, van Soolingen D, Raupach B, Kaufmann SH. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. The Journal of clinical investigation. 2005; 115(9); 2472-2479. [PubMed: 16110326].
  22. Gupta et al., 2007: Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine. 2007 May 10; 25(19); 3742-51. [PubMed: 17321015].
  23. Hall et al., 2009: Hall LJ, Clare S, Pickard D, Clark SO, Kelly DL, El Ghany MA, Hale C, Dietrich J, Andersen P, Marsh PD, Dougan G. Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein. Vaccine. 2009; 27(49); 6894-6904. [PubMed: 19755145].
  24. Hamasur et al., 2003: Hamasur B, Haile M, Pawlowski A, Schroder U, Williams A, Hatch G, Hall G, Marsh P, Kallenius G, Svenson SB. Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine. 2003 Sep 8; 21(25-26); 4081-93. [PubMed: 12922145].
  25. Hernandez et al., 2010: Hernandez Pando R, Aguilar LD, Smith I, Manganelli R. Immunogenicity and protection induced by a Mycobacterium tuberculosis sigE mutant in a BALB/c mouse model of progressive pulmonary tuberculosis. Infection and immunity. 2010; 78(7); 3168-3176. [PubMed: 20457786].
  26. Hess et al., 1998: Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, Kaufmann SH. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proceedings of the National Academy of Sciences of the United States of America. 1998 Apr 28; 95(9); 5299-304. [PubMed: 9560270].
  27. Hess et al., 1999: Hess J, Kaufmann SH. Live antigen carriers as tools for improved anti-tuberculosis vaccines. FEMS immunology and medical microbiology. 1999 Feb; 23(2); 165-73. [PubMed: 10076914 ].
  28. Hinchey et al., 2007: Hinchey J, Lee S, Jeon BY, Basaraba RJ, Venkataswamy MM, Chen B, Chan J, Braunstein M, Orme IM, Derrick SC, Morris SL, Jacobs WR, Porcelli SA. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. The Journal of clinical investigation. 2007 Aug 1; 117(8); 2279-2288. [PubMed: 17671656].
  29. Hinchey et al., 2011: Hinchey J, Jeon BY, Alley H, Chen B, Goldberg M, Derrick S, Morris S, Jacobs WR Jr, Porcelli SA, Lee S. Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis. PloS one. 2011; 6(1); e15857. [PubMed: 21264335].
  30. Hondalus et al., 2000: Hondalus MK, Bardarov S, Russell R, Chan J, Jacobs WR Jr, Bloom BR. Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infection and immunity. 2000; 68(5); 2888-2898. [PubMed: 10768986].
  31. Horwitz et al., 2000: Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic' S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proceedings of the National Academy of Sciences of the United States of America. 2000 Dec 5; 97(25); 13853-8. [PubMed: 11095745].
  32. Hwang et al., 2005: Hwang SA, Kruzel ML, Actor JK. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis. International immunopharmacology. 2005; 5(3); 591-599. [PubMed: 15683854].
  33. Im et al., 2007: Im EJ, Saubi N, Virgili G, Sander C, Teoh D, Gatell JM, McShane H, Joseph J, Hanke T. Vaccine Platform for Prevention of Tuberculosis and Mother-to-Child Transmission of HIV-1 through Breastfeeding. Journal of virology. 2007 Jun 27; ; . [PubMed: 17596303].
  34. Infante et al., 2005: Infante E, Aguilar LD, Gicquel B, Pando RH. Immunogenicity and protective efficacy of the Mycobacterium tuberculosis fadD26 mutant. Clinical and experimental immunology. 2005; 141(1); 21-28. [PubMed: 15958066].
  35. Kamath et al., 1999: Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infection and immunity. 1999 Apr; 67(4); 1702-7. [PubMed: 10085007].
  36. Kaufmann, 2005: Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends in immunology. 2005 Dec; 26(12); 660-7. [PubMed: 16246622 ].
  37. Khatri et al., 2014: Khatri B, Whelan A, Clifford D, Petrera A, Sander P, Vordermeier HM. BCG Δzmp1 vaccine induces enhanced antigen specific immune responses in cattle. Vaccine. 2014; ; . [PubMed: 24394444].
  38. Khera et al., 2005: Khera A, Singh R, Shakila H, Rao V, Dhar N, Narayanan PR, Parmasivan CN, Ramanathan VD, Tyagi AK. Elicitation of efficient, protective immune responses by using DNA vaccines against tuberculosis. Vaccine. 2005 Dec 1; 23(48-49); 5655-65. [PubMed: 16157425 ].
  39. Kolibab et al., 2010: Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clinical and vaccine immunology : CVI. 2010; 17(5); 793-801. [PubMed: 20357059].
  40. Kumar et al., 2003: Kumar P, Amara RR, Challu VK, Chadda VK, Satchidanandam V. The Apa protein of Mycobacterium tuberculosis stimulates gamma interferon-secreting CD4+ and CD8+ T cells from purified protein derivative-positive individuals and affords protection in a guinea pig model. Infection and immunity. 2003; 71(4); 1929-1937. [PubMed: 12654810].
  41. Langermans et al., 2001: Langermans JA, Andersen P, van Soolingen D, Vervenne RA, Frost PA, van der Laan T, van Pinxteren LA, van den Hombergh J, Kroon S, Peekel I, Florquin S, Thomas AW. Divergent effect of bacillus Calmette-Guérin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(20); 11497-11502. [PubMed: 11562492].
  42. Li et al., 1999: Li Z, Howard A, Kelley C, Delogu G, Collins F, Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infection and immunity. 1999; 67(9); 4780-4786. [PubMed: 10456931].
  43. Lowrie et al., 1997: Lowrie DB, Silva CL, Colston MJ, Ragno S, Tascon RE. Protection against tuberculosis by a plasmid DNA vaccine. Vaccine. 1997; 15(8); 834-838. [PubMed: 9234527].
  44. Luo et al., 2004: Luo XD, Zhu DY, Chen Q, Jiang Y, Jiang S, Yang C. [A study of the protective effect of the DNA vaccine encoding tubercle antigen 85B with MPT64 in mice challenged with Mycobacterium tuberculosis]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases. 2004; 27(9); 611-616. [PubMed: 15498274].
  45. Martin et al., 2006: Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, Bordat Y, Soto CY, Clark SO, Hatch GJ, Aguilar D, Ausina V, Gicquel B. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine. 2006 Apr 24; 24(17); 3408-19. [PubMed: 16564606 ].
  46. McShane et al., 2005: McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinburgh, Scotland). 2005 Jan-Mar; 85(1-2); 47-52. [PubMed: 15687027].
  47. Miki et al., 2004: Miki K, Nagata T, Tanaka T, Kim YH, Uchijima M, Ohara N, Nakamura S, Okada M, Koide Y. Induction of protective cellular immunity against Mycobacterium tuberculosis by recombinant attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/MPT51. Infection and immunity. 2004; 72(4); 2014-2021. [PubMed: 15039321].
  48. Mollenkopf et al., 2001: Mollenkopf HJ, Groine-Triebkorn D, Andersen P, Hess J, Kaufmann SH. Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA. Vaccine. 2001 Jul 16; 19(28-29); 4028-35. [PubMed: 11427279].
  49. Morris et al., 2000: Morris S, Kelley C, Howard A, Li Z, Collins F. The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine. 2000; 18(20); 2155-2163. [PubMed: 10715531].
  50. Mustafa, 2009: Mustafa AS. Th1 cell reactivity and HLA-DR binding prediction for promiscuous recognition of MPT63 (Rv1926c), a major secreted protein of Mycobacterium tuberculosis. Scandinavian journal of immunology. 2009; 69(3); 213-222. [PubMed: 19281533].
  51. Oksanen et al., 2013: Oksanen KE, Halfpenny NJ, Sherwood E, Harjula SK, Hammarén MM, Ahava MJ, Pajula ET, Lahtinen MJ, Parikka M, Rämet M. An adult zebrafish model for preclinical tuberculosis vaccine development. Vaccine. 2013; 31(45); 5202-5209. [PubMed: 24055305].
  52. Olsen et al., 2001: Olsen, A.W., L.A.H. van Pinxteren, P.B Rasmussen, and P. Andersen. Protection of Mice with a Tuberculosis Subunit Vaccine Based on a Fusion Protein of Antigen 85B and ESAT-6. Infect. Immun.. 2001; 69(5); 2773-2778.
  53. Palma et al., 2007: Palma C, Iona E, Giannoni F, Pardini M, Brunori L, Orefici G, Fattorini L, Cassone A. The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice. Cellular microbiology. 2007; 9(6); 1455-1465. [PubMed: 17250590].
  54. Palma et al., 2010: Palma C, Vendetti S, Cassone A. Role of 4-1BB receptor in the control played by CD8(+) T cells on IFN-gamma production by Mycobacterium tuberculosis antigen-specific CD4(+) T Cells. PloS one. 2010; 5(6); e11019. [PubMed: 20544034].
  55. Parra et al., 2004: Parra M, Pickett T, Delogu G, Dheenadhayalan V, Debrie AS, Locht C, Brennan MJ. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infection and immunity. 2004; 72(12); 6799-6805. [PubMed: 15557600].
  56. Perez et al., 2001: Perez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Molecular microbiology. 2001 Jul; 41(1); 179-87. [PubMed: 11454210].
  57. Pinto et al., 2004: Pinto R, Saunders BM, Camacho LR, Britton WJ, Gicquel B, Triccas JA. Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Guérin vaccine. The Journal of infectious diseases. 2004; 189(1); 105-112. [PubMed: 14702160].
  58. Quintana et al., 2003: Quintana FJ, Carmi P, Mor F, Cohen IR. DNA fragments of the human 60-kDa heat shock protein (HSP60) vaccinate against adjuvant arthritis: identification of a regulatory HSP60 peptide. Journal of immunology (Baltimore, Md. : 1950). 2003; 171(7); 3533-3541. [PubMed: 14500649].
  59. Randhawa et al., 2011: Randhawa AK, Shey MS, Keyser A, Peixoto B, Wells RD, de Kock M, Lerumo L, Hughes J, Hussey G, Hawkridge A, Kaplan G, Hanekom WA, Hawn TR. Association of human TLR1 and TLR6 deficiency with altered immune responses to BCG vaccination in South African infants. PLoS pathogens. 2011; 7(8); e1002174. [PubMed: 21852947].
  60. Sambandamurthy et al., 2002: Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, Collins FM, Morris SL, Jacobs WR Jr. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nature medicine. 2002; 8(10); 1171-1174. [PubMed: 12219086].
  61. Sambandamurthy et al., 2006: Sambandamurthy VK, Derrick SC, Hsu T, Chen B, Larsen MH, Jalapathy KV, Chen M, Kim J, Porcelli SA, Chan J, Morris SL, Jacobs WR Jr. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine. 2006; 24(37-39); 6309-6320. [PubMed: 16860907].
  62. Singh et al., 2011: Singh VK, Srivastava V, Singh V, Rastogi N, Roy R, Shaw AK, Dwivedi AK, Srivastava R, Srivastava BS. Overexpression of Rv3097c in Mycobacterium bovis BCG abolished the efficacy of BCG vaccine to protect against Mycobacterium tuberculosis infection in mice. Vaccine. 2011; 29(29-30); 4754-4760. [PubMed: 21565242].
  63. Singhal et al., 2011: Singhal A, Mathys V, Kiass M, Creusy C, Delaire B, Aliouat el M, Dartois V, Kaplan G, Bifani P. BCG induces protection against Mycobacterium tuberculosis infection in the Wistar rat model. PloS one. 2011; 6(12); e28082. [PubMed: 22162757].
  64. Skeiky et al., 2004: Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, Campos-Neto A, Lobet Y, Dalemans W, Orme IM, Reed SG. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. Journal of immunology (Baltimore, Md. : 1950). 2004 Jun 15; 172(12); 7618-28. [PubMed: 15187142].
  65. Skeiky et al., 2005: Skeiky YA, Alderson MR, Ovendale PJ, Lobet Y, Dalemans W, Orme IM, Reed SG, Campos-Neto A. Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41. Vaccine. 2005; 23(30); 3937-3945. [PubMed: 15917115].
  66. Smith et al., 2001: Smith DA, Parish T, Stoker NG, Bancroft GJ. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infection and immunity. 2001; 69(2); 1142-1150. [PubMed: 11160012].
  67. Stephens et al., 2007: Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007; 369(9580); 2196-2210. [PubMed: 17604802].
  68. Sugawara et al., 2007: Sugawara I, Li Z, Sun L, Udagawa T, Taniyama T. Recombinant BCG Tokyo (Ag85A) protects cynomolgus monkeys (Macaca fascicularis) infected with H37Rv Mycobacterium tuberculosis. Tuberculosis (Edinburgh, Scotland). 2007 Aug 24; ; . [PubMed: 17720625 ].
  69. Sun et al., 2004: Sun R, Converse PJ, Ko C, Tyagi S, Morrison NE, Bishai WR. Mycobacterium tuberculosis ECF sigma factor sigC is required for lethality in mice and for the conditional expression of a defined gene set. Molecular microbiology. 2004; 52(1); 25-38. [PubMed: 15049808].
  70. SWEDBERG, 1951: SWEDBERG B. Studies in experimental tuberculosis; an investigation of some problems of immunity and resistance. Acta medica Scandinavica. Supplementum. 1951; 254; 1-120. [PubMed: 14837707].
  71. Tanghe et al., 1999: Tanghe A, Lefèvre P, Denis O, D'Souza S, Braibant M, Lozes E, Singh M, Montgomery D, Content J, Huygen K. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. Journal of immunology (Baltimore, Md. : 1950). 1999; 162(2); 1113-1119. [PubMed: 9916741].
  72. Thom et al., 2012: Thom RE, Elmore MJ, Williams A, Andrews SC, Drobniewski F, Marsh PD, Tree JA. The expression of ferritin, lactoferrin, transferrin receptor and solute carrier family 11A1 in the host response to BCG-vaccination and Mycobacterium tuberculosis challenge. Vaccine. 2012; 30(21); 3159-3168. [PubMed: 22426328].
  73. Tsenova et al., 2006: Tsenova L, Harbacheuski R, Moreira AL, Ellison E, Dalemans W, Alderson MR, Mathema B, Reed SG, Skeiky YA, Kaplan G. Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infection and immunity. 2006; 74(4); 2392-2401. [PubMed: 16552069].
  74. Verreck et al., 2001: Verreck FA, de Vries RR, Ottenhoff TH. Setting a course for intervening in host-pathogen interactions. Trends in immunology. 2001 Nov; 22(11); 588-90. [PubMed: 11698199 ].
  75. Verreck et al., 2009: Verreck FA, Vervenne RA, Kondova I, van Kralingen KW, Remarque EJ, Braskamp G, van der Werff NM, Kersbergen A, Ottenhoff TH, Heidt PJ, Gilbert SC, Gicquel B, Hill AV, Martin C, McShane H, Thomas AW. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PloS one. 2009; 4(4); e5264. [PubMed: 19367339].
  76. Vipond et al., 2006: Vipond J, Clark SO, Hatch GJ, Vipond R, Marie Agger E, Tree JA, Williams A, Marsh PD. Re-formulation of selected DNA vaccine candidates and their evaluation as protein vaccines using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinburgh, Scotland). 2006 May-Jul; 86(3-4); 218-24. [PubMed: 16520093].
  77. Vordermeier et al., 2004: Vordermeier HM, Rhodes SG, Dean G, Goonetilleke N, Huygen K, Hill AV, Hewinson RG, Gilbert SC. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology. 2004 Jul; 112(3); 461-70. [PubMed: 15196215].
  78. Wang et al., 2004: Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, Hitt M, Xing Z. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. Journal of immunology (Baltimore, Md. : 1950). 2004; 173(10); 6357-6365. [PubMed: 15528375].
  79. Wang et al., 2009: Wang QL, Pan Q, Ma Y, Wang K, Sun P, Liu S, Zhang XL. An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis. Vaccine. 2009; 27(48); 6712-6722. [PubMed: 19733584].
  80. Wang et al., 2010: Wang D, Xu J, Feng Y, Liu Y, Mchenga SS, Shan F, Sasaki J, Lu C. Liposomal oral DNA vaccine (mycobacterium DNA) elicits immune response. Vaccine. 2010; 28(18); 3134-3142. [PubMed: 20197133].
  81. Wu et al., 2008: Wu Y, Woodworth JS, Shin DS, Morris S, Behar SM. Vaccine-elicited 10-kilodalton culture filtrate protein-specific CD8+ T cells are sufficient to mediate protection against Mycobacterium tuberculosis infection. Infection and immunity. 2008; 76(5); 2249-2255. [PubMed: 18332205].
  82. Zaks et al., 2006: Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Bosio C, Dow S. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. Journal of immunology (Baltimore, Md. : 1950). 2006; 176(12); 7335-7345. [PubMed: 16751377].

Mycoplasma gallisepticum

  1. Barbour et al., 2000: Barbour EK, Hamadeh SK, Eidt A. Infection and immunity in broiler chicken breeders vaccinated with a temperature-sensitive mutant of Mycoplasma gallisepticum and impact on performance of offspring. Poultry science. 2000; 79(12); 1730-1735. [PubMed: 11194034].
  2. Gates et al., 2008: Gates AE, Frasca S, Nyaoke A, Gorton TS, Silbart LK, Geary SJ. Comparative assessment of a metabolically attenuated Mycoplasma gallisepticum mutant as a live vaccine for the prevention of avian respiratory mycoplasmosis. Vaccine. 2008; 26(16); 2010-2019. [PubMed: 18342996].
  3. Kumar et al., 2003: Kumar P, Amara RR, Challu VK, Chadda VK, Satchidanandam V. The Apa protein of Mycobacterium tuberculosis stimulates gamma interferon-secreting CD4+ and CD8+ T cells from purified protein derivative-positive individuals and affords protection in a guinea pig model. Infection and immunity. 2003; 71(4); 1929-1937. [PubMed: 12654810].
  4. Merck Vet Manual: M. gallisepticum: Merck Veterinary Manual- Mycoplasma gallisepticum Infection [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/203402.htm]
  5. Saito et al., 1993: Saito S, Fujisawa A, Ohkawa S, Nishimura N, Abe T, Kodama K, Kamogawa K, Aoyama S, Iritani Y, Hayashi Y. Cloning and DNA sequence of a 29 kilodalton polypeptide gene of Mycoplasma gallisepticum as a possible protective antigen. Vaccine. 1993; 11(10); 1061-1066. [PubMed: 8212828].
  6. Wiki: Mycoplasma gallisepticum: Mycoplasma gallisepticum [http://en.wikipedia.org/wiki/Mycoplasma_gallisepticum]

Mycoplasma hyopneumoniae

  1. Maes et al., 2008: Maes D, Segales J, Meyns T, Sibila M, Pieters M, Haesebrouck F. Control of Mycoplasma hyopneumoniae infections in pigs. Veterinary microbiology. 2008; 126(4); 297-309. [PubMed: 17964089].
  2. Okamba et al., 2010: Okamba FR, Arella M, Music N, Jia JJ, Gottschalk M, Gagnon CA. Potential use of a recombinant replication-defective adenovirus vector carrying the C-terminal portion of the P97 adhesin protein as a vaccine against Mycoplasma hyopneumoniae in swine. Vaccine. 2010; 28(30); 4802-4809. [PubMed: 20472025].
  3. Wiki: M. hyopneumoniae: Wiki: Mycoplasma hyopneumoniae [http://en.wikipedia.org/wiki/Mycoplasma_hyopneumoniae]

Mycoplasma synoviae

  1. MicrobeWiki: Mycoplasma synoviae: Mycoplasma synoviae [http://microbewiki.kenyon.edu/index.php/Mycoplasma_synoviae]
  2. Morrow et al., 1998: Morrow CJ, Markham JF, Whithear KG. Production of temperature-sensitive clones of Mycoplasma synoviae for evaluation as live vaccines. Avian diseases. 1998; 42(4); 667-670. [PubMed: 9876833].

Neisseria meningitidis

  1. Carmenate et al., 2004: Carmenate T, Canaán L, Alvarez A, Delgado M, González S, Menéndez T, Rodés L, Guillén G. Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates. FEMS immunology and medical microbiology. 2004; 40(3); 193-199. [PubMed: 15039094].
  2. Comanducci et al., 2002: Comanducci M, Bambini S, Brunelli B, Adu-Bobie J, Aricò B, Capecchi B, Giuliani MM, Masignani V, Santini L, Savino S, Granoff DM, Caugant DA, Pizza M, Rappuoli R, Mora M. NadA, a novel vaccine candidate of Neisseria meningitidis. The Journal of experimental medicine. 2002; 195(11); 1445-1454. [PubMed: 12045242].
  3. FDA: Menactra: FDA: Menactra [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094053.htm]
  4. FDA: MenHibrix: FDA: MenHibrix Package insert [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm308566.htm]
  5. FDA: Menomune– A/C/Y/W-135: FDA Menomune– A/C/Y/W-135 Neisseria meningitidis vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094054.htm]
  6. FDA: Menveo: FDA: Menveo [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201342.htm]
  7. Giuliani et al., 2006: Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, Cartocci E, Ciucchi L, Di Marcello F, Ferlicca F, Galli B, Luzzi E, Masignani V, Serruto D, Veggi D, Contorni M, Morandi M, Bartalesi A, Cinotti V, Mannucci D, Titta F, Ovidi E, Welsch JA, Granoff D, Rappuoli R, Pizza M. A universal vaccine for serogroup B meningococcus. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(29); 10834-10839. [PubMed: 16825336].
  8. Li et al., 2004: Li Y, Sun YH, Ison C, Levine MM, Tang CM. Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci. Infection and immunity. 2004; 72(1); 345-351. [PubMed: 14688114].
  9. Lissolo et al., 1995: Lissolo L, Maitre-Wilmotte G, Dumas P, Mignon M, Danve B, Quentin-Millet MJ. Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infection and immunity. 1995; 63(3); 884-890. [PubMed: 7868259].
  10. Martin et al., 1997: Martin D, Cadieux N, Hamel J, Brodeur BR. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. The Journal of experimental medicine. 1997; 185(7); 1173-1183. [PubMed: 9104804].
  11. O'dwyer et al., 2004: O'dwyer CA, Reddin K, Martin D, Taylor SC, Gorringe AR, Hudson MJ, Brodeur BR, Langford PR, Kroll JS. Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential. Infection and immunity. 2004; 72(11); 6511-6518. [PubMed: 15501782].
  12. Pizza et al., 2000: Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, Galeotti CL, Luzzi E, Manetti R, Marchetti E, Mora M, Nuti S, Ratti G, Santini L, Savino S, Scarselli M, Storni E, Zuo P, Broeker M, Hundt E, Knapp B, Blair E, Mason T, Tettelin H, Hood DW, Jeffries AC, Saunders NJ, Granoff DM, Venter JC, Moxon ER, Grandi G, Rappuoli R. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (New York, N.Y.). 2000; 287(5459); 1816-1820. [PubMed: 10710308].
  13. Pizza et al., 2008: Pizza M, Donnelly J, Rappuoli R. Factor H-binding protein, a unique meningococcal vaccine antigen. Vaccine. 2008; 26 Suppl 8; I46-48. [PubMed: 19388164].
  14. Prinz et al., 2003: Prinz DM, Smithson SL, Kieber-Emmons T, Westerink MA. Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide. Immunology. 2003; 110(2); 242-249. [PubMed: 14511238].
  15. Saukkonen et al., 1989: Saukkonen K, Leinonen M, Abdillahi H, Poolman JT. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine. 1989; 7(4); 325-328. [PubMed: 2510417].
  16. Stephens et al., 2007: Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007; 369(9580); 2196-2210. [PubMed: 17604802].
  17. Sun et al., 2005: Sun Y, Li Y, Exley RM, Winterbotham M, Ison C, Smith H, Tang CM. Identification of novel antigens that protect against systemic meningococcal infection. Vaccine. 2005; 23(32); 4136-4141. [PubMed: 15964482].
  18. Textbook of Bacteriology: Staphylococcus bacteriaPrint this Page Pathogenic Neisseriae: Gonorrhea, Neonatal Ophthalmia and Meningococcal Meningitis [http://textbookofbacteriology.net/neisseria]
  19. West et al., 2001: West D, Reddin K, Matheson M, Heath R, Funnell S, Hudson M, Robinson A, Gorringe A. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infection and immunity. 2001; 69(3); 1561-1567. [PubMed: 11179327].

Neospora caninum

  1. Alaeddine et al., 2005: Alaeddine F, Keller N, Leepin A, Hemphill A. Reduced infection and protection from clinical signs of cerebral neosporosis in C57BL/6 mice vaccinated with recombinant microneme antigen NcMIC1. The Journal of parasitology. 2005; 91(3); 657-665. [PubMed: 16108562].
  2. Buxton et al., 2002: Buxton D, McAllister MM, Dubey JP. The comparative pathogenesis of neosporosis. Trends in parasitology. 2002; 18(12); 546-552. [PubMed: 12482540].
  3. Cannas et al., 2003: Cannas A, Naguleswaran A, Müller N, Eperon S, Gottstein B, Hemphill A. Vaccination of mice against experimental Neospora caninum infection using NcSAG1- and NcSRS2-based recombinant antigens and DNA vaccines. Parasitology. 2003; 126(Pt 4); 303-312. [PubMed: 12741509].
  4. Cho et al., 2005: Cho JH, Chung WS, Song KJ, Na BK, Kang SW, Song CY, Kim TS. Protective efficacy of vaccination with Neospora caninum multiple recombinant antigens against experimental Neospora caninum infection. The Korean journal of parasitology. 2005; 43(1); 19-25. [PubMed: 15793355].
  5. Debache et al., 2010: Debache K, Guionaud C, Alaeddine F, Hemphill A. Intraperitoneal and intra-nasal vaccination of mice with three distinct recombinant Neospora caninum antigens results in differential effects with regard to protection against experimental challenge with Neospora caninum tachyzoites. Parasitology. 2010; 137(2); 229-240. [PubMed: 19835644].
  6. Dubey, 2003: Dubey JP. Review of Neospora caninum and neosporosis in animals. The Korean journal of parasitology. 2003; 41(1); 1-16. [PubMed: 12666725].
  7. Ellis et al., 2008: Ellis J, Miller C, Quinn H, Ryce C, Reichel MP. Evaluation of recombinant proteins of Neospora caninum as vaccine candidates (in a mouse model). Vaccine. 2008; 26(47); 5989-5996. [PubMed: 18789996].
  8. Jenkins et al., 2004: Jenkins MC, Tuo W, Dubey JP. Evaluation of vaccination with Neospora caninum protein for prevention of fetal loss associated with experimentally induced neosporosis in sheep. American journal of veterinary research. 2004; 65(10); 1404-1408. [PubMed: 15524328].
  9. Romero et al., 2004: Romero JJ, Pérez E, Frankena K. Effect of a killed whole Neospora caninum tachyzoite vaccine on the crude abortion rate of Costa Rican dairy cows under field conditions. Veterinary parasitology. 2004; 123(3-4); 149-159. [PubMed: 15325041].
  10. Vemulapalli et al., 2007: Vemulapalli R, Sanakkayala N, Gulani J, Schurig GG, Boyle SM, Lindsay DS, Sriranganathan N. Reduced cerebral infection of Neospora caninum in BALB/c mice vaccinated with recombinant Brucella abortus RB51 strains expressing N. caninum SRS2 and GRA7 proteins. Veterinary parasitology. 2007; 148(3-4); 219-230. [PubMed: 17651896].
  11. Wiki: Neospora caninum: Neospora caninum [http://en.wikipedia.org/wiki/Neospora_caninum]

Newcastle disease virus

  1. Lee et al., 2008: Lee YJ, Sung HW, Choi JG, Lee EK, Yoon H, Kim JH, Song CS. Protection of chickens from Newcastle disease with a recombinant baculovirus subunit vaccine expressing the fusion and hemagglutininneuraminidase proteins. Journal of veterinary science. 2008; 9(3); 301-308. [PubMed: 18716451].
  2. Meeusen et al., 2007: Meeusen EN, Walker J, Peters A, Pastoret PP, Jungersen G. Current status of veterinary vaccines. Clinical microbiology reviews. 2007; 20(3); 489-510. [PubMed: 17630337].
  3. Sakaguchi et al., 1996: Sakaguchi M, Nakamura H, Sonoda K, Hamada F, Hirai K. Protection of chickens from Newcastle disease by vaccination with a linear plasmid DNA expressing the F protein of Newcastle disease virus. Vaccine. 1996; 14(8); 747-752. [PubMed: 8817820].
  4. Wiki: Newcastle disease: Newcastle disease [http://en.wikipedia.org/wiki/Newcastle_disease_virus]
  5. Wu et al., 2000: Wu YT, Peng DX, Liu XF, Liu WZ, Zhang RK. [A recombinant fowlpox virus expressing the fusion protein of Newcastle disease virus strain F48E8 and its protective efficacy]. Sheng wu gong cheng xue bao = Chinese journal of biotechnology. 2000; 16(5); 591-594. [PubMed: 11191764].

Nipah virus

  1. Guillaume et al., 2004: Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, Marianneau P, Chua KB, Lam SK, Buckland R, Deubel V, Wild TF. Nipah virus: vaccination and passive protection studies in a hamster model. Journal of virology. 2004; 78(2); 834-840. [PubMed: 14694115].
  2. Guillaume et al., 2006: Guillaume V, Contamin H, Loth P, Grosjean I, Courbot MC, Deubel V, Buckland R, Wild TF. Antibody prophylaxis and therapy against Nipah virus infection in hamsters. Journal of virology. 2006; 80(4); 1972-1978. [PubMed: 16439553].
  3. Wiki: Nipah virus: Henipavirus [http://en.wikipedia.org/wiki/Henipavirus]

Orf Virus

  1. Wiki: Orf disease: Wiki: Orf Disease [http://en.wikipedia.org/wiki/Orf_disease]

Parainfluenza virus

  1. CDC - Human Parainfluenza Viruses: Human Parainfluenza Viruses [http://www.cdc.gov/parainfluenza/about/overview.html]
  2. Le et al., 2012: Le Bayon JC, Lina B, Rosa-Calatrava M, Boivin G. Recent developments with live-attenuated recombinant paramyxovirus vaccines. Reviews in medical virology. 2012; ; . [PubMed: 22570186].

Pasteurella multocida

  1. Dagleish et al., 2007: Dagleish MP, Hodgson JC, Ataei S, Finucane A, Finlayson J, Sales J, Parton R, Coote JG. Safety and protective efficacy of intramuscular vaccination with a live aroA derivative of Pasteurella multocida B:2 against experimental hemorrhagic septicemia in calves. Infection and immunity. 2007; 75(12); 5837-5844. [PubMed: 17875632].
  2. Gong et al., 2013: Gong Q, Qu N, Niu M, Qin C, Cheng M, Sun X, Zhang A. Immune responses and protective efficacy of a novel DNA vaccine encoding outer membrane protein of avian Pasteurella multocida. Veterinary immunology and immunopathology. 2013; 152(3-4); 317-324. [PubMed: 23340446].
  3. Harper et al., 2006: Harper M, Boyce JD, Adler B. Pasteurella multocida pathogenesis: 125 years after Pasteur. FEMS microbiology letters. 2006; 265(1); 1-10. [PubMed: 17107417].
  4. Muneer et al., 1994: Muneer R, Akhtar S, Afzal M. Evaluation of three oil-adjuvant vaccines against Pasteurella multocida in buffalo calves. Revue scientifique et technique (International Office of Epizootics). 1994; 13(3); 837-843. [PubMed: 7949356].
  5. Tan et al., 2010: Tan HY, Nagoor NH, Sekaran SD. Cloning, expression and protective capacity of 37 kDa outer membrane protein gene (ompH) of Pasteurella multocida serotype B:2. Tropical biomedicine. 2010; 27(3); 430-441. [PubMed: 21399583].
  6. Wiki: P. multocida: Wiki: Pasteurella multocida [http://en.wikipedia.org/wiki/Pasteurella_multocida]

Pigeonpox virus

  1. Vriends et al., 2005: Matthew M Vriends; Tommy E Erskine; Diane Jacky; Michele Earle-Bridges. Pox and Pigeon-Related Viruses. 74-76. Pigeons. 2005. Barron's, Hauppauge, NY.

Piscirickettsia salmonis

  1. Fryer and Hedrick, 2003: Fryer JL, Hedrick RP. Piscirickettsia salmonis: a Gram-negative intracellular bacterial pathogen of fish. Journal of fish diseases. 2003; 26(5); 251-262. [PubMed: 12962234].

Plasmodium spp.

  1. Adams et al., 2002: Adams S, Brown H, Turner G. Breaking down the blood-brain barrier: signaling a path to cerebral malaria?. Trends in parasitology. 2002 Aug; 18(8); 360-6. [PubMed: 12377286].
  2. Aidoo et al., 2000: Aidoo M, Lalvani A, Gilbert SC, Hu JT, Daubersies P, Hurt N, Whittle HC, Druihle P, Hill AV. Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3. Infection and immunity. 2000 Jan; 68(1); 227-32. [PubMed: 10603392].
  3. Alonso et al., 2004: Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004 Oct 16-22; 364(9443); 1411-20. [PubMed: 15488216].
  4. Arevalo-Herrera et al., 2005: Arevalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincon A, Saul A, Mu J, Long C, Miller L, Herrera S. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein. The American journal of tropical medicine and hygiene. 2005 Nov; 73(5 Suppl); 32-7. [PubMed: 16291764].
  5. Audran et al., 2005: Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, Druilhe P, Spertini F. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infection and immunity. 2005 Dec; 73(12); 8017-26. [PubMed: 16299295].
  6. BenMohamed et al., 2004: BenMohamed L, Thomas A, Druilhe P. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infection and immunity. 2004 Aug; 72(8); 4376-84. [PubMed: 15271893].
  7. Bergmann-Leitner et al., 2007: Bergmann-Leitner ES, Duncan EH, Leitner WW, Neutzner A, Savranskaya T, Angov E, Tsokos GC. C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei. Vaccine. 2007; 25(45); 7732-7736. [PubMed: 17931754].
  8. Bergmann-Leitner et al., 2010: Bergmann-Leitner ES, Mease RM, De La Vega P, Savranskaya T, Polhemus M, Ockenhouse C, Angov E. Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PloS one. 2010; 5(8); e12294. [PubMed: 20808868].
  9. Bledsoe, 2005: Bledsoe GH. Malaria primer for clinicians in the United States. Southern medical journal. 2005 Dec; 98(12); 1197-204; quiz 1205, 1230. [PubMed: 16440920].
  10. Bojang et al., 2001: Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001 Dec 8; 358(9297); 1927-34. [PubMed: 11747915].
  11. Bonnefoy et al., 1994: Bonnefoy S, Gysin J, Blisnick T, Guillotte M, Carcy B, Pereira da Silva L, Mercereau-Puijalon O. Immunogenicity and antigenicity of a Plasmodium falciparum protein fraction (90-110 kDa) able to protect squirrel monkeys against asexual blood stages. Vaccine. 1994; 12(1); 32-40. [PubMed: 8303938].
  12. Bracho et al., 2009: Bracho G, Zayas C, Wang L, Coppel R, Pérez O, Petrovsky N. AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5. Malaria journal. 2009; 8; 35. [PubMed: 19250541].
  13. Breman, 2001: Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. The American journal of tropical medicine and hygiene. 2001 Jan-Feb; 64(1-2 Suppl); 1-11. [PubMed: 11425172].
  14. Bruna-Romero et al., 2004: Bruna-Romero O, Rocha CD, Tsuji M, Gazzinelli RT. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Vaccine. 2004 Sep 9; 22(27-28); 3575-84. [PubMed: 15315836].
  15. Burgess et al., 2005: Burgess BR, Schuck P, Garboczi DN. Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule. The Journal of biological chemistry. 2005 Nov 4; 280(44); 37236-45. [PubMed: 16135515].
  16. Butler et al., 2011: Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, Harty JT. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell host & microbe. 2011; 9(6); 451-462. [PubMed: 21669394].
  17. Carter et al., 1995: Carter R, Coulson A, Bhatti S, Taylor BJ, Elliott JF. Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs48/45 and Pf12. Molecular and biochemical parasitology. 1995 May; 71(2); 203-10. [PubMed: 7477102].
  18. Carvalho et al., 2004: Carvalho LJ, Oliveira SG, Theisen M, Alves FA, Andrade MC, Zanini GM, Brígido MC, Oeuvray C, Póvoa MM, Muniz JA, Druilhe P, Daniel-Ribeiro CT. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scandinavian journal of immunology. 2004; 59(4); 363-372. [PubMed: 15049780].
  19. Castellanos et al., 2007: Castellanos A, Arevalo-Herrera M, Restrepo N, Gulloso L, Corradin G, Herrera S. Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys. Memorias do Instituto Oswaldo Cruz. 2007 Jun; 102(3); 411-6. [PubMed: 17568948].
  20. Chen et al., 2000: Chen Q, Schlichtherle M, Wahlgren M. Molecular aspects of severe malaria. Clinical microbiology reviews. 2000 Jul; 13(3); 439-50. [PubMed: 10885986].
  21. Daly and Long, 1993: Daly TM, Long CA. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. Infection and immunity. 1993; 61(6); 2462-2467. [PubMed: 8363656].
  22. Daubersies et al., 2000: Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JA, Ollomo B, BenMohamed L, Slierendregt B, Eling W, Van Belkum A, Dubreuil G, Meis JF, Guérin-Marchand C, Cayphas S, Cohen J, Gras-Masse H, Druilhe P. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nature medicine. 2000; 6(11); 1258-1263. [PubMed: 11062538].
  23. Dobaño and Doolan, 2007: Dobaño C, Doolan DL. Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa. Molecular immunology. 2007; 44(11); 3037-3048. [PubMed: 17303242].
  24. Doolan et al., 1996: Doolan DL, Sedegah M, Hedstrom RC, Hobart P, Charoenvit Y, Hoffman SL. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. The Journal of experimental medicine. 1996; 183(4); 1739-1746. [PubMed: 8666931].
  25. Douradinha et al., 2007: Douradinha B, van Dijk MR, Ataide R, van Gemert GJ, Thompson J, Franetich JF, Mazier D, Luty AJ, Sauerwein R, Janse CJ, Waters AP, Mota MM. Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection. International journal for parasitology. 2007; 37(13); 1511-1519. [PubMed: 17604034].
  26. Dunachie et al., 2006: Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, Andersen RF, Bejon P, Goonetilleke N, Poulton I, Webster DP, Butcher G, Watkins K, Sinden RE, Levine GL, Richie TL, Schneider J, Kaslow D, Gilbert SC, Carucci DJ, Hill AV. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infection and immunity. 2006; 74(10); 5933-5942. [PubMed: 16988273].
  27. Eksi et al., 2006: Eksi S, Czesny B, van Gemert GJ, Sauerwein RW, Eling W, Williamson KC. Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production. Molecular microbiology. 2006 Aug; 61(4); 991-8. [PubMed: 16879650].
  28. El et al., 2010: El Sahly HM, Patel SM, Atmar RL, Lanford TA, Dube T, Thompson D, Lee Sim BK, Long C, Keitel WA. The Safety and Immunogenicity of Recombinant EBA 175-RII NG Malaria Vaccine in Healthy Adults Living in a Non-Endemic Area. Clinical and vaccine immunology : CVI. 2010; ; . [PubMed: 20702657].
  29. Escalante et al., 1998: Escalante AA, Freeland DE, Collins WE, Lal AA. The evolution of primate malaria parasites based on the gene encoding cytochrome b from the linear mitochondrial genome. Proceedings of the National Academy of Sciences of the United States of America. 1998 Jul 7; 95(14); 8124-9. [PubMed: 9653151].
  30. Eslava et al., 2010: Eslava I, Payares G, Pernia BM, Holder AA, Spencer LM. Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii. Malaria journal. 2010; 9; 46. [PubMed: 20146804].
  31. Etlinger et al., 1991: Etlinger HM, Caspers P, Matile H, Schoenfeld HJ, Stueber D, Takacs B. Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum. Infection and immunity. 1991; 59(10); 3498-3503. [PubMed: 1894356].
  32. Fanning et al., 2003: Fanning SL, Czesny B, Sedegah M, Carucci DJ, van Gemert GJ, Eling W, Williamson KC. A glycosylphosphatidylinositol anchor signal sequence enhances the immunogenicity of a DNA vaccine encoding Plasmodium falciparum sexual-stage antigen, Pfs230. Vaccine. 2003 Jul 4; 21(23); 3228-35. [PubMed: 12804852].
  33. Flanagan et al., 2003: Flanagan KL, Mwangi T, Plebanski M, Odhiambo K, Ross A, Sheu E, Kortok M, Lowe B, Marsh K, Hill AV. Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. The American journal of tropical medicine and hygiene. 2003 Apr; 68(4); 421-30. [PubMed: 12875291].
  34. Flanagan et al., 2006: Flanagan KL, Plebanski M, Odhiambo K, Sheu E, Mwangi T, Gelder C, Hart K, Kortok M, Lowe B, Robson KJ, Marsh K, Hill AV. Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. The American journal of tropical medicine and hygiene. 2006 Mar; 74(3); 367-75. [PubMed: 16525093].
  35. Gantt et al., 2000: Gantt S, Persson C, Rose K, Birkett AJ, Abagyan R, Nussenzweig V. Antibodies against thrombospondin-related anonymous protein do not inhibit Plasmodium sporozoite infectivity in vivo. Infection and immunity. 2000 Jun; 68(6); 3667-73. [PubMed: 10816526].
  36. Garcia et al., 2006: Garcia JE, Puentes A, Patarroyo ME. Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design. Clinical microbiology reviews. 2006 Oct; 19(4); 686-707. [PubMed: 17041140].
  37. Genton et al., 2003: Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine. 2003 Dec 8; 22(1); 30-41. [PubMed: 14604568].
  38. Genton et al., 2003a: Genton B, Anders RF, Alpers MP, Reeder JC. The malaria vaccine development program in Papua New Guinea. Trends in parasitology. 2003 Jun; 19(6); 264-70. [PubMed: 12798084].
  39. Gilbert et al., 2006: Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, Keating SM, Berthoud T, Webster D, McShane H, Hill AV. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine. 2006 May 22; 24(21); 4554-61. [PubMed: 16150517].
  40. Girard et al., 2007: Girard MP, Reed ZH, Friede M, Kieny MP. A review of human vaccine research and development: malaria. Vaccine. 2007 Feb 19; 25(9); 1567-80. [PubMed: 17045367].
  41. Grüner et al., 2007: Grüner AC, Mauduit M, Tewari R, Romero JF, Depinay N, Kayibanda M, Lallemand E, Chavatte JM, Crisanti A, Sinnis P, Mazier D, Corradin G, Snounou G, Rénia L. Sterile protection against malaria is independent of immune responses to the circumsporozoite protein. PloS one. 2007; 2(12); e1371. [PubMed: 18159254].
  42. Greenwood et al., 2005: Greenwood BM, Bojang K, Whitty CJ, Targett GA. Malaria. Lancet. 2005 Apr 23-29; 365(9469); 1487-98. [PubMed: 15850634].
  43. Hay et al., 2004: Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. The Lancet infectious diseases. 2004 Jun; 4(6); 327-36. [PubMed: 15172341].
  44. Heal et al., 1999: Heal KG, Hill HR, Stockley PG, Hollingdale MR, Taylor-Robinson AW. Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids. Vaccine. 1999 Sep; 18(3-4); 251-8. [PubMed: 10506649].
  45. Healer et al., 1997: Healer J, McGuinness D, Hopcroft P, Haley S, Carter R, Riley E. Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230. Infection and immunity. 1997 Aug; 65(8); 3017-23. [PubMed: 9234748].
  46. Heppner et al., 2005: Heppner DG Jr, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF, Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L, Darko CA, Withers MR, Ogutu B, Polhemus ME, Fukuda M, Pichyangkul S, Gettyacamin M, Diggs C, Soisson L, Milman J, Dubois MC, Garcon N, Tucker K, Wittes J, Plowe CV, Thera MA, Duombo OK, Pau MG, Goudsmit J, Ballou WR, Cohen J. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005 Mar 18; 23(17-18); 2243-50. [PubMed: 15755604].
  47. Hillier et al., 2005: Hillier CJ, Ware LA, Barbosa A, Angov E, Lyon JA, Heppner DG, Lanar DE. Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infection and immunity. 2005 Apr; 73(4); 2109-15. [PubMed: 15784552].
  48. Hoffman et al., 1994: Hoffman SL, Sedegah M, Hedstrom RC. Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine. Vaccine. 1994; 12(16); 1529-1533. [PubMed: 7879419].
  49. Hoffman et al., 1997: Hoffman SL, Doolan DL, Sedegah M, Aguiar JC, Wang R, Malik A, Gramzinski RA, Weiss WR, Hobart P, Norman JA, Margalith M, Hedstrom RC. Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use. Vaccine. 1997; 15(8); 842-845. [PubMed: 9234529].
  50. Horii et al., 2010: Horii T, Shirai H, Jie L, Ishii KJ, Palacpac NQ, Tougan T, Hato M, Ohta N, Bobogare A, Arakaki N, Matsumoto Y, Namazue J, Ishikawa T, Ueda S, Takahashi M. Evidences of Protection Against Blood-stage Infection of Plasmodium falciparum by the Novel Protein Vaccine SE36. Parasitology international. 2010; ; . [PubMed: 20493274].
  51. Joy et al., 2003: Joy DA, Feng X, Mu J, Furuya T, Chotivanich K, Krettli AU, Ho M, Wang A, White NJ, Suh E, Beerli P, Su XZ. Early origin and recent expansion of Plasmodium falciparum. Science (New York, N.Y.). 2003 Apr 11; 300(5617); 318-21. [PubMed: 12690197].
  52. Kaba et al., 2009: Kaba SA, Brando C, Guo Q, Mittelholzer C, Raman S, Tropel D, Aebi U, Burkhard P, Lanar DE. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. Journal of immunology (Baltimore, Md. : 1950). 2009; 183(11); 7268-7277. [PubMed: 19915055].
  53. Kaufman et al., 2005: Kaufman TS, Ruveda EA. The quest for quinine: those who won the battles and those who won the war. Angewandte Chemie (International ed. in English). 2005 Jan 28; 44(6); 854-85. [PubMed: 15669029].
  54. Kester et al., 2007: Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG Jr, Hall T, Wellde BT, White K, Sun P, Schwenk R, Krzych U, Delchambre M, Voss G, Dubois MC, Gasser RA Jr, Dowler MG, O'Brien M, Wittes J, Wirtz R, Cohen J, Ballou WR. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine. 2007 Jul 20; 25(29); 5359-66. [PubMed: 17574311].
  55. Kocken et al., 2002: Kocken CH, Withers-Martinez C, Dubbeld MA, van der Wel A, Hackett F, Valderrama A, Blackman MJ, Thomas AW. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infection and immunity. 2002 Aug; 70(8); 4471-6. [PubMed: 12117958].
  56. Komisar, 2007: Komisar JL. Malaria vaccines. Frontiers in bioscience : a journal and virtual library. 2007 May 1; 12; 3928-55. [PubMed: 17485348].
  57. Kristoff, 2007: Kristoff J. Malaria stage-specific vaccine candidates. Current pharmaceutical design. 2007; 13(19); 1989-99. [PubMed: 17627532].
  58. Kumar et al., 1995: Kumar S, Yadava A, Keister DB, Tian JH, Ohl M, Perdue-Greenfield KA, Miller LH, Kaslow DC. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Molecular medicine (Cambridge, Mass.). 1995; 1(3); 325-332. [PubMed: 8529111].
  59. Kushwaha et al., 2001: Kushwaha A, Rao PP, Suresh RP, Chauhan VS. Immunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli. Parasite immunology. 2001 Aug; 23(8); 435-44. [PubMed: 11489167].
  60. Kwiatkowski et al., 1997: Kwiatkowski D, Marsh K. Development of a malaria vaccine. Lancet. 1997 Dec 6; 350(9092); 1696-701. [PubMed: 9400530].
  61. Kwon et al., 2005: Kwon YU, Soucy RL, Snyder DA, Seeberger PH. Assembly of a series of malarial glycosylphosphatidylinositol anchor oligosaccharides. Chemistry (Weinheim an der Bergstrasse, Germany). 2005 Apr 8; 11(8); 2493-504. [PubMed: 15729674].
  62. Labaied et al., 2007: Labaied M, Harupa A, Dumpit RF, Coppens I, Mikolajczak SA, Kappe SH. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infection and immunity. 2007; 75(8); 3758-3768. [PubMed: 17517871].
  63. Lal et al., 1996: Lal AA, Hughes MA, Oliveira DA, Nelson C, Bloland PB, Oloo AJ, Hawley WE, Hightower AW, Nahlen BL, Udhayakumar V. Identification of T-cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in an adult population exposed to malaria. Infection and immunity. 1996 Mar; 64(3); 1054-9. [PubMed: 8641760].
  64. Langermans et al., 2006: Langermans JA, Hensmann M, van Gijlswiik M, Zhang D, Pan W, Giersing BK, Locke E, Dubovsk F, Wittes J, Thomas AW. Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques. Human vaccines. 2006 Sep-Oct; 2(5); 222-6. [PubMed: 17035731].
  65. Le et al., 2000: Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, Kumar S, Wang R, Doolan DL, Maguire JD, Parker SE, Hobart P, Norman J, Hoffman SL. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine. 2000; 18(18); 1893-1901. [PubMed: 10699338].
  66. Li et al., 2007: Li SL, Zhang DM, Cao Y, Pan WQ. [Expression and immunogenicity evaluation of ectodomain and subdomains of Plasmodium berghei apical membrane antigen 1]. Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases. 2007; 25(1); 1-5. [PubMed: 17639690].
  67. Mauduit et al., 2009: Mauduit M, Grüner AC, Tewari R, Depinay N, Kayibanda M, Chavatte JM, Franetich JF, Crisanti A, Mazier D, Snounou G, Rénia L. A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites. PloS one. 2009; 4(11); e7717. [PubMed: 19890387].
  68. McConkey et al., 2003: McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature medicine. 2003; 9(6); 729-735. [PubMed: 12766765].
  69. Meis et al., 1983: Meis JF, Verhave JP, Jap PH, Sinden RE, Meuwissen JH. Malaria parasites--discovery of the early liver form. Nature. 1983 Mar 31-Apr 6; 302(5907); 424-6. [PubMed: 6339945].
  70. Mohmmed et al., 2005: Mohmmed A, Kishore S, Patra KP, Dasaradhi PV, Malhotra P, Chauhan VS. Identification of karyopherin beta as an immunogenic antigen of the malaria parasite using immune mice and human sera. Parasite immunology. 2005; 27(5); 197-203. [PubMed: 15987343].
  71. Moll et al., 2007: Moll K, Pettersson F, Vogt AM, Jonsson C, Rasti N, Ahuja S, Spångberg M, Mercereau-Puijalon O, Arnot DE, Wahlgren M, Chen Q. Generation of cross-protective antibodies against Plasmodium falciparum sequestration by immunization with an erythrocyte membrane protein 1-duffy binding-like 1 alpha domain. Infection and immunity. 2007; 75(1); 211-219. [PubMed: 17074852].
  72. Moore et al., 2004: Moore AC, Hill AV. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunological reviews. 2004 Jun; 199; 126-43. [PubMed: 15233731].
  73. Moore et al., 2005: Moore AC, Gallimore A, Draper SJ, Watkins KR, Gilbert SC, Hill AV. Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance. Journal of immunology (Baltimore, Md. : 1950). 2005 Dec 1; 175(11); 7264-73. [PubMed: 16301631].
  74. Moormann et al., 2006: Moormann AM, John CC, Sumba PO, Tisch D, Embury P, Kazura JW. Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen-1 and thrombospondin-related adhesive protein in residents of a malaria holoendemic area. The American journal of tropical medicine and hygiene. 2006 Apr; 74(4); 585-90. [PubMed: 16606988].
  75. Morais et al., 2006: Morais CG, Soares IS, Carvalho LH, Fontes CJ, Krettli AU, Braga EM. Antibodies to Plasmodium vivax apical membrane antigen 1: persistence and correlation with malaria transmission intensity. The American journal of tropical medicine and hygiene. 2006 Oct; 75(4); 582-7. [PubMed: 17038677].
  76. Mueller et al., 2005: Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature. 2005; 433(7022); 164-167. [PubMed: 15580261].
  77. Oliveira-Ferreira et al., 2000: Oliveira-Ferreira J, Miyahira Y, Layton GT, Savage N, Esteban M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Zavala F. Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus. Vaccine. 2000; 18(17); 1863-1869. [PubMed: 10699335].
  78. Ong'echa et al., 2003: Ong'echa JM, Lal AA, Terlouw DJ, Ter Kuile FO, Kariuki SK, Udhayakumar V, Orago AS, Hightower AW, Nahlen BL, Shi YP. Association of interferon-gamma responses to pre-erythrocytic stage vaccine candidate antigens of Plasmodium falciparum in young Kenyan children with improved hemoglobin levels: XV. Asembo Bay Cohort Project. The American journal of tropical medicine and hygiene. 2003 May; 68(5); 590-7. [PubMed: 12812352].
  79. Pal-Bhowmick et al., 2007: Pal-Bhowmick I, Mehta M, Coppens I, Sharma S, Jarori GK. Protective properties and surface localization of Plasmodium falciparum enolase. Infection and immunity. 2007; 75(11); 5500-5508. [PubMed: 17785475].
  80. Parker et al., 2001: Parker SE, Monteith D, Horton H, Hof R, Hernandez P, Vilalta A, Hartikka J, Hobart P, Bentley CE, Chang A, Hedstrom R, Rogers WO, Kumar S, Hoffman SL, Norman JA. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine. Gene therapy. 2001; 8(13); 1011-1023. [PubMed: 11438836].
  81. Pasquetto et al., 1997: Pasquetto V, Fidock DA, Gras H, Badell E, Eling W, Ballou WR, Belghiti J, Tartar A, Druilhe P. Plasmodium falciparum sporozoite invasion is inhibited by naturally acquired or experimentally induced polyclonal antibodies to the STARP antigen. European journal of immunology. 1997; 27(10); 2502-2513. [PubMed: 9368603].
  82. Pearce et al., 2004: Pearce JA, Hodder AN, Anders RF. The alanine-rich heptad repeats are intact in the processed form of Plasmodium falciparum MSP3. Experimental parasitology. 2004 Nov-Dec; 108(3-4); 186-9. [PubMed: 15582517].
  83. Petritus and Burns, 2008: Petritus PM, Burns JM Jr. Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection. Journal of immunology (Baltimore, Md. : 1950). 2008; 180(1); 444-453. [PubMed: 18097046].
  84. PF11_0344 in GeneDB: PF11_0344 in GeneDB [http://www.genedb.org/genedb/Dispatcher?formType=navBar&organism=malaria&desc=yes&wildcard=yes&name=PF11_0344&ohmr=.&ohmr2=.]
  85. PF13_0201 in GeneDB: PF13_0201 in GeneDB [http://www.genedb.org/genedb/Search?organism=malaria&name=PF13_0201&isid=true]
  86. PFL1385c in GeneDB: PFL1385c in GeneDB [http://www.genedb.org/genedb/Search?organism=malaria&name=PFL1385c&isid=true]
  87. Pichyangkul et al., 2004: Pichyangkul S, Gettayacamin M, Miller RS, Lyon JA, Angov E, Tongtawe P, Ruble DL, Heppner DG Jr, Kester KE, Ballou WR, Diggs CL, Voss G, Cohen JD, Walsh DS. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine. 2004 Sep 28; 22(29-30); 3831-40. [PubMed: 15364429].
  88. Polhemus et al., 2007: Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs CL, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Dubois MC, Ofori-Anyinam O, De-Kock E, Ballou WR, Heppner DG Jr. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine. 2007 May 22; 25(21); 4203-12. [PubMed: 17442466].
  89. Pye et al., 1997: Pye D, Vandenberg KL, Dyer SL, Irving DO, Goss NH, Woodrow GC, Saul A, Alving CR, Richards RL, Ballou WR, Wu MJ, Skoff K, Anders RF. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Vaccine. 1997; 15(9); 1017-1023. [PubMed: 9261951].
  90. Robson et al., 1998: Robson KJ, Dolo A, Hackford IR, Doumbo O, Richards MB, Keita MM, Sidibe T, Bosman A, Modiano D, Crisanti A. Natural polymorphism in the thrombospondin-related adhesive protein of Plasmodium falciparum. The American journal of tropical medicine and hygiene. 1998 Jan; 58(1); 81-9. [PubMed: 9452297].
  91. Rogers et al., 2001: Rogers WO, Baird JK, Kumar A, Tine JA, Weiss W, Aguiar JC, Gowda K, Gwadz R, Kumar S, Gold M, Hoffman SL. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infection and immunity. 2001; 69(9); 5565-5572. [PubMed: 11500430].
  92. Rosa et al., 2004: Rosa DS, Tzelepis F, Cunha MG, Soares IS, Rodrigues MM. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunology letters. 2004 Apr 15; 92(3); 259-68. [PubMed: 15081621].
  93. Sakai et al., 2003: Sakai T, Hisaeda H, Nakano Y, Zhang M, Takashima M, Ishii K, Maekawa Y, Matsumoto S, Nitta Y, Miyazaki Ji, Yamamoto S, Himeno K. Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice. Vaccine. 2003; 21(13-14); 1432-1444. [PubMed: 12615440].
  94. Sanchez et al., 2001: Sanchez GI, Sedegah M, Rogers WO, Jones TR, Sacci J, Witney A, Carucci DJ, Kumar N, Hoffman SL. Immunogenicity and protective efficacy of a Plasmodium yoelii Hsp60 DNA vaccine in BALB/c mice. Infection and immunity. 2001; 69(6); 3897-3905. [PubMed: 11349057].
  95. Saul et al., 1992: Saul A, Lord R, Jones GL, Spencer L. Protective immunization with invariant peptides of the Plasmodium falciparum antigen MSA2. Journal of immunology (Baltimore, Md. : 1950). 1992; 148(1); 208-211. [PubMed: 1727867].
  96. Schneider et al., 1998: Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AV. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature medicine. 1998; 4(4); 397-402. [PubMed: 9546783].
  97. Seeberger et al., 2004: Seeberger PH, Soucy RL, Kwon YU, Snyder DA, Kanemitsu T. A convergent, versatile route to two synthetic conjugate anti-toxin malaria vaccines. Chemical communications (Cambridge, England). 2004 Aug 7; (15); 1706-7. [PubMed: 15278147].
  98. Sim et al., 2001: Sim BK, Narum DL, Liang H, Fuhrmann SR, Obaldia N 3rd, Gramzinski R, Aguiar J, Haynes JD, Moch JK, Hoffman SL. Induction of biologically active antibodies in mice, rabbits, and monkeys by Plasmodium falciparum EBA-175 region II DNA vaccine. Molecular medicine (Cambridge, Mass.). 2001; 7(4); 247-254. [PubMed: 11471569].
  99. Singh et al., 2003: Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infection and immunity. 2003 Dec; 71(12); 6766-74. [PubMed: 14638762].
  100. Sirima et al., 2007: Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A, Derme AI, Diarra A, Ouedraogo A, Soulama I, Cuzzin-Ouattara N, Cousens S, Leroy O. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine. 2007 Mar 30; 25(14); 2723-32. [PubMed: 17280744].
  101. Stewart et al., 2007: Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, Cobb M, Burge JR, Larson D, Ware LA, Demoitie MA, Weverling GJ, Bayat B, Custers JH, Dubois MC, Cohen J, Goudsmit J, Heppner DG Jr. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infection and immunity. 2007 May; 75(5); 2283-90. [PubMed: 17307942].
  102. Stoute et al., 2006: Stoute JA, Heppner DG Jr, Mason CJ, Siangla J, Opollo MO, Kester KE, Vigneron L, Voss G, Walter MJ, Tornieporth N, Cohen JD, Ballou WR. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya. The American journal of tropical medicine and hygiene. 2006 Jul; 75(1); 166-70. [PubMed: 16837726].
  103. Stowers et al., 2002: Stowers AW, Chen Lh LH, Zhang Y, Kennedy MC, Zou L, Lambert L, Rice TJ, Kaslow DC, Saul A, Long CA, Meade H, Miller LH. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America. 2002 Jan 8; 99(1); 339-44. [PubMed: 11752405].
  104. Sturm et al., 2006: Sturm A, Amino R, van de Sand C, Regen T, Retzlaff S, Rennenberg A, Krueger A, Pollok JM, Menard R, Heussler VT. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science (New York, N.Y.). 2006 Sep 1; 313(5791); 1287-90. [PubMed: 16888102].
  105. Talman et al., 2004: Talman AM, Domarle O, McKenzie FE, Ariey F, Robert V. Gametocytogenesis: the puberty of Plasmodium falciparum. Malaria journal. 2004 Jul 14; 3; 24. [PubMed: 15253774].
  106. Tarun et al., 2007: Tarun AS, Dumpit RF, Camargo N, Labaied M, Liu P, Takagi A, Wang R, Kappe SH. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. The Journal of infectious diseases. 2007; 196(4); 608-616. [PubMed: 17624848].
  107. Thera et al., 2006: Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, Diemert DJ, Heppner DG, Stewart VA, Angov E, Soisson L, Leach A, Tucker K, Lyke KE, Plowe CV. Safety and allele-specific immunogenicity of a malaria vaccine in malian adults: results of a phase I randomized trial. PLoS clinical trials. 2006 Nov 24; 1(7); e34. [PubMed: 17124530].
  108. Tsai et al., 2009: Tsai CW, Duggan PF, Jin AJ, Macdonald NJ, Kotova S, Lebowitz J, Hurt DE, Shimp RL Jr, Lambert L, Miller LH, Long CA, Saul A, Narum DL. Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure. Molecular and biochemical parasitology. 2009; 164(1); 45-56. [PubMed: 19073223].
  109. Valderrama-Aguirre et al., 2005: Valderrama-Aguirre A, Quintero G, Gómez A, Castellanos A, Pérez Y, Méndez F, Arévalo-Herrera M, Herrera S. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. The American journal of tropical medicine and hygiene. 2005; 73(5 Suppl); 16-24. [PubMed: 16291762].
  110. Vincent et al., 1999: Vincent AA, Fanning S, Caira FC, Williamson KC. Immunogenicity of malaria transmission-blocking vaccine candidate, y230.CA14 following crosslinking in the presence of tetanus toxoid. Parasite immunology. 1999 Nov; 21(11); 573-81. [PubMed: 10583858].
  111. Wan et al., 2007: Wan Omar A, Roslaini AM, Ngah ZU, Azahari AA, Zahedi M, Baharudin O. A recombinant 19 kDa Plasmodium berghei merozoite surface protein 1 formulated with alum induces protective immune response in mice. Tropical biomedicine. 2007; 24(1); 119-126. [PubMed: 17568385].
  112. Wang et al., 2004: Wang L, Goschnick MW, Coppel RL. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge. Infection and immunity. 2004; 72(10); 6172-6175. [PubMed: 15385527].
  113. Wang et al., 2005: Wang R, Richie TL, Baraceros MF, Rahardjo N, Gay T, Banania JG, Charoenvit Y, Epstein JE, Luke T, Freilich DA, Norman J, Hoffman SL. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infection and immunity. 2005; 73(5); 2863-2872. [PubMed: 15845492].
  114. Webster et al., 2005: Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen RF, Bejon P, Butcher G, Sinden R, Skinner MA, Gilbert SC, Hill AV. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(13); 4836-4841. [PubMed: 15781866].
  115. Xu et al., 2000: Xu H, Hodder AN, Yan H, Crewther PE, Anders RF, Good MF. CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization. Journal of immunology (Baltimore, Md. : 1950). 2000; 165(1); 389-396. [PubMed: 10861076].
  116. Yoshida et al., 2000: Yoshida S, Kashiwamura SI, Hosoya Y, Luo E, Matsuoka H, Ishii A, Fujimura A, Kobayashi E. Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite. Biochemical and biophysical research communications. 2000; 271(1); 107-115. [PubMed: 10777689].
  117. Yuen et al., 2007: Yuen D, Leung WH, Cheung R, Hashimoto C, Ng SF, Ho W, Hui G. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development. Vaccine. 2007 Jan 5; 25(3); 490-9. [PubMed: 16949181].
  118. Zhou et al., 2006: Zhou Z, Todd CW, Wohlhueter RM, Price A, Xiao L, Schnake P, Bonner PC, Martin AM, Goldman IF, De La Vega P, Udhayakumar V, Lal AA. Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli. Human vaccines. 2006 Jan-Feb; 2(1); 14-23. [PubMed: 17012909].

Poliovirus

  1. FDA: IPOL: FDA: IPOL vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm180053.htm]
  2. FDA: licensed vaccines: FDA: licensed vaccines [http://www.fda.gov/Cber/vaccine/licvacc.htm]
  3. FDA: Pediarix: FDA: Pediarix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm146759.htm]
  4. FDA: Pentacel: FDA: Pentacel [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172502.htm]
  5. Health Canada DPD: Health Canada Drug Product Database [www.hc-sc.gc.ca]
  6. Mahon et al., 1995: Mahon BP, Katrak K, Nomoto A, Macadam AJ, Minor PD, Mills KH. Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor. The Journal of experimental medicine. 1995; 181(4); 1285-1292. [PubMed: 7699320].
  7. Poliovax: Medicinenet.com: Poliovax [http://www.medicinenet.com/poliovirus_vaccine-injection/article.htm]
  8. SP: IPV: SP: Inactived Poliomyelitis Vaccine – IPV [https://www.vaccineshoppecanada.com/secure/pdfs/ca/ipv_E.pdf]
  9. Wiki: Poliovirus: Wiki: Poliovirus [http://en.wikipedia.org/wiki/Poliovirus]

Porcine circovirus 2

  1. Ferrari et al., 2000: Ferrari M, Brack A, Romanelli MG, Mettenleiter TC, Corradi A, Dal Mas N, Losio MN, Silini R, Pinoni C, Pratelli A. A study of the ability of a TK-negative and gI/gE-negative pseudorabies virus (PRV) mutant inoculated by different routes to protect pigs against PRV infection. Journal of veterinary medicine. B, Infectious diseases and veterinary public health. 2000; 47(10); 753-762. [PubMed: 11204130].
  2. Gillespie et al., 2009: Gillespie J, Opriessnig T, Meng XJ, Pelzer K, Buechner-Maxwell V. Porcine circovirus type 2 and porcine circovirus-associated disease. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine. 2009; 23(6); 1151-1163. [PubMed: 19780932].
  3. Shen et al., 2008: Shen HG, Zhou JY, Huang ZY, Guo JQ, Xing G, He JL, Yan Y, Gong LY. Protective immunity against porcine circovirus 2 by vaccination with ORF2-based DNA and subunit vaccines in mice. The Journal of general virology. 2008; 89(Pt 8); 1857-1865. [PubMed: 18632956].
  4. Wang et al., 2007: Wang X, Jiang P, Li Y, Jiang W, Dong X. Protection of pigs against post-weaning multisystemic wasting syndrome by a recombinant adenovirus expressing the capsid protein of porcine circovirus type 2. Veterinary microbiology. 2007; 121(3-4); 215-224. [PubMed: 17215092].
  5. Wiki: Porcine circovirus: Porcine circovirus [http://en.wikipedia.org/wiki/Porcine_circovirus]

Porcine parvovirus

  1. Mengeling, 2006: Barbara E. Straw, Jeffery J. Zimmerman, Sylvie D'Allaire, and David J. Taylor. Porcine Parvovirus. 373-382. Diseases of Swine, Ninth Edition. 2006. Wiley-Blackwell, Oxford.

Porcine respiratory and reproductive syndrome virus

  1. Cho and Dee, 2006: Cho JG, Dee SA. Porcine reproductive and respiratory syndrome virus. Theriogenology. 2006; 66(3); 655-662. [PubMed: 16730057].
  2. Hou et al., 2008: Hou YH, Chen J, Tong GZ, Tian ZJ, Zhou YJ, Li GX, Li X, Peng JM, An TQ, Yang HC. A recombinant plasmid co-expressing swine ubiquitin and the GP5 encoding-gene of porcine reproductive and respiratory syndrome virus induces protective immunity in piglets. Vaccine. 2008; 26(11); 1438-1449. [PubMed: 18262692].
  3. Jiang et al., 2006: Jiang Y, Xiao S, Fang L, Yu X, Song Y, Niu C, Chen H. DNA vaccines co-expressing GP5 and M proteins of porcine reproductive and respiratory syndrome virus (PRRSV) display enhanced immunogenicity. Vaccine. 2006; 24(15); 2869-2879. [PubMed: 16446016].
  4. Mateu and Diaz, 2008: Mateu E, Diaz I. The challenge of PRRS immunology. Veterinary journal (London, England : 1997). 2008; 177(3); 345-351. [PubMed: 17644436].
  5. Pirzadeh and Dea, 1998: Pirzadeh B, Dea S. Immune response in pigs vaccinated with plasmid DNA encoding ORF5 of porcine reproductive and respiratory syndrome virus. The Journal of general virology. 1998; 79 ( Pt 5); 989-999. [PubMed: 9603313].
  6. Tian et al., 2009: Tian ZJ, An TQ, Zhou YJ, Peng JM, Hu SP, Wei TC, Jiang YF, Xiao Y, Tong GZ. An attenuated live vaccine based on highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) protects piglets against HP-PRRS. Veterinary microbiology. 2009; 138(1-2); 34-40. [PubMed: 19339125].
  7. Xue et al., 2004: Xue Q, Zhao YG, Zhou YJ, Qiu HJ, Wang YF, Wu DL, Tian ZJ, Tong GZ. Immune responses of swine following DNA immunization with plasmids encoding porcine reproductive and respiratory syndrome virus ORFs 5 and 7, and porcine IL-2 and IFNgamma. Veterinary immunology and immunopathology. 2004; 102(3); 291-298. [PubMed: 15507312].

Porcine rotavirus

  1. Li et al., 2010: Li YJ, Ma GP, Li GW, Qiao XY, Ge JW, Tang LJ, Liu M, Liu LW. Oral vaccination with the porcine rotavirus VP4 outer capsid protein expressed by Lactococcus lactis induces specific antibody production. Journal of biomedicine & biotechnology. 2010; 2010; 708460. [PubMed: 20625406].

Porphyromonas gulae

  1. Fournier et al., 2001: Fournier D, Mouton C, Lapierre P, Kato T, Okuda K, Ménard C. Porphyromonas gulae sp. nov., an anaerobic, gram-negative coccobacillus from the gingival sulcus of various animal hosts. International journal of systematic and evolutionary microbiology. 2001; 51(Pt 3); 1179-1189. [PubMed: 11411686].
  2. Hamada et al., 2008: Hamada N, Takahashi Y, Watanabe K, Kumada H, Oishi Y, Umemoto T. Molecular and antigenic similarities of the fimbrial major components between Porphyromonas gulae and P. gingivalis. Veterinary microbiology. 2008; 128(1-2); 108-117. [PubMed: 17977673].

Pseudomonas aeruginosa

  1. Finke et al., 1990: Finke M, Duchêne M, Eckhardt A, Domdey H, von Specht BU. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli. Infection and immunity. 1990; 58(7); 2241-2244. [PubMed: 2114360].
  2. Holder et al., 2001: Holder IA, Neely AN, Frank DW. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infection and immunity. 2001; 69(9); 5908-5910. [PubMed: 11500471].
  3. Price et al., 2001: Price BM, Galloway DR, Baker NR, Gilleland LB, Staczek J, Gilleland HE Jr. Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa. Infection and immunity. 2001; 69(5); 3510-3515. [PubMed: 11292786].
  4. Saha et al., 2006: Saha S, Takeshita F, Sasaki S, Matsuda T, Tanaka T, Tozuka M, Takase K, Matsumoto T, Okuda K, Ishii N, Yamaguchi K, Klinman DM, Xin KQ, Okuda K. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Vaccine. 2006; 24(37-39); 6240-6249. [PubMed: 16806598].
  5. Salyers and Whitt., 2002: Abigail A. Salyers, Dixie D. Whitt. Pseudomonas aeruginosa and Related Species, a Lesson in Versatility. 247-62. Bacterial Pathogenesis: A Molecular Approach. 2002. ASM Press, Washington D.C. USA.
  6. Textbook of Bacteriology: Pseudomonas [http://www.textbookofbacteriology.net/pseudomonas.html]
  7. Zaidi et al., 2006: Zaidi TS, Priebe GP, Pier GB. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Infection and immunity. 2006; 74(2); 975-983. [PubMed: 16428743].

Pseudorabies virus

  1. Brockmeier and Mengeling, 1996: Brockmeier SL, Mengeling WL. Comparison of the protective response induced by NYVAC vaccinia recombinants expressing either gp50 or gII and gp50 of pseudorabies virus. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 1996; 60(4); 315-317. [PubMed: 8904669].
  2. Chang et al., 1998: Chang SW, Bu J, Rompato G, Garmendia AE. A vector DNA vaccine encoding pseudorabies virus immediate early protein demonstrates partial protection in mice against lethal virus challenge. Viral immunology. 1998; 11(1); 27-36. [PubMed: 9586695].
  3. Dijkstra et al., 1997: Dijkstra JM, Gerdts V, Klupp BG, Mettenleiter TC. Deletion of glycoprotein gM of pseudorabies virus results in attenuation for the natural host. The Journal of general virology. 1997; 78 ( Pt 9); 2147-2151. [PubMed: 9292000].
  4. Eo et al., 2006: Eo SK, Yoon HA, Aleyas AG, Park SO, Han YW, Chae JS, Lee JH, Song HJ, Cho JG. Systemic and mucosal immunity induced by oral somatic transgene vaccination against glycoprotein B of pseudorabies virus using live attenuated Salmonella typhimurium. FEMS immunology and medical microbiology. 2006; 47(3); 451-461. [PubMed: 16872383].
  5. Ferrari et al., 2000: Ferrari M, Brack A, Romanelli MG, Mettenleiter TC, Corradi A, Dal Mas N, Losio MN, Silini R, Pinoni C, Pratelli A. A study of the ability of a TK-negative and gI/gE-negative pseudorabies virus (PRV) mutant inoculated by different routes to protect pigs against PRV infection. Journal of veterinary medicine. B, Infectious diseases and veterinary public health. 2000; 47(10); 753-762. [PubMed: 11204130].
  6. Fuchs et al., 1990: Fuchs W, Rziha HJ, Lukàcs N, Braunschweiger I, Visser N, Lütticken D, Schreurs CS, Thiel HJ, Mettenleiter TC. Pseudorabies virus glycoprotein gI: in vitro and in vivo analysis of immunorelevant epitopes. The Journal of general virology. 1990; 71 ( Pt 5); 1141-1151. [PubMed: 1693164].
  7. Grabowska et al., 2009: Grabowska AK, Lipińska AD, Rohde J, Szewczyk B, Bienkowska-Szewczyk K, Rziha HJ. New baculovirus recombinants expressing Pseudorabies virus (PRV) glycoproteins protect mice against lethal challenge infection. Vaccine. 2009; 27(27); 3584-3591. [PubMed: 19464538].
  8. Han et al., 2008: Han YW, Aleyas AG, George JA, Kim SJ, Kim HK, Yoon HA, Yoo DJ, Kang SH, Kim K, Eo SK. Polarization of protective immunity induced by replication-incompetent adenovirus expressing glycoproteins of pseudorabies virus. Experimental & molecular medicine. 2008; 40(6); 583-595. [PubMed: 19116444].
  9. Jöns et al., 1997: Jöns A, Gerdts V, Lange E, Kaden V, Mettenleiter TC. Attenuation of dUTPase-deficient pseudorabies virus for the natural host. Veterinary microbiology. 1997; 56(1-2); 47-54. [PubMed: 9228681].
  10. Katayama et al., 1997: Katayama S, Okada N, Yoshiki K, Okabe T, Shimizu Y. Protective effect of glycoprotein gC-rich antigen against pseudorabies virus. The Journal of veterinary medical science / the Japanese Society of Veterinary Science. 1997; 59(8); 657-663. [PubMed: 9300361].
  11. Kimman et al., 1994: Kimman TG, De Wind N, De Bruin T, de Visser Y, Voermans J. Inactivation of glycoprotein gE and thymidine kinase or the US3-encoded protein kinase synergistically decreases in vivo replication of pseudorabies virus and the induction of protective immunity. Virology. 1994; 205(2); 511-518. [PubMed: 7975253].
  12. Matsuda et al., 1992: Matsuda Tsuchida A, Katayama S, Okada N, Okabe T, Sasaki N. Protection from pseudorabies virus challenge in mice by a combination of purified gII, gIII and gVI antigens. The Journal of veterinary medical science / the Japanese Society of Veterinary Science. 1992; 54(3); 447-452. [PubMed: 1322712].
  13. Merck Vet Manual: Pseudorabies: Merck Veterinary Manual- Pseudorabies [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/102200.htm]
  14. Peeters et al., 1994: Peeters B, Bouma A, de Bruin T, Moormann R, Gielkens A, Kimman T. Non-transmissible pseudorabies virus gp50 mutants: a new generation of safe live vaccines. Vaccine. 1994; 12(4); 375-380. [PubMed: 8178562].
  15. Shiau et al., 2001: Shiau AL, Chu CY, Su WC, Wu CL. Vaccination with the glycoprotein D gene of pseudorabies virus delivered by nonpathogenic Escherichia coli elicits protective immune responses. Vaccine. 2001; 19(23-24); 3277-3284. [PubMed: 11312026].
  16. Vrublevskaia et al., 2007: Vrublevskaia VV, Musienko VS, Skarga IuIu, Morenkov OS. [Immunological characteristics of Aujeszky's disease virus glycoprotein]. Voprosy virusologii. 2007; 52(3); 33-37. [PubMed: 17601050].
  17. Weigel et al., 2003: Weigel RM, Hahn EC, Scherba G. Survival and immunization of raccoons after exposure to pseudorabies (Aujeszky's disease) virus gene-deleted vaccines. Veterinary microbiology. 2003; 92(1-2); 19-24. [PubMed: 12488067].
  18. Wiki: Pseudorabies: Pseudorabies [http://en.wikipedia.org/wiki/Pseudorabies]

Psittacid herpesvirus 1

  1. Katoh et al., 2010: Katoh H, Ogawa H, Ohya K, Fukushi H. A review of DNA viral infections in psittacine birds. The Journal of veterinary medical science / the Japanese Society of Veterinary Science. 2010; 72(9); 1099-1106. [PubMed: 20424393].
  2. Merck Vet Manual: Pacheco's Disease: Merck Veterinary Manual: Pacheco's Disease [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/170223.htm]

Rabbit hemorrhagic disease virus

  1. Wiki: Rabbit haemorrhagic disease: Rabbit haemorrhagic disease [https://en.wikipedia.org/wiki/Rabbit_haemorrhagic_disease]
  2. Yuan et al., 2013: Yuan D, Qu L, Liu J, Guo D, Jiang Q, Lin H, Si C. DNA vaccination with a gene encoding VP60 elicited protective immunity against rabbit hemorrhagic disease virus. Veterinary microbiology. 2013; 164(1-2); 1-8. [PubMed: 23419819].

Rabies virus

  1. Brochier et al., 1991: Brochier B, Kieny MP, Costy F, Coppens P, Bauduin B, Lecocq JP, Languet B, Chappuis G, Desmettre P, Afiademanyo K. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature. 1991; 354(6354); 520-522. [PubMed: 1758494].
  2. FDA: Imovax: FDA: Imovax vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm180097.htm]
  3. FDA: Rabavert: FDA: Rabavert vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm133517.htm]
  4. Fujii et al., 1994: Fujii H, Takita-Sonoda Y, Mifune K, Hirai K, Nishizono A, Mannen K. Protective efficacy in mice of post-exposure vaccination with vaccinia virus recombinant expressing either rabies virus glycoprotein or nucleoprotein. The Journal of general virology. 1994; 75 ( Pt 6); 1339-1344. [PubMed: 8207400].
  5. Kaur et al., 2010: Kaur M, Saxena A, Rai A, Bhatnagar R. Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2010; 24(1); 173-183. [PubMed: 19741168].
  6. Lodmell et al., 2000: Lodmell DL, Ray NB, Ulrich JT, Ewalt LC. DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL). Vaccine. 2000; 18(11-12); 1059-1066. [PubMed: 10590326].
  7. Mackowiak et al., 1999: Mackowiak M, Maki J, Motes-Kreimeyer L, Harbin T, Van Kampen K. Vaccination of wildlife against rabies: successful use of a vectored vaccine obtained by recombinant technology. Advances in veterinary medicine. 1999; 41; 571-583. [PubMed: 9890044].
  8. Manning et al., 2008: Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, Meltzer MI, Dhankhar P, Vaidya SA, Jenkins SR, Sun B, Hull HF. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 2008; 57(RR-3); 1-28. [PubMed: 18496505].
  9. Morimoto et al., 2005: Morimoto K, Shoji Y, Inoue S. Characterization of P gene-deficient rabies virus: propagation, pathogenicity and antigenicity. Virus research. 2005; 111(1); 61-67. [PubMed: 15896403].
  10. Osorio et al., 1999: Osorio JE, Tomlinson CC, Frank RS, Haanes EJ, Rushlow K, Haynes JR, Stinchcomb DT. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine. 1999; 17(9-10); 1109-1116. [PubMed: 10195621].
  11. Rabavert: Rabavert Package Insert [http://www.novartisvaccines.com/downloads/diseases-products/us-pl-rabavert.pdf]
  12. Rupprecht et al., 2004: Rupprecht CE, Hanlon CA, Slate D. Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control. Developments in biologicals. 2004; 119; 173-184. [PubMed: 15742629].
  13. Stoffregen et al., 2006: Stoffregen WC, Olsen SC, Bricker BJ. Parenteral vaccination of domestic pigs with Brucella abortus strain RB51. American journal of veterinary research. 2006; 67(10); 1802-1808. [PubMed: 17014337].
  14. Takita-Sonoda et al., 1993: Takita-Sonoda Y, Fujii H, Mifune K, Ito Y, Hiraga M, Nishizono A, Mannen K, Minamoto N. Resistance of mice vaccinated with rabies virus internal structural proteins to lethal infection. Archives of virology. 1993; 132(1-2); 51-65. [PubMed: 8352659].
  15. Wiki: Rabies: Wiki: Rabies [http://en.wikipedia.org/wiki/Rabies]
  16. Wu et al., 2011: Wu X, Franka R, Henderson H, Rupprecht CE. Live attenuated rabies virus co-infected with street rabies virus protects animals against rabies. Vaccine. 2011; ; . [PubMed: 21514343].
  17. Xiang et al., 1994: Xiang ZQ, Spitalnik S, Tran M, Wunner WH, Cheng J, Ertl HC. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology. 1994; 199(1); 132-140. [PubMed: 8116236].

Reticuloendotheliosis Virus

  1. Drechsler et al., 2013: Drechsler Y, Tkalcic S, Saggese MD, Shivaprasad HL, Ajithdoss DK, Collisson EW. A DNA vaccine expressing ENV and GAG offers partial protection against reticuloendotheliosis virus in the prairie chicken (Tympanicus cupido). Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians. 2013; 44(2); 251-261. [PubMed: 23805542].

Ricin toxin of Ricinus communis

  1. Mayo Clinic - Ricin poisoning: Ricin poisoning [http://www.mayoclinic.com/health/ricin/AN02211]
  2. Smallshaw et al., 2002: Smallshaw JE, Firan A, Fulmer JR, Ruback SL, Ghetie V, Vitetta ES. A novel recombinant vaccine which protects mice against ricin intoxication. Vaccine. 2002; 20(27-28); 3422-3427. [PubMed: 12213413].

Rickettsia spp

  1. Carl et al., 1990: Carl M, Dobson ME, Ching WM, Dasch GA. Characterization of the gene encoding the protective paracrystalline-surface-layer protein of Rickettsia prowazekii: presence of a truncated identical homolog in Rickettsia typhi. Proceedings of the National Academy of Sciences of the United States of America. 1990; 87(21); 8237-8241. [PubMed: 2122457].
  2. Crocquet-Valdes et al., 2001: Crocquet-Valdes PA, Díaz-Montero CM, Feng HM, Li H, Barrett AD, Walker DH. Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis. Vaccine. 2001; 20(5-6); 979-988. [PubMed: 11738766].
  3. Díaz-Montero et al., 2001: Díaz-Montero CM, Feng HM, Crocquet-Valdes PA, Walker DH. Identification of protective components of two major outer membrane proteins of spotted fever group Rickettsiae. The American journal of tropical medicine and hygiene. 2001; 65(4); 371-378. [PubMed: 11693887].
  4. Seong et al., 1997: Seong SY, Huh MS, Jang WJ, Park SG, Kim JG, Woo SG, Choi MS, Kim IS, Chang WH. Induction of homologous immune response to Rickettsia tsutsugamushi Boryong with a partial 56-kilodalton recombinant antigen fused with the maltose-binding protein MBP-Bor56. Infection and immunity. 1997; 65(4); 1541-1545. [PubMed: 9119501].
  5. Textbook of Bacteriology: Online Textbook of Bacteriology: Rickettsial Diseases [http://www.textbookofbacteriology.net/Rickettsia_2.html]
  6. Wiki: Rickettsia: Rickettsia [http://en.wikipedia.org/wiki/Rickettsia]

Riemerella anatipestifer

  1. Merck Vet Manual: Riemerella anatipestifer: Merck Veterinary Manual- Riemerella anatipestifer Infection: Introduction [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/204000.htm]

Rift Valley Fever virus

  1. Lagerqvist et al., 2009: Lagerqvist N, Näslund J, Lundkvist A, Bouloy M, Ahlm C, Bucht G. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virology journal. 2009; 6; 6. [PubMed: 19149901].
  2. Wallace et al., 2006: Wallace DB, Ellis CE, Espach A, Smith SJ, Greyling RR, Viljoen GJ. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine. 2006; 24(49-50); 7181-7189. [PubMed: 16870311].
  3. Wiki: Rift Valley Fever virus: Rift Valley Fever [http://en.wikipedia.org/wiki/Rift_valley_fever_virus]

Rotavirus

  1. Choi et al., 2002: Choi AH, McNeal MM, Flint JA, Basu M, Lycke NY, Clements JD, Bean JA, Davis HL, McCluskie MJ, VanCott JL, Ward RL. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine. 2002; 20(13-14); 1733-1740. [PubMed: 11906760].
  2. FDA: ROTARIX: FDA: ROTARIX vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm133920.htm]
  3. FDA: RotaTeq: FDA: RotaTeq vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094063.htm]
  4. Garaicoechea et al., 2008: Garaicoechea L, Olichon A, Marcoppido G, Wigdorovitz A, Mozgovoj M, Saif L, Surrey T, Parreño V. Llama-derived single-chain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in vitro and confer protection against diarrhea in mice. Journal of virology. 2008; 82(19); 9753-9764. [PubMed: 18632867].
  5. Herrmann et al., 1996: Herrmann JE, Chen SC, Fynan EF, Santoro JC, Greenberg HB, Robinson HL. DNA vaccines against rotavirus infections. Archives of virology. Supplementum. 1996; 12; 207-215. [PubMed: 9015117].
  6. Herrmann et al., 1999: Herrmann JE, Chen SC, Jones DH, Tinsley-Bown A, Fynan EF, Greenberg HB, Farrar GH. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology. 1999; 259(1); 148-153. [PubMed: 10364499].
  7. McClenahan et al., 2011: McClenahan SD, Krause PR, Uhlenhaut C. Molecular and infectivity studies of porcine circovirus in vaccines. Vaccine. 2011; 29(29-30); 4745-4753. [PubMed: 21569811].
  8. McNeal et al., 2007: McNeal MM, Basu M, Bean JA, Clements JD, Lycke NY, Ramne A, Löwenadler B, Choi AH, Ward RL. Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge. Vaccine. 2007; 25(33); 6224-6231. [PubMed: 17629371].
  9. Offit et al., 1986: Offit PA, Clark HF, Blavat G, Greenberg HB. Reassortant rotaviruses containing structural proteins vp3 and vp7 from different parents induce antibodies protective against each parental serotype. Journal of virology. 1986; 60(2); 491-496. [PubMed: 3021983].
  10. Redmond et al., 1993: Redmond MJ, Ijaz MK, Parker MD, Sabara MI, Dent D, Gibbons E, Babiuk LA. Assembly of recombinant rotavirus proteins into virus-like particles and assessment of vaccine potential. Vaccine. 1993; 11(2); 273-281. [PubMed: 8382422].
  11. Siadat-Pajouh and Cai, 2001: Siadat-Pajouh M, Cai L. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant. Viral immunology. 2001; 14(1); 31-47. [PubMed: 11270595].
  12. Wiki: Rotavirus: Wiki: Rotavirus [http://en.wikipedia.org/wiki/Rotavirus]

Rubella virus

  1. FDA: Meruvax II: FDA: Meruvax II vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094064.htm]
  2. FDA: MMR-II: FDA: MMR-II Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094050.htm]
  3. FDA: Proquad: FDA: Proquad Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm188806.htm]
  4. Wiki: Rebella: Wiki: Rebella [http://en.wikipedia.org/wiki/Rubella]

Salmonella spp.

  1. Adriaensen et al., 2007: Adriaensen C, De Greve H, Tian JQ, De Craeye S, Gubbels E, Eeckhaut V, Van Immerseel F, Ducatelle R, Kumar M, Hernalsteens JP. A live Salmonella enterica serovar Enteritidis vaccine allows serological differentiation between vaccinated and infected animals. Infection and immunity. 2007; 75(5); 2461-2468. [PubMed: 17261603].
  2. Allam et al., 2011: Allam US, Krishna MG, Lahiri A, Joy O, Chakravortty D. Salmonella enterica Serovar Typhimurium Lacking hfq Gene Confers Protective Immunity against Murine Typhoid. PloS one. 2011; 6(2); e16667. [PubMed: 21347426].
  3. Babu et al., 2004: Babu U, Dalloul RA, Okamura M, Lillehoj HS, Xie H, Raybourne RB, Gaines D, Heckert RA. Salmonella enteritidis clearance and immune responses in chickens following Salmonella vaccination and challenge. Veterinary immunology and immunopathology. 2004; 101(3-4); 251-257. [PubMed: 15350755].
  4. Bansal et al., 2010: Bansal A, Paliwal PK, Sagi SS, Sairam M. Effect of adjuvants on immune response and protective immunity elicited by recombinant Hsp60 (GroEL) of Salmonella typhi against S. typhi infection. Molecular and cellular biochemistry. 2010; 337(1-2); 213-221. [PubMed: 19851830].
  5. Boyle et al., 2007: Boyle EC, Bishop JL, Grassl GA, Finlay BB. Salmonella: from pathogenesis to therapeutics. Journal of bacteriology. 2007; 189(5); 1489-1495. [PubMed: 17189373].
  6. Burns et al: Megan Egg – protection for commercial layers against Salmonella enteritidis infection for consumer protection [http://www.fda.gov/ohrms/dockets/dockets/00n0504/00N-0504_emc-001650-02.pdf]
  7. Cao et al., 1992: Cao Y, Wen Z, Lu D. Construction of a recombinant oral vaccine against Salmonella typhi and Salmonella typhimurium. Infection and immunity. 1992; 60(7); 2823-2827. [PubMed: 1612747].
  8. Cárdenas and Clements, 1992: Cárdenas L, Clements JD. Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clinical microbiology reviews. 1992; 5(3); 328-342. [PubMed: 1498769].
  9. Chatfield et al., 1992: Chatfield SN, Strahan K, Pickard D, Charles IG, Hormaeche CE, Dougan G. Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model. Microbial pathogenesis. 1992; 12(2); 145-151. [PubMed: 1584006].
  10. Chaudhuri et al., 2009: Chaudhuri RR, Peters SE, Pleasance SJ, Northen H, Willers C, Paterson GK, Cone DB, Allen AG, Owen PJ, Shalom G, Stekel DJ, Charles IG, Maskell DJ. Comprehensive identification of Salmonella enterica serovar typhimurium genes required for infection of BALB/c mice. PLoS pathogens. 2009; 5(7); e1000529. [PubMed: 19649318].
  11. Cheminay and Hensel, 2007: Cheminay C, Hensel M. Rational design of Salmonella recombinant vaccines. International journal of medical microbiology : IJMM. 2007; ; . [PubMed: 17888730 ].
  12. Choi et al., 2010: Choi J, Shin D, Ryu S. Salmonella enterica serovar Typhimurium ruvB mutant can confer protection against salmonellosis in mice. Vaccine. 2010; 28(39); 6436-6444. [PubMed: 20670908].
  13. Coynault et al., 1996: Coynault C, Robbe-Saule V, Norel F. Virulence and vaccine potential of Salmonella typhimurium mutants deficient in the expression of the RpoS (sigma S) regulon. Molecular microbiology. 1996; 22(1); 149-160. [PubMed: 8899717].
  14. Curtiss and Kelly, 1987: Curtiss R 3rd, Kelly SM. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infection and immunity. 1987; 55(12); 3035-3043. [PubMed: 3316029].
  15. Curtiss et al., 1988: Curtiss R 3rd, Goldschmidt RM, Fletchall NB, Kelly SM. Avirulent Salmonella typhimurium delta cya delta crp oral vaccine strains expressing a streptococcal colonization and virulence antigen. Vaccine. 1988; 6(2); 155-160. [PubMed: 3291452].
  16. Dorman et al., 1989: Dorman CJ, Chatfield S, Higgins CF, Hayward C, Dougan G. Characterization of porin and ompR mutants of a virulent strain of Salmonella typhimurium: ompR mutants are attenuated in vivo. Infection and immunity. 1989; 57(7); 2136-2140. [PubMed: 2543631].
  17. Dougan et al., 1987: Dougan G, Maskell D, Pickard D, Hormaeche C. Isolation of stable aroA mutants of Salmonella typhi Ty2: properties and preliminary characterisation in mice. Molecular & general genetics : MGG. 1987; 207(2-3); 402-405. [PubMed: 3039297].
  18. FDA: Vivotif: FDA: Vivotif Vaccine for Salmonella [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094070.htm]
  19. Frech et al., 1998: Frech G, Weide-Botjes M, Nussbeck E, Rabsch W, Schwarz S. Molecular characterization of Salmonella enterica subsp. enterica serovar Typhimurium DT009 isolates: differentiation of the live vaccine strain Zoosaloral from field isolates. FEMS microbiology letters. 1998; 167(2); 263-269. [PubMed: 9809427].
  20. Galdiero et al., 1999: Galdiero M, Marcatili A, Cipollaro de l'Ero G, Nuzzo I, Bentivoglio C, Galdiero M, Romano Carratelli C. Effect of transforming growth factor beta on experimental Salmonella typhimurium infection in mice. Infection and immunity. 1999; 67(3); 1432-1438. [PubMed: 10024591].
  21. Game Bird Health - Broilact: Game Bird Health - Broilact [http://www.gamebirdhealth.co.uk/broilact.htm]
  22. Germanier and Füer, 1975: Germanier R, Füer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. The Journal of infectious diseases. 1975; 131(5); 553-558. [PubMed: 1092768].
  23. Gilbreath et al., 2011: Gilbreath JJ, Colvocoresses Dodds J, Rick PD, Soloski MJ, Merrell DS, Metcalf ES. Enterobacterial Common Antigen Mutants of Salmonella enterica serovar Typhimurium Establish a Persistent Infection and Provide Protection Against Subsequent Lethal Challenge. Infection and immunity. 2011; ; . [PubMed: 22025511].
  24. Hormaeche et al., 1991: Hormaeche CE, Joysey HS, Desilva L, Izhar M, Stocker BA. Immunity conferred by Aro- Salmonella live vaccines. Microbial pathogenesis. 1991; 10(2); 149-158. [PubMed: 1890952].
  25. Humphreys et al., 1999: Humphreys S, Stevenson A, Bacon A, Weinhardt AB, Roberts M. The alternative sigma factor, sigmaE, is critically important for the virulence of Salmonella typhimurium. Infection and immunity. 1999; 67(4); 1560-1568. [PubMed: 10084987].
  26. Kaneshige et al., 2009: Kaneshige T, Yaguchi K, Ohgitani T. Siderophore receptor IroN is an important protective antigen against Salmonella infection in chickens. Avian diseases. 2009; 53(4); 563-567. [PubMed: 20095157].
  27. Kaniga et al., 1998: Kaniga K, Compton MS, Curtiss R 3rd, Sundaram P. Molecular and functional characterization of Salmonella enterica serovar typhimurium poxA gene: effect on attenuation of virulence and protection. Infection and immunity. 1998; 66(12); 5599-5606. [PubMed: 9826331].
  28. Kincy-Cain et al., 1996: Kincy-Cain T, Clements JD, Bost KL. Endogenous and exogenous interleukin-12 augment the protective immune response in mice orally challenged with Salmonella dublin. Infection and immunity. 1996; 64(4); 1437-1440. [PubMed: 8606114].
  29. Kustanova et al., 2006: Kustanova GA, Murashev AN, Karpov VL, Margulis BA, Guzhova IV, Prokhorenko IR, Grachev SV, Evgen'ev MB. Exogenous heat shock protein 70 mediates sepsis manifestations and decreases the mortality rate in rats. Cell stress & chaperones. 2006; 11(3); 276-286. [PubMed: 17009601].
  30. Lee et al., 2007: Lee HY, Cho SA, Lee IS, Park JH, Seok SH, Baek MW, Kim DJ, Lee SH, Hur SJ, Ban SJ, Lee YK, Han YK, Cho YK, Park JH. Evaluation of phoP and rpoS mutants of Salmonella enterica serovar Typhi as attenuated typhoid vaccine candidates: virulence and protective immune responses in intranasally immunized mice. FEMS immunology and medical microbiology. 2007; 51(2); 310-318. [PubMed: 17725620].
  31. Levine et al., 2007: Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007; 45 Suppl 1; S24-28. [PubMed: 17582564].
  32. Liu et al., 2008: Liu T, König R, Sha J, Agar SL, Tseng CT, Klimpel GR, Chopra AK. Immunological responses against Salmonella enterica serovar Typhimurium Braun lipoprotein and lipid A mutant strains in Swiss-Webster mice: potential use as live-attenuated vaccines. Microbial pathogenesis. 2008; 44(3); 224-237. [PubMed: 17997275].
  33. Matsuda et al., 2010: Matsuda K, Chaudhari AA, Kim SW, Lee KM, Lee JH. Physiology, pathogenicity and immunogenicity of lon and/or cpxR deleted mutants of Salmonella Gallinarum as vaccine candidates for fowl typhoid. Veterinary research. 2010; 41(5); 59. [PubMed: 20487719].
  34. Matsui et al., 2003: Matsui H, Suzuki M, Isshiki Y, Kodama C, Eguchi M, Kikuchi Y, Motokawa K, Takaya A, Tomoyasu T, Yamamoto T. Oral immunization with ATP-dependent protease-deficient mutants protects mice against subsequent oral challenge with virulent Salmonella enterica serovar typhimurium. Infection and immunity. 2003; 71(1); 30-39. [PubMed: 12496146].
  35. Methner et al., 1997: Methner U, Barrow PA, Martin G, Meyer H. Comparative study of the protective effect against Salmonella colonisation in newly hatched SPF chickens using live, attenuated Salmonella vaccine strains, wild-type Salmonella strains or a competitive exclusion product. International journal of food microbiology. 1997; 35(3); 223-230. [PubMed: 9105931].
  36. Nagarajan et al., 2009: Nagarajan AG, Balasundaram SV, Janice J, Karnam G, Eswarappa SM, Chakravortty D. SopB of Salmonella enterica serovar Typhimurium is a potential DNA vaccine candidate in conjugation with live attenuated bacteria. Vaccine. 2009; 27(21); 2804-2811. [PubMed: 19428891].
  37. Park et al., 2010: Park SI, Jeong JH, Choy HE, Rhee JH, Na HS, Lee TH, Her M, Cho KO, Hong Y. Immune response induced by ppGpp-defective Salmonella enterica serovar Gallinarum in chickens. Journal of microbiology (Seoul, Korea). 2010; 48(5); 674-681. [PubMed: 21046347].
  38. Pasetti et al., 1999: Pasetti MF, Anderson RJ, Noriega FR, Levine MM, Sztein MB. Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clinical immunology (Orlando, Fla.). 1999; 92(1); 76-89. [PubMed: 10413655].
  39. Paterson et al., 2009: Paterson GK, Northen H, Cone DB, Willers C, Peters SE, Maskell DJ. Deletion of tolA in Salmonella Typhimurium generates an attenuated strain with vaccine potential. Microbiology (Reading, England). 2009; 155(Pt 1); 220-228. [PubMed: 19118362].
  40. Penha et al., 2010: Penha Filho RA, de Paiva JB, da Silva MD, de Almeida AM, Berchieri A Jr. Control of Salmonella Enteritidis and Salmonella Gallinarum in birds by using live vaccine candidate containing attenuated Salmonella Gallinarum mutant strain. Vaccine. 2010; 28(16); 2853-2859. [PubMed: 20153354].
  41. Pesciaroli et al., 2011: Pesciaroli M, Aloisio F, Ammendola S, Pistoia C, Petrucci P, Tarantino M, Francia M, Battistoni A, Pasquali P. An attenuated Salmonella enterica serovar Typhimurium strain lacking the ZnuABC transporter induces protection in a mouse intestinal model of Salmonella infection. Vaccine. 2011; ; . [PubMed: 21219981].
  42. Peters et al., 2010: Peters SE, Paterson GK, Bandularatne ES, Northen HC, Pleasance S, Willers C, Wang J, Foote AK, Constantino-Casas F, Scase TJ, Blacklaws BA, Bryant CE, Mastroeni P, Charles IG, Maskell DJ. Salmonella enterica serovar typhimurium trxA mutants are protective against virulent challenge and induce less inflammation than the live-attenuated vaccine strain SL3261. Infection and immunity. 2010; 78(1); 326-336. [PubMed: 19884329].
  43. Piao et al., 2010: Piao HH, Tam VT, Na HS, Kim HJ, Ryu PY, Kim SY, Rhee JH, Choy HE, Kim SW, Hong Y. Immunological responses induced by asd and wzy/asd mutant strains of Salmonella enterica serovar Typhimurium in BALB/c mice. Journal of microbiology (Seoul, Korea). 2010; 48(4); 486-495. [PubMed: 20799091].
  44. Roesler et al., 2004: Roesler U, Marg H, Schröder I, Mauer S, Arnold T, Lehmann J, Truyen U, Hensel A. Oral vaccination of pigs with an invasive gyrA-cpxA-rpoB Salmonella Typhimurium mutant. Vaccine. 2004; 23(5); 595-603. [PubMed: 15542179].
  45. Rosu et al., 2007: Rosu V, Chadfield MS, Santona A, Christensen JP, Thomsen LE, Rubino S, Olsen JE. Effects of crp deletion in Salmonella enterica serotype Gallinarum. Acta veterinaria Scandinavica. 2007; 49; 14. [PubMed: 17488512].
  46. Sagi et al., 2006: Sagi SS, Paliwal P, Bansal A, Mishra C, Khan N, Mustoori SR, Ilavazhagan G, Sawhney RC, Banerjee PK. Studies on immunogenicity and protective efficacy of DnaJ of Salmonella Typhi against lethal infection by Salmonella Typhimurium in mice. Vaccine. 2006; 24(49-50); 7135-7141. [PubMed: 16887241].
  47. Salvat et al., 1992: Salvat G, Lalande F, Humbert F, Lahellec C. Use of a competitive exclusion product (Broilact) to prevent Salmonella colonization of newly hatched chicks. International journal of food microbiology. 1992; 15(3-4); 307-311. [PubMed: 1419536 ].
  48. Schneitz and Renney, 2003: Schneitz C, Renney DJ. Effect of a commerical competitive exclusion product on the colonization of Salmonella infantis in day-old pheasant chicks. Avian diseases. 2003; 47(4); 1448-1451. [PubMed: 14708995 ].
  49. Selke et al., 2007: Selke M, Meens J, Springer S, Frank R, Gerlach GF. Immunization of pigs to prevent disease in humans: construction and protective efficacy of a Salmonella enterica serovar Typhimurium live negative-marker vaccine. Infection and immunity. 2007; 75(5); 2476-2483. [PubMed: 17296750].
  50. Sydenham et al., 2000: Sydenham M, Douce G, Bowe F, Ahmed S, Chatfield S, Dougan G. Salmonella enterica serovar typhimurium surA mutants are attenuated and effective live oral vaccines. Infection and immunity. 2000; 68(3); 1109-1115. [PubMed: 10678914].
  51. Tacket and Levine, 2007: Tacket CO, Levine MM. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007; 45 Suppl 1; S20-23. [PubMed: 17582563].
  52. Tacket et al., 2000: Tacket CO, Sztein MB, Wasserman SS, Losonsky G, Kotloff KL, Wyant TL, Nataro JP, Edelman R, Perry J, Bedford P, Brown D, Chatfield S, Dougan G, Levine MM. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infection and immunity. 2000; 68(3); 1196-1201. [PubMed: 10678926].
  53. Tennant et al., 2011: Tennant SM, Wang JY, Galen JE, Simon R, Pasetti MF, Gat O, Levine MM. Engineering and pre-clinical evaluation of attenuated non-typhoidal Salmonella strains serving as live oral vaccines and as reagent strains. Infection and immunity. 2011; ; . [PubMed: 21807911].
  54. Typhim Vi: FDA: Typhim Vi Vaccine for Salmonella [http://www.fda.gov/cber/label/typhimviLB.pdf]
  55. Vorob'ev et al., 2009: Vorob'ev DS, Semenova IB, Kurbatova EA, Sveshnikov PG, Naroditskiĭ BS, Logunov DIu, Vaneeva NP. [Assessment of protective effect of heat shock protein-lypopolysaccharide of Salmonella typhimurium recombinant construction in mice]. Zhurnal mikrobiologii, epidemiologii, i immunobiologii. 2009; (3); 38-41. [PubMed: 19621817].
  56. Wang et al., 2000: Wang JY, Noriega FR, Galen JE, Barry E, Levine MM. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909. Infection and immunity. 2000; 68(8); 4647-4652. [PubMed: 10899868].
  57. Zhang-Barber et al., 1998: Zhang-Barber L, Turner AK, Dougan G, Barrow PA. Protection of chickens against experimental fowl typhoid using a nuoG mutant of Salmonella serotype Gallinarum. Vaccine. 1998; 16(9-10); 899-903. [PubMed: 9682335].

Sarcocystis neurona

  1. Ellison and Witonsky, 2009: Ellison S, Witonsky S. Evidence that antibodies against recombinant SnSAG1 of Sarcocystis neurona merozoites are involved in infection and immunity in equine protozoal myeloencephalitis. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 2009; 73(3); 176-183. [PubMed: 19794889].
  2. Marsh et al., 2004: Marsh AE, Lakritz J, Johnson PJ, Miller MA, Chiang YW, Chu HJ. Evaluation of immune responses in horses immunized using a killed Sarcocystis neurona vaccine. Veterinary therapeutics : research in applied veterinary medicine. 2004; 5(1); 34-42. [PubMed: 15150728].
  3. USDA Agricultural Research Service: Sarcocystis neurona: EPM/Sarcocystis neuorna [http://www.ars.usda.gov/Main/docs.htm?docid=11028]

SARS-CoV

  1. Du et al., 2008: Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S, Wu C, Jin DY, Yuen KY, Zhou Y, Zheng BJ. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 2008; 26(13); 1644-1651. [PubMed: 18289745].
  2. Hu et al., 2007: Hu H, Lu X, Tao L, Bai B, Zhang Z, Chen Y, Zheng F, Chen J, Chen Z, Wang H. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice. Clinical and vaccine immunology : CVI. 2007; 14(7); 894-901. [PubMed: 17494640].
  3. Lamirande et al., 2008: Lamirande EW, DeDiego ML, Roberts A, Jackson JP, Alvarez E, Sheahan T, Shieh WJ, Zaki SR, Baric R, Enjuanes L, Subbarao K. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. Journal of virology. 2008; 82(15); 7721-7724. [PubMed: 18463152].
  4. Sheets et al., 2006: Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, Kong WP, Nabel GJ, Gomez PL. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicological sciences : an official journal of the Society of Toxicology. 2006; 91(2); 610-619. [PubMed: 16569729].
  5. Sims et al., 2008: Sims AC, Burkett SE, Yount B, Pickles RJ. SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium. Virus research. 2008; 133(1); 33-44. [PubMed: 17451829].
  6. Wiki: SARS: Wiki: Sever Acute Respiratory Syndrome [http://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome]

Schistosoma japonicum

  1. Balen et al., 2007: Balen J, Zhao ZY, Williams GM, McManus DP, Raso G, Utzinger J, Zhou J, Li YS. Prevalence, intensity and associated morbidity of Schistosoma japonicum infection in the Dongting Lake region, China. Bulletin of the World Health Organization. 2007; 85(7); 519-526. [PubMed: 17768500].
  2. Da'dara et al., 2008: Da'dara AA, Li YS, Xiong T, Zhou J, Williams GM, McManus DP, Feng Z, Yu XL, Gray DJ, Harn DA. DNA-based vaccines protect against zoonotic schistosomiasis in water buffalo. Vaccine. 2008; 26(29-30); 3617-3625. [PubMed: 18524429].
  3. Gan et al., 2004: Gan Y, Shi YE, Bu LY, Zhu XH, Ning CX, Zhu HG. Immune responses against Schistosoma japonicum after vaccinating mice with a multivalent DNA vaccine encoding integrated membrane protein Sj23 and cytokine interleukin-12. Chinese medical journal. 2004; 117(12); 1842-1846. [PubMed: 15603716].
  4. Wang et al., 2013: Wang L, Liu W, Yang M, Peng D, Chen L. Development of a Streptococcus gordonii vaccine strain expressing Schistosoma japonicum Sj-F1 and evaluation of using this strain for intranasal immunization in mice. Parasitology research. 2013; 112(4); 1701-1708. [PubMed: 23403993].
  5. Wei et al., 2009: Wei F, Liu Q, Zhai Y, Fu Z, Liu W, Shang L, Men J, Gao S, Lian H, Jin H, Chen C, Lin J, Shi Y, Xia Z, Zhu XQ. IL-18 enhances protective effect in mice immunized with a Schistosoma japonicum FABP DNA vaccine. Acta tropica. 2009; 111(3); 284-288. [PubMed: 19467215].
  6. Zhou et al., 2000: Zhou S, Liu S, Song G, Xu Y, Sun W. Protective immunity induced by the full-length cDNA encoding paramyosin of Chinese Schistosoma japonicum. Vaccine. 2000; 18(27); 3196-3204. [PubMed: 10856799].

Schistosoma mansoni

  1. CDC - Schistosomiasis: Parasites - Schistosomiasis [http://www.cdc.gov/parasites/schistosomiasis/gen_info/faqs.html]
  2. Da'dara et al., 2001: Da'dara AA, Skelly PJ, Wang MM, Harn DA. Immunization with plasmid DNA encoding the integral membrane protein, Sm23, elicits a protective immune response against schistosome infection in mice. Vaccine. 2001; 20(3-4); 359-369. [PubMed: 11672898].
  3. Shalaby et al., 2003: Shalaby KA, Yin L, Thakur A, Christen L, Niles EG, LoVerde PT. Protection against Schistosoma mansoni utilizing DNA vaccination with genes encoding Cu/Zn cytosolic superoxide dismutase, signal peptide-containing superoxide dismutase and glutathione peroxidase enzymes. Vaccine. 2003; 22(1); 130-136. [PubMed: 14604580].
  4. Siddiqui et al., 2003: Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, Lloyd JD, Pompa J, Villalovos RM, Paz M. Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. Vaccine. 2003; 21(21-22); 2882-2889. [PubMed: 12798631].

Shigella

  1. Altboum et al., 2001: Altboum Z, Barry EM, Losonsky G, Galen JE, Levine MM. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Infection and immunity. 2001; 69(5); 3150-3158. [PubMed: 11292735].
  2. Barnoy et al., 2010: Barnoy S, Jeong KI, Helm RF, Suvarnapunya AE, Ranallo RT, Tzipori S, Venkatesan MM. Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Vaccine. 2010; 28(6); 1642-1654. [PubMed: 19932216].
  3. Chakrabarti et al., 1999: Chakrabarti MK, Bhattacharya J, Bhattacharya MK, Nair GB, Bhattacharya SK, Mahalanabis D. Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis. Acta paediatrica (Oslo, Norway : 1992). 1999; 88(2); 161-165. [PubMed: 10102148].
  4. Coster et al., 1999: Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti PJ, Hale TL. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infection and immunity. 1999; 67(7); 3437-3443. [PubMed: 10377124].
  5. Hartman and Venkatesan, 1998: Hartman AB, Venkatesan MM. Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Infection and immunity. 1998; 66(9); 4572-4576. [PubMed: 9712824].
  6. Hartman et al., 1991: Hartman AB, Powell CJ, Schultz CL, Oaks EV, Eckels KH. Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains. Infection and immunity. 1991; 59(11); 4075-4083. [PubMed: 1937767].
  7. Kärnell et al., 1993: Kärnell A, Cam PD, Verma N, Lindberg AA. AroD deletion attenuates Shigella flexneri strain 2457T and makes it a safe and efficacious oral vaccine in monkeys. Vaccine. 1993; 11(8); 830-836. [PubMed: 8356844].
  8. Klee et al., 1997: Klee SR, Tzschaschel BD, Fält I, Kärnell A, Lindberg AA, Timmis KN, Guzmán CA. Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1. Infection and immunity. 1997; 65(6); 2112-2118. [PubMed: 9169740].
  9. Kotloff et al., 1992: Kotloff KL, Herrington DA, Hale TL, Newland JW, Van De Verg L, Cogan JP, Snoy PJ, Sadoff JC, Formal SB, Levine MM. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infection and immunity. 1992; 60(6); 2218-2224. [PubMed: 1587589].
  10. Kotloff et al., 2000: Kotloff KL, Noriega FR, Samandari T, Sztein MB, Losonsky GA, Nataro JP, Picking WD, Barry EM, Levine MM. Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infection and immunity. 2000; 68(3); 1034-1039. [PubMed: 10678904].
  11. Kotloff et al., 2002: Kotloff KL, Taylor DN, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, Venkatesan M, Hartman A, Picking WD, Katz DE, Campbell JD, Levine MM, Hale TL. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infection and immunity. 2002; 70(4); 2016-2021. [PubMed: 11895966].